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Abstract 
Over the last 10-15 years pharmaceuticals have been identified as a widespread 
pollutant in freshwater systems having entered the environment predominantly via the 
domestic sewage system where removal by treatment systems is often poor.  This thesis 
provides detailed reviews and meta-analyses of existing data regarding pharmaceutical 
pollutants, examines the occurrence of five pharmaceuticals in semi-rural and urban 
catchments of West Yorkshire and their effects on freshwater ecosystems using both 
laboratory and field experiments.   
 A critical review and meta-analysis of 155 published pharmaceutical papers 
found 204 pharmaceuticals were present in rivers across large parts of Europe, North 
America and Asia.  However, spatial and methodological gaps were identified in the 
research body with almost no research evident in Africa, South America, the Middle East 
and large parts of Asia.  Furthermore, research effort was focused around a small 
number of commonly studied compounds often employing poorly representative grab 
sampling techniques. 
 Treated and untreated effluent of sewage treatment plants, combined sewer 
overflows and their receiving freshwaters were monitored for five pharmaceuticals 
(diclofenac, erythromycin, ibuprofen, mefenamic acid and propranolol).  All compounds 
were detected at very high frequencies across all samples confirming them as a 
ubiquitous and widespread pollutant in freshwaters.  Data showed pronounced seasonal 
(winter maxima) and diurnal (late morning and late evening) peaks in concentrations.  
Periods of high flow were characterised by reduced concentrations, possibly due to 
dilution within receiving waters.  No appreciable attenuation of pharmaceuticals was 
observed across an intensively sampled 5 km study reach of the River Aire in Leeds 
suggesting the pollution burden placed on rivers by pharmaceuticals extends well 
downstream of individual waste water point sources. 
 Laboratory experiments revealed significant increases in mortality of the 
freshwater shrimp Gammarus pulex were observed during extended exposures to 
environmental levels of erythromycin and when combined in mixture with propranolol.  A 
first application of 1H NMR environmental metabolomics to the study of pharmaceutical 
effects on freshwater biota was coupled with this experiment highlighting its potential use 
in ecotoxicological research.  Sublethal, metabolic changes associated with energy 
storage and metabolism were observed with potential future applications for biomarker 
development centred on the osmolyte TMAO. 
 The pharmaceuticals studied here were found to pose no detectable risk to leaf 
litter decomposition in streams although a further experiment demonstrated a reduction 
in organic matter processing of freshwater sediments, coupled with some complex 
stimulatory and inhibitory effects on respiration and nutrient cycling at environmentally 
iv 
 
relevant concentrations.  Taken as a whole this work has added substantial knowledge 
to this growing research area and has allowed the construction of a conceptual 
framework that links measured environmental concentrations with effects at the sublethal 
and individual organism level mediated to the ecosystem and functional level via complex 
interactions between macroinvertebrates and microbial communities. 
 Overall, this body of research has demonstrated that pharmaceuticals should be 
treated as a widespread pollutant of on-going major concern capable of eliciting 
significant effects on freshwater ecosystems.  Therefore, they require substantial further 
research and scrutiny from regulators and policy makers if the negative consequences 
of their presence in rivers are to be avoided or mitigated. 
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1 INTRODUCTION AND CONTEXT 
Human society relies on rivers for myriad functions and services including: drinking 
water, irrigation, navigation, transport, recreation and waste disposal.  Despite 
accounting for just 0.4 % of the Earth's surface and 0.006 % of the Earth’s freshwater 
they are estimated to contain 6 % of all described species and provide 5.1 % of global 
ecosystem services worth an estimated $1.7 trillion per year (Costanza et al., 1997; Giller 
& Malmqvist, 1998; Dudgeon et al., 2006). Despite their importance, human interventions 
are threatening the biodiversity of over 65 % of global rivers (Vorosmarty et al., 2010) 
which in turn impacts upon their ability to provide the vital services upon which human 
civilisation relies.  Over abstraction for drinking water and irrigation, flow and channel 
modification, invasive species, pollution and climate change are all playing a part in 
drastically altering the physical, chemical and biological makeup of rivers (Giller & 
Malmqvist, 1998).  The level of threat to freshwater biodiversity is strongly related to the 
presence of large human populations and degradation increases downstream 
associated with large urban settlements (Abell et al., 2008).  Even such alarming 
assessments of global river systems are likely to be an underestimate of the true situation 
owing to insufficient information on a range of stressors such as mining, interbasin 
transfers and pollution by synthetic compounds such as pharmaceuticals (Vorosmarty et 
al., 2010). 
A recent survey of EU citizens asked participants to list their main environmental 
concerns; 47 % of respondents listed water pollution as their second highest concern 
(behind climate change) and a further 35 % chose the potential health impacts of 
chemicals used in everyday life as their 6th (EC, 2008a).  Research on the occurrence, 
fate and effects of emerging contaminants in the environment has, thus, grown rapidly in 
recent years and has focussed mainly on pharmaceuticals. Pharmaceuticals are 
comprised of a vast array of compounds used to treat, prevent and cure diseases and 
include: antibiotics, analgesics, anti-inflammatories, anti-depressants, cancer treatments 
and x-ray diagnostics amongst many others.  This broad group of substances certainly 
falls within the classification of 'everyday chemicals'.  The consumption of 
pharmaceuticals occurs worldwide where people have access to medical care and 
continues at all times regardless of season (Daughton, 2001).  Individual households 
contribute insignificant amounts when considered in isolation but the cumulative 
contributions of thousands and even millions of households, particularly within urbanised 
areas, means that environmental contamination by pharmaceuticals has become an 
increasingly important scientific concern in recent years (Kümmerer, 2008a).  This has 
been aided by the substantial refinement in analytical techniques such as high-
performance liquid chromatography (HPLC), enabling detection of these previously 
cryptic pollutants.  The study of pharmaceuticals in the environment represents a 
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departure from the more ‘conventional’ pollutants which tend to be highly delineated with 
high volume inputs from industry or diffuse inputs from agriculture.  Unlike conventional 
pollutants, very little is known about the environmental fate and effects of 
pharmaceuticals and there are no current statutory water quality limits in the European 
Union (UK Parliament, 2012). 
The dispersed consumption of pharmaceuticals takes places predominantly in 
domestic households with varying but significant amounts entering the sewage system 
either from direct disposal or post-consumption excretion.  As such, effluent from sewage 
treatment plants (STPs) is widely considered to be the major source of pharmaceuticals 
to surface waters.  This is because of generally poor removal rates during conventional 
sewage treatment (primary and secondary) due to the non-volatile, polar nature of such 
compounds (Kümmerer, 2009a).  There is, thus concern that pharmaceuticals present 
at ultra-trace concentrations may be adversely affecting freshwater ecosystems, 
particularly those adjacent to sewage outfalls.  Of most concern is the potential for long-
term, multigenerational exposure of aquatic organisms to low levels with even easily 
degraded compounds exhibiting ‘pseudo-persistence’ due to continual replenishment 
(Daughton, 2001). 
Over the last thirty or so years, European and UK legislation has been responsible 
for a steady improvement in general water quality triggered largely by greater investment 
in sewage treatment facilities during the 1980s and 1990s (Thompson, 2006; EA, 2012; 
Vaughan & Ormerod, 2012).  However, this improvement has slowed in recent years and 
only 26 % of English and Welsh rivers satisfy ‘good ecological status’ requirements of 
the Water Framework Directive (2000/60/EC; (EC, 2000)).  This has been blamed partly 
on the need for water quality management to broaden from the existing narrow focus on 
point source pollution and a small number of prescribed pollutant lists (EA, 2012).  More 
subtle environmental effects such as endocrine disruption in rivers demonstrate that 
pollutants are still eliciting negative consequences in freshwater ecosystems (Luoma, 
1999; Pawlowski et al., 2004).  
The majority of current ecotoxicological pharmaceutical research has focused on 
short-term, usually acute exposures at concentrations unlikely to occur in the natural 
environment (Fent, 2008; Santos et al., 2010).  However, the main concern in 
environmental exposures is the potential for chronic or long-term toxicity at low-level 
concentrations, the effects of pharmaceutical mixtures and impacts on populations, 
communities and ecosystem functioning (Hughes et al., 2013).  Also, relatively little data 
on the occurrence of pharmaceuticals has been gathered with existing research heavily 
biased towards western Europe and north America (Hughes et al. 2013).  There is a 
clear need for further research into both the occurrence and effects of pharmaceutical 
compounds in river ecosystems.  In depth understanding of the spatial and temporal 
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variability of pharmaceutical pollution will help to inform future management and policy 
decisions.  Further knowledge on the effects of environmental exposure to 
pharmaceuticals on individual aquatic organisms and whole ecosystem structure and 
function will aid in prioritising the highest risk compounds for future interventions.  Thus, 
this thesis will aim to add substantially to current knowledge on the spatial and temporal 
aspects of pharmaceutical pollution in rivers and the effects of such pollution on 
ecosystem structure and function.  
Chapter 2 presents a comprehensive review of the literature covering existing 
research on the consumption, environmental occurrence and effects of human use 
pharmaceuticals in freshwater ecosystems.  Chapter 3 outlines a systematic review of 
existing pharmaceutical occurrence research across the globe and highlights spatial and 
methodological research gaps.  Chapter 4 presents results from several monitoring 
campaigns in two UK semi-rural and urban catchments examining spatial and temporal 
variation in pharmaceutical concentrations in rivers.  Chapter 5 presents the first 
application of NMR environmental metabolomics techniques alongside an extended 
exposure of the freshwater amphipod Gammarus pulex to two pharmaceutical 
compounds in mixture.  Chapter 6 outlines the results of two experiments examining the 
effect of pharmaceutical exposure on the microbial and macroinvertebrate mediated 
decomposition of leaf litter in freshwaters.  Chapter 7 examines the effects of exposure 
to pharmaceuticals on respiration in freshwater sediments and the effects on nutrient 
exchange with overlying waters.  Finally, Chapter 8 presents a thesis outline and 
research synthesis and also highlights limitations, research gaps and opportunities for 
continued research in this area. 
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2 REVIEW OF PHARMACEUTICAL POLLUTION RESEARCH 
2.1 Chapter overview 
During the course of this study, a thorough review of existing literature on 
pharmaceuticals and their consumption, environmental occurrence, fate and potential 
impacts in aquatic ecosystems was conducted.  This helped to define clear aims and 
objectives and progress research with particular reference to known gaps in data and 
knowledge.  The first section of this chapter gives an introduction to emerging 
environmental contaminants and how PPCPs and particularly pharmaceuticals fit into 
this category.  After this is a consideration of pharmaceutical consumption data and 
patterns across Europe and the globe but with particular emphasis on the UK.  The third 
section summarises current knowledge on the known and potential sources of 
pharmaceuticals into a number of environmental components (including soils, surface 
waters and groundwater) but with a particular focus on rivers and the fate of such 
compounds in freshwater ecosystems.  The fourth section details existing knowledge on 
the presence of pharmaceuticals in the environment, again with a focus on human-use 
compounds in rivers.  Following this is a summary of the existing research and data gaps 
on the potential ecotoxicological and environmental impacts of pharmaceuticals in rivers.  
The last section focuses on the legislative and policy drivers in the EU and UK and 
concludes with a short summary of research needs in the broad area of pharmaceutical 
pollution of rivers. 
2.2 A brief history of emerging contaminants 
Much has been achieved in the latter part of the 20th century onwards in improving the 
quality of surface waters in the developed world and rivers such as the Thames have 
come a long way from their days as ‘open sewers’ in the 19th century.  However, 
significant threats to water quality from human activity remain (Tinsley, 1998).  
Environmental legislation such as the Environmental Protection Act (1990), the Urban 
Waste Water Treatment Directive (UWWT; 91/271/EEC) and the Drinking Water 
Directive (98/83/EC) focused on reducing the environmental levels of organic pollution 
and a number of prescribed pollutants in order to improve water quality.  These pieces 
of legislation, particularly the UWWT Directive, triggered further investment by water 
companies into sewage treatment facilities which has largely been responsible for a 
steady improvement in general river water quality in England and Wales since the 1990s 
(EA, 2012; Vaughan & Ormerod, 2012).  Similar legislation was enacted in the USA with 
the Federal Water Pollution Control Amendments of 1972 (often abbreviated as the 
Clean Water Act) which introduced controls on the discharge of toxic substances to 
surface waters and provided substantial federal grants for the construction of sewage 
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treatment plants.  Initially, sewage treatment efforts focused on the removal of microbial 
contamination and organic pollution with a more recent shift towards nutrient (nitrogen 
and phosphorous) stripping (Thompson, 2006).   
The Water Framework Directive (EC, 2000) requires member states of the European 
Union to achieve ‘good ecological status’ for all inland and coastal waters.  This has been 
classified using both chemical and biological indicators thereby integrating the effects of 
all polluting substances present in the aquatic environment and not just those 
‘conventional’ pollutants currently monitored.  The Environment Agency estimates that 
only 26 % of English and Welsh rivers currently meet these requirements showing a clear 
need to broaden the scope of water quality management from the existing narrow focus 
on point sources and prescribed lists (EA, 2012).  Daughton (2004a) stated that 
conventional pollutants represent only a tiny proportion of the total number of pollutants 
present in the aquatic environment and that rivers and their ecosystems are being 
exposed to a wide variety of pollutants that are either unregulated or unidentified.  
Indeed, Luoma (1999) points out that although legislation and technology have been 
successful in reducing the number of overt pollution events (e.g. fish kills) the discovery 
of more subtle environmental effects, such as endocrine disruption in fish (Pawlowski et 
al., 2004), means that pollutants are still exerting a significant influence on river 
ecosystems. 
Recent developments in analytical techniques have highlighted the presence of a 
number of ‘emerging contaminants’ present at trace or ultra-trace concentrations in the 
environment.  Research and regulation for emerging contaminants represents a 
significant departure from conventional pollutants as many of these substances are 
produced industrially but subsequently enter the environment through domestic, 
commercial and agricultural use via both point and diffuse sources (USGS, 2009).  The 
concept of an emerging contaminant is an interesting one as there are a number of ways 
in which a substance can be considered to be ‘emerging’ (Daughton, 2004a): 
 Previously recognised or naturally occurring substances with a newly identified 
environmental impact; 
 Synthesis and subsequent release of a newly derived substance into the 
environment; 
 Advances in analytical techniques allowing the detection of very low 
environmental concentrations of a substance that is likely to have had a long-
term environmental presence; 
 Changes in usage or disposal methods for an existing substance representing a 
new environmental input. 
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The broad class of emerging contaminants includes myriad anthropogenic and naturally-
occurring substances including brominated flame retardants, disinfection by-products, 
hormones, endocrine disrupting compounds, PPCPs and surfactants (Petrovic, 2008).  
These substances have been linked to a range of acute and chronic effects such as 
endocrine disruption, teratogenicity, interference with reproduction, immune system 
depression and behavioural changes (see Smital, 2008 for a review).  Despite these 
documented impacts and the potential for human health effects the majority of emerging 
contaminants are not routinely monitored nor are they generally subject to legislative or 
regulatory scrutiny (Daughton, 2007; Farré et al., 2008).  A report by the Royal 
Commission on Environmental Pollution (2003) described the lack of knowledge, risk 
assessment and regulation of so many chemicals as a key area for concern. 
The broad group of PPCPs fits neatly into the class of emerging contaminants as 
the vast majority of these compounds are not subject to regulatory scrutiny and it is only 
in recent years that a significant amount of research has been conducted into their 
environmental presence and potential impacts (Daughton & Ternes, 1999; Daughton, 
2001).  Furthermore, due to their generally non-volatile nature, these compounds have 
the capacity to readily enter the environment, particularly surface waters.  However, 
Daughton (2004a) suggested that PPCPs be considered as an ‘emerging concern’ as 
most of these compounds are likely to have had a stable environmental presence since 
their initial commercial release which in some cases can be over 50 years ago.  For 
example aspirin has been marketed and sold worldwide since 1899 (Jeffreys, 2005).  It 
is only recently that analytical techniques have become sufficiently refined to detect the 
very low environmental concentrations of PPCPs which are generally within the low ng 
L-1 to low µg L-1 range (Kümmerer, 2009a).   
In view of these concerns, stakeholders from government, industry and academia 
ranked PPCPs in a list of the top five surface and groundwater contaminants of concern 
in the USA and Europe (Doerr-MacEwen & Haight, 2006).  However, Williams (2005) 
questioned the scientific basis for grouping pharmaceuticals and personal care products 
under the same banner based purely on their emerging status.  Indeed, pharmaceuticals 
and PCPs are subject to quite different regulatory oversight and consumption patterns; 
furthermore the inherent bioactivity of pharmaceuticals may merit a specific framework 
for risk assessment that distinguishes them from PCPs (Tarazona, 2005).  Based on 
these suggestions, this thesis will focus solely on pharmaceuticals and PCPs will only be 
considered to provide a wider context from the literature.  Furthermore, for similar 
reasons as above, this thesis will focus only on human-use pharmaceutical compounds 
and will not specifically consider those compounds used solely or largely in veterinary 
medicine. 
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2.3 Pharmaceutical consumption  
2.3.1 Consumption and disposal of pharmaceuticals across the globe 
Consumption can vary significantly between individual countries for a wide variety of 
reasons; within Europe, the United Kingdom, France and Germany account for 46 % of 
the pharmaceuticals market followed by Russia, Spain and Italy (EEA, 2010).  Cohen et 
al. (2007) found that the rate and speed of the drug approval processes in individual 
countries were major factors affecting consumption; the USA approved 15-18 % more 
drugs than the other countries.  The cost per prescription and evenness of availability 
within the individual countries also played a role in overall pharmaceutical consumption.  
For example, access to the vast majority of approved pharmaceuticals is guaranteed in 
the UK but this is not so in the USA where access is dependent on an individual’s 
insurance arrangements.  The NHS guarantees access to all approved pharmaceuticals 
for all UK citizens either free at the point of need or for a fixed flat-rate prescription cost 
and the UK government claim that as many as 89 % of prescription items are dispensed 
free of charge through various exemptions (BBC, 2009a).   
Pharmaceutical sales vary considerably both internationally and within the EU 
(Figure 2-1a).  These data show the clear dominance of the USA in the world market 
which is singly greater than the rest of the world combined.  The UK is similarly dominant 
within the EU accounting for almost half of the total sales in 2007.  However, this is not 
the case when the average annual spend per capita is considered (Figure 2-1b) as the 
UK spends considerably less than the USA and several other European countries.  This 
may be due to differences in healthcare provision between nations and also the 
Pharmaceutical Price Regulation Scheme which operates in the UK (DoH, 2009).  
Disposal methods can also vary significantly between countries particularly within the EU 
where a number of countries classify pharmaceuticals as ‘special waste’ that must be 
returned to a pharmacy; return rates range from 0.19 tonnes million capita-1 for Croatia 
to 237 tonnes million capita-1 in Switzerland (EEA, 2010). 
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Country 
Global sales share 
(%) 
 
(b) 
USA 54 
UK 19 
Switzerland 11 
Japan 6 
France 5 
Germany 3 
Belgium <1 
Denmark <1 
Israel <1 
Figure 2-1: (a) Sales share of the world’s top 100 prescription medicines in 2007 and 
(b) Average annual per capita medicines expenditure in 2008 
(adapted from ABPI (2010)) 
2.3.2 Spatial and temporal variation in pharmaceutical consumption 
The spatial variation in consumption of pharmaceuticals within an individual country can 
depend on a number of factors (Bush & Rabin, 1976; Davey et al., 2002; Schafheutle et 
al., 2002; Porteous et al., 2005; Cohen et al., 2007; Davey et al., 2008; Daughton, 
2009a): 
 Local population demographics; 
 Level of education; 
 Self-reported or perceived health status; 
 Prescription exemption status or prescription charge (varies across the UK); 
 Current prescriptions; 
 Advertising; 
 Local prescribing practices or cultural practices; 
 Perceptions of short or long-term risks associated with drugs; 
 Disposable income and patient willingness to spend money; 
 Local NHS trust budgets or funding decisions. 
Porteous et al. (2005) confirmed existing evidence that women, more highly educated, 
younger (<60 years old) people and those with a self-perceived fair to poor health status 
were significantly more likely to regularly use OTC analgesics.  They found that 55 % of 
respondents in Scotland had recently used OTC analgesics compared to 68 % consulted 
0 100 200 300 400 500 600
UK - £200
Italy - £247
Sweden - £255
Denmark - £268
Germany - £269
Austria - £283
Ireland - £319
Japan - £324
Belgium - £327
France - £372
USA - £507
Annual expenditure per person, 2008 (£)
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in a survey of English university students (French & James, 2008).  The age of a 
particular population can influence the prevalence of illness and pharmaceutical 
consumption; for example only 17 % of 15-34 year olds in Finland are prescribed NSAIDs 
compared to 34 % of those aged 75 and over (Ahonen, 1992).  Johnson et al. (2007) 
suggested that an average age in a small rural catchment that exceeded the national 
average by 3.8 years may have contributed to slightly higher than expected modelled 
concentrations of pharmaceuticals in a receiving river. 
The consumption of individual pharmaceuticals can also show marked seasonal 
variation.  Goossens et al. (2005) found peaks in the consumption of certain antibiotics 
during winter in Europe due to an increase in respiratory tract infections during the colder 
months.  However, this variation was not prevalent for all antibiotics; for example 
ciprofloxacin demonstrates little effectiveness against the streptococci causing 
respiratory tract infections (Hooper, 2002) and as such shows no appreciable winter 
peaks.  Seasonal allergic rhinitis (hay-fever) is a common condition during the summer 
months when higher levels of antiallergic drugs or specific immunotherapy injections are 
consumed due to elevated pollen counts (Smith et al., 2004).  Seasonal influenza has 
long been considered a self-limiting, controllable disease despite its high morbidity and 
mortality rate.  However, with increasingly virulent seasonal and pandemic flu strains 
such as avian flu (H5N1) and more recently swine flu (H1N1) more attention has been 
given to public health measures such as vaccination programmes and the use of antiviral 
drugs (ACP, 2006; Sahni & Mossad, 2009).  Clearly, the consumption of vaccines, 
antivirals (e.g. Tamiflu) and other pharmaceuticals to treat seasonal diseases will be 
strongly related to disease prevalence or particular outbreaks such as a flu pandemic 
(Straub, 2009). 
This spatial and temporal variation in consumption of pharmaceuticals means 
that annual consumption rates do not give an accurate indication of the use (and 
subsequent environmental release) of certain compounds at fixed points in time or at 
specific locations.  Thompson (2006) highlighted the potential for the ageing UK 
population to cause a long-term shift in the amounts and types of drugs being prescribed; 
this concern was echoed in a recent workshop on pharmaceuticals in the environment 
(EEA, 2010).  Other potential drivers for increasing consumption include: expanding 
populations, increases in direct advertising/marketing, patent expirations causing a shift 
to less expensive generic drugs and new uses for existing drugs (Daughton, 2003).  
However, consumption data are still highly useful for providing a national overview of 
widely used compounds and in helping to identify those compounds likely to have the 
greatest environmental footprint. 
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2.3.3 Pharmaceutical consumption in the UK 
Information on total consumption of pharmaceuticals in the UK or elsewhere is not readily 
available (Thompson, 2006) but is clearly very important when prioritising compounds 
for occurrence or effects studies in the environment.  Ayscough et al. (2000) obtained 
data from the Department of Health stating that approximately 3000 pharmaceutically 
active substances are approved for human use in the UK although not all of these are 
necessarily available on the market at any given time.  Pascoe et al. (2003) discovered 
that there were 19 835 Marketing Authorisations for medicinal products covering 5091 
active ingredients which target around 500 distinct biochemical receptors.  All of these 
figures are likely to be higher today as new products are frequently being developed and 
brought to market. Ayscough et al. (2000) highlighted the difficulty of obtaining an overall 
picture of total consumption due to a number of different agencies holding data on 
various aspects of consumption including community dispensing, hospital usage and 
over-the-counter (OTC) purchases. 
The NHS Prescription Pricing Authority (PPA) began publishing data on the total 
number of prescriptions issued in England from 2000 onwards (Thompson, 2006), split 
into a number of prescribing categories (Table 2-1).  In the 2008/09 financial year, the 
NHS prescribed a total of 841 000 000 items at a total cost of almost £ 8.2 billion (NHS, 
2008a; NHS, 2009a).  It must be noted that these data do not include hospital usage, 
OTC drugs or prescriptions made in Wales, Scotland or Northern Ireland.  It is estimated 
that as much as 20 % of pharmaceutical prescriptions are accounted for by a relatively 
small number of patients in hospitals (Sebastine & Wakeman, 2003).  Therefore, the data 
presented below provide a useful summary and indication of the likely high risk classes 
in terms of usage but they must not be considered comprehensive. 
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Table 2-1: Summary of English prescribing data in England 2007-2009 
Prescribing Category 
Volume 
(no. prescriptions, millions) 
Cost  
(£, millions) 
2007/08 2008/09 2007/08 2008/09 
Cardiovascular 253.70 268.38 1736.12 1618.83 
Central nervous 136.75 144.72 1670.21 1667.76 
Endocrine 68.23 73.18 898.95 910.35 
Gastro-intestinal 60.37 64.83 466.13 449.19 
Respiratory 53.42 56.05 899.04 960.86 
Infection 40.30 41.24 199.73 186.09 
All others 180.35 193.46 2227.03 2365.60 
Total 793.12 841.86 8097.21 8158.68 
Sources: (NHS, 2008a; NHS, 2009a) 
 
A much more detailed dataset is the NHS Prescription Costs Analysis (NHS, 2009b) 
which collects data on all NHS drug usage, including that in hospitals across the whole 
of the UK.  The total cost of drugs in 2008 was estimated at £ 11.6 billion with hospital 
consumption accounting for 28.7 % of overall costs.  These data are useful because they 
present the number of prescriptions for individual pharmaceutical compounds and 
preparations prescriptions. Consumption data show a number of specific 
pharmaceuticals that are consistently prescribed in very high numbers; these include 
bendroflumethiazide, levothyroxine sodium and aspirin which showed steady increases 
over a five year period (Table 2-2).  In addition there are a number of drugs that have 
risen notably in rank from 1997 onwards.  The most obvious of these is simvastatin (a 
blood lipid modifier) whose prescriptions have increased by 1400 % since 1997 making 
it the most widely prescribed drug in 2008.  This was despite simvastatin only being 
approved for UK use in the mid-1990s (Thompson, 2006) and low doses being made 
available OTC in 2004 (Nash & Nash, 2004).  
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Table 2-2: Estimated prescription volumes and rankings for the top 10 prescribed drugs in the UK in 2008  
Compound 
Therapeutic 
class 
DDD (mg 
day-1) 
Prescriptions (thousands) and rank in brackets 
1997 1999 
2000 
England 
only 
2004 2005 2006 2007 2008 
Simvastatin Lipid modifier 30.0 
2400.0  
(47) 
- - 
12680.9  
(6) 
16536.9  
(4) 
22556.1  
(2) 
29353.5  
(2) 
33853.5  
(1) 
Aspirin NSAID 4000.0 
11634.6  
(3) 
13900.0  
(2) 
16769.0  
(1) 
23641.7  
(1) 
25883.3  
(1) 
27971.7  
(1) 
30210.4  
(1) 
32682.0  
(2) 
Levothyroxine Sodium Thyroid hormones 0.2 - - - 
14237.8  
(5) 
15607.7  
(6) 
17095.7  
(4) 
18736.4  
(4) 
20426.4  
(3) 
Bendroflumethiazide Diuretic 2.5 
7591.5  
(8) 
9600.0  
(7) 
- 
18839.8  
(2) 
19791.1  
(2) 
19667.7  
(3) 
19304.1  
(3) 
19151.5  
(4) 
Salbutamol Inhalant 10.0 
16167.8  
(2) 
16700.0  
(1) 
- 
16182.4  
(4) 
16368.6  
(5) 
16613.1  
(5) 
17046.7  
(5) 
17887.8  
(5) 
Ramipril 
ACE inhibitor 
(pain) 
2.5 - - - 
8978.7  
(13) 
10258.9  
(13) 
12074.2  
(11) 
15005.1  
(7) 
17417.3  
(6) 
Paracetamol Analgesic 3000.0 
9569.5  
(6) 
10400.0  
(4) 
10636.0  
(4) 
12360.7  
(8) 
14281.1  
(7) 
15113.3  
(7) 
16062.4  
(6) 
17398.4  
(7) 
Omeprazole 
Proton pump 
inhibitor 
20.0 - - - 
5597.2  
(22) 
8324.0  
(17) 
10961.4  
(13) 
13074.0  
(12) 
15634.3  
(8) 
Amlodipine 
Selective calcium 
channel blocker 
5.0 - - - 
8191.9  
(15) 
9291.1  
(15) 
11238.5  
(12) 
13324.0  
(11) 
14961.1  
(9) 
Atenolol Beta-blocker 75.0 
8133.0  
(7) 
10000.0  
(5) 
11554.0  
(3) 
17349.0  
(3) 
17589.2  
(3) 
16605.4  
(6) 
14961.6  
(8) 
14319.4  
(10) 
DDD: defined daily dose (http://www.whocc.no/atc_ddd_index/) 
Sources: (Ayscough et al., 2000; Jones et al., 2001; Jones et al., 2002; NHS, 2005; NHS, 2006; Thompson, 2006; NHS, 2007; NHS, 2008b; NHS, 2009b) 
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Whilst the data sets based on prescription numbers are the most widely available, such 
ranking of compounds does not necessarily hold true if total consumption mass is 
considered.  For example, Thompson (2006) found that although cardiovascular drugs 
exceeded NSAIDS in terms of prescription numbers, NSAIDs far exceeded 
cardiovascular drugs in mass terms due to greater dosages.  The technique of using 
Defined Daily Doses (DDD) and prescription numbers has been employed to estimate 
mass consumption (for example see Sebastine and Wakeman (2003)).  However, this 
methodology does have limitations as dosages for individual patients, compounds or 
mixtures may differ from the DDD and no correction is made for the reduced doses for 
children (Goossens et al., 2005).  Furthermore, not all patients complete the full course 
of medication and this may remain unused for an extended period of time prior to disposal 
(Bound et al., 2006).   
When such data are compiled they reveal differing trends between therapeutic 
classes (Table 2-3).  Certain NSAIDs and analgesics (paracetamol and aspirin) which 
are prescribed widely for osteoarthritis and back pain show consistently high 
consumption (>50 tonnes year-1).  Consumption of amoxicillin, an antibiotic, remains 
consistently high although this does appear to be steadily dropping from 1997 onwards.  
Other antibiotics such as flucloxacillin, erythromycin and furosemide which were widely 
used in 1997 and the early 2000s have seen a marked decline in recent years.  This may 
be due to general practitioners following prescribing guidelines more closely or a more 
general fall in the number of respiratory infections (Thompson, 2006).  Goossens et al. 
(2005) identified a general increase in broad-spectrum antibiotics at the expense of 
narrow-spectrum compounds although these older antibiotics are still widely prescribed, 
particularly in northern Europe.  Cardiovascular drugs such as simvastatin have seen 
significant increases in consumption in recent years (Table 2-2; Table 2-3). These data 
outline well the importance of using up-to-date consumption statistics as prescribing 
trends are shown to vary from year to year. 
Data on pharmaceutical consumption volumes highlight marked variation 
between different years and studies for the same pharmaceuticals.  For example, Webb 
(2001a) estimated 2000 tonnes of paracetamol were consumed in 1995 but Sebastine & 
Wakeman (2003) estimated only 403 tonnes and the 2004-2008 PCA estimates range 
from 37 to 52 tonnes.  The source and coverage of the data may create discrepancies 
between years that cannot be explained by actual changes in consumption.  For 
example, the 1995 estimates (Webb, 2001a) were obtained directly from Intercontinental 
Medical Statistics but it is not clear whether these data include OTC use or amalgamates 
the use of paracetamol in other end-products (e.g. Co-codamol) although such a high 
estimate would suggest they do.  Furthermore, the Sebastine and Wakeman (2003) data 
for 2000 do not include OTC or hospital consumption but all of these estimates are 
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considerably larger than those derived directly from the 2004-2008 NHS PCA data which 
do include hospital prescriptions.  It is likely that consumption figures based solely on 
PCA data are significantly underestimating total consumption as they do not include OTC 
purchases or the inclusion of single APIs in multiple products.  For example, Thompson 
(2006) used data from Huschek et al. (2004) to estimate that UK prescription data for 
paracetamol represented only 20.6 % of total usage; if this was extrapolated using the 
2008 PCA estimate from Table 2-3 then the total annual consumption would be 253.4 
tonnes.   
Overall, there is a broad trend of increasing consumption of prescription 
pharmaceuticals in the UK with modest changes in some classes of antibiotics, steady 
and sustained increases in the consumption of painkillers (particularly aspirin) and 
NSAIDs and the rapid rise of blood lipid regulators and other cardiovascular drugs used 
to prevent or treat long-term conditions.  Clearly, such an increase is of major concern 
as a source of potential freshwater pollution by pharmaceutical compounds.  The better 
collation of consumption data in a form accessible to environmental scientists should be 
seen as a priority in order to inform and prioritise future research into the occurrence and 
effects of pharmaceuticals in the environment. 
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Table 2-3: Estimated consumption of 26 widely prescribed pharmaceuticals in the UK using data from the NHS PCA and previous studies  
Pharmaceutical 
Estimated annual consumption1 (tonnes) 
1995 1999 1997 2000 2004 2005 2005 2006 2007 2008 
Simvastatin - - - 2.67 0.38 0.22 0.50 0.68 0.88 1.02 
Aspirin 770.00 55.60 46.54 78.57 94.57 - 103.53 111.89 120.84 130.73 
Levothyroxine Sodium - - - - 0.01 - 0.01 0.01 0.01 0.01 
Bendroflumethiazide - 0.02 0.02 - 0.05 0.05 0.05 0.05 0.05 0.05 
Salbutamol - 0.17 0.16 - 0.16 0.19 0.16 0.17 0.17 0.18 
Ramipril - - - - 0.02 0.02 0.03 0.03 0.04 0.04 
Paracetamol 200.00 31.20 28.71 403.11 37.08 97.20 42.84 45.34 48.19 52.20 
Omeprazole - - - 3.44 0.01 - 0.14 0.22 0.26 0.31 
Amlodipine - - - - 0.04 - 0.02 0.06 0.67 0.08 
Atenolol - 0.75 0.61 28.98 1.30 1.35 1.32 1.25 1.12 1.07 
Co-codamol (paracetamol/codeine) - - 29.85 444.34 40.53 - 47.63 51.11 54.24 57.46 
Amoxicillin - - 16.59 71.47 12.51 41.60 12.97 12.55 13.53 13.27 
Atorvastatin - - - - 0.23 0.12 0.26 0.26 0.22 0.21 
Ibuprofen - - - 162.91 5.63 5.28 5.80 5.49 5.38 7.39 
Flucloxacillin - - - 23.38 6.03 25.60 6.02 6.33 6.40 6.56 
Propranolol Hydrochloride - - - 8.16 0.40 - 0.41 0.41 0.42 0.44 
Carbamazepine - - - 40.35 2.36 - 2.34 2.34 2.37 2.40 
Erythromycin 67.70 - - 26.48 2.16 12.80 2.15 2.09 2.17 2.05 
Metoprolol Tartrate - - - 2.63 0.12 - 0.13 0.14 0.14 0.14 
Metformin 106.10 - - 205.79 14.83 15.20 16.67 18.43 20.48 23.23 
Co-proxamol 
(dextropropoxyphene/paracetamol) 
- - 32.51 336.21 23.07 - 9.39 4.45 3.06 1.22 
Co-Trimoxazole 
(trimethoprim/sulfamethoxazole) 
- - - - 0.10 - 0.11 0.11 0.12 0.13 
Furosemide - - - - 0.40 0.42 0.41 0.42 0.43 0.45 
Naproxen - - - 35.14 0.51 - 0.57 0.58 0.65 0.90 
Diclofenac - - - 26.11 0.78 0.72 0.85 0.85 0.89 0.84 
Oxytetracycline 33.70 -  27.20 1.01 4.00 0.97 0.91 0.91 0.89 
Notes:  
1. Total annual consumption estimated by multiplying the prescription number by the Defined Daily Dose as at 
http://www.whocc.no/atc_ddd_index/; 
Sources: (Ayscough et al., 2000; Jones et al., 2001; Webb, 2001; Jones et al., 2002; Sebastine & Wakeman, 2003; NHS, 2005; NHS, 
2006; Thompson, 2006; NHS, 2007; NHS, 2008b; NHS, 2009b) 
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2.3.4 Over-the-counter (OTC) consumption in the UK 
Current UK government policy encourages the self-care of minor, self-limiting illnesses 
and as such a number of previously prescription drugs are now available OTC (Porteous 
et al., 2005).  In 2008 the total value of the OTC market was £ 2.3 billion with consumers 
purchasing 977 million packs of over 1000 commercially available products (PAGB, 
2010).  Clearly, the OTC market rivals the prescription sector both in terms of financial 
and consumption volume; therefore it is vital that any assessment of total pharmaceutical 
consumption takes the OTC sector into account.  Data are collected on the total spent 
on a range of OTC therapeutic areas but, unlike prescription data, statistics for individual 
compounds are not freely available.  However, these overall data are still useful in 
highlighting trends (Table 2-4) (PAGB, 2010).  Furthermore, a 1997 study (PAGB, 1997) 
found that almost 88 % of OTC drugs purchased were used for two days or less, 
suggesting that a significant majority of purchased remedies may be only partly used 
with the remainder being stored for a later date or disposed of.  There is a clear trend in 
increasing sales revenue for OTC medicines with an overall 38 % increase from 2000-
2008.  However, without specific statistics relating to sales volumes it is difficult to 
attribute how much of this growth in market value is due to increased consumer demand 
rather than cost increases or inflation.  Unfortunately such information is commercially 
sensitive and is not readily available.   
As with prescription pharmaceuticals, the available data indicate a strong increase in 
consumption with particularly strong growth for skin treatments, eye care, sleeping aids 
and smoking cessation products (Table 2-4).  This growth in sales represents an 
increase in the potential source of pollution by such compounds in freshwaters. This is 
of particular concern given that existing pharmaceutical pollution research tends to focus 
on a small number of widely used prescription compounds and OTC pain relief.  For 
example, little or no monitoring has been conducted for smoking cessation products 
(Hughes et al., 2013) and as such these represent an unknown risk in terms of 
environmental pollution.  Better data on actual consumption volumes/masses would 
enable research into such pollution to prioritise the highest risk compounds. 
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Table 2-4: Summary of OTC pharmaceutical sales in the UK from 2000-2008  
Therapeutic class 
Total sales (£ millions) 
2000 2001 2002 2003 2004 2005 2006 2007 2008 
% inc.  
(2000-
2008) 
Pain relief 396 407 416 465 460 471 500 527 539 36 
Skin treatments 253 276 299 353 377 386 416 423 420 66 
Cough/cold/sore 
throat 
341 351 339 376 357 369 390 437 453 33 
Gastro-intestinal 187 192 210 236 253 257 264 262 262 40 
Medicated 
mouthwash 
16 17 20 23 25 26 27 26 28 76 
Hay fever remedies 54 64 68 79 76 79 88 79 85 56 
Eye care 32 34 38 39 40 41 43 46 48 51 
Sleeping aids 12 13 24 28 30 31 32 35 37 198 
Smoking cessation 58 65 72 778 84 89 92 108 101 72 
Vitamins  
and minerals 
307 293 277 296 321 326 333 336 322 5 
TOTAL 1658 1711 1762 1973 2023 2074 2184 2282 2294 38 
Source: (PAGB, 2009) 
 
2.4 Environmental sources and fate of pharmaceuticals 
Pharmaceuticals comprise a vast array of compounds that are produced, consumed and 
disposed of in a variety of settings including agriculture, veterinary medicine, hospitals, 
domestic households and commercial settings.  As such, there are numerous pathways 
of entry into the environment including point, diffuse, continuous and intermittent sources 
some of which receive some form of biological or chemical treatment or dilution whereas 
others may pass directly into the environment (Figure 2-2).  Therefore, this section will 
briefly outline these sources with a particular focus on those discharging to the aquatic 
environment. 
2.4.1 Pharmaceutical manufacturing facilities (PMFs) 
Losses of pharmaceuticals to the environment during their manufacture are generally 
considered to be negligible given the high economic value of the products and strict good 
practice regulations imposed on manufacturers, particularly in Europe and North 
America (Velagaleti & Gill, 2001; Kümmerer, 2009a).  The use of degradation techniques 
and technology such as scrubbers and filters to minimise waste streams are also widely 
adopted by manufacturers (USEPA, 1997).  However, there is some evidence for 
detectable levels in manufacturing effluents.  Larsson et al. (2007) detected the antibiotic 
ciprofloxacin at levels 1000x greater than the toxic threshold for some bacteria in effluent 
from a large Indian manufacturer, and ecotoxicological studies on the same effluent 
demonstrated adverse effects on amphibians and fish (Carlsson et al., 2009).  High 
levels in manufacturing effluent have also been detected in Norway with a total loading 
of 2000 kg year-1 of the same antibiotic (Thomas & Langford, 2008).  Phillips et al. (2010) 
surveyed a number of STPs in New York, USA that receive waste water from both PMFs 
and pharmaceutical formulation facilities (PFFs).  These effluent concentrations were 
generally below 1 µg L-1 but several compounds did exceed this level including 
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oxycodone (analgesic; 1,700 µg L-1) and metaxolone (muscle relaxant; 3800 µg L-1).  
Indeed Li et al. (2008) found very high concentrations of up to 800 mg L-1 and 2 mg L-1 
in effluent and receiving waters respectively from a STP serving an antibiotic 
manufacturing facility in China.  
Further monitoring is required to either challenge or support the assumption that 
manufacturing inputs are negligible although it must be noted that the effects are likely 
to be highly localised and restricted to areas with a large manufacturing presence 
(Daughton, 2007). 
2.4.2 Veterinary pharmaceuticals 
This section provides a brief overview of veterinary pharmaceuticals in order to provide 
context for human-use compounds and in order to compare and contrast the different 
environmental pathways and risks.  A wide range of veterinary pharmaceuticals are used 
to prevent disease and promote growth in livestock production and aquaculture (Boxall 
et al., 2002).  However, the use of antibiotics as growth promoters for livestock was 
banned by the EU in 2006 (Kemper, 2008; Kools, 2008).  The major classes of veterinary 
pharmaceuticals include anti-parasitic agents and antibiotics.  This range of compounds 
includes those specifically designed for veterinary use and a number that are also used 
by humans (Jørgensen & Halling-Sørensen, 2000). 
There are a number of review articles available on the use and exposure pathways 
of veterinary pharmaceuticals in the environment (Boxall et al., 2002; Sarmah et al., 
2006) and as such these will only be briefly summarised here.  The major potential 
exposure routes include: 
 Consumption of large quantities of pharmaceuticals in combined animal feeding 
operations (CAFOs); 
o Agricultural land application of manure or slurry from CAFOs as fertiliser 
has the potential to contaminate soils, groundwater and surface waters 
via overland flow, subsurface flow and drain flow (Boxall et al., 2002); 
o Airborne transport of contaminated dust via the ventilation systems in 
CAFOs (Zahn et al., 2001); 
o Leakage from manure/slurry storage systems and waste lagoons 
(USEPA, 2000; Sarmah et al., 2006).  
 Direct deposition of dung from treated livestock (Wall & Strong, 1987); 
 Direct contamination of sediment beneath aquaculture facilities with treated feed 
and via contaminated faeces (Samuelsen et al., 1992); 
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 Treatment of companion animals; this is not likely to be a significant source as 
these animals are not treated in large numbers in intensively reared conditions 
(Boxall et al., 2002); 
 Washing off of topically applied treatments directly into rivers; this is likely to be 
a sporadic and highly localised source (Daughton & Ternes, 1999); 
 Disposal of unwanted or expired pharmaceutical products. 
The vast majority of research into veterinary pharmaceuticals has focused on the 
application of manure/slurry from CAFOs as fertiliser.  A study by the US EPA (2000) 
estimated that as much as 80 % of administered antibiotics could enter waste lagoons.  
The ultimate fate of veterinary (and human) pharmaceuticals is dependent on a number 
of factors (Tolls, 2001; Kay et al., 2004; Kay et al., 2005a; Kay et al., 2005b; Blackwell 
et al., 2007; Blackwell et al., 2009; Gielen et al., 2009; Monteiro & Boxall, 2009): 
 The physical-chemical nature of the compound which will dictate the extent of 
degradation in both the manure and the soil; 
 The affinity of the compound for solid phases; 
 The length of time that manure or slurry is stored prior to application; 
 Soil type (pH and clay content) and moisture content play a major role in dictating 
loss to the aqueous phase; 
 Prevailing climatic and weather conditions; 
 The application regime of the manure or slurry, particularly with regards to total 
loads, frequency and timing; 
 The drainage regime of the agricultural land and the presence of piped drainage 
networks; 
 The presence of other contaminants within a mixture. 
The major source of veterinary pharmaceuticals is via indirect application of 
manure/slurry after excretion.  In addition, some inactive metabolites or conjugates have 
the potential to be re-transformed into parent compounds after excretion meaning a 
significant proportion of administered pharmaceuticals can enter the environment 
(Warman & Thomas, 1981). 
Jones-Lepp & Stevens (2007) presented a review of the potential for agricultural 
application of human sewage sludge to be a source of pharmaceuticals to the 
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environment.  Their review found concentrations ranging from low µg kg-1 to low g kg-1; 
these concentrations depended on the type of compound and the degree of sludge pre-
treatment prior to application with synthetic musks generally found at the highest levels.  
However, the agricultural application of sewage sludge in the EU is in decline due to 
public concern over pathogens and pollution despite a 1986 European Directive 
(86/278/EEC) to regulate the practice (Jones-Lepp & Stevens, 2007).  Studies have also 
found pharmaceuticals to be present in soil irrigated with reclaimed wastewater generally 
within the ng g-1 range (Kinney et al., 2006). 
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Figure 2-2: Environmental sources and fate of PPCPs 
(USEPA, 2010) 
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2.4.3 Human-use pharmaceuticals 
This section highlights the main pathways by which human-use pharmaceutical 
compounds enter the environment, particularly freshwater ecosystems.  The actual 
occurrence of pharmaceuticals in the environment will be summarised elsewhere 
(Section 2-5; Chapters 3 and 4).  The main environmental sources of pharmaceuticals 
are listed below and each will be considered in more detail (Figure 2-2): 
 Disposal of pharmaceuticals via solid waste and subsequent landfill or 
incineration; 
 Disposal of pharmaceuticals down the drain into the domestic sewage system; 
 Domestic consumption and subsequent excretion to the sewage system which 
passes through a sewage treatment plant (STP) prior to discharge to surface 
waters; 
 Washing off of topically applied treatments into the domestic sewage system 
(Daughton & Ruhoy, 2009b); 
 Consumption and subsequent excretion in hospitals and long-term care facilities.  
The effluent generally undergoes the same treatment processes as domestic 
effluent (Kümmerer, 2001a); 
 Discharge of raw or partially treated sewage from combined sewer overflows 
(CSOs) during a flood or significant rainfall event; 
 Leakage from aging or poorly maintained infrastructure and illegal ‘straight-
piping’ of sewage direct to surface waters (Daughton, 2007); 
 Application of treated sewage sludge from STPs to agricultural land as fertiliser 
or the reuse of treated wastewater for irrigation (Daughton, 2004b; Daughton, 
2004c); 
 Leachate from landfills or buried waste storage systems (e.g. cess tanks, see 
Halling-Sorensen et al. (1998)). 
2.4.3.1 Domestic disposal to solid and liquid waste streams 
A survey by Kuspis & Krenzelok (1996) found that disposal of pharmaceuticals either 
into solid waste or down the drain was common in the USA despite instructions on 
packaging regarding proper disposal.  Bound et al. (2006) conducted a similar survey in 
the UK and found that 63 % of unused pharmaceuticals disposal was to solid waste and 
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22 % down the drain.  Clearly, this represents a potentially significant source of 
pharmaceuticals to the environment, particularly as they are passing unmodified into the 
waste streams and demonstrates a clear case for more appropriate disposal (Bound et 
al., 2006).  Niquille & Bugnon (2008) suggest that community pharmacies and 
practitioners should be more involved in encouraging the return of unused 
pharmaceuticals but also to proactively reduce potential disposal through better 
prescription practices and encouraging patient adherence.  Washing of dermal residues 
during bathing is generally considered to be a minor or inconsequential sources but 
recent reviews by Daughton & Ruhoy (2009a; 2009b) suggest that more research 
emphasis be placed on these routes particularly as the potential for pollution prevention 
will be greater when compared to post-consumption excretion.   Although direct disposal 
does carry an environmental risk this should be weighed against the risk of inappropriate 
use or inadvertent poisonings (particularly to infants and the elderly) when large amounts 
of unused or unwanted drugs are stored long-term (Daughton, 2007). 
Studies have shown that leachate from landfill and underground waste storage 
systems (e.g. cess tanks) can contain concentrations of pharmaceuticals which then 
contaminate ground water and possibly aquifers used for drinking water abstraction 
(Halling-Sørensen, 1998).  Up to the 1970s it was common practice to dispose of 
pharmaceutical industry waste to landfills with no leachate collection systems.  The 
resultant leachate plumes contained detectable concentrations of three pharmaceuticals 
decades after they were first disposed of (Holm et al., 1995). 
2.4.3.2 Hospitals and long-term care facilities 
Hospitals and long-term care facilities represent concentrated points of consumption for 
pharmaceuticals and other compounds used for medicinal purposes such as 
anaesthetics, diagnostic (e.g. x-ray) contrast media and disinfectants.  The usage 
patterns and compounds used within hospitals often vary significantly from those in 
households due to different prescribing practices between hospital staff and general 
practitioners (GPs) (Kümmerer, 2001a).  In addition, certain drug types are prescribed 
much more widely in hospitals; Sebastine & Wakeman (2003) estimate that as much as 
80 % of antibiotics are prescribed in hospitals.  These hospital-specific drugs are 
generally weighted towards those with high acute toxicity and genotoxicity and which are 
used for short-term therapy or diagnostics (Daughton, 2007).   However, the basic 
pathways of entry to the waste streams are similar to the domestic setting and include: 
excretion of parent or metabolised compounds, washing off of topically applied 
substances and washing of residues from equipment or clothing into the sewage system.  
Furthermore, there is the potential for outpatients to excrete substances taken during a 
hospital visit into the domestic sewage system after they return home; this is particularly 
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the case for anti-cancer drugs where much of the treatment is now handled in outpatient 
departments (Rowney et al., 2009).  Larger, more specialised hospitals represent 
significant concentrated point sources for particular drugs (Moldovan, 2006).  Studies 
have shown that concentrations of pharmaceuticals in hospital effluent are higher than 
those detected in STP effluent (Kümmerer, 2001a; Kümmerer, 2009b; Kümmerer, 
2009c).  However, the total volume of effluent leaving hospitals is much lower than from 
domestic households and the dilution by domestic wastewater can be by more than a 
factor of 100.  However, there is the potential for hospitals to make a significant 
contribution, particularly for smaller STPs that serve a relatively small ‘sewer catchment’ 
but which may have a large hospital within them (Jørgensen & Halling-Sørensen, 2000). 
2.4.3.3 Domestic consumption and excretion 
Domestic consumption and excretion follow similar pathways to hospitals usage as 
effluent from both is generally conveyed within the same combined sewer system prior 
to treatment.  The major difference between hospital and domestic effluent will be in the 
types and quantities of pharmaceuticals present (Kümmerer, 2001a).  The main routes 
of pharmaceutical uptake in humans are oral intake and injection after which they are 
metabolised to varying degrees depending on individual compound properties 
(Sebastine & Wakeman, 2003).  After ingestion, pharmaceuticals undergo partial or 
complete Phase I metabolism (oxidation, reduction or hydrolysis) before Phase II 
metabolism (conjugation with glucornic, sulphate, acetic or amino acids).  This produces 
polar metabolites which are then excreted in the urine and do not usually exhibit 
pharmacological activity (Ayscough et al., 2000).  Pharmaceuticals are then excreted in 
the urine and/or faeces prior to discharge to the domestic sewage system.  The urine 
and faeces contain a mixture of parent compounds, metabolites and inactive conjugated 
substances (Sebastine & Wakeman, 2003).  The degree to which a parent compound is 
metabolised is strongly influenced by individual factors including: genetics, age, gender, 
health/disease status and individual metabolic idiosyncrasies as well as the 
pharmacokinetic characteristics of the compound and its delivery form (Daughton, 2007).  
In addition to this inactive conjugated metabolites have the potential to be re-transformed 
into active metabolites or parent compounds after excretion (Warman, 1981). 
Lienert et al. (2007) conducted a thorough review of the metabolism and 
excretion of 212 APIs which highlighted large variability both within and between different 
therapeutic classes and even for individual APIs.  X-ray contrast media were the most 
readily excreted via urine with 94% unchanged parent compound lost via this route.  The 
extent of metabolised products lost via urine varies between groups from an average of 
6 % for antidepressants to 100 % for blood lipid regulators.  However, it must be noted 
that variation between compounds in the same group also ranged from 0 to 100 % and 
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certain individual compounds can skew the average of an entire group.  Also, individual 
compounds can demonstrate variation ranging from 0 to 100 % which is strongly 
dependent on the factors mentioned above (Figure 2-3) (Daughton, 2007).  Such a high 
proportion of excretion via urine amongst certain therapeutic use classes may mean that 
urine source separation techniques could play a role in reducing the input of 
pharmaceuticals into the sewage system (Lienert et al., 2007a; Lienert et al., 2007b). 
 
Figure 2-3: Excretion of analgesics, beta-blockers, antidepressants and cytostatics via 
urine 
[Bars indicate average for each group and error bars indicate min and max values if 
available (Lienert et al., 2007a)] 
2.4.3.4 Sewage treatment plants (STPs) 
In the UK, the majority of effluent from domestic households and hospitals is conveyed 
through a combined sewer system to a sewage treatment plant where it undergoes 
treatment prior to being discharged to rivers or the sea.  O’Brien & Dietrich (2004) 
estimate that 80 % of European wastewater passes through a STP although the 
proportion in England and Wales is much higher with 96 % entering a STP and 80 % 
receiving at least secondary level treatment.  80 % of the 11 000 billion litres of sewage 
effluent produced daily in England and Wales is of domestic origin (Mason, 2002).  
However, each STP varies in both amount and composition of the effluent it receives 
and the treatment technologies it employs.  The Urban Waste Water Treatment Directive 
(91/271/EEC) requires the treatment of effluent from all settlements of >2000 population 
equivalent (p.e.).  This includes the reduction of biochemical oxygen demand (BOD), 
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chemical oxygen demand (COD) and total suspended solids by primary (e.g. settling) 
and secondary (e.g. biological) treatment.  Apart from reducing organic pollution some 
STPs discharging to sensitive areas (drinking or eutrophic waters) are also required to 
reduce the levels of nitrate and phosphate in effluent discharge.  Furthermore Directive 
2008/105/EC (EC, 2008b) lists 33 priority substances and 8 other pollutants that must 
be monitored for and maintained within strict Environmental Quality Standards (EQS) 
and in some cases discharges or emissions phased out within 20 years.  Many of these 
compounds are likely to be detectable within STP effluent.  This Priority List covers a 
range of pollutants including heavy metals, industrial chemicals and a small number of 
pesticides and biocides (e.g. alachlor, DDT, diuron, endosulfan and isoproturon).  A 
proposed amendment to this Directive (EC, 2012) would add 15 additional substances 
to this list including two pharmaceuticals (the NSAID, diclofenac and the synthetic 
oestrogen, EE2).  Initial proposals recommended an EQS of 10 ng L-1 for diclofenac 
although this was later removed and now both diclofenac and EE2 are merely named on 
the list without an EQS.  The reason for removal was an estimated £ 27 billion additional 
cost over 20 years in the UK alone for advanced waste water treatment deemed 
necessary to meet the proposed EQS targets (UK Parliament, 2012).  Furthermore, the 
pharmaceutical industry stated that the evidence of negative environmental effects was 
flawed and that much more information was required for policy development (EC, 2012). 
O’Brien & Dietrich (2004) raised the issue of an increasing burden on existing 
STPs due to urban expansion thus reducing treatment efficiencies.  In recent years, 
much research has been conducted on the presence of pharmaceuticals in STP influent, 
effluent and adjacent surface waters (Hughes et al., 2013) aided by developments in 
analytical techniques such as GC-MS and HPLC-MS (Kümmerer, 2009a).  STP effluent 
is generally considered to be the major source of pharmaceuticals into the environment, 
particularly surface waters (Heberer, 2002; Daughton, 2004c; Jones et al., 2005; 
Tambosi et al., 2010).  These point sources are particularly important as they discharge 
continuously into surface waters which allow even those pharmaceuticals with very low 
environmental half-lives to demonstrate ‘pseudo-persistence’ as any compound lost to 
degradation is continually replenished (Daughton, 2001).  This has potentially important 
implications for aquatic organisms as their exposure will generally be low-level (chronic) 
and life-long or even multi-generational with the potential for toxic effects to manifest 
slowly which may then go undetected or be attributed to natural change (Daughton, 
2004a; Daughton, 2004c). 
Once a pharmaceutical compound has reached the aquatic phase degradation can occur 
through biotransformation but it is thought that abiotic processes play a much more 
important role.  Hydrolysis is likely to be negligible for pharmaceuticals but direct and 
indirect photolysis can play a major role in removal, particularly close to the water surface 
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(Farré et al., 2008).  Photolysis has been shown to be the major removal process for 
diclofenac (Buser et al., 1998) but removal is strongly dependent on substance 
properties, solar irradiation (and hence on latitude and season) and the presence of 
photosensitiser constituents in the water column (Fent et al., 2006).  Some sorption to 
sediment and suspended particles does occur but this is generally considered to be low, 
particularly for those compounds present in ionic forms at ambient pH (Scheytt et al., 
2005).   
2.4.3.5 Pharmaceutical removal during sewage treatment 
The degree of removal of a pharmaceutical depends on a number of factors but is largely 
dictated by the treatment technologies in place and the physico-chemical properties of 
the individual compound (Santos et al., 2010).  Pharmaceuticals have a wide variety of 
structures and functional groups but unsaturated aliphatic compounds, esters, nitriles 
and aromatic alcohols are generally more biodegradable whereas compounds with long, 
highly branched side chains, iodide, nitro and azo functional groups are generally more 
recalcitrant (Tunkel et al., 2000; Jones et al., 2005).  An early study by Richardson & 
Bowron (1985) examined a number of highly used substances (including clofibrate, 
aspirin, ibuprofen, paracetamol and a range of antibiotics) for their biodegradability 
during sewage treatment.  They found that many of these substances (apart from 
paracetamol, ibuprofen and aspirin) were either non-biodegradable or only partially bio-
degraded during treatment.  Adsorption to the solid (sludge) phase and biodegradation 
are the key elimination processes in STPS.  Adsorption depends on hydrophobic and 
electrostatic interactions with pH playing a key role in dictating the ionic state of 
compounds and whether or not they remain in the soluble phase.   
Generally acidic pharmaceuticals such as ibuprofen are poorly adsorbed during 
treatment as they occur as hydrophilic ions at neutral pH.  Biodegradation (aerobic and/or 
anaerobic) is therefore the key elimination process for dissolved pharmaceuticals and 
also for re-transformation of conjugated metabolites to parent compounds (Fent et al., 
2006).  Biotransformation (or biodegradation) can range from partial transformation to 
complete mineralisation of a pharmaceutical by microorganisms (bacteria) using these 
compounds as an energy source.  A fundamental factor governing the degree of 
biodegradation is the structure of the bacterial community within the STP.  This 
community can be comprised of fast growing generalists that can degrade a wide variety 
of chemicals and more specialised organisms that occupy narrower niches and may 
have generation times of several days.  The structure of the bacterial community within 
STPs depends upon pH, temperature, redox potential and also the substrate (i.e. 
pharmaceutical) concentrations (Kümmerer et al., 2005).  High substrate concentrations 
often favour generalists whereas specialists tend to thrive in low concentration, nutrient 
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poor conditions.  Furthermore, very high concentrations of certain compounds can be 
directly toxic to all or parts of the microbial community within a STP which can have a 
significant impact on treatment efficiency (Kümmerer et al., 2005).  A STP with a high 
microbial density and species richness will be able to degrade the largest range of 
pharmaceuticals under fluctuating conditions. 
Removal rates in STPs are highly variable and range from 0 to 100 % depending 
on site and compound specific factors (Table 2-5).  Numerous reviews are available on 
this subject (Fent et al., 2006; Onesios et al., 2009).  Some compounds demonstrate 
consistently low removal rates throughout various studies; for example carbamazepine 
never showed removal rates of greater than 30 % whereas paracetamol was consistently 
removed by more than 90 % (Onesios et al., 2009). Generally, the secondary treatment 
phase is much more effective at removal than the primary phase.  The variation in 
removal rates is not surprising given the diverse nature of pharmaceuticals and also local 
factors such as treatment technology, wastewater volumes, temperature and weather.  
Even individual compounds can show different elimination rates, for example diclofenac 
is eliminated between 17 % and 100 % at different STPs (Fent et al., 2006).  This may 
in part be due to the chiral nature of many pharmaceuticals that are often administered 
as racemic mixtures.  Different enantiomers of the same compound are known to behave 
differently in the environment and this may have implications for removal during 
treatment and the subsequent fate and transport in the aquatic environment (Kümmerer 
et al., 2005).   
Some studies have compared the removal efficiency of a laboratory STP with 
that of a full-scale treatment works; Letzel et al. (2010) showed relatively good 
agreement between laboratory removal of the pyschostimulant Ritalin (13 %) and an 
activated sludge STP (23 %).  However, these studies often only consider the gross 
difference in parent compounds prior to treatment (i.e. raw sewage influent) and post-
treatment (i.e. treated effluent) with often little or no attempt to understand the 
mechanisms of removal (i.e. biodegradation, mineralisation and metabolism) and the 
potential for compounds to be re-transformed to the parent state (Jones et al., 2005).  
Also, the OECD guidelines for testing biodegradability (e.g. the ‘closed bottle test’ OECD 
301D) stipulate very high initial concentrations (mg L-1) which are not representative of 
average influent concentrations at STPs (ng L-1 to µg L-1).  Therefore the results from 
such experiments should be used with caution and further research on removal 
efficiencies is required (Jones et al., 2005). 
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Table 2-5: Summary of sewage treatment plant removal 
efficiencies for 16 widely used pharmaceuticals 
Compound 
Treatment stage removal efficiency (%) 
Primary Secondary1 Tertiary2 
Aspirin  81-100  
Atenolol   >90 
Carbamazepine 0 0-45 0-81 
Clofibric acid  51-91  
Diclofenac  0-80 25-54 
Erythromycin  38-100 0-89 
Fluoxetine 10 85  
Ibuprofen 14-44 0-100 0-99 
Ketoprofen   >90 
Mefenamic acid  87-97 0-100 
Metoprolol   >90 
Oxytetracycline  0  
Paracetamol  86-100  
Propranolol  0-96 83 
Salbutamol  95  
Sulfamethoxazole  18-100 27-87 
Notes:   
1. Includes both fixed film and suspended technologies i.e. trickling 
biological filters and activated sludge 
2. Includes a range of technologies such as sand filtration, ozonation and 
biological nutrient removal 
Sources: (Ternes, 1998; Stumpf et al., 1999; Kanda, 2003; Paxeus, 2004; 
Versteeg et al., 2005; Jones et al., 2007; Maurer et al., 2007; Nakada et al., 
2007; Coetsier et al., 2009; Lundström et al., 2010; Tambosi et al., 2010) 
Blank cells mean no data available 
 
Clearly, STPs were designed and constructed to reduce the levels of organic and nutrient 
pollution in surface waters and there are currently no treatment technologies available 
that are specifically designed to remove or reduce pharmaceutical concentrations in 
sewage effluent.  However, some existing technologies such as membrane filtration and 
photo-oxidation have shown promising removal rates for pharmaceuticals but these have 
additional capital and energy burdens (Heberer, 2008; Martins et al., 2008).  One study 
(Lundström et al., 2010) compared the removal efficiencies of conventional treatment 
with sand filtration, membrane bio-reactors, moving-bed biofilm reactors and ozonation 
as additional treatments.  The study found that generally ozonation was the most 
effective at removal but that the resulting effluent was slightly more toxic compared to 
other treatments; this was most likely due to the formation of toxic transformation by-
products.  Zheng et al. (2010) demonstrated very efficient removal (96 %) of the antibiotic 
oxytetracycline with ozonation at a dose of 657 mg O3 L-1.  
Simpler, process orientated measures such as increasing the hydraulic retention 
time (HRT) within a STP and using mature activated sludge can also improve the 
biodegradation of some compounds during treatment (Fent et al., 2006).  Indeed, one 
study (Onesios et al., 2009) found that many pharmaceuticals have a critical solids 
retention time (SRT) and HRT below which there is very little removal.  They also found 
that removal rates were generally higher during summer, perhaps due to lower influent 
flow rates, increases in retention times and elevated temperatures.  Kanda et al. (2003) 
also found that increased retention times can improve removal and placed treatment 
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technologies in the following order based on pharmaceutical removal efficiency: filter bed 
< non nitrifying activated sludge < nitrifying activated sludge < oxidation ditch.  This same 
study also showed that final effluent concentrations can vary throughout the day (likely 
due to a combination of fluctuating influent concentrations, flow rates and removal 
efficiencies; Figure 2-4).  Models are also available which attempt to predict the removal 
of pharmaceuticals during various stages of the sewage treatment process.  For 
example, Jones et al. (2002) used the STPWIN model to predict the fate of 25 
pharmaceuticals and found that total removal for most compounds was predicted as <5 
% except ibuprofen which had a predicted removal of 29 %. 
 
Figure 2-4: Daily variation in ibuprofen effluent concentrations at an activated sludge 
STW 
(Kanda, 2003) 
2.4.3.6 Combined sewer overflows (CSOs) 
CSOs are designed to divert excess storm water into surface waters during a high rainfall 
or flood event to prevent flooding in urban areas.  They remove the need for large, high 
capacity sewer systems and the provision of expensive additional capacity in STPs that 
would be unused during normal flow conditions (Mulliss et al., 1997).  Furthermore, they 
allow the discharge of storm water effluent at controlled and managed locations which 
are owned and operated by the water companies and regulated by the Environment 
Agency (in England and Wales).  The EA maintain a register of CSO discharge consents 
which stipulate the operational limits for each CSO and requires that they only discharge 
during heavy rainfall or snowmelt events (i.e. that they do not discharge routinely during 
normal, dry conditions).   
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Generally speaking, premises (both domestic and commercial) constructed since 
the 1960s will discharge to a non-combined sewerage system but this means a 
significant proportion of the UK sewage system is combined (i.e. urban runoff is mixed 
with domestic sewage) resulting in dilute but untreated effluent being discharged directly 
into receiving waters (both rivers and the sea) (Water UK, 2009).  During the early 1990s 
it was estimated that there were 25 000 CSOs in the UK with as many as one third of 
these being classed as unsatisfactory under the terms of the UWWT Directive 
(Thompson Rpm, 2006).  These discharges generally occur when rainfall and river levels 
are high allowing greater dilution of the CSO effluent.  Besides pharmaceuticals, CSO 
effluent can contain a wide variety of pollutants including anoxic bacterial scums from 
roadside catch pits, suspended material and heavy metals from road surfaces, dog 
faeces and seasonally high levels of chloride from road-salting operations (Mason, 
2002).   
Unlike STP effluent, CSOs are designed only to discharge on a sporadic basis 
and studies have found that the frequency, duration and volume of overflows can be 
used as an indicator of deterioration in water quality (Lau et al., 2002).  However, recent 
findings by the popular media (BBC, 2009) highlighted a number of CSOs in England 
and Wales that were discharging more frequently and in some cases hundreds of times 
per year.  The UK water industry economic regulator Ofwat (http://www.ofwat.gov.uk/) 
included as part of the latest 5 year Periodic Review (PR09 for the period 2010-2015) a 
requirement for the water industry as a whole to invest £ 985 million in capital expenditure 
to reduce unsatisfactory intermittent discharges from CSOs and other emergency 
overflows which is a requirement of the UWWT Directive (Ofwat, 2009).  Furthermore, 
the Flood and Water Management Act which became law in April 2010 (HMSO, 2010) 
requires the adoption of sustainable urban drainage systems (SUDS) in some types of 
new development which it is hoped will go some way in reducing the volume of surface 
runoff during heavy rainfall and help to reduce the frequency of CSO discharges (Water 
UK, 2009).  
The significant degradation of chemical, physical and biological quality of 
receiving waters due to CSO discharges is well documented (Saul, 1989).  CSOs have 
the potential to release significant amounts of pharmaceuticals into receiving waters 
without undergoing any form of treatment and could be a major source into the 
environment, particularly for those compounds that would otherwise be well removed 
during the treatment process.  Boyd et al. (2004) surveyed storm water channels in New 
Orleans and found that pharmaceutical concentrations increased with rainfall suggesting 
a ‘first flush’ response where heavily contaminated sediment in the pipes is re-suspended 
during the initial stages of a storm event.  Mulliss et al. (1997) discovered a similar 
flushing response for nitrate and phosphate and Old et al. (2003) for suspended 
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sediment concentrations during CSO discharges to UK rivers.  Ellis (2006) suggests that 
the presence of pharmaceuticals in urban waters far from STP discharges are most likely 
a result of sporadic releases from CSOs and other cross-connections or leakages in 
ageing sewer systems.  Clearly, understanding the contribution of these non-STP point 
sources to overall pharmaceutical levels in receiving waters requires more research 
particularly as the relationship between flow and contamination is strongly catchment 
and site specific for individual CSOs (Old et al., 2003).   
To date there has been no published research focusing specifically on 
pharmaceuticals in CSO discharges in the UK despite their potential to represent 
significant sources of pharmaceutical pollution.  The degree of risk will be strongly 
dependent on the individual CSO, its contributing sewer ‘catchment’ and the frequency 
of overflow events.  A further concern is that many CSO outfalls are ‘flapped’ in order to 
prevent flow backup from high levels in the receiving channel (Figure 2-5) but this may 
lead to CSOs discharging when river levels have receded and the subsequent dilution of 
effluent is much lower.  Ellis  (1979) recorded high suspended sediment concentrations 
in the falling limbs of storm hydrographs believed to be due to release from CSOs that 
were drowned and hydraulically locked during the flood peak.  However, Kolpin et al. 
(2004) have demonstrated the opposite phenomenon where concentrations due to storm 
water effluent decreased with increasing stream flow and the subsequent dilution.  
Therefore, analysis of CSO effluent and receiving waters should be a research priority in 
an attempt to quantify this currently overlooked source. 
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(a) 
 
(b) 
Figure 2-5: Examples of a  'flapped' (a) combined sewer overflow outfall [centre of 
image] and (b) sewage treatment plant overflow 
2.4.4 Pharmaceutical sources to the aquatic environment: a hierarchy of 
importance 
It is generally agreed that STP effluent is the predominant source of human 
pharmaceuticals to the aquatic environment (Halling-Sørensen, 1998; Heberer, 2002; 
Santos et al., 2010) as this integrates discharges from domestic households, commercial 
properties and hospitals into a single point source for each STP which discharges 
continuously to its receiving waters.  However, CSOs have been subject to very little 
research, particularly for emerging contaminants and as such these should be prioritised 
due to their capacity to discharge untreated effluent albeit on a generally sporadic basis.  
The remaining potential sources (indirectly via agricultural application) are likely to be 
less important as any pharmaceuticals will be subject to degradation and transformation 
in the terrestrial environment (see Section 2.4.2). 
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2.5 Occurrence of pharmaceuticals in the environment 
This section will summarise existing research on the occurrence of pharmaceuticals in a 
range of environmental compartments, including soils, the atmosphere and groundwater.  
The main focus of this section will be on the occurrence and fate of human use 
pharmaceuticals in STP effluent and receiving freshwater systems. 
2.5.1 Expansion of research 
Apart from a few pioneering studies which detected drugs in the aquatic environment in 
the 1970s and 1980s (Hignite & Azarnoff, 1977; Aherne et al., 1985; Richardson, 1985; 
Aherne et al., 1990) the majority of studies into the environmental occurrence of 
pharmaceuticals have been conducted from the late 1990s onwards due to the advent 
of analytical techniques such as high performance liquid chromatography coupled with 
tandem mass spectrometry (HPLC-MS/MS) (Daughton, 2001).  This is despite concerns 
about the potential environmental effects of pharmaceuticals being raised by the UK 
government as early as 1969 (Swann et al., 1969).  Williams (2005) conducted a review 
of pharmaceutical occurrence research from the 1970s to 2004 and found that an 
average of one paper per year was written from 1975 to 1995 which rose to over 50 in 
2004.  The majority of these studies were conducted in Germany (56 %) with only 5 % 
in the UK.  However the ’detection‘ rate of pharmaceuticals varied significantly from 14 
% in the USA, 40 % in the UK and 70 % in Switzerland highlighting the importance of 
locally relevant occurrence data.  A review of the publically available citations database 
maintained by the US EPA (USEPA, 2010) showed a similar increase in publications 
from 1950 onwards (Figure 2-6).  The data show a relatively small number of studies 
from the 1950s to the 1980s and a seemingly exponential increase in the publication rate 
from the mid-1990s onwards with a current mean publication rate of over 764 articles per 
year.  It must be noted that this database includes literature covering both 
pharmaceuticals and personal care products and contains journal articles, books, web 
pages, reports and other grey literature (USEPA, 2010).   
Hughes et al. (2013) conducted a systematic review of pharmaceutical 
occurrence research using the Web of Knowledge publications database.  They identified 
236 studies from 13 journals, which had specifically identified pharmaceutical 
compounds in STP effluent or receiving waters.  The analyses showed a clear upward 
trend in publications from the late 1990s onwards (the earliest included paper was from 
1998) and the majority of studies (over 80 %) were published between 2005 and 2010 
(Figure 2-7).  It was hypothesised that this increase was driven by advancements in 
analytical techniques, evidenced by the relatively high proportion (22 %) of studies 
published in journals with a specific analytical focus such as Journal of Chromatography 
A, Analytical and Bioanalyitcal Chemistry and Talanta (Hughes et al., 2013). 
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Figure 2-6: Summary of PPCP publications from 1950-2009 
(USEPA, 2010) 
 
Figure 2-7: Number of publications identifying pharmaceutical compounds in sewage 
treatment plant effluent or receiving waters from a systematic review of the Web of 
Knowledge publications database 
(Hughes et al., 2013) 
 
A number of review articles (Halling-Sørensen, 1998; Heberer, 2002; Fent et al., 2006; 
Calisto & Esteves, 2009; Santos et al., 2010; Hughes et al., 2013) and three editions of 
a textbook  (Kümmerer, 2001b; 2004a; 2008a) have been published focusing solely on 
PPCPs in the environment.  Furthermore, special volumes of the journals Chemosphere 
(April 2000: Volume 40 Issue 7), Environmental Toxicology and Chemistry (December 
2009: Volume 28 Issue 12) and Science of the Total Environment (Virtual Special Issue: 
http://tinyurl.com/muz64ck) have been published which dealt solely with this issue.  The 
tones of these review articles and particularly the textbook edited by Klaus Kümmerer 
(2001b; 2004; 2008a) shifted from the early 2000s to the present.  The 1st edition of 
0
200
400
600
800
1000
1200
1400
1950 1960 1970 1980 1990 2000 2010
C
o
u
n
t 
o
f 
e
n
tr
ie
s
 i
n
 d
a
ta
b
a
s
e
Year
0
5
10
15
20
25
30
35
40
45
50
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
P
u
b
lic
a
ti
o
n
s
Year
Decade
Mean 
publications 
per year
1950-1959 0.8
1960-1969 0.9
1970-1979 3.9
1980-1989 11.3
1990-1999 77.8
2000-2009 764.1
36 
 
Kummerer’s textbook (2001b) had a majority of chapters devoted to summarising 
occurrence data whereas the latest edition (2008a) has much more emphasis on 
understanding the effects of pharmaceuticals and gaps in current knowledge.  The books 
and review articles present useful summaries of existing data from across the world so 
they will not be reproduced here.  However, there is no published article that presents 
the UK occurrence data in one single place and so these values will be presented later 
in this chapter as they are particularly relevant to this study.   
Kasprzyk-Hordern et al. (2007) estimated that between 80 and 150 PPCPs have 
been explicitly studied for their occurrence in various environmental compartments.  
Hughes et al. (2013) synthesised global pharmaceutical research via a systematic review 
of research and found a total of 203 pharmaceutical compounds identified in rivers 
across 41 countries.  Despite the relatively large number of compounds monitored, the 
majority of research effort has so far focused on just 14 widely used substances.  
Furthermore, research is spatially biased towards North America and Europe with 
perhaps the most research conducted in Germany.  The greater emphasis on 
pharmaceutical occurrence research in Europe is perhaps due to higher concentration 
of sewage outfalls, lower per-capita water usage and lower stream flows (resulting in 
less dilution) when compared to North America (Daughton, 2001).  Based on the findings 
of Hughes et al. (2013) very little or no research has been conducted in Africa, South 
America, the Middle East and large parts of Asia. However, as the previous section on 
pharmaceutical consumption has demonstrated, the transfer of measured environmental 
concentrations is not appropriate between countries due to variations in consumption 
and also differing levels of sewage treatment.  
2.5.2 Occurrence in non-aquatic environmental compartments 
Pharmaceuticals have been widely detected in a range of environmental compartments 
including: surface water, ground water, soils, landfill leachate, sewage sludge, manure 
and in marine waters and sediment (Daughton & Ruhoy, 2009b).  Active pharmaceutical 
ingredients (APIs) have even been detected in drinking water and in the Arctic 
environment (Stan et al., 1994; Kallenborn et al., 2008). This section will give a very brief 
overview of the occurrence data for non-aquatic compartments in order to provide 
context.  A small number of studies have shown veterinary antibiotics may enter the 
airborne phase within and outside CAFOs (Zahn et al., 2001; Chapin et al., 2005). 
However, the generally non-volatile nature of pharmaceuticals means that airborne 
exposure is not considered to be a major concern, except perhaps for communities living 
downwind of large CAFOS (Wing & Wolf, 2000). 
Pharmaceuticals can enter soils by direct deposition from cattle, the application 
of manure/slurry from animal rearing or the application of human sewage sludge (see 
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Section 2.4.2).  Furthermore, the use of reclaimed wastewater for irrigation and aquifer 
recharge can act as an indirect source (Xu et al., 2009).  Ternes et al. (2007) analysed 
soil water samples for 52 pharmaceuticals and two musk fragrances from a German field 
that had been treated with sewage sludge for 45 years.  Only four of the compounds 
were detected in soil water (up to several µg L-1) despite being consistently present in 
the associated STP effluent.  A number of European studies (Winckler, 2000; Hamscher 
et al., 2002; Hamscher et al., 2005) have detected antimicrobials in agricultural soils 
ranging from 4.5 µg kg-1 to over 900 µg kg-1.  It should be noted that a number of the 
detections were well above the detailed risk assessment trigger value for soil 
concentrations of 100 µg kg-1 (EMEA, 2006).  The concentrations detected also vary with 
soil depth (Hamscher et al., 2002) and with soil pH, microbial communities and redox 
conditions (Sarmah et al., 2006).  River and marine sediments directly adjacent to fish 
farms have been studied for the presence of pharmaceuticals, particularly antibiotics.  
These compounds are administered to the fish as a feed additive which can enter the 
sediment as food falls directly through the farm cages or in fish faeces; concentrations 
ranging from 100 to 4900 µg kg-1 have been detected (Jacobsen & Berglind, 1988; 
Capone et al., 1996). 
The disposal of unwanted or unused pharmaceuticals into solid waste accounts 
for the majority of household disposal in the UK (Bound, 2006).  All or some of this solid 
waste may then be sent to a landfill site where pharmaceuticals can collect and 
contaminate ground and surface waters.  This is of particular concern for landfills where 
there are no leachate collection and treatment technologies in place (Kümmerer, 2009a).  
A study at a Florida landfill found a total of 22 APIs (equivalent to 22 910 mg) in 2800 kg 
of solid waste, representing an average of 8.1 mg kg-1 (Musson & Townsend, 2009).  
Holm et al. (1995) conducted a study on a landfill site which received solid waste from 
the pharmaceutical industry from the 1940s to the 1970s; they found very high 
concentrations of sulphonamides (up to 5 mg L-1) and the analgesic propylphenazone 
(up to 4 mg L-1) adjacent to the landfill.  However, concentrations decreased rapidly within 
50 metres downstream of the groundwater plume and none of the compounds exceeded 
the detection limit after 150 metres.  This was due to anaerobic degradation, dilution and 
sorption (Holm et al., 1995).  The presence of pharmaceuticals in groundwater is a 
concern as it is often a source of drinking water and the persistence of compounds may 
be greater due to reduced microbial activity and the absence of photochemical 
breakdown processes (Jones et al., 2001).  Indeed, Stan et al. (1994) detected the blood 
lipid regulator clofibrate in German drinking water at concentrations ranging from 10 to 
165 ng L-1 indicating this compound is readily persistent in the environment, this 
hypothesis is further supported by its regular detection in European surface waters 
(Halling-Sørensen, 1998).   
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2.5.3 Occurrence in STP effluent and receiving waters 
The vast majority of occurrence studies have focused on effluent from STPs discharging 
to surface river water as these are considered to be the major source of pharmaceuticals 
into the environment (Ellis, 2006).  Pharmaceutical occurrence studies have been 
conducted in at least 41 countries although research is extremely limited or absent in 
most of South America, central and southern Asia and Africa (Hughes et al., 2013).  
Perhaps the most comprehensive single study to date is that of Kolpin et al. (2002) who 
monitored for the presence of 95 micro-pollutants (including a range of prescription and 
non-prescription drugs, antibiotics, disinfectants and fragrances) in 139 polluted streams 
across the USA.  In some streams as many as 38 of the target compounds were 
detected.  Review articles are available which summarise much of this global occurrence 
data so these will not be reproduced here (Halling-Sørensen, 1998; Ayscough et al., 
2000; Jones et al., 2001; Heberer, 2002; Daughton, 2004a; Enick & Moore, 2007; 
Caliman & Gavrilescu, 2009; Kümmerer, 2009a; Kümmerer, 2009b; Kümmerer, 2009c; 
Pal et al., 2010; Brausch & Rand, 2011; Hughes et al., 2013).  However, a detailed 
breakdown of pharmaceutical occurrence in UK rivers is given to provide the research 
background for this thesis (Table 2-6).  A detailed global synthesis and critical evaluation 
of research into the occurrence of over 200 pharmaceutical compounds detected in rivers 
across 41 countries is given in Chapter 3. 
A total of 69 pharmaceutical compounds have been identified in UK rivers or STP 
effluent.  Overall, median pharmaceutical concentrations in receiving waters are in the 
low tens of ng L-1 range for all but the most widely used compounds (i.e. painkillers and 
antibiotics).  Receiving water maxima frequently exceed 100 ng L-1 for most compounds 
and several exceeding 1000 ng L-1 (predominantly antibiotics and painkillers such as 
erythromycin and ibuprofen).  The mean receiving water concentration across all 
compounds was 134.6 ng L-1 with the highest recorded concentration of 7731 ng L-1 for 
the painkiller tramadol.  Effluent concentrations are generally greater than respective 
receiving waters with a median concentration across all compounds of 1547 ng L-1.  Here 
painkillers, antibiotics, antiepileptics and cardiovascular drugs demonstrated the highest 
concentrations.  The highest measured effluent concentration was again for the painkiller 
tramadol (97 616 ng L-1).  Where compounds were identified in both STP effluent and 
receiving waters, median concentrations were greater in effluent for all but five 
compounds out of a total of 38 (clofibric acid, clotrimazole dextropropoxyphene, 
salbutamol, sulfamethoxazole).  Effluent concentrations were generally 19 x greater than 
the respective receiving water values although such comparisons should be treated with 
caution given differences in sampling and analyses between studies (Table 2-6; 2-7).  
This supports the prevailing evidence that STP effluent is the dominant pharmaceutical 
source to rivers.   
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Table 2-6: Summary of pharmaceutical occurrence in UK rivers 
Compound 
Therapeutic 
class 
Concentration 
(ng L-1) 
Mean 
detection 
freq (%)3 
Catchment(s) or 
location(s) 
References 
Med1 Max2 
Amitriptyline Antidepressants 2.0 17.0 43.8 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Amoxicillin Antibiotics 117 622.0 29.5 Taff and Ely Kasprzyk-Hordern et al. (2007); Kasprzyk-Hordern et al. (2008) 
Amphetamine Illicit drugs 5.5 9.0 53.4 Taff and Ely Kasprzyk-Hordern et al. (2007); Kasprzyk-Hordern et al. (2008) 
Aspirin Painkillers 31.0 36.0 46.8 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Atenolol 
Other 
cardiovascular 
drugs 
124.3 560.0 86.4 Taff and Ely 
Kasprzyk-Hordern et al. (2007); Kasprzyk-Hordern et al. (2008); 
Kasprzyk-Hordern et al. (2009) 
Bendroflumethiazide 
Other 
cardiovascular 
drugs 
1.0 15.0 2.1 Taff and Ely Kasprzyk-Hordern et al. (2008) ) 
Benzoylecgonine Painkillers 13.0 17.0 47.3 Taff and Ely Kasprzyk-Hordern et al. (2008); Zuccato et al. (2008) 
Bezafibrate 
Blood lipid 
regulators 
30.4 76.0 49.4 Taff and Ely 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009); 
Loos et al. (2009) 
Bleomycin 
Cancer 
treatments 
 17.0  SE England Aherne et al. (1990) 
Carbamazepine Antiepileptics 95.5 684.0 92.3 
Sussex Ouse, Taff, 
Ely, Fleetwood, 
Lancaster, 
Glasgow, Hull, 
Middlesbrough, 
Runcorn, 
Edinburgh, Stafford 
and Naburn Lock 
Zhang et al. (2008); Zhang & Zhou (2007); Kasprzyk-Hordern et al. 
(2007); Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. 
(2009); Loos et al. (2009); Zhou et al. (2009) ) 
Chloramphenicol Antibiotics 4.0 40.0 3.9 Taff and Ely Kasprzyk-Hordern et al. (2008) 
Cimetidine 
Gastro-
intestinal drugs 
35.5 220.0 75.1 Taff and Ely 
Kasprzyk-Hordern et al. (2007); Kasprzyk-Hordern et al. (2008); 
Kasprzyk-Hordern et al. (2009) 
Clofibrate 
Blood lipid 
regulators 
40.0   Thames Richardson & Bowron (1985) 
Clofibric acid 
Blood lipid 
regulators 
14.8 164.0 31.5 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Clotrimazole Others 20.8 34.0 100.0 Tyne Roberts & Thomas (2006) 
Cocaine Illicit drugs 4.0 6.0 10.6 Taff and Ely Kasprzyk-Hordern et al. (2008); Zuccato et al. (2008) 
Codeine Painkillers 165.0 815.0 84.0 Taff and Ely 
Kasprzyk-Hordern et al. (2007); Kasprzyk-Hordern et al. (2008); 
Kasprzyk-Hordern et al. (2009) 
Dextropropoxyphene Painkillers 285.0 682.0 35.3 Thames and Tyne 
Richardson & Bowron (1985); Ashton et al. (2004); Roberts & 
Thomas (2006) 
Diazepam Others 10.0   Thames Richardson & Bowron (1985) 
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Table 2-6: Summary of pharmaceutical occurrence in UK rivers 
Compound 
Therapeutic 
class 
Concentration 
(ng L-1) 
Mean 
detection 
freq (%)3 
Catchment(s) or 
location(s) 
References 
Med1 Max2 
Diclofenac Painkillers 13.9 568.0 70.9 
Sussex Ouse, Lea, 
Thames, 
Fleetwood, 
Lancaster, 
Glasgow, Hull, 
Middlesbrough, 
Runcorn, 
Edinburgh, Stafford 
and Naburn Lock 
Zhang et al. (2008); Zhang & Zhou (2007); Ashton et al. (2004); 
Ellis (2006); Hilton & Thomas (2003); Kasprzyk-Hordern et al. 
(2008); Kasprzyk-Hordern et al. (2009); Loos et al. (2009); Zhou et 
al. (2009) 
Diltiazem 
Other 
cardiovascular 
drugs 
12.0 65.0 56.3 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Erythromycin Antibiotics 185.2 1022.0 58.0 
Thames, Taff and 
Ely 
Richardson & Bowron (1985); Ashton et al. (2004); Hilton & 
Thomas (2003); Kasprzyk-Hordern et al. (2007); Kasprzyk-Hordern 
et al. (2008); Kasprzyk-Hordern et al. (2009) 
Furosemide 
Other 
cardiovascular 
drugs 
31.0 630.0 63.0 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Gabapentin Antiepileptics 434.5 1887.0 94.2 Taff and Ely 
Kasprzyk-Hordern et al. (2007); Kasprzyk-Hordern et al. (2008); 
Kasprzyk-Hordern et al. (2009) 
Gemfibrozil 
Blood lipid 
regulators 
 2.0 35.0 
Fleetwood, 
Lancaster, 
Glasgow, Hull, 
Middlesbrough, 
Runcorn, 
Edinburgh, Stafford 
and Naburn Lock 
Loos et al. (2009) 
Ibuprofen Painkillers 447.7 5044.0 73.5 
Thames, Lea, Taff, 
Ely, Tyne, 
Fleetwood, 
Lancaster, 
Glasgow, Hull, 
Middlesbrough, 
Runcorn, 
Edinburgh, Stafford 
and Naburn Lock 
Ashton et al. (2004); Bound & Voulvoulis (2006); Ellis (2006); 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009); 
Loos et al. (2009); Roberts & Thomas (2006) 
Indomethacin Painkillers 1.1 3.0 100.0 
Sussex Ouse, Taff, 
Ely 
Zhang et al. (2008); Zhang & Zhou (2007); Zhou et al. (2009) 
Ketoprofen Painkillers 1.5 14.0 74.1 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
MDA Illicit drugs 3.0 4.0   Zuccato et al. (2008 ) 
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Table 2-6: Summary of pharmaceutical occurrence in UK rivers 
Compound 
Therapeutic 
class 
Concentration 
(ng L-1) 
Mean 
detection 
freq (%)3 
Catchment(s) or 
location(s) 
References 
Med1 Max2 
MDMA (ecstasy) Illicit drugs 4.0 6.0   Zuccato et al. (2008) 
Mefenamic acid Painkillers 47.0 366.0 60.9 
Thames, Taff and 
Ely 
Ashton et al. (2004); Bound & Voulvoulis (2006); Hilton & Thomas 
(2003); Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. 
(2009) 
Metoprolol 
Other 
cardiovascular 
drugs 
7.5 12.0 94.4 Taff and Ely 
Kasprzyk-Hordern et al. (2007); Kasprzyk-Hordern et al. (2008); 
Kasprzyk-Hordern et al. (2009) 
Metronidazole Antibiotics 3.5 24.0 66.1 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Miconazole Others 8.0 9.0 100.0 Thames Roberts & Bersuder (2006) 
Morphine Painkillers 8.0 42.0   Zuccato et al. (2008) 
Naproxen Painkillers 22.5 146.0 82.4 
Taff, Ely, 
Fleetwood, 
Lancaster, 
Glasgow, Hull, 
Middlesbrough, 
Runcorn, 
Edinburgh, Stafford 
and Naburn Lock 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009); 
Loos et al. (2009) 
Paracetamol Painkillers 194.1 2382.0 89.3 
Thames, Lea, Taff, 
Ely, Tyne, 
Fleetwood, 
Lancaster, 
Glasgow, Hull, 
Middlesbrough, 
Runcorn, 
Edinburgh, 
Stafford, Naburn 
Lock 
Bound & Voulvoulis (2006); Ellis (2006); Kasprzyk-Hordern et al. 
(2007); Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. 
(2009) 
Propranolol 
Other 
cardiovascular 
drugs 
38.2 215.0 76.2 
Sussex Ouse, Taff, 
Ely, Thames, Lea 
and Tyne 
Ashton et al. (2004); Ellis (2006); Hilton & Thomas (2003); 
Kasprzyk-Hordern et al. (2007); Kasprzyk-Hordern et al. (2008); 
Kasprzyk-Hordern et al. (2009); Roberts & Thomas (2006); Zhang 
& Zhou (2007); Zhang et al. (2008); Zhou et al. (2009) 
Ranitidine 
Gastro-
intestinal drugs 
7.0 73.0 22.7 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Salbutamol 
Respiratory 
drugs 
69.0 471.0 41.3 Taff and Ely 
Bound & Voulvoulis (2006); Kasprzyk-Hordern et al. (2008); 
Kasprzyk-Hordern et al. (2009) 
Sulfamethoxazole Antibiotics  95.8 73.7 
Sussex Ouse, 
Thames, Taff, Ely, 
Fleetwood, 
Lancaster, 
Zhang & Zhou (2007); Richardson & Bowron (1985); Kasprzyk-
Hordern et al. (2008); Loos et al. (2009); Zhou et al. (2009) 
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Table 2-6: Summary of pharmaceutical occurrence in UK rivers 
Compound 
Therapeutic 
class 
Concentration 
(ng L-1) 
Mean 
detection 
freq (%)3 
Catchment(s) or 
location(s) 
References 
Med1 Max2 
Glasgow, Hull, 
Middlesbrough, 
Runcorn, 
Edinburgh, Stafford 
and Naburn Lock 
Sulfapyridine Antibiotics 17.5 142.0 55.3 Taff and Ely 
Kasprzyk-Hordern et al. (2007); Kasprzyk-Hordern et al. (2008); 
Kasprzyk-Hordern et al. (2009) 
Sulfasalazine Antibiotics 26.8 168.0 81.2 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Tamoxifen 
Cancer 
treatments 
78.0 212.0 100.0 Tyne Roberts & Thomas (2006) 
Tetracycline Antibiotics 1000.0   Thames Richardson & Bowron (1985) 
Theophylline 
Respiratory 
drugs 
1000.0    Richardson & Bowron (1985) 
Tramadol Painkillers 1771.0 7731.0 80.5 Taff and Ely 
Kasprzyk-Hordern et al. (2007); Kasprzyk-Hordern et al. (2008); 
Kasprzyk-Hordern et al. (2009) 
Trimethoprim Antibiotics 23.3 569.0 62.2 Taff, Ely and Tyne 
Ashton et al. (2004); Hilton & Thomas (2003); Kasprzyk-Hordern et 
al. (2008); Kasprzyk-Hordern et al. (2009); Roberts & Thomas 
(2006) 
Valsartan 
Other 
cardiovascular 
drugs 
16.0 144.0 94.1 Taff and Ely 
Kasprzyk-Hordern et al. (2007); Kasprzyk-Hordern et al. (2008); 
Kasprzyk-Hordern et al. (2009) 
Notes: 
Median value of all concentrations from combined studies 
Maximum value of all concentrations from combined studies 
Mean detection frequency of all samples from combined studies (not all studies stated detection frequencies) 
Blank cells indicate data were unavailable 
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Table 2-7: Summary of pharmaceutical occurrence in treated STP effluent discharging to UK rivers 
Compound 
Therapeutic 
class 
Concentration 
(ng L-1) 
Mean 
detectio
n freq 
(%)3 
Catchment(s) or 
location(s) 
References 
Med1 Max2 
Amitriptyline Antidepressan
ts 
141.0 357.0 85.5 Taff and Ely 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Amphetamine Illicit drugs 3.0 11.0  Taff, Ely and 
Thames 
Boles & Wells (2010) 
Aspirin 
(acetylsalicylic 
acid) 
Painkiller 349.0 85.0 71.0 Taff, Ely and 
Thames 
Richardson & Bowron (1985); Kasprzyk-Hordern et al. (2008); 
Kasprzyk-Hordern et al. (2009) 
Atenolol Other 
cardiovascular 
drugs 
2496.5 7602.0 100.0 Taff and Ely 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Bendroflumethiazi
de 
Other 
cardiovascular 
drugs 
11.0 58.0 19.0 Taff and Ely Aherne et al. (1990) 
Bezafibrate Blood lipid 
regulators 
204.0 667.0 92.0 Taff and Ely 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Bleomycin Cancer 
treatments 
15.8 19.0  SE England 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Carbamazepine Antiepileptics 1066.8 4596.0 100.0 Taff, Ely, Sussex 
Ouse 
Zhang et al. (2008); Zhang & Zhou (2007); Kasprzyk-Hordern et al. 
(2008); Kasprzyk-Hordern et al. (2009); Zhou et al. (2009) 
Chloramphenicol Antibiotics 21.0 69.0 25.0 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Chlorpromazine Other CNS 
drugs 
10.0 11.0 33.3 Thames Roberts & Bersuder (2006) 
Cimetidine Gastro-
intestinal 
drugs 
1533.5 9395.0 100.0 Taff and Ely 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Clofibric acid Blood lipid 
regulators 
10.5 75.0 43.5 Taff and Ely Kasprzyk-Hordern et al. (2009; 2008); Roberts & Thomas (2006) 
Clotrimazole Others 14.0 27.0  Tyne Roberts & Thomas (2006) 
Codeine Painkillers 3993.5 15593.0 100.0 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Dextropropoxyphe
ne 
Painkillers 160.3 585.0 74.0 Tyne Ashton et al. (2004); Hilton & Thomas (2003); Roberts & Thomas 
(2006) 
Diclofenac Painkillers 192.1 2349.0 93.0 Taff, Ely, Lea, 
Thames, Sussex 
Ouse, Tyne 
Zhang et al. (2008); Zhang & Zhou (2007); Ashton et al. (2004); Ellis 
(2006); Hilton & Thomas (2003); Kasprzyk-Hordern et al. (2008); 
Kasprzyk-Hordern et al. (2009); Roberts & Thomas (2006); Zhou et al. 
(2009) 
Diltiazem Other 
cardiovascular 
drugs 
312.0 1156.0 100.0 Taff and Ely 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Ephedrine Illicit drugs 12.6 14.8  Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
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Table 2-7: Summary of pharmaceutical occurrence in treated STP effluent discharging to UK rivers 
Compound 
Therapeutic 
class 
Concentration 
(ng L-1) 
Mean 
detectio
n freq 
(%)3 
Catchment(s) or 
location(s) 
References 
Med1 Max2 
Erythromycin Antibiotics 761.0 2841.0 72.0 Taff, Ely, Tyne Ashton et al. (2004); Hilton & Thomas (2003); Kasprzyk-Hordern et al. 
(2008); Kasprzyk-Hordern et al. (2009); Roberts & Thomas (2006) 
Fluoxetine Antidepressan
ts 
33.5 34.0 33.3 Thames Roberts & Bersuder (2006) 
Furosemide Other 
cardiovascular 
drugs 
895.0 1956.0 96.0 Taff and Ely 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Gabapentin Antiepileptics 9169.5 42611.0 100.0 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Ibuprofen Painkillers 1437.7 27256.0 92.0 Tyne Kanda et al. (2003); Ashton et al. (2004); Ellis (2006); Hilton & Thomas 
(2003); Jones et al. (2007); Kasprzyk-Hordern et al. (2008); Kasprzyk-
Hordern et al. (2009); Roberts & Thomas (2006) 
Indomethacin Painkillers 16.2   Sussex Ouse Zhang & Zhou (2007); Zhou et al. (2009) 
Ketoprofen Painkillers 17.0 37.0 72.0 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
MDMA (ecstasy) Illicit drugs 5.0 10.0  Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Mefenamic acid Painkillers 274.6 1440.0 84.3 Tyne Ashton et al. (2004); Hilton & Thomas (2003); Jones et al. (2007); 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009); 
Roberts & Thomas (2006) 
Methotrexate Cancer 
treatments 
1000.0   SE England Aherne et al. (1985) 
Metoprolol  Other 
cardiovascular 
drugs 
55.0 130.0 100.0 Taff and Ely 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Metronidazole Antibiotics 309.0 561.0 100.0 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Miconazole Others 9.0  100.0 Thames Roberts & Bersuder (2006) 
Naproxen Painkillers 270.0 703.0 96.0 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Paracetamol Painkillers 4038.7 24525.0 93.0 Taff and Ely Ellis (2006); Jones et al. (2007); Kasprzyk-Hordern et al. (2008); 
Kasprzyk-Hordern et al. (2009) 
Propranolol Other 
cardiovascular 
drugs 
151.8 523.0 100.0 Taff, Ely, Sussex 
Ouse, Lea Thames, 
Tyne 
Zhang et al. (2008); Zhang & Zhou (2007); Ashton et al. (2004); Ellis 
(2006); Hilton & Thomas (2003); Kasprzyk-Hordern et al. (2008); 
Kasprzyk-Hordern et al. (2009); Roberts & Thomas (2006); Zhou et al. 
(2009) 
Pseudoephedrine Illicit drugs 26.7 27.7  Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Ranitidine Gastro-
intestinal 
drugs 
324.5 783.0 87.5 Taff and Ely 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Salbutamol Respiratory 
drugs 
36.5 234.0 87.0 Taff and Ely Jones et al. (2007); Kasprzyk-Hordern et al. (2009; 2008) 
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Table 2-7: Summary of pharmaceutical occurrence in treated STP effluent discharging to UK rivers 
Compound 
Therapeutic 
class 
Concentration 
(ng L-1) 
Mean 
detectio
n freq 
(%)3 
Catchment(s) or 
location(s) 
References 
Med1 Max2 
Simvastatin Blood lipid 
regulators 
5.0 20.0 19.0 Taff and Ely 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Sulfamethoxazole Antibiotics 23.6 132.0 50.0 Taff, Ely, Sussex 
Ouse 
Zhang et al. (2008); Zhang & Zhou (2007); Ashton et al. (2004); 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009); Zhou et 
al. (2009) 
Sulfapyridine Antibiotics 366.0 1112.0 100.0 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Sulfasalazine Antibiotics 242.3 2185.0 100.0 Taff and Ely Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Tamoxifen Cancer 
treatments 
199.0 369.0 4.0 Tyne Ashton et al. (2004); Roberts & Thomas (2006) 
Tramadol Painkillers 35980.
0 
97616.0 100.0 Taff and Ely 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Trimethoprim Antibiotics 501.8 3052.0 82.5 Taff, Ely, Tyne Ashton et al. (2004); Hilton & Thomas (2003); Kasprzyk-Hordern et al. 
(2008); Kasprzyk-Hordern et al. (2009); Roberts & Thomas (2006) 
Valsartan Other 
cardiovascular 
drugs 
173.0 711.0 96.0 Taff and Ely 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Venlafaxine Antidepressan
ts 
130.0 248.3  Taff and Ely 
Kasprzyk-Hordern et al. (2008); Kasprzyk-Hordern et al. (2009) 
Notes: 
Median value of all concentrations from combined studies 
Maximum value of all concentrations from combined studies 
Mean detection frequency of all samples from combined studies (not all studies stated detection frequencies) 
Blank cells indicate data were unavailable 
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These data are in agreement with occurrence data from other countries which generally 
lie within the range of a few ng L-1 up to tens of µg L-1 (Hughes et al., 2013).  Williams 
(2005) showed the average detection concentration in surface waters for human 
pharmaceuticals was 43 ng L-1 (compared to 18 ng L-1 for drinking water, 159 ng L-1 for 
ground water and 360 ng L-1 for treated STP effluent).  These data show substantial 
variation between minimum and maximum concentrations ranging up to a factor of >1300 
for paracetamol within the same study (Kasprzyk-Hordern et al., 2007).  There are a 
number of possible factors for such wide variation which may include: climate, weather 
and flow conditions, position within the catchment, STP specific factors (treatment 
technologies, flow rates, retention times, removal efficiencies and overflows etc.) and 
nature of the channel sediment which can affect both the input of pharmaceuticals 
associated with sewage effluent and the degradation in receiving waters (Kümmerer et 
al., 2005).  For example, the biodegradation rate of synthetic oestrogens in UK rivers has 
been shown to vary by a factor of 10 due to season and catchment location (Jürgens et 
al., 2002). The degree of dilution of sewage effluent in receiving waters is also a critical 
factor. Waiser et al. (2010) found a range of pharmaceuticals at relatively high 
concentrations (µg L-1) in a glacier fed river in Canada; certain reaches of this river 
comprised almost 100 % sewage effluent during periods of the year when glacial melt 
water is absent resulting in a dilution factor of 0.   
2.5.3.1 Non-steroidal anti-inflammatory drugs (NSAIDs) and painkillers 
The widely consumed NSAIDs (such as ibuprofen, paracetamol and diclofenac) were 
readily detected in these studies and at some of the highest concentrations in both STP 
effluent (up to 27 000 ng L-1 for ibuprofen) and receiving waters (5044 ng L-1 for 
ibuprofen).  Perhaps surprisingly, aspirin which was the second most widely prescribed 
drug in 2008 (130.7 tonnes, see Table 2-2) and is also a popular generic OTC pain 
reliever,  was only detected in relatively low river concentrations with a median of 4 ng L-
1 and a maximum of just 36 ng L-1.  This is likely due to the fact that approximately 80 % 
of the active ingredient in aspirin (acetylsalicylic acid) is readily metabolised (to salicylic 
acid) in the human liver (Levy, 1972).  However, these metabolites have been shown to 
have toxic effects on Daphnia magna (Marques et al., 2004).  Ibuprofen, by contrast is 
excreted 70-80 % in active forms which is a possible reason for its high detected 
concentrations (Pounds et al., 2008). The analgesic dextropropoxyphene was detected 
in generally lower concentrations (median river concentration 285 ng L-1) than other 
NSAIDs.  Perhaps this is due to the relatively small DDD of 200 mg even though it was 
prescribed 380 000 times (ranked 287th) in 2008 as co-proxamol in combination with 
paracetamol (see Table 2-3).  The total prescribed amount of dextropropoxyphene in 
2008 was an estimated 0.08 tonnes compared to 1.22 tonnes of co-proxamol 
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demonstrating that paracetamol accounts for the large majority of active pharmaceutical 
ingredients in this particular treatment.  Richardson and Bowron (1985) detected 
dextropropoxyphene in UK surface waters in the 1980s and estimated an environmental 
half-life of >1 year. 
2.5.3.2 Antibiotics 
After the NSAIDs, antibiotics were generally detected in the highest concentrations in 
effluent and receiving waters.  The macrolide antibiotic erythromycin and the β-lactam 
antibiotic amoxicillin were detected at the highest receiving water concentrations at 
maximums of 1022 and 622 ng L-1 respectively.  It is worth noting that the prescription 
volume of these two antibiotics has reduced within recent years with amoxicillin falling 
from rank 1 in 2005 to rank 13 in 2008 and erythromycin falling from 7 to 85 in the same 
period (NHS 2006; 2009b).  Therefore, the peak concentrations measured for 
erythromycin by Ashton et al. (2004) may not be reached if measured today.  Also, the 
peak concentration reported by Kasprzyk-Hordern et al. (2008) for amoxicillin may be 
considerably less than in 2005 when this compound was prescribed much more widely.  
These examples highlight the importance of up to date information on both consumption 
and environmental occurrence.  The sulphonamide antibiotic sulfamethoxazole is often 
combined with trimethoprim to form co-trimoxazole which was prescribed 65 500 times 
in 2008 resulting in a mass consumption of just 0.13 tonnes (see Table 2-3) which is 
reflected in the relatively low receiving water concentrations (maximum 37 ng L-1).  
However, the major metabolite acetyl-sulfamethoxazole was detected at slightly higher 
levels of up to 2235 ng L-1 and 240 ng L-1 in effluent and receiving waters respectively.  
As little as 15% of sulfamethoxazole is excreted as the parent compound and up to 43% 
can be excreted as the acetyl-sulfamethoxazole metabolite (van der Ven et al., 1994).  
Furthermore Radke et al. (2009) found that these metabolites can retransform into the 
parent compounds under environmental conditions.   
2.5.3.3 Blood lipid regulators and cardiovascular drugs 
Clofibric acid is the major active metabolite of the blood lipid regulator clofibrate and has 
been readily detected in surface waters in the UK and other countries; approximately 96 
% of the parent compound is excreted as active clofibric acid or its conjugates (Winkler 
et al., 2001).  Clofibrate has now been withdrawn from usage in much of Western Europe 
(it was not present in the 2008 PCA dataset) and replaced with other cholesterol lowering 
drugs after evidence of increased mortality rates amongst clofibrate treated patients 
(WHO, 1984).  Despite this, clofibric acid continues to be detected in the environment 
and is known to be highly persistent and mobile in the aquatic phase (see Heberer, 
2002).  It is also known to be very resistant to both sewage (5-51% removal; Ternes, 
1998; Zweiner & Frimmel, 2003) and drinking water treatment (Ternes et al., 2002).  
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Clofibric acid has been detected in Berlin tap water at concentrations up to 165 ng L-1 
(see Heberer et al., 1998).  Simvastatin is a drug used to regulate cholesterol levels in 
the blood (similar to clofibrate) and prevent cardiovascular disease and has risen from 
rank 47th in prescription numbers in 1997 to rank 1st in 2008 (see Table 2-2) but the 
relatively low DDD of 30 mg day-1 meant that only 1.02 tonnes were prescribed in 2008.  
This is reflected in the relatively low frequency of detection in the UK (when compared 
to NSAIDs and antibiotics) and the low concentrations in receiving waters (<50 ng L-1).  
However, blood lipid regulators alongside other drug types such as antiepileptics and 
contraceptives tend to be prescribed to patients on a long-term or permanent basis so 
the inputs of these drugs may represent a continuous source into the aquatic 
environment with much less seasonal variation (see Bound et al., 2006). 
Beta-blockers are a class of pharmaceuticals used primarily for the treatment of 
cardiac arrhythmia (abnormal electrical activity in the heart), hypertension (high blood 
pressure) and as protection following myocardial infarction (heart attack).  Of these 
compounds, atenolol was the most widely prescribed in 2008 followed by propranolol 
and metoprolol and this order is reflected in the occurrence data in (see Tables 2-3 and 
2-4) with maximum receiving water concentrations of 560, 215 and 12 ng L-1 respectively.  
Propranolol was the most frequently detected beta-blocker in UK surface waters with 
Ashton et al. (2004) finding it to be ubiquitous in all samples taken.  However, it must be 
noted that propranolol was frequently analysed in all of the studies shown in Table 2-5 
whereas atenolol and metoprolol were only analysed for in three of the studies.  Another 
reason for the possible variation in detected concentrations is the percentage excretion 
of unchanged parent compound which varies from <0.5, 10-30 and 50 % for propranolol, 
metoprolol and atenolol respectively (Kasprzyk-Hordern et al., 2007).  The metabolites 
of metoprolol are deactivated whereas approximately 20 % of the propranolol 
metabolites are in the form of glucuronide conjugates which have the potential to be re-
transformed into the parent compound. 
2.5.3.4 Other widely used drugs 
Salbutamol is a bronchodilator used in the treatment of bronchospasm for sufferers of 
asthma or other similar obstructive pulmonary disease.  It was the fifth most widely 
prescribed compound in 2008 but its low DDD of 10 mg day-1 and its predominant inhaled 
administration route (Moore et al., 1994) may be the reason for infrequent detection and 
generally low measured concentrations in UK surface waters (average 76 ng L-1).  Also, 
only an estimated 30 % of salbutamol is excreted unmetabolised by humans (see 
Kasprzyk-Hordern et al., 2007). Carbamazepine is an anticonvulsant and mood stabiliser 
used in the treatment of epilepsy and other disorders such as ADHD (attention-deficit 
hyperactivity disorder).  It was the 77th most widely prescribed drug in 2008 (see Tables 
50 
 
2-3 and 2-4) but the relatively high DDD of 1000 mg day-1 results in a total estimated 
consumption of 2.4 tonnes.  Table 2-5 shows that carbamazepine was quite widely 
detected at relatively high concentrations up to a maximum of 684 ng L-1 in the River 
Ouse (Zhou et al., 2009).  Carbamazepine was found to be ubiquitously present in 
samples taken by Kasprzyk-Hordern et al. (2008) in South Wales although they found 
another antiepileptic (gabapentin) to also be ubiquitous and at higher concentrations 
(maximum 1887 ng L-1).  This difference can be explained by the excretion ratios which 
is approximately 100 % unchanged for gabapentin but only 3 % unchanged for 
carbamazepine.  Both substances were found to be persistent in river water and 
demonstrated poor removal during sewage treatment (Kasprzyk-Hordern et al., 2008).  
Much higher concentrations of carbamazepine have been detected in Berlin (up to 1075 
ng L-1; Heberer (2002) and the River Elbe (up to 7100 ng L-1; Wiegel et al. 2004).  Studies 
into the occurrence of metabolites and transformation products are much less common; 
a recent review by Mompelat et al. (2009) found that over 160 pharmaceuticals had been 
explicitly studied but only 30 by-products.  This is surprising as some studies indicate 
that the environmental concentrations of metabolites and transformation can match or 
even exceed those of the parent compound (Celiz et al., 2009). 
This summary of the UK occurrence data for pharmaceuticals demonstrates how 
river water and effluent concentrations can vary between regions and even within the 
same river across multiple years.  Therefore, it is important that any study into the 
potential impacts of pharmaceuticals on river ecosystems is accompanied with relevant, 
local and up-to-date occurrence data so that laboratory and field studies can be informed 
by realistic environmental concentrations for that particular river.  In turn, these 
occurrence studies and compound selection should be designed using the most relevant 
and recent consumption data available.  A long-term routine monitoring study for a 
number of compounds (of differing use classes) at a range of STPs with different 
treatment technologies will provide valuable data on seasonal variations in effluent and 
receiving water concentrations.  Higher temporal resolution monitoring will also provide 
much needed data on how these concentrations vary over shorter time steps particularly 
in response to heavy rainfall events.  Finally, sampling a longer stretch of river away from 
the immediate influence of STP effluent discharges will further understanding of the fate 
and transport of pharmaceuticals in freshwater ecosystems. 
2.5.4 Predicting the occurrence of pharmaceuticals in rivers 
The data presented in section 2.5.3 and elsewhere (e.g. Hughes et al., 2013) 
demonstrate that there is a relative paucity of studies with an explicit focus on the 
presence of pharmaceuticals in surface waters (Tables 2-6 and 2-7).  Using the UK as 
an example, most studies have been conducted in southern and southeast England and 
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Wales.  Clearly, the geographic spread of these studies is biased to densely populated 
urban areas and the relevant research institutions but as the previous section (Section 
2.2.3) demonstrates, these occurrence data may not represent surface water 
concentrations in other parts of the UK.  In response to this some efforts have been made 
to predict potential surface water concentrations using models that combine water quality 
and hydrological flow models in a GIS environment.  The most frequently used model in 
Europe is GREAT-ER (Geography Referenced Regional Exposure Assessment Tool for 
European Rivers; see http://www.great-er.org/pages/home.cfm for details and technical 
documentation).  Other models used in north America include LF2000-WQX (Low Flows 
200-Water Quality modelling eXtension; Keller & Young (2004; 2006)) and PhATETM 
(Pharmaceutical Assessment and Transport Evaluation; Anderson et al., (2004)), a mass 
balance model developed for use in US surface waters. 
Two of these models have been applied explicitly to pharmaceuticals in the UK; 
Johnson et al. (2007) used LF2000-WQX to predict diclofenac and propranolol 
concentrations in a small rural catchment in Devon (England) and Johnson et al. (2008) 
used GREAT-ER to predict river concentrations of the anti-cancer drug 5-fluorouracil in 
the Aire and Calder catchments in West Yorkshire (England).  Both of these studies 
presented their final results for the 90th percentile flow; a low flow that is exceeded 90 % 
of the time and so can be assumed to be worst-case due to minimal levels of dilution.   
The rural study found concentrations were generally low (<1 ng L-1) except immediately 
downstream of some STPs where concentrations were >25 ng L-1.  Much higher 
concentrations were predicted for the more densely populated and urbanised Aire and 
Calder catchments (983 people km-2 c.f. 15 people km-2 in the Devon study) where 
concentrations ranging from 5 to >50 ng L-1 were predicted for long stretches of the 
catchment.  Schowanek & Webb (2002) also used GREAT-ER to predict concentrations 
of five pharmaceuticals and the synthetic oestrogen EE2 in the Aire catchment.  The final 
predicted environmental concentrations (PECs) ranged from 20 ng L-1 for 
dextropropoxyphene to 6800 ng L-1 for paracetamol.  These models can also produce 
geographically referenced graphical outputs to give users an idea of how concentrations 
vary across a catchment (e.g. Figure 2-8). 
Modelling studies predict relatively low concentrations in the upper reaches which 
increase as the burden of STP discharge increases downstream and the catchments 
become gradually more influenced by urban areas; this is particularly evident in the Aire 
and Calder.  Direct comparisons between these two modelled catchments are difficult as 
the authors chose to model different pharmaceuticals in each study and neither of these 
models was directly validated through analysis of the compounds measured in water 
samples.  However, validation of these models was undertaken using chloride and 
orthophosphate for the Devon catchment (Johnson et al., 2007) and boron and a 
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detergent for the Aire and Calder (Neal et al., 1998; Fox et al., 2000).  Both models were 
able to predict these concentrations reasonably well but it is questionable whether the 
same can be assumed for the much more varied and biologically active class of 
pharmaceuticals.  Schowanek & Webb (2002) attempted to validate their results with 
measured environmental concentrations (MECs) from previous studies and found that 
GREAT-ER over predicted for paracetamol and under predicted for 
dextropropoxyphene.  They attributed these errors to variations in consumption patterns 
between the modelled and MEC catchments, simplistic or worst-case assumptions about 
treatment removal and the poor representation of some in-stream degradation processes 
such as photolysis.   
 
 
(a) (b) 
Figure 2-8: (a) Predicted 5-fluorouracil concentrations in the Aire and Calder 
Catchments in Yorkshire under low flow conditions using GREAT-ER, (b) Predicted 
propranolol concentrations (ng L-1) in the Tamar catchment in Devon under low flow 
conditions using LF2000-WQX  
(Johnson et al., 2007; Johnson et al., 2008) 
 
Modelling may be useful in directing and prioritising compounds and catchments for more 
detailed occurrence studies without the need for preliminary fieldwork.  Versteeg et al. 
(2005) conducted basic comparisons between predicted and measured environmental 
concentrations for dextropropoxyphene and paracetamol in the Aire catchment (Table 2-
8).  
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Table 2-8: Comparison between predicted and measured concentrations in the River 
Aire catchment, UK 
(data adapted from Versteeg et al. 2005) 
API Human 
loss  
(%) 
STP 
removal 
(%) 
In-
stream 
decay 
(day-1) 
Basic 
PECsurfacewater  
(ng L-1)1 
GREAT-ER 
PECsurfacewater  
(ng L-1)2 
MECsurfacewater 
(ng L-1)3 
Dextropropoxyphene 99 0 0 7.5 20 58 
Paracetamol 10 98 0.047 630 6800 <50 
Notes: 
Basic predicted environmental concentration calculated as part of the environmental risk assessment 
process: assumes a mean wastewater flow of 259L person-1 day-1 and a dilution factor of 10 
This is the 90th percentile PEC under mean flow conditions 
Measured environmental concentration; data taken from Hilton et al. (2003) 
 
These data show that the basic PEC is 3 to 10 times lower than the GREAT-ER 
predictions suggesting the dilution factor of 10 may be overestimating actual dilution in 
the Aire.  The MEC for dextropropoxyphene was approximately 3 and 10 times greater 
than the GREAT-ER and basic estimates respectively whilst the PECs for paracetamol 
were more than ten times greater than the MECs.  Possible reasons for these 
discrepancies include varying flow magnitudes in the Aire during water sampling 
(compared with the mean flow assumed during PEC calculation) and a lack of more 
reliable consumption, metabolism and treatment removal data for these pharmaceuticals 
(Versteeg et al., 2005).  Thompson (2006) conducted comparisons between MECs and 
PECs for a total of 10 pharmaceuticals and found that PECs gave generally good 
agreements (within one order of magnitude) but were over-estimates for all but one 
compound (diazepam).  Aspirin was the most notable anomaly in these comparisons as 
it was grossly overestimated by the PEC calculation (by a factor > 10 000).   This was 
likely due to the high metabolism and removal of aspirin during treatment which is 
assumed to be 0 % in the basic PEC calculation.  It also must be noted that these two 
comparison studies used different consumption and MEC data. 
A comparison between monitoring and GREAT-ER predictions was also 
conducted by Küster et al. (2010) for the beta-blocker propranolol; these results indicated 
an agreement consistently within a factor of 2 for three European catchments (Germany 
and Switzerland).  However, these agreements were not as strong for another beta-
blocker atenolol which is much more readily biodegradable and this factor was not 
accounted for in the model.  The research summarised above indicate the potential 
applications of models such as GREAT-ER to screen a large number of pharmaceutical 
compounds for potential environmental risk and to use the results to better inform 
monitoring campaigns of STP effluent and rivers. 
2.5.5 The fate of pharmaceutical compounds in surface waters 
Consideration must be given to the transport and fate of pharmaceutical compounds 
once they enter river systems as research into their occurrence and effects rely on such 
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knowledge to highlight key areas of risk.  In their most basic forms, the risk assessment 
models mentioned earlier (such as GREAT-ER; Schowanek et al., 2001) make the 
simple assumption of first-order decay along a river reach once a compound has entered 
via a STP outfall.  However, this is oversimplified especially given the huge array of 
different pharmaceutical compounds with widely varying physico-chemical properties 
that enter rivers (Table 2-9).  The ultimate transport and fate of pharmaceuticals in rivers 
are subject to a number of key processes including (Farré et al., 2008; USEPA, 2010): 
 Photo transformation (both direct and indirect reactions via UV radiation); 
 Physical-chemical alteration, degradation and ultimately mineralisation; 
 Volatilisation; 
 Dispersion and dilution; 
 Biological uptake and alteration. 
The relative importance of the above processes has been shown to vary between 
specific compounds with different properties and depend on site-specific factors (Table 
2-9).  Pharmaceuticals demonstrate a wide range of solubilities (see Table 2-9) which 
will have a distinct impact on their transport and fate within aqueous systems; it is 
expected that more soluble compounds will readily pass through STPs.  The acid 
dissociation constant (pKa) gives an indication of the degree to which a specific 
compound will dissociate into ionic forms.  The majority of pharmaceutical compounds 
listed below (Table 2-9) have positive pKa values indicating they are moderate or weak 
acids and will remain largely in their parent (i.e. active, non-dissociated form) at 
environmental pH and temperature ranges (Harrison & deMora, 1996).  Log KOW is a the 
ratio of concentrations between the aqueous phase and the model hydrophobic phase 
(octanol) and can be seen as a measure of how hydrophilic/hydrophobic a chemical 
substance is (Leo et al., 1971).  The guidelines for environmental risk assessment of 
pharmaceuticals in the EU suggest that any compounds with log KOW greater than 4 
should be considered persistent, bioaccumulative and toxic (PBT; EMEA, 2006).  Most 
pharmaceuticals demonstrate lower values but some compounds do approach the PBT 
threshold indicating varying degrees of hydrophobicity.  Sorption to the solid phase (Kd) 
or to organic carbon (KOC) is also highly variable between compounds; although 
substances containing amine functional groups (e.g. propranolol) appear to sorb more 
readily than neutral or carboxylic acid pharmaceuticals such as paracetamol and 
ibuprofen (Yamamoto et al., 2009).  Brown et al. (2007) identified NSAIDs as a key group 
as they demonstrate sufficient solubility to avoid sorption during passage through STPs 
but are sufficiently lipophilic to bioconcentrate in aquatic organisms.  Furthermore, 
55 
 
sorption to organic carbon is dependent on the amount of carbon available either 
suspended in freshwaters or in sediments and is therefore likely to be highly variable 
across temporal and spatial scales in complex river systems (Giller & Malmqvist, 1998).  
All of these parameters are in turn dependent on temperature and pH both of which vary 
in freshwater systems (Harrison & deMora, 1996); this highlights the need for a 
combination of lab and field experiments if the fate of pharmaceuticals is to be better 
understood. 
Natural attenuation in the environment plays a key role in decontamination with 
associated implications for water quality and the ecological status of freshwaters (Farré 
et al., 2008).  However, estimates of environmental fate depend strongly on experimental 
conditions (lab vs. field studies) and particularly the testing system used (e.g. water only 
or a combined sediment/water system and the presence/absence of biota).  Identical 
compounds can demonstrate varying attenuation between different studies (attenuation 
of diclofenac ranged from 0 to 69 % across reaches of several kilometres in three studies 
by the same research group; see Table 2-9).  This is most likely due to specific local and 
experimental factors. 
Despite these complications, the available data suggest that direct or indirect 
photo-degradation is the dominant removal mechanism for most pharmaceutical 
compounds in surface waters (Mompleat et al. 2009).  Local factors play a large role in 
determining ultimate fate and transport of pharmaceutical compounds.  For example, 
latitude, cloud cover, rainfall, riparian and aquatic vegetation, channel depth and turbidity 
can act as strong controls on photo-degradation in rivers and such factors have been 
used to explain low, variable attenuation of photo labile compounds such as diclofenac 
(Packer et al., 2003).  Flow rates and velocities have been shown to have a significant 
effect on downstream transport and attenuation with greater removal generally observed 
during low flow events due to longer travel times and reduced turbidity (Kolpin et al., 
2004; Radke et al. 2010).  Research into the fate and transport of pharmaceuticals in 
freshwaters is relatively sparse and there are only a small number of laboratory and field 
studies.  However, the available data show variability within and between compounds, 
testing regimes and field sites (Table 2-9).  Much more research is necessary if the fate 
of these compounds is to be understood.  It is clear that the assumption of first-order 
decay in rivers used by risk assessment models (e.g. Schowanek et al. 2001) is unsafe 
and wherever possible reliable experimental data, preferably combining laboratory and 
field techniques, should be used to inform this aspect of the risk assessment process. 
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Table 2-9: Summary of environmental fate and transport data for selected pharmaceutical compounds in rivers 
Compound Physicochemical 
properties 
Dominant attenuation 
mechanism (lab or field) 
Transport and attenuation Environmental half-
life (days) 
Reference 
Atenolol Kd = 1.3-110 
KOC = 310 - 5000 
log KOW = 0.16 
Solubility = 300 mg L-1 
pKa = 9.6 
Lab: water/sediment system  2.3-3.0 (water) 
2.3-3.0 
(water/sediment) 
Ramil et al. 
(2009) 
Acebutolol log KOW = 1.71 
Solubility = 259 mg  
L-1 
Lab: water/sediment system  2.0-5.9 (water) 
10.9-27.7 
(water/sediment) 
Ramil et al. 
(2009) 
Bezafibrate 
log KOW = 4.25 
Solubility = 0.335 mg 
L-1 
Lab: biodegradation 50% removal along 87km and 113km 
under slow and fast water-sediment 
exchange 
4.3-8.4 
(biodegradation) 
Kunkel & 
Radke (2008) 
Field: none 0% removal along 16km stretch of small 
river 
 Kunkel & 
Radke (2011) 
Bisoprolol log KOW = 1.87 
Solubility = 2240 mg L-
1 
Lab: water/sediment system  3.9-8.4 (water) 
8.6-27.7 
(water/sediment) 
Ramil et al. 
(2009) 
Carbamazepine 
Kd = 0.08 – 1.8 
KOC = 0.01 – 0.06 
log KOW = 2.45 
Solubility = 17.7 mg L-1 
pKa = 13.9 
Field: unknown 0% removal along 11km stretch of 
shallow river 
 Gross et al. 
(2004) 
Field: unknown  63.0 Tixier et al. 
(2003) 
Lab: water/sediment system  328.0 Löffler et al. 
(2005) 
Celiprolol 
log KOW = 1.92 
Solubility = 93.9 mg L-1 
Lab: water/sediment system  3.0-13.1 (water) 
23.9-67.0 
(water/sediment) 
Ramil et al. 
(2009) 
Ciprofloxacin log KOW = 0.28 
Solubility = 0.0003 mg 
L-1 
pKa = 6.1 
Lab: biodegradation  >29.0 (biodegradation) Girardi et al. 
(2011) 
Clofibric acid 
log KOW = 2.57 
Solubility = 583 mg L-1 
Lab: biodegradation   Kunkel & 
Radke (2008) 
Field: biofilm 35% removal along 16km stretch of small 
river 
2.5 Kunkel & 
Radke (2011) 
Field: unknown  >63.0 Tixier et al. 
(2003) 
Lab: water/sediment system  119.0 Löffler et al. 
(2005) 
Diclofenac 
log KOW = 4.02 
Field: photolysis and sediment 
biotransformation 
69% and 41% removal along a 12km 
river during sunny and rainy conditions  
 Kunkel & 
Radke (2012) 
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Table 2-9: Summary of environmental fate and transport data for selected pharmaceutical compounds in rivers 
Compound Physicochemical 
properties 
Dominant attenuation 
mechanism (lab or field) 
Transport and attenuation Environmental half-
life (days) 
Reference 
Solubility = 2430 mg L-
1 
pKa = 4.0 
Lab: biodegradation 50% removal along 193km and 144km 
under slow and fast water-sediment 
exchange 
5.5-18.6 
(biodegradation) 
Kunkel & 
Radke (2008) 
Field: photolysis  8 Tixier et al. 
(2003) 
Lab: photolysis  <0.1 
(rapid photolysis) 
Buser et al. 
(1998) 
Field: none 0% removal along 16km stretch of small 
river 
 Kunkel & 
Radke (2011) 
Gemfibrozil 
log KOW = 4.77 
Solubility = 10.9 mg L-1 
Field: photolysis 64-72% removal along 12km stretch 
depending on time of day 
0.6 (photolysis) Lin et al., 
(2006) 
Lab :biodegradation 50% removal along 278km under fast 
water-sediment exchange 
2.5 (biodegradation) Kunkel & 
Radke (2008) 
Field: unknown 58% to 67% removal along 11km stretch 
of shallow river 
 Gross et al. 
(2004) 
Ibuprofen 
Kd = 0.09 – 0.9 
KOC = 0.01 – 9.4 
log KOW = 3.79 
Solubility = 21 mg L-1 
pKa = 4.91 
Field: none Full transport along 12km  Kunkel & 
Radke (2012) 
Field: photolysis 87% removal along 12km stretch 
depending on time of day 
0.1-0.6 (photolysis) Lin et al., 
(2006) 
Lab: biodegradation 50% removal along 53km and 66km 
under slow and fast water-sediment 
exchange 
2.5-5.1 
(biodegradation) 
Kunkel & 
Radke (2008) 
Lab: biodegradation  >37.0 (photolysis) 
20.0 (biodegradation) 
Buser et al. 
(1999) 
Field: unknown 47% to 83% removal along 11km stretch 
of shallow river 
 Gross et al. 
(2004) 
Field: biofilm 100% removal along 16km stretch of 
small river 
0.4 Kunkel & 
Radke (2011) 
Field: sorption  32 Tixier et al. 
(2003) 
Lab: water/sediment system  <6.0 Löffler et al. 
(2005) 
Ivermectin 
 
Lab: water/sediment system  15.2 Löffler et al. 
(2005) 
Ketoprofen 
log KOW = 3.12 
Solubility = 51 mg L-1 
pKa = 4.45 
Field: unknown 100% removal along 11km stretch of 
shallow river 
 Gross et al. 
(2004) 
Field: photolysis and 
biotransformation 
  Tixier et al. 
(2003) 
Metoprolol 
 
Field: none 0% removal along 16km stretch of small 
river 
 Kunkel & 
Radke (2011) 
Lab: water/sediment system  4.1-8.7 (water) 
17.8-28.9 
(water/sediment) 
Ramil et al. 
(2009) 
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Table 2-9: Summary of environmental fate and transport data for selected pharmaceutical compounds in rivers 
Compound Physicochemical 
properties 
Dominant attenuation 
mechanism (lab or field) 
Transport and attenuation Environmental half-
life (days) 
Reference 
Nadolol log KOW = 0.81 
Solubility = 8330 mg L-
1 
Lab: water/sediment system  3.1-3.7 (water) 
4.0-9.0 
(water/sediment) 
Ramil et al. 
(2009) 
Naproxen 
log KOW = 3.18 
Solubility = 15.9 mg L-1 
pKa = 4.15 
Field: sediment 
biotransformation 
50% and 43% attenuation along 12km 
river during sunny and rainy conditions 
 Kunkel & 
Radke (2012) 
Field: photolysis 75-100% removal along 12km stretch 
depending on time of day 
0.3-0.6 (photolysis) Lin et al., 
(2006) 
Field: unknown 100% removal along 11km stretch of 
shallow river 
 Gross et al. 
(2004) 
Lab: biodegradation 50% removal along 144km and 272km 
under slow and fast water-sediment 
exchange 
10.3-13.9 
(biodegradation) 
Kunkel & 
Radke (2008) 
Field: photolysis and 
biotransformation 
 14 Tixier et al. 
(2003) 
Field: none 0% removal along 16km stretch of small 
river 
 Kunkel & 
Radke (2011) 
Oxazepam log KOW = 2.24 
Solubility = 179 mg L-1 
Lab: water/sediment system  54.0 Löffler et al. 
(2005) 
Paracetamol Kd = 1.0 – 7.7 
KOC = 170 - 13000 
log KOW = 0.46 
Solubility = 0.0004 mg 
L-1 
pKa = 9.38 
Lab: water/sediment system  3.1 
Löffler et al. 
(2005) 
Pindolol log KOW = 1.75 
Solubility = 7880 mg L-
1 
Lab: water/sediment system  0.1-0.5 (water) 
0.1-0.5 
(water/sediment) 
Ramil et al. 
(2009) 
Propranolol 
log KOW = 2.60 
Solubility = 31.7 mg L-1 
pKa = 9.4 
Field: sediment 
biotransformation 
70% and 42% attenuation along 12km 
river during sunny and rainy conditions 
 Kunkel & 
Radke (2012) 
Lab: water/sediment system  0.4-1.8 (water) 
9.9-33.0 
(water/sediment) 
Ramil et al. 
(2009) 
Sotalol 
log KOW = 0.24 
Solubility = 5510 mg L-
1 
Field: photolysis and sediment 
biotransformation 
42% and 36% attenuation along 12km 
river during sunny and rainy conditions 
 Kunkel & 
Radke (2012) 
Lab: water/sediment system  7.6-8.2 (water) 
11.4-30.0 
(water/sediment) 
Ramil et al. 
(2009) 
Sulfamethoxazole 
log KOW = 0.89 
Solubility = 610 mg L-1 
Field: sediment 
biotransformation 
26% and 25% attenuation along 12km 
river during sunny and rainy conditions 
 Kunkel & 
Radke (2012) 
Lab: water/sediment system  25.6 (biodegradation in 
sediment) 
Radke et al. 
(2009) 
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2.6 Consequences of pharmaceuticals in the environment 
2.6.1 Introduction to current ecotoxicological methods and concerns for 
pharmaceuticals 
Definitions for the science of ecotoxicology range from a focus on individual organisms 
like that of Jørgensen (1990) towards more focus on higher levels of biological 
organisation like that of Walker et al. (2001) who emphasised the study of harmful effects 
on ecosystems.  In fact, ecotoxicological effects can be demonstrated from biomolecular 
and cellular scales, through to single organisms, populations and ecosystems and 
potentially up to landscape and biosphere scales (Newman & Unger, 2003).  Processes 
at one level draw mechanisms from the level below and exhibit consequences at the 
level above (Caswell, 1996).  Therefore, ecotoxicologists should consider all levels of 
ecological organisation across a range of temporal scales if they are to understand, 
predict, prevent and mitigate the impacts of toxic substances in the environment 
(Newman & Unger, 2003). 
Recent research has attempted to understand their potential environmental 
impacts (Daughton, 2007).  The widely reported 95 % decline in vulture (Gyps 
benegalensis) populations in India and Pakistan has been directly linked to the anti-
inflammatory drug diclofenac which caused renal failure, visceral gout and uric acid 
accumulation eventually leading to death (Oaks et al., 2004).  Vultures consumed 
livestock carcasses that had been treated with diclofenac and subsequent lethal effects 
for vultures were observed at just 10 % of the recommended mammalian dose.  This 
cause was only discovered after exhausting more 'traditional' causes of death (heavy 
metal poisoning, viruses, bacteria etc.) and as a result veterinary application of 
diclofenac is now banned in India (Dorne et al., 2007).  This is an excellent example of 
the unintentional release of a pharmaceutical into the environment and a subsequent 
devastating impact on a non-target organism manifesting at population level.  
Unintended environmental consequences have been experienced for other species, 
such as an increase in food availability for the feral dog (Canis familiaris) and rat (Rattus 
spp.); this also brings associated public health and social concerns (Dorne et al., 2007).  
It must be noted that traditional acute toxicity tests conducted in the laboratory did not, 
and could not anticipate the effects on Gyps vultures because of their focus on short-
term effects on single species (Oaks et al., 2004).   
Another widely studied and acknowledged impact on non-target organisms is that 
of the synthetic oestrogen ethinylestradiol (EE2, used in the human contraceptive pill) on 
fish and other aquatic organisms.  Concentrations as low as 0.1 to 5.0 ng L-1 have been 
linked with reductions in fecundity, suppression of male secondary sexual 
characteristics, intersex and population failure due to reduced fertility in a number of fish 
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species (Nash et al., 2004; Pawlowski et al., 2004; Colman et al., 2009). Other chemical 
compounds produced and consumed in domestic and industrial settings have been 
widely acknowledged to disrupt the endocrine system in fish and to mimic the action of 
natural oestrogens (Mittwoch et al., 1993; Ashby et al., 1997).  Compounds such as 
detergents, pesticides and surfactants have been shown to elicit such effects with high 
concentrations capable of feminising male fish, particularly those present in rivers which 
receive high STP effluent loads (Jobling & Sumpter, 1993; Purdom et al., 1994; Sumpter, 
1995; Tyler et al., 1998).  The above examples highlight the potential for unforeseen 
consequences for organisms at all trophic levels and environmentally relevant 
concentrations.  This section of the literature review will summarise current knowledge 
and data gaps on the ecotoxicological impacts of pharmaceuticals with a particular focus 
on aquatic organisms.  
2.6.1.1 Standardised toxicity testing procedures 
Pharmaceuticals are subject to very rigorous pharmacological, mammalian toxicology 
and clinical testing prior to approval for human use but Pascoe et al. (2003) highlighted 
a paucity of data examining their effects on aquatic fauna, particularly important 
freshwater taxa such as invertebrates.  Sanderson et al. (2003) estimate that 
ecotoxicological data is publicly available for just 1 % of approved human 
pharmaceuticals.  Despite the need for ecotoxicological studies to consider a range of 
ecological levels and temporal scales, the vast majority of data that do exist have been 
derived from short-term acute toxicological studies using a range of standard organisms 
in idealised laboratory experiments (Santos et al., 2010).  These acute toxic effects are 
generally manifested through non-specific mechanisms of action (MOAs) usually 
disrupting cellular membranes (known as narcosis) resulting in cell death (cytotoxicity) 
or oxidative stress that results in cellular damage (Fent, 2008).  Generally, these tests 
are conducted in line with established guidance such as the Organisation for Economic 
Co-operation and Development (OECD) Guidelines for Testing of Chemicals Section 2 
and include a range of organisms, toxicological endpoints and life stages: 
 OECD Report 201 (OECD, 2011) – Alga, Growth Inhibition Test – assesses the 
effect of a substance on the growth rate of unicellular algal species (e.g. 
Selenastrum capricornutum) – 72 hour duration; 
 OECD Report 202 (OECD, 2004) – Daphnia sp., Part I Acute Immobilisation Test 
and Part II Reproduction Test – assesses the effects on swimming as well as the 
timing and rate of reproduction of the planktonic crustacean, Daphnia magna – 
48 hours for Part I and up to four weeks for Part II which should include 
approximately nine batches of offspring; 
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 OECD Report 210 (OECD, 1992) – Fish, Early Life Stage Toxicity Test – 
assesses lethal and sub-lethal effects on fertilised eggs.  The report includes a 
list of recommended fish species such as Rainbow Trout (Oncorhynchus mykissi) 
and Zebrafish (Brachydanio rerio) – continues until all hatched fish are free-
feeding which can be > 1 month; 
 OECD Report 221 (OECD, 2006) – Lemna sp. Growth Inhibition Test – 7-day test 
to assess the impact on growth of the free-floating aquatic macrophyte genus 
Lemna (usually Lemna gibba or L. minor – 7 days). 
Other tests include the effects on soil microorganisms, honeybees, sediment dwelling 
Chironomids and respiration of activated sludge; the guidelines for these are available 
freely on the OECD website (OECD, 2012).  Data from these experiments are fitted to a 
dose-response model from which either the LC50 (median lethal concentration), EC50 
(median effective concentration), lowest-observed-effect-concentration (LOEC) and no-
observed-effect concentration (NOEC) can be calculated (Newman & Unger, 2003).  The 
majority of these tests are concerned with acute toxicity which will have an effect on the 
organism in question within 96 hours (Sprague, 1969) although some such as OECD 
Reports 202 and 204 (OECD, 1984; OECD, 2004) look at prolonged toxicity for up to 
four weeks.  However, even 14 day tests of fish toxicity do not cover a sufficient 
proportion of their life cycle to be classed as chronic studies (Suter, 1993). 
2.6.2 Summary of short-term toxicity data 
There are a number of reviews of the toxicity of pharmaceuticals to aquatic organisms 
available in Crane et al. (2006), Enick & Moore (2007), Fent et al. (2006), Fent (2008), 
Halling-Sørensen et al. (1998), Hughes et al. (2013), Santos et al. (2010) and Webb 
(2001).  As such, these data will not be replicated here but rather an overview of general 
acute toxic effects is presented.   
The review articles show that short-term toxicity can vary markedly for the same 
compound across trophic levels and even between similar species.  For example, D. 
magna is much more tolerant of diclofenac when compared to the macrophyte Lemna 
minor and the beta-blocker metoprolol when compared to another crustacean 
Ceriodaphnia dubia (Cleuvers, 2003; Ferrari et al., 2003).  Data also show that acute 
toxicity varies with exposure time and toxicity endpoint and that final LC50 or EC50 values 
can vary due to differing susceptibility of sourced test organisms and actual exposure 
concentrations (when nominal concentrations are used) (Fent, 2008).  These data also 
show that generally very high concentrations (>1 to 10 mg L-1) are required to elicit an 
acute toxic effect over short time scales.  These concentrations are generally well above 
those encountered in the aquatic environment, often exceeding them by several orders 
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of magnitude (103 to 107; (Fent et al., 2006)).  Webb (2001) compared the acute toxicity 
responses in various trophic levels and found that the antidepressant, antibiotic and 
antipsychotic compounds were generally the most toxic and that algae were generally 
the most sensitive organisms.  A similar comparison by Jones et al. (2002) identified the 
same high risk compound classes (Table 2-10).  Hughes et al. (2013) compared the 
measured environmental concentrations of major classes of pharmaceuticals and their 
potential risk of chronic toxicity to fish, invertebrates, bacteria, algae and plants in 
freshwater ecosystems.  At particular risk were invertebrates and fish due to exposure 
to relatively high concentrations of antibiotics and cardiovascular drugs (particularly in 
Asia); antidepressants and painkillers pose a similar risk in North America.  Contrast 
media and tranquilisers were also identified as posing a significant global risk to fish and 
invertebrates.  Despite this such compounds remain relatively poorly studied both in 
terms of their environmental occurrence and ecotoxicology. 
There are some notable exceptions to the rule of low acute toxicity.  For example 
the antidepressants fluoxetine and fluvoxamine demonstrate acute toxicity to green 
algae (EC50 = 31 000 ng L-1) and Sphaerium clam species (4 hour LOEC = 3000 ng L-1) 
at much lower concentrations (Webb, 2001; Brooks et al., 2003).  Also, carbamazepine 
demonstrates acute lethality to zebrafish at 43 000 ng L-1 (Santos et al., 2010).  However, 
the maximum measured environmental concentration of fluoxetine was 596 ng L-1 taken 
from estuarine samples in New York, USA (Benotti & Brownawell, 2007) and the global 
median concentration was 17.8 ng L-1 (Hughes et al., 2013).  Fluvoxamine has only been 
studied twice in the environment with median and maximum concentrations of 0.7 and 
4.6 ng L-1 respectively (Vasskog et al., 2008; Schultz et al., 2010).  Carbamazepine is 
much more widely studied in the environment with at least 50 studies detecting it 
(Hughes et al., 2013; Loos et al., 2009) at median and maximum concentrations of 176 
and 11 561 ng L-1 respectively. 
These data demonstrate that for most compounds the margin of safety for acute toxicity 
is high but there are exceptions to this rule.  This may be of particular concern in areas 
immediately adjacent to large or poorly performing STPs, CSOs or pharmaceutical 
manufacturing facilities (Hughes et al., 2013).  The widely held opinion that the risk of 
acute toxicity is low (Fent, 2008) does therefore hold for most compound classes but 
further research is required. 
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Table 2-10: Summary of toxicity of pharmaceuticals to aquatic organisms 
(adapted from Jones et al., 2002) 
Substances Extremely 
toxic  
EC50  
<0.1 mg L-1 
Very toxic  
EC50  
0.1-1 mg L-1 
Toxic  
EC50  
1-10 mg L-1 
Harmful 
EC50  
10-100 mg L-1 
Non-toxic 
EC50  
>100 mg L-1 
Analgesics   D D, E  
Antibiotics A B    
Antidepressants  D    
Anti-epileptics   C  D, E 
Cardiovascular  D    
Cytostatics  A  D, E  
X-ray contrast 
media 
    A, B, D, E 
Most sensitive taxonomic groups: A (micro-organisms), B (algae), C (cnidarians), D (crustaceans), E 
(fish). 
2.6.3 Summary of long-term and chronic toxicity data 
Fent (2008) states that 38 % of tested compounds showed acute toxicity above 100 mg 
L-1, classifying them as “not harmful to aquatic organisms” according to EU Directive 
2001/83/EC.  Given this and the generally low risk of widespread, frequent acute toxicity 
the focus of toxicological testing should address the potential for long-term and chronic 
effects at environmentally realistic concentrations (Hughes et al., 2013).  This is of 
particular relevance to aquatic organisms adjacent to STP outfalls for which there is 
potential for life-long and multigenerational exposure through the ‘pseudo-persistence’ 
of continually discharging effluent (Daughton, 2001).  However, there is a relative lack of 
chronic data perhaps due to the increased costs, logistics and analytical requirements of 
longer exposure times or the assessment of sub-lethal endpoints.  A chronic toxicity 
study is defined by convention to be at least 10 % of the species’ life span (Suter, 1993) 
but this is often not achieved and much shorter tests are incorrectly classed as chronic 
(Newman & Unger, 2003).   More investigations into specific receptors, effects, life 
stages and life cycle studies are almost completely lacking for the vast majority of 
pharmaceuticals (Fent et al., 2006). 
Reviews of chronic ecotoxicological data are available elsewhere (see references 
in Section 2.6.2 and Hughes et al., 2013) which provide useful indicators of likely sub-
lethal impacts resulting from longer-term exposure to low level concentrations.  This 
continuous, chronic exposure is of particular concern as any negative effects may 
accumulate and manifest so slowly that they will be attributed to natural, ecological 
succession and by the time they have been identified the effects may be irreversible 
(Daughton & Ternes, 1999).  These review data show that the majority of chronic toxicity 
values lie within the range of 10 µg L-1 to >10 mg L-1 which are generally at least 1 to 2 
orders of magnitude greater than the concentrations measured in sewage effluent; this 
gap is greater when dilution in receiving waters is taken into account (Hughes et al., 
2013).  This demonstrates that the margin of safety between measured and toxic 
concentrations is much narrower for chronic toxicity.   
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Indeed, there are some compounds which demonstrate chronic toxicity at or close to 
concentrations measured in the environment.  For example, ibuprofen has been shown 
to affect the polyp structure of Hydra vulgaris at 10 000 ng L-1 (Pascoe et al., 2003) and 
has been detected in Turkish rivers at concentrations up to 31 323 ng L-1 (Loos et al., 
2009) with a global median of 517 ng L-1 (Hughes et al., 2013).  Propranolol has also 
been shown to reduce fecundity and recruitment in Japanese medaka (Oryzias latipes) 
at 500 ng L-1 (Huggett et al., 2002) which corresponds with the maximum environmental 
concentration of 590 ng L-1 measured in a German river (Ternes, 1998); although the 
global median concentration was just 19 ng L-1 (Hughes et al., 2013).  Fluoxetine 
demonstrates chronic toxicity at some of the lowest concentrations; for example fathead 
minnow (Pimephales promelas) escape velocity was reduced at a concentration of just 
25 ng L-1 which in turn, may have secondary impacts on predator avoidance (Painter et 
al., 2009).  This concentration is very close to the global median river concentration of 
18 ng L-1 indicating a strong likelihood of chronically toxic effects in fish (Hughes et al., 
2013).  However, no information is available on the length of time at which rivers were at 
the ‘maximum’ exposure to these measured concentrations and as such direct 
comparisons between laboratory exposures of several hours to several weeks and 
instantaneous samples of river concentrations should be treated with some caution. 
There are also examples of positive (or at least non-adverse) effects at relatively 
low concentrations.  For example, fluoxetine caused an increase in brood size of Daphnia 
at 36 000 ng L-1 which may be attributed to a toxicological phenomenon known as 
hormesis (Flaherty & Dodson, 2005).  This bi-phasic response may be an adaptive 
change to low levels of stress resulting in increased fitness for a finite period of time, 
often at the expense of growth (Figure 2-9; (Calabrese & Baldwin, 2002)). 
 
Figure 2-9: Graphical example of a U-shaped hormetic dose response 
(Calabrese, 2004) 
 
Apart from a few exceptions (Oetken et al., 2005; Triebskorn et al., 2007; Nentwig, 2008; 
Painter, 2009), most toxicological studies focus on non-specific endpoints of growth, 
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survival, reproduction and immobilisation to the individual with much less emphasis on 
species-specific endpoints (e.g. polyp structure test of Pascoe et al. (2003)).  There is 
even less evidence of research addressing behavioural, morphological or physiological 
responses and a clear need for much more research into effects at the population, 
community or ecosystem level (Figure 2-10; Santos et al. (2010)).  Ankley et al. (2005) 
suggest adopting other species into standard ecotoxicological testing to represent taxa 
that are currently overlooked.  For example Chironomus are sediment-dwelling aquatic 
insects that may be particularly useful for testing for a number of reasons: insects are a 
critical group of aquatic organisms, they have a number of distinct life stages which may 
vary in sensitivity and unlike most test invertebrates (e.g. cladocerans) they reproduce 
sexually, a process which may be sensitive to pharmaceuticals. 
 
Figure 2-10: (a) Acute vs. chronic ecotoxicological studies (b) Principal endpoints used 
in ecotoxicological studies (relative %)  
(data collected from 94 articles published between 1996 and 2009; Santos et al. (2010)) 
2.6.4 The effects of pharmaceutical mixtures 
Single compound studies can only go so far in predicting the total toxic burden or 
‘exposure totality’ of aquatic organisms in the environment; Daughton (2003) describes 
this as the ‘4Ts’ of toxicant-totality-tolerance-trajectory which accounts for an organism’s 
complete exposure timeline.  Environmental parameters, particularly pH, may have an 
influence on speciation which can influence the hydrophobicity and subsequently the 
bioavailability of pharmaceuticals but this has only rarely been investigated (Fent et al., 
2006).  As well as the dynamic physico-chemical nature of the aquatic environment, 
pharmaceuticals are present not as individual compounds but as a multi-component 
mixture including a vast array of compounds, their transformation products and 
metabolites alongside other organic and inorganic pollutants (Fent, 2008).  Furthermore, 
it is likely that the relative proportions of individual compounds in this mixture will fluctuate 
over time as the concentrations of pharmaceuticals in sewage effluent are known to be 
highly variable (Kanda et al., 2003).  Despite this, only a limited number of studies have 
been conducted looking at the effects of pharmaceutical mixtures and their toxicity to 
aquatic organisms.   
Cleuvers (2003; 2004) evaluated the mixture toxicity of NSAIDs and other 
pharmaceuticals on Daphnia magna, algae and L. minor.  These studies found that drugs 
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acting in combination follow the concept of concentration addition (CA) although the 
combination effect was slightly stronger for Daphnia.  This is a very important conclusion 
as compounds present in the environment below their individual NOECs can still exert a 
toxic effect when acting in combination.  Dietrich et al. (2010) tested the effects of a 
mixture of four diverse pharmaceuticals (carbamazepine, diclofenac, metoprolol and 
17α-ethinylestradiol) on the moulting and reproduction of the freshwater amphipod 
Gammarus fossarum.  The study found no significant effects on reproduction but some 
disruption to moulting and growth in control individuals.  
Pharmaceuticals with similar mechanisms of action (MOAs) tend to follow 
concentration addition but those with dissimilar MOAs have been found to follow 
independent action (IA), where only those compounds with an effect at that particular 
concentration will contribute (Escher et al., (2005).  A study by Dyer et al. (2000) 
suggests that cumulative baseline toxicity (narcosis) of mixtures with a large number of 
compounds may dominate over the combined effect of specific MOAs, particularly if the 
mixture components are below individual effect thresholds. Baseline toxicity is a non-
specific disturbance of cellular membranes due to the solid-phase partitioning of 
hydrophobic pollutants and this constitutes the minimal toxicity of every chemical 
(Newman & Unger, 2003). Christensen et al. (2006; 2007) concluded that concentration 
addition was the dominant mixture model for antibiotics and antidepressants although 
some synergistic effects were present for combinations of erythromycin and 
oxytetracycline used in aquaculture.  Overall, Cleuvers (2003) recommended that CA be 
assumed unless evidence indicates otherwise.  Even mixture toxicity tests have a 
number of limitations for use in representing actual environmental conditions (Backhaus, 
2008): 
 Different degradation kinetics between compounds means the relative 
concentrations in the mixture will vary over time; 
 Inability to infer the effects of individual compounds from the mixture; 
 The mixtures are often relatively simple with <10 component compounds; 
 The mixture is static with no compounds being added or lost whereas 
environmental mixtures are dynamic in time; 
 Toxicity can only be inferred for the specific mixture(s) tested for and the results 
are not applicable for different mixtures. 
Indeed, O’Brien & Dietrich (2004) suggest that the situation of pharmaceutical mixture 
toxicity is so complex that the most economically viable solution would be to simply 
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upgrade all European STPs; although this opinion has not been widely discussed 
amongst the scientific community or water industry. 
2.6.5 Toxicity of pharmaceutical metabolites and transformation products 
There have been relatively few studies focusing specifically on the environmental toxicity 
of pharmaceutical transformation products and metabolites to aquatic organisms.  This 
is despite a recommendation in the EMEA (2006) guidelines on risk assessment to 
explicitly consider any metabolite that may be present at a concentration >10 % of the 
parent compound (Celiz et al., 2009).  Perhaps the most widely studied is clofibric acid, 
an active metabolite of the blood lipid regulator clofibrate which is known to persist in the 
environment and has been the subject of a number of ecotoxicological studies (Halling-
Sørsensen et al., 1998).  Miao & Metcalfe (2003) monitored the occurrence of 
carbamazepine in surface waters; this drug is considered to be particularly problematic 
with approximately 30 associated metabolites.  Just 3 % of the parent compound is 
excreted in its active form and this study revealed the occurrence of one metabolite at 
three times the concentration of carbamazepine.  La Farré et al. (2008) conducted a 
review of ecotoxicological data with a particular focus on transformation products and 
suggested that more research effort be spent on these as some have been found to be 
more toxic or present in higher environmental concentrations than their parent 
compounds.  For example, transformation products of paracetamol after sewage 
treatment were found to be up to 58x more toxic to mice when compared with the parent 
compound (Bedner & MacCrehan, 2005).   
It is generally considered that transformation products or metabolites are more 
polar and hence less bioavailable, for example the phototransformation products of 
propranolol were found to be less toxic to algae and rotifers (Liu et al., 2009).  However, 
the same authors recommend that risk assessment of a parent compound that is mostly 
or completely metabolised in the human body is not representative and that the risk 
assessment procedures should be more flexible allowing assessors to specifically target 
transformation products in such cases.  Lienert et al. (2007b) conducted a modelling 
study using quantitative structure activity relationships to predict the mixture toxicity of 
parent compounds and metabolites for 30 pharmaceuticals.  This review concluded that 
human metabolism generally decreases overall mixture toxicity for most pharmaceuticals 
but certain APIs have specifically acting metabolites which may serve to increase toxicity.  
Therefore, they recommended that metabolites be considered as an integral part of the 
risk assessment process. 
2.6.6 Multiple stressors 
Pharmaceuticals not only interact within mixtures of other pharmaceutical compounds 
but also the very large number of other chemicals in everyday use; this is estimated to 
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be between 30 000 and 100 000 in developed nations (Mihaich et al., 2005).  In addition 
to these myriad chemicals, aquatic organisms are exposed to other natural or man-made 
stressors which include: 
 pollution (in its many forms); 
 habitat degradation; 
 reduced food availability; 
 exotic or invasive species; 
 disease; 
 pH, temperature, DO, salinity, turbidity etc.; 
 artificial flow regimes (increased flooding or excessive low flows). 
Prioritising the ecological impact of pharmaceuticals relative to these other stressors is 
a difficult task but one that must be addressed in order that research and regulatory 
scrutiny can be focused best on those stressors having the greatest impact.  
Furthermore, it must be realised that different stressors can interact and influence each 
other.  For example, changes in pH can alter the ionic state of pharmaceutical 
compounds which can in turn affect their bioavailability (Mihaich et al., 2005). 
2.6.7 Environmental relevance of toxicity studies 
The assumption behind standardised laboratory tests is that through testing the most 
‘sensitive’ species and applying safety factors the structural and functional components 
of the whole aquatic ecosystem are protected (Graney et al., 1994).  However, idealised 
single species tests cannot predict potential indirect effects in complex ecosystems 
(Brooks et al., 2003).  There are a wide variety of factors which can influence an 
organism’s response during toxicological testing (Figure 2-11; Mason, 2002).  The 
majority of these factors are not considered during standardised testing with only age, 
sex, water quality and life cycle being routinely accounted for.  Environmental factors 
such as temperature and pH can also be added to this list which can strongly influence 
the speciation and uptake of toxic substances (Mason, 2002). 
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Figure 2-11: Factors influencing an organism’s response during standard toxicity 
testing 
(adapted from Mason (2002)) 
 
Attempts have been made to simulate the environmental effects of pharmaceutical 
mixtures in model or artificial ecosystems known as microcosms and mesocosms.  
These can be either closed or open to the environment and may be placed in the field or 
laboratory.  Mesocosms are generally larger than microcosms, with field installations 
which allow a part of the natural environment to be brought under experimental control.  
Mesocosms have the distinct advantage of being much more representative of natural 
conditions than studies in laboratory aquariums and hence are more ecologically 
relevant.  This comes at the price of reduced replicability within the system, thus reducing 
the probability of detecting changes due to treatment (Rowe & Dunson, 1994).  Despite 
these issues, mesocosms represent a vital part of the experimental continuum between 
simplified laboratory tests and field studies (Wilbur, 1989).   
Mesocosms can also allow the inclusion of a representative community including 
bacteria, diatoms, algae, macroinvertebrates and possibly fish to adequately represent 
a natural system (Mihaich et al., 2005).  Sanderson et al. (2009) stated that the high cost 
per study makes sufficient replication difficult.  This is in agreement with Kraufvelin 
(1998) who highlighted the natural variability in ecosystem variables and the often 
impractically high number of replicates needed to draw statistically robust conclusions 
from mesocosm studies.  ‘Aquarium individuality’ is a phenomenon where two otherwise 
identical systems (mesocosms) are the same at the outset but diverge from one another 
over time due to small undetectable differences at the beginning of the study (Kraufvelin, 
1998).  Clearly, micro and mesocosms are extremely useful because they provide 
conditions of the natural environment whilst having capacity for replication and control 
70 
 
over experimental parameters but their limitations must be acknowledged (Graney et al., 
1994).  Field studies have also been used to assess the effects of emerging 
contaminants on aquatic organisms.  For example fish can be placed in cages 
downstream of STPs to test for the effects of oestrogenic chemicals (Jobling & Sumpter, 
1993; Purdom et al., 1994; Sumpter, 1995; Tyler et al., 1998; Mihaich et al., 2005). 
2.6.8 Microcosm and mesocosm studies of pharmaceutical effects 
Despite their obvious advantages, studies employing artificial ecosystems to examine 
the effects of pharmaceuticals on freshwaters are relatively sparse.  Brain et al. (2004a; 
2004b) conducted still water mesocosm studies using 12 000 L containers in which a 
semi-natural ecosystem containing algae, zooplankton, macrophytes and fish species 
was created.  Twenty five individual compounds and an eight pharmaceutical mixture 
were tested on two aquatic macrophyte species (Lemna gibba and Myriophyllum 
sibiricum) over a 35-day period which showed that somatic endpoints were the most 
sensitive.  Effects on growth were observed at high but environmentally relevant 
concentrations of >37 µg L-1 with antibiotics (chlortetracycline, lomefloxacin, levofloxacin 
and sulfamethoxazole) and the blood lipid regulator, atorvastatin, proving the most toxic.  
However, the observed effects were not above the biologically significant population 
threshold of 20 % mortality (Christman et al., 1994). A further study by Laird et al. (2007) 
used the same microcosms to assess the toxicity of a mixture of three antidepressants 
on zooplankton and found that such mixtures did not pose a risk at environmental 
concentrations.  This is contrary to the observed high acute toxicity of these compounds 
in isolation (see Sections 2.5.2 and 2.5.3).   A further study by Richards et al. (2004) 
found that a three pharmaceutical mixture (ibuprofen, fluoxetine and ciprofloxacin) had 
diverse effects at environmentally realistic concentrations (≥6000 ng L-1) across different 
trophic levels.  The effects included: increased fish and macrophyte mortality and 
abundance, reduced diversity and community-level effects on plankton.  Finally, 
Sanderson et al. (2007) used the same facilities to assess the impact of the veterinary 
drug ivermectin and concluded that 30 to 1000 ng L-1 caused significant reductions in 
zooplankton species richness but no corresponding decrease in total abundance.  This 
was due to a dominance shift in Cladocerans from sediment-dwelling (Chydorus sp.) to 
more littoral and pelagic species; this is perhaps due to the high sorption potential of 
ivermectin in sediments (Sanderson et al., 2007).  Wilson et al. (2003) used natural algal 
assemblages sampled from up and downstream of an STP outfall to examine the effects 
of ciprofloxacin and triclosan (an antimicrobial agent often used in cleaning personal care 
products) on algal community structure.  Environmentally relevant concentrations (120 
to 1500 ng L-1) caused significant changes in both total algal biomass and community 
structure; the changes were less pronounced in the downstream samples where 
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continuous exposure to effluent may have increased the adaptation of algal communities.  
Furthermore, there was evidence of a dose-response relationship whereby increasing 
concentrations of these compounds were associated with a decrease in algal species 
richness.  Brodin et al. (2013) used laboratory microcosms to expose perch (Perca 
fluviatilis) to environmentally relevant concentrations of the anti-anxiety drug oxazepam 
for seven days.  Fish exposed at 1800 ng L-1 fed at a greater rate and were more active 
but less social.  Fish exposed at 910 000 ng L-1 displayed increased boldness with 
potential secondary consequences for predation risk.   
These examples highlight the value of experimental studies in identifying effects 
ranging from the individual to ecosystem level that would not be possible using 
standardised laboratory procedures.  One of the main advantages of mesocosm and 
field studies is their potential to identify impacts which are mediated through complex 
intra and inter-specific interactions.  A whole lake study conducted in Ontario, Canada 
found that additions of low levels of EE2 (5 to 6 ng L-1) caused fathead minnow 
populations to collapse due to vastly reduced recruitment.  This continued for three years 
after the addition of EE2 ceased (Kidd, 2007).  Such a drastic effect on one species may 
have knock-on effects through the rest of the ecosystem.  For example, McMahon et al. 
(2012) demonstrated the effects of fungicides (≥164 µg L-1 over four weeks) on a range 
of species, community and ecosystem level responses in a relatively complex 
mesocosm.  They found that mortality was increased for algae, invertebrates, 
macrophytes and amphibians as well as reductions in leaf litter decomposition and net 
primary productivity.  Applications of similar tests to the effects of pharmaceuticals at 
environmentally relevant concentrations are necessary if such complex, indirect effects 
are to be understood. 
2.6.9 Functional indicators of stress response 
Although, the micro and mesocosm studies mentioned above are more representative 
of environmental conditions when compared to simplified laboratory studies, the 
endpoints assessed are often the same with a focus on individual growth and mortality 
with often little consideration of ecosystem functioning.  Functional measures have a 
number of key advantages over structural ones and furthermore it is possible for changes 
in structure to occur with no corresponding change in functioning and vice versa. Despite 
this, bioassessment is overwhelmingly based on structural measures alone (Matthews 
et al., 1982; Gessner & Chauvet, 2002).   
An often cited concern over the use of functional indicators for monitoring stressor 
impacts is their inherent environmental variability and reduced replicability (Hill et al., 
2000).  However, Niemi et al. (1993) found that functional measures were generally more 
sensitive in detecting stressor impact and recovery.  Despite this, most effects studies 
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continue to focus on single-species examinations of toxicity (Rosi-Marshall & Royer, 
2012). 
2.6.9.1 Leaf litter decomposition in freshwater ecosystems 
This section will examine the importance of the decomposition of leaf litter in freshwater 
ecosystems and how this functional process has been adopted in the effects testing of 
pharmaceuticals.  Inputs of allochthonous carbon to streams in the form of coarse 
particulate organic matter (CPOM) can be a major energy source in freshwater 
ecosystems.  Input rates depend on latitude, season, riparian vegetation cover and 
rainfall (Giller & Malmqvist, 1998), varying from 7.5 g C m-2 y-1 for high order streams to 
1394 g C m-2 year-1 for low order streams (Conners & Naiman, 1984; Webster et al., 
1995).  These inputs have been shown to be limiting in some streams (Richardson, 
1991).  The decomposition of leaf litter is influenced by: leaf species (more 'woody' plants 
take longer to decompose), water temperature, pH, water chemistry, flow and the 
community composition of macroinvertebrates, fungi and microorganisms (Giller & 
Malmqvist, 1998). 
Decaying leaf litter from terrestrial inputs contains cellulose, lignin and other resistant 
carbohydrate compounds, which are not readily available as a food source to most 
aquatic animals.  Therefore, the carbon within is released through three physical and 
biological processes, which can all act simultaneously (Webster & Benfield, 1986): 
 Rapid leaching of dissolved organic carbon (DOC) and soluble inorganic 
constituents accounting for up to 25 % mass loss; 
 Microbial and fungal colonisation and decomposition – these penetrate the leaf 
surface with hydrolysing enzymes capable of degrading cellulose which can 
convert up to 75 % of leaf mass into fine particulate organic matter (FPOM).  
Furthermore, these processes aid breakdown by macroinvertebrates through 
‘softening’ the leaf tissue and increasing palatability; 
 Biological and mechanical fragmentation – the physical action of flow can 
breakdown leaf tissue into FPOM but, more importantly, invertebrate shredders 
bite and feed on leaves releasing material as FPOM.  The contribution of 
invertebrates to total decomposition can be >40 % where they are abundant.  
CPOM breakdown rates are higher when macroinvertebrates are present 
(Webster & Benfield, 1986).  In turn, the activities of shredding 
macroinvertebrates serves to increase the surface area available for microbial 
colonisation (Giller & Malmqvist, 1998). 
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These processes aid the conversion of CPOM to FPOM and in turn to DOC which is then 
available as an energy source to other aquatic organisms.  Without these conversions, 
the carbon would be unavailable at higher trophic levels and downstream transport would 
be reduced (Giller & Malmqvist, 1998).  Disruption of detrital processing in low-order 
streams has been shown to significantly reduce the downstream export of organic 
material which can in turn affect downstream macroinvertebrate assemblages 
(particularly collectors and filterers).  This has been demonstrated experimentally by 
Cummins et al. (1973) and Cuffney et al. (1990).  Indeed experiments have shown that 
carbon storage, processing and downstream transport occurs predominantly in low-order 
streams whereas the majority of carbon consumption occurs in higher-order streams, 
highlighting the importance of this upstream-downstream link (Naiman et al., 1987; 
Cuffney et al., 1990).  Therefore, the decomposition of leaf litter is a key ecosystem 
function with important implications for energy flow and nutrient cycling (Giller & 
Malmqvist, 1998).  For example, Wallace et al. (1997) showed that removing leaf litter 
inputs leads to a 40 % reduction in secondary production and abundance drops for 
shredders, collectors and predators.  This clearly demonstrates the potential for changes 
in leaf litter breakdown to act as a bottom-up control cascading to higher trophic levels. 
The second of the three phases of Webster & Benfield’s (1986) conceptualised 
decomposition regime includes direct decomposition by fungal and microbial 
communities as well as the softening of leaf tissue for macroinvertebrate shredders.  
Irons et al. (1994) showed that as temperature decreased (with increasing latitude and 
altitude) the relative importance of microbial/fungal processing decreased when 
measured as a proportion of total decomposition rates from up to 70 % at 35 ° latitude to 
approximately 10 % at 65 ° latitude.  However, even when the fungal and microbial stage 
is less important in terms of total mass of decomposition there are still significant 
implications for food quality and selection by invertebrates (Graça et al., 2001).  Studies 
have shown that macroinvertebrate shredders may actually derive a small but significant 
proportion of their dietary energy requirements from the fungal and microbial 
communities which have colonised decaying leaf tissue rather than from the leaves 
themselves (Merritt et al., 1984).  Furthermore, the shredder Gammarus has been shown 
to actively select leaf tissue that has been pre-conditioned by fungal/microbial 
communities both in the laboratory and in field studies (Graça, 1993; Graça et al., 2001).  
There are a number of possible reasons why Gammarus actively choose pre-conditioned 
leaves (Giller & Malmqvist, 1998) which include: ‘softening’ of leaf tissue rendering it 
more amenable to shredding, fungal and microbial communities lending a more palatable 
'flavour' to the leaf tissue, and the increased energy contained within the fungal/microbial 
colonisers. 
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The relative abundance of fungal and bacterial communities present on colonised 
leaves may also influence overall decomposition rates.  Studies have shown that fungi 
dominate the microbial biomass colonising leaf litter (fungi accounted for up to 99.8 % of 
biomass) and that increasing nutrient concentrations stimulated leaf litter decomposition 
(Gulis & Suberkropp, 2003a; Gulis & Suberkropp, 2003b).  However, when fungi were 
excluded (and hence only bacteria were present) the decomposition rate was reduced, 
particularly at high nutrient concentrations.  This suggests that fungi are overwhelmingly 
dominant in terms of colonisation (biomass) and microbial decomposition and that 
bacteria are subject to strong competition for the available resources of carbon in leaf 
litter. 
2.6.9.2 The effects of pharmaceuticals on leaf litter decomposition 
There are very few examples of studies that assess the effects of pharmaceuticals on 
ecosystem structure and functioning which can in turn impact on important ecological 
factors such as resilience, redundancy, nutrient cycling and energy availability.  One 
exception is the study of Bundschuh et al. (2009) which tested the effects of a mixture of 
five antibiotics on the food selection and decomposition of leaf litter by Gammarus.  This 
study found that breakdown of antibiotic-treated leaf disks was greater than control disks, 
possibly due to increased conditioning of the leaves by fungal communities triggered by 
competitive release due to a reduction in the colonising bacterial communities.  It is also 
possible that the bacterial communities developed resistance to the antibiotic 
compounds during the treatment period (as demonstrated for soil bacteria exposed to a 
sulphonamide antibiotic by Schmitt et al. (2005) but the initial competitive advantage 
gained by colonising fungi during the early stages was sufficient for them to maintain 
dominance.  It is also reasonable to hypothesise that reduced nutritional quality of leaf 
material may lead to an increase in processing by detritivores to maintain necessary 
dietary intake (Maul et al., 2006a).  Hahn & Schulz (2007) found the opposite effect from 
a mixture of two different antibiotics (oxytetracycline and sulfadiazine) whereby 
Gammarus pulex preferred leaves conditioned in the absence of antibiotics but this 
caused no change in the total decomposition rate.  Notably, neither of these studies 
conducted parallel exposures of individual compounds in isolation so it is not possible to 
attribute changes to specific antibiotics or to evaluate any additive or antagonistic effects 
of these compounds in mixture.  Furthermore, no studies are currently available which 
examine the effects of non-antibiotic pharmaceuticals on the breakdown of leaf litter in 
freshwaters. 
2.6.9.3 Sediment respiration, carbon and nutrient cycling 
Early studies of DOC in stream sediments showed that concentrations were generally 
higher in groundwater and sediment pore waters when compared to the overlying waters 
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(Moss, 1988).  This shows that stream sediments are biologically active zones which 
modify the chemical nature of water passing through them and act as both sinks and 
sources for carbon and nutrients from both upwelling groundwater and down welling 
stream water (Rutherford & Hynes, 1987).  The majority of metabolic activity in small 
streams occurs within bed sediments, either at the sediment-water interface or in the 
deeper hyporheic zone (Sobczak & Findlay, 2002). The microbial processes within 
sediments play a major role in carbon and nutrient cycling in rivers.  This is of particular 
importance as the downstream fluxes of DOC are frequently the largest components of 
stream organic matter budgets (Rutherford & Hynes, 1987). 
Respiration occurring in streams, even with relatively small hyporheic zones has 
been shown to account for more than 40 % of whole ecosystem respiration.  This process 
can increase overall ecosystem efficiency by allowing more rapid recycling of carbon and 
nutrients that would otherwise be lost to downstream transport (Battin, 1999; Battin et 
al., 2003).  The degree to which the hyporheic zone can influence whole river ecosystem 
functioning depends on a number of factors including: physical dimensions, 
biogeochemistry, temperature, oxygen, nutrient supply and the proportion of total flow 
rate passing via the hyporheic zone.  Many important ecosystem functions (primary 
productivity, respiration and nutrient cycling) occur either at the sediment-water interface 
or within the top few centimetres of the hyporheic zone (Battin, 1999; Battin et al., 2003).   
There are two general mechanisms of carbon supply to stream sediments; these 
are the burial of POC during episodic disturbances and the direct transport of suspended 
POC and DOC via intrusions from river water or groundwater (Findlay, 1995).  Coarse 
and fine POC can be directly utilised by invertebrates but this is not often the case for 
DOC where some form of microbial transformation into a particulate form is necessary.  
The relatively slow velocity of pore waters (when compared to the overlying stream 
water) can allow ample time for the microbial metabolism of bioavailable solutes 
including DOC and nutrients.  Sobczak & Findlay (2002) have shown that DOC losses 
along hyporheic flowpaths can be as high as 50 % and this depends predominantly on 
microbial metabolism and less so on other parameters such as dilution, residence time 
and initial DOC concentrations. 
2.6.9.4 The role of microbial communities in decomposition and nutrient cycling 
Rosenfeld & Roff (1991) have shown that respiration by benthic microbial communities 
(particularly bacteria) can exceed whole stream primary production in forested streams.  
These communities consist of autotrophic filamentous algae, cyanobacteria, diatoms, 
fungi and heterotrophic bacteria.  The major energy source for bacterial communities is 
DOC leached from detritus, excreted by consumers or released by their own enzymatic 
degradation of detritus (Miller, 1987). These communities are responsible for significant 
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energy fluxes and nutrient cycling both within the hyporheic zone and in exchange with 
overlying waters (Giller & Malmqvist, 1998).  Therefore, any change in benthic respiration 
by microorganisms has the potential to significantly alter the stream P/R ratio (e.g. Wilson 
et al. (2004)).   
Smith (1973) estimated that bacteria were responsible for the majority of 
sediment respiration (30 to 60 %) whereas macrofaunal respiration accounted for just 5 
to 26 %.  The major energy source for bacteria is DOC and thus the transfer of energy 
and nutrients through this ‘microbial loop’ is particularly important as only a few animal 
species are capable of directly assimilating DOC (Giller & Malmqvist, 1998).  The 
disruption of microbial cycling in sediments can reduce ecosystem productivity and 
cause the sediment to become a carbon sink, rendering organic carbon and nutrients 
unavailable for secondary productivity which will have knock-on effects via food web 
interactions (Burton, 1991).  Microbial communities present within pore waters play a 
major role in both the respiration of sediment and DOC cycling required making it 
available to other trophic levels.  Therefore, pharmaceuticals (particularly those designed 
to target microorganisms such as antibiotics and antifungals) have the potential to alter 
or disrupt these sediment dwelling organisms which in turn may impact on the important 
ecosystem functions they perform. 
2.6.9.5 The effect of stressors on sediment respiration and nutrient cycling 
Community respiration (CR) in stream sediments is a widely measured attribute of 
ecosystem functioning that has been shown to be a sensitive indicator of ecosystem 
stress (Hill et al., 1998).  Studies comparing CR to other functional attributes in stream 
ecosystems have shown it is the most sensitive to perturbations from a range of stressors 
(Matthews et al., 1982).  For example, Crossey et al. (1988) showed CR was significantly 
increased (by of 2-3x) in a Montana stream experiencing chronic heavy metal pollution 
but structural indices of the periphyton community did not show any change.  Bunn et al. 
(1999) found that both gross primary production (GPP) and CR were highly sensitive to 
changes in catchment land use.  Reductions in riparian vegetation cover lead to 
increases in both processes and crucially a shift in affected ecosystems from being net 
carbon consumers (P<R) to net producers (P>R). 
Bunch & Burnot (2011) examined the effects of ibuprofen and paracetamol at 
environmentally realistic concentrations (100-1000 ng L-1 and 55-10000 ng L-1, 
respectively) on sediment respiration and nitrate uptake using both in vitro and in situ 
techniques.  In vitro exposures demonstrated increased respiration rates at low levels of 
both pharmaceuticals and a slight inhibition of respiration at the highest exposure of 
paracetamol.  Furthermore, lower levels of paracetamol appeared to enhance nitrate 
uptake.  None of the above differences were evident in the more variable in situ 
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experiments although this may be due to the long exposure history to pharmaceuticals 
at the site yielding greater adaptation and tolerance in the microbial community.  The 
picture is further complicated as different pharmaceutical compounds may be stimulatory 
(due to the uptake of pharmaceuticals as a nutritive source) or inhibitory (due to direct 
toxic effects) although this is dependent on specific compound properties (Lawrence et 
al., 2005).  Certain antibiotics (amoxicillin, clarithromycin and erythromycin) have been 
shown to reduce the denitrification rates of specialised sediment-dwelling bacteria 
although this effect was only seen at relatively high concentrations (1 mg L-1; Costanzo 
et al. (2005)).  Similar effects are widely known to occur within nitrogen cycling processes 
in STPs (Gomez et al., 1996; Campos et al., 2001).  Despite the inherent complexities in 
such processes there is ample evidence that low levels of pharmaceutical compounds 
can have a significant impact on stream microbial activity and the uptake of nitrogen 
which may have further implications for autotrophic production and algal blooms (Dodds 
& Welch, 2000).  
2.6.9.6 The effects of pharmaceuticals on freshwater microbial communities and 
processes 
Antibiotic compounds are known to cause effects on microbial community structure in 
both the soil and water environment as well as changes in associated ecosystem 
functions such as nitrogen cycling, methanogenesis and sulphate reduction (Ding & He, 
2010).  Maul et al. (2006a) found that environmentally relevant concentrations of the 
antibiotic ciprofloxacin (100 000 ng L-1) caused a significant shift in microbial community 
composition and a decrease in microbial respiration.  However, this change in microbial 
communities did not translate to any significant change in leaf litter decomposition or 
growth of two detritivore species (Gammarus spp. and a caddisfly species, Lepidostoma 
liba).  There were three possible reasons for this: 
 The complex matrix of water, sediment and leaf material used in the experiment 
may have reduced the bioavailability of ciprofloxacin; 
 Functional redundancy within the microbial communities (i.e. fungi) may have 
persisted and provided the necessary enzymes for leaf breakdown and the 
additional nutritional source for detritivores (Wohl et al., 2004); 
 Some detritivores (e.g. Gammarus) may be able to endogenously produce the 
necessary enzymes to digest leaf material or to rely on endosymbionts within 
their gut (Monk, 1977; McGrath & Matthews, 2000) 
All of these studies demonstrate the potential for pharmaceuticals (and antibiotics in 
particular) to have a direct impact on leaf litter breakdown which is widely considered to 
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be an important source of organic matter and energy in streams (Cummins et al., 1973; 
Petersen & Cummins, 1974; Cummins & Klug, 1979).  However, there are further areas 
that require research, namely using more realistic exposure concentrations at 
environmentally measured levels.  For example, both Bundschuh et al. (2009) and Hahn 
& Schulz (2007) experiments used 20 000 to 200 000 ng L-1 exposures whereas median 
environmental concentrations are generally <1000 ng L-1.  However, there are examples 
of highly polluted rivers receiving effluent from pharmaceutical manufacturing facilities 
where concentrations well exceed the LOECs observed in the laboratory (Li et al., 2008; 
Fick et al., 2009; Lin & Tsai, 2009; Hughes et al., 2013).  Even for less polluted rivers, 
the margin of safety is just one or two orders of magnitude and more research is clearly 
needed.  Furthermore, no consideration has been given to other pharmaceutical classes 
(e.g. NSAIDs or beta-blockers).  Finally, the studies mentioned above were conducted 
entirely in the laboratory under controlled conditions whereas actual rates in situ may be 
impacted differently under dynamic environmental conditions.   One particular question 
is how pharmaceutical exposure during the leaf pre-conditioning process will affect 
colonisation by whole macroinvertebrate communities and not just isolated species of 
detritivores in the laboratory (e.g. Arsuffi & Suberkropp, 1989). 
Antibiotics have also been shown to impact on other aspects of ecosystem 
functioning; for example, Wilson et al. (2004) showed that a mixture of four tetracycline 
antibiotics increased CR in a microcosm study at low concentrations.  However, gross 
primary productivity (GPP) was less affected resulting in a reduced community 
metabolism (P/R ratio).  Also the net daily metabolism (P-R) resulted in an oxygen deficit 
which increased with concentration.  Such changes in the balance between production 
and respiration are common in stressed ecosystems and indicate an inefficient state as 
more oxygen is consumed than is produced by autotrophs (Odum, 1985).   
Another study by Näslund et al. (2008) indicated that the antibiotic ciprofloxacin 
had a negative impact on the bacterial diversity in marine sediments which in turn 
reduced the degradation rate of an organic contaminant (pyrene). Although the 
relationship between bacterial community structure and function is complex (Bell et al., 
2005) the degradation of pollutants is an important ecosystem service with obvious 
socioeconomic value (Costanza et al., 1997).  As above, no studies have been 
conducted into how non-antibiotic pharmaceuticals affect community respiration and 
potential knock-on effects. For example, the microbial cycling of dissolved organic 
carbon and nutrients within sediment pore waters and subsequent exchange with 
overlying stream water (Sobczak & Findlay, 2002). 
Pharmaceuticals may also alter inter-specific interactions within aquatic 
ecosystems.  For example, Morley et al. (2009) conducted a review of literature on the 
impacts of pharmaceuticals on aquatic host-parasite relationships.  This review 
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concluded that some pharmaceuticals may alter host physiology and immunology 
rendering them more susceptible to parasites and that some parasites may be 
developing resistance to certain compounds.  Painter et al. (2009) conducted a study 
which used high speed video recordings to examine the changes in predator avoidance 
speed of fish exposed to mixtures of antidepressants at ng L-1 concentrations.  This study 
found that certain individual compounds (e.g. fluoxetine) did not slow predator avoidance 
but slowing was consistent when the antidepressants were mixed; such a toxic effect 
may have important indirect effects on survival and reproduction that have yet to be 
determined.   
Pharmaceuticals clearly have the potential to impose subtle changes on 
individual behaviour, survival and reproduction, which may in turn manifest at the 
population level and be further mediated via food-web interactions to yield an effect at 
the ecosystem level.  Parallel examples and lessons can be drawn from trophic 
interaction studies for non-pharmaceutical compounds.  Maul et al. (2006b) 
demonstrated the trophic transfer and subsequent bioaccumulation of PCBs 
(polychlorinated biphenyls) via sediment-dwelling aquatic insects to tree swallows 
(Tachycineta bicolor).  This transfer route may also be active for pharmaceuticals present 
in rivers and aquatic sediments, particularly those compounds with high log KOW (i.e. 
more lipophilic compounds).  However, elucidating these extremely complex interactions 
will be difficult and much further research is required although it is vital that experiments 
should combine organism-level effects with structural and functional indicators and food-
web interactions in order to provide a more holistic and relevant understanding of real 
world processes (Matthews et al., 1982; Brown et al., 2011). 
2.6.10 Limitations of current ecotoxicological testing procedures 
The field of ecotoxicology draws many of its principles from human and mammalian 
toxicology which rightly focus on the protection of individuals from toxic effects.  This is 
less relevant from an ecological perspective where greater emphasis should be placed 
on impacts at the population, community and ecosystem level (Calow, 1998).  A possible 
exception to this would be the protection of critically endangered species in a particular 
area (Dorne et al. 2007).  However, very few attempts have been made to directly relate 
the toxic effects of pharmaceuticals from individuals up to population level and beyond.  
This could be achieved using life-history models, such as the Euler-Lotka equation, to 
predict population multiplication rates (Calow, 1997).  In the absence of reliable 
population-level effects data, two approaches are available to extrapolate individual 
toxicity data to that at a ‘systems’ level but these are based on a number of key 
assumptions: 
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 The Assessment Factor (AF) approach simply divides the lowest available single-
species toxicity (i.e. LOEC) by an arbitrary amount considered safe for the 
ecosystem.  A similar approach is adopted during risk assessment to extrapolate 
acute to chronic ratio (ACR) data.  The value of the AF or ACR depends on 
available experimental data and is arbitrarily defined with no explicit ecological 
basis (Dorne et al., 2007).  Ankley et al. (2005) call for a high quality database of 
AFs and (ACRs) for a range of species, MOAs and endpoints; 
 The Species Sensitivity Distribution (SSD) approach fits a statistical distribution 
over all available toxicity data.  The usual assumption is that that protection of 95 
% of individuals will maintain a viable population.  This assumes that the SSD 
calculated from known data is representative of all species, particularly the most 
sensitive ones (Posthuma, 2002). 
However, the species used in standard toxicity tests are typically selected more for their 
amenability to laboratory culture rather than any direct ecological relevance (Fent, 2008).  
A test species should be representative of the aquatic ecosystem in question and its 
sensitivity should be high to ensure other (less sensitive) species are protected (Newman 
& Unger, 2003).  A modelling study conducted by Stark et al. (2004) concluded that 
Daphnia spp. were the least sensitive amongst six other arthropod species; this suggests 
levels deemed non-toxic to Daphnia individuals or populations in the laboratory may not 
be protective of other species in the aquatic environment.  Henschel et al. (1997) tested 
the relative sensitivity of standard (i.e. acute) and non-standard toxicity tests to four 
pharmaceuticals and found that for three compounds it was the non-standard methods 
that were most sensitive.  These studies indicate that the standard battery of toxicity tests 
may be underestimating the potential for toxic effects of pharmaceuticals in the 
environment (Länge & Dietrich, 2002; Kümmerer et al., 2004b). 
Attention must also be drawn to the concept of NOECs etc. which are actually 
just indicators of a statistical difference between treatments within an experiment (which 
in turn are strongly influenced by experimental design) and do not have any direct 
mechanistic, ecological or toxicological relevance (Newman & Unger, 2003).  Jager 
(2012) calls the widespread use of NOECs an “outdated...bad habit” that should be 
replaced with more widespread use of mechanistic models.  Furthermore, the concept 
of a NOEC implies there is a threshold concentration below which no adverse effect will 
occur; known as the ‘threshold model’ (Newman & Unger, 2003).  Some toxic stressors 
(such as radiation) are believed to have no threshold as cancerous tumours can be 
initiated from damage to the DNA in a single cell resulting from a single exposure event 
(Newman & Unger, 2003).  The same may be true for anti-cancer drugs (antineoplastics 
or cytotoxic drugs) which are known to have fetotoxic, genotoxic and teratogenic 
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properties (Kümmerer, 2001a).  This would mean that a single exposure to an extremely 
low dose would have a probability (albeit very low) of eliciting a toxic effect to an 
individual. 
2.6.11 How to improve the ecotoxicological testing of pharmaceuticals 
The above review of ecotoxicological data has identified a distinct bias towards idealised 
laboratory experiments focusing on short-term, acute endpoints on a small number of 
individual, standard species.  These tests are relatively easy and cheap to conduct and 
are useful for inter-comparisons but they do not adequately capture the diverse range of 
toxicological effects that pharmaceuticals can cause.  Fent et al. (2006) suggest that 
ecotoxicological studies be much more targeted based on existing information that is 
readily available from human and mammalian studies during the pharmaceutical 
development process, this includes:  
 Known receptors or target molecules; 
 Known side effects; 
 Known drug-drug interactions as a possible indicator of mixture toxicity; 
 Pharmacokinetic properties (Adsorption-Distribution-Metabolism-Excretion: 
ADME) i.e. what the body does to the drug; 
 Pharmacodynamic properties (drug-receptor interactions and the relationship 
between dose and effect) i.e. what the drug does to the body; 
 Any known specific MOAs. 
Targeting studies based on MOAs and receptor sites is particularly promising as many 
of these are known to be strongly evolutionarily conserved and can be present in lower 
animal forms such as fish and invertebrates (see Fent et al., 2006).  For example, 
NSAIDs work by inhibiting one or both of the two isoforms of the cyclooxygenase enzyme 
(COX-1 and COX-2) which regulate the synthesis of prostaglandins which in turn play a 
role in pain and inflammatory response.  COX enzymes occur in fish but their role in 
prostaglandin synthesis is not fully understood in lower invertebrates. This may mean 
that NSAIDs inhibit prostaglandins in the same way but the resultant effect is different 
(Fent et al., 2006).  Triebskorn et al. (2007) conducted a more targeted study looking at 
the structural changes caused by pharmaceuticals in the liver, kidney and gills of fish; 
they discovered that diclofenac caused a particularly strong reaction and eventually 
induced cell death (necrosis).  The LOECs derived from this study were up to three 
orders of magnitude lower than those derived from the more traditional tests suggesting 
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that standardised tests may be missing toxic effects or quite dramatically 
underestimating their toxic potential in surface waters (Kümmerer et al., 2004b).  Certain 
classes of pharmaceuticals have also been shown to inhibit the cytochome-P450 (CYP) 
enzymes in fish; this is a widely preserved metabolic pathway for the removal of 
xenobiotics and is thought to be the major oxidative system for most pharmaceuticals 
(see Dorne et al., 2007).  For example, antidepressants were shown to inhibit more than 
90 % of a particular CYP isoform having potential implications for metabolism and 
accumulation of toxins within the organism.   
Despite the usefulness of targeted studies the lack of a similar receptor sites in 
aquatic organisms does not necessarily mean the compound in question will not cause 
adverse effects.   We know from human toxicology that these can be caused by 
previously unrecognised interactions and unknown receptor sites which are poorly 
characterised in aquatic organisms; this means that the transfer of data from human and 
mammalian toxicology should be done with caution (Cleuvers, 2005).  Finally, Owen et 
al. (2010) highlight the importance of repeating studies prior to drawing important 
conclusions about potential environmental effects.  This study repeated a 28 day growth 
test of Rainbow Trout (Oncorhynchus mykiss) exposed to clofibric acid; the initial 
experiment found a concentration-dependent reduction in growth at exposures greater 
than 100 ng L-1.  However, a larger repeat study found no such effect on growth.  This 
highlights the importance of considering data in detail, particularly when no repeats are 
available or when comparing what would otherwise appear to be similar studies. 
2.6.12 Complex and unexpected effects of pharmaceuticals in the environment 
Even with knowledge of MOAs and presence of appropriate receptors in non-target 
organisms, there is still the potential for pharmaceuticals to elicit unexpected effects due 
to receptor systems performing different functions in these organisms. The class of 
antidepressants known as SSRIs (selective serotonin reuptake inhibitors) are an 
excellent example of this (Fong, 2001).  Serotonin is a neurotransmitter involved in 
regulating hormonal and neuronal mechanisms but is also important for feeding and 
reproduction (Berger et al., 2009).  SSRIs are used as antidepressants in humans but 
serotonin is well conserved even amongst lower invertebrates and can affect such 
diverse functions as immune response, appetite, behaviour and sexual function (Fong, 
1998a; Fong et al., 1998b).  However, some SSRIs are known to strongly affect the 
reproductive behaviour of shellfish whereas others have little or no effect (Fong, 2001).  
Brodin et al. (2013) found that low concentrations of the anti-anxiety drug oxazepam 
increased the boldness but reduced the social activity of European perch (Perca 
fluviatilis) with implications for predation and feeding rates. These complex, adverse and 
unexpected effects in non-target organisms are likely to increase as newly developed 
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pharmaceuticals begin to target much more fundamental receptors including individual 
proteins or mechanisms involved with signal transduction or cell division all of which are 
very well conserved in evolution (Seiler, 2002).   
Indirect effects may also be propagated through different trophic levels via inter-
specific or predator-prey interactions. De Lange et al. (2006) found that fluoxetine and 
ibuprofen reduced activity of G. pulex at 10-100 ng L-1 whilst increasing activity at higher 
concentrations 1000 to 1 000 000 ng L-1) due to stress or flight response (i.e. movement 
away from a stressor).  Reduced activity could have subsequent effects on feeding and 
energy uptake and on predator avoidance without being directly lethal to Gammarus 
individuals.  Initially, this may be beneficial to predators due to increased prey 
consumption but would then become detrimental due to overexploitation of the prey 
resource.  Studies have also shown that pharmaceuticals can have indirect effects on 
survival and reproduction mediated through processes such as host-parasite relations 
and predator avoidance (Morley et al., 2009; Painter et al., 2009). 
2.6.12.1 The need to consider biological uptake, bioavailability and bioaccumulation 
Current aquatic ecotoxicological methods quote the final toxicity of a compound in terms 
of its aqueous concentration in the surrounding water (e.g. LOEC = 1000 ng L-1).  Such 
concentration values give no direct indication of uptake and accumulation within the test 
organism’s tissue (and/or blood and plasma) and assume that the concentration in the 
biological compartment is at steady state with the surrounding water.  However, many 
factors can affect the uptake and potential bioconcentration/bioaccumulation of toxic 
compounds (Mace, 2002) including: 
 bioavailability of the compound (influenced by temperature, pH, solid phase 
partitioning, log KOW etc.); 
 temperature and the subsequent impacts on organism physiology; 
 other organism and species specific factors such as size, age, sex, diet and lipid 
content; 
 internal fate and therefore the internal active dose at the receptor site, this may 
be dependent on the plasma half-life and the degree and rate of metabolism 
(Mihaich et al., 2005).  Huggett et al. (2005) suggest using the plasma active 
dose derived during mammalian and human screening as an indicator of potential 
activity thresholds in aquatic organisms. 
There is a requirement to test uptake into fish from surrounding water when a drug's log 
KOW exceeds 3 (EMEA, 2006).  However, this requirement is waived if the substance is 
rapidly degraded in the environment (Koschorreck & Hickmann, 2008) but even readily 
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degraded compounds that are ‘pseudo-persistent’ may still have the potential to 
bioconcentrate.  Such standardised tests cannot account for the natural variations in 
uptake to tissue (for the myriad reasons listed above).  In particular they do not account 
for important environmental parameters (such as pH) which can strongly affect 
speciation and subsequent bioavailability of acidic or basic pharmaceuticals (Fent, 
2008). 
Due to these myriad factors, uptake and bioconcentration of pharmaceuticals 
vary dramatically between compounds and species.  For example Schwaiger et al. 
(2004) found the bioconcentration factor (BCF) of diclofenac varied between 3 and 2732 
in brown trout.  The final BCF was dependent on the surrounding water concentration 
and on the tissue type analysed with liver tissue demonstrating the highest BCF; this is 
despite diclofenac having a low log KOW.  An additional study by Brown et al. (2007) used 
the Fish Plasma Model (FPM) to predict uptake into O. mykiss and compare these with 
laboratory and field tissue samples.  The NSAIDs (and the blood lipid regulator 
gemfibrozil) were selected as their log KOW range meant they were sufficiently soluble to 
avoid sorption to sludge during sewage treatment but lipophilic enough to 
bioconcentrate.  This study found marked differences in BCF between drugs and field 
sites sampled with the lowest BCF of 5 measured for diclofenac ranging to a BCF of 18 
667 for ibuprofen at the same site.  These values were considerably higher than the 
BCFs derived in the laboratory which ranged from 0.1 to 63.0.  Environmental conditions 
(temperature, pH), pharmaceutical mixtures and the presence of colloidal material are 
likely to be the reasons for such striking differences (Brown et al., 2007).  The FPM model 
generally underestimated BCFs due to it being developed for non-ionic, lipophilic 
pollutants.  Underestimation in such a model may render it unsuitable for risk assessment 
of pharmaceuticals where it is often best to overestimate risk particularly during early 
screening stages.  Dussault et al. (2009) found that the BCF of EE2 ranged between 0.8 
and 142 depending on species (Chironomus or Hyalella) and whether the exposure route 
was water-only or via sediment.  These studies indicate the complex nature of uptake 
and bioconcentration of pharmaceuticals in complex environmental systems. 
2.6.12.2 The development and use of biomarkers 
The use of biomarkers for EDCs is relatively well established in fish and invertebrates.  
The most widely used is vitellogenin, a precursor to the egg-yolk proteins (vitellins; see 
Matozzo et al. (2008) for a review).  However, such a specific biomarker is not available 
for pharmaceuticals given their diverse nature.  An attempt at identifying biomarkers of 
exposure in mussels to three pharmaceuticals (carbamazepine, caffeine and 
methotrexate) and an extract of STP effluent was made by Martin-Diaz et al. (2009).  
This study used enzymes associated with phase I and II metabolism, oxidative stress 
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and DNA damage as indicators of exposure and found that varying effects were induced 
depending on the compound and exposure concentration.  However, such biomarkers 
would not necessarily be solely indicative of pharmaceutical exposure in the natural 
environment given the complex nature of STP effluent which contains myriad other 
xenobiotics capable of inducing oxidative stress and xenobiotic metabolism pathways. 
One possible answer to this question is the emerging field of metabolomics; the 
study of chemical metabolic fingerprints left behind by cellular processes which can 
detect minute but important disturbances that other techniques may miss (Daviss, 2005).  
Rapid advancements in analytical techniques such as chromatography and nuclear 
magnetic resonance (NMR) spectroscopy mean that reliable quantification of a large 
number of metabolites (i.e. the metabolic profile or ‘metabolome’) is now possible (Fernie 
et al., 2004).  A metabolite is defined as a small molecule (< 2.5 kDa in size) that is either 
an intermediate or the product of metabolism (Preti, 2005).  Metabolic profiling can be 
used to quantify both an organisms ‘normal metabolic operating range’ (Viant, 2007) and 
to detect the physiological and metabolic changes caused by specific stressors such as 
temperature, pH or the toxic action of a specific compound or mixture (Robertson, 2005). 
The application of these techniques to characterise an organism’s response to 
natural and anthropogenic stressors is known as environmental metabolomics.  When 
an organism becomes stressed or is exposed to a toxicant this triggers specific molecular 
changes, altering its phenotype, which can in theory be measured and quantified.  
Environmental metabolomics is the newest of the suite of so called ‘omics’ techniques 
alongside genomics, transcriptomics and proteomics (Viant, 2007).  Omics offer a key 
advantage over more traditional biochemical methods in that they allow rapid and 
simultaneous assessments of tens, hundreds and even thousands of endpoints 
(metabolites) which, coupled with statistical methods such as principal component 
analysis (PCA), make it a powerful tool in discovering biomarker profiles of toxicant 
exposure, disease and stressor response (Viant et al., 2008).  However, it is estimated 
that even the best analytical techniques can currently only detect around 1000 of the 
existing metabolites (Viant et al., 2003a) and practitioners should stay well acquainted 
with this rapidly developing field.  Environmental metabolomics studies tend to focus 
more on questions rather than hypotheses which allows for the discovery of unexpected 
relationships and responses which in turn can generate hypotheses about the underlying 
biochemical causes (Bundy et al., 2009). 
2.6.12.3 NMR spectroscopy  
There are a range of analytical techniques available to metabolomics researchers 
including the hybrid technologies: gas chromatography or liquid chromatography coupled 
with mass spectrometry (GC-MS and LC-MS), nuclear magnetic resonance (NMR) 
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spectroscopy, capillary electrophoresis, Fourier transform infrared spectroscopy and 
direct infusion mass spectrometry (Koek et al., 2011).  The two most widely adopted 
analytical methods are NMR and LC-MS both of which have key but differing advantages 
over other techniques.  NMR is considered to be a high throughput, highly reproducible, 
platform requiring minimal sample preparation; however compared to LC-MS it is less 
advantageous in terms of sensitivity and the number of resolvable metabolites 
(Robertson, 2005; Aliferis & Chrysayi-Tokousbalides, 2011).  Scalbert et al. (2009) found 
that 62 % of metabolomics studies in human nutrition used proton (1H) NMR despite this 
technique only being able to identify around 60 specific metabolites compared to >1000 
from MS-based techniques (Lindon & Nicholson, 2008a; Lindon & Nicholson, 2008b).  A 
further key advantage of NMR spectroscopy is the ability to derive absolute 
concentrations of metabolites by adding an internal standard of known concentration; 
this is not as straightforward with MS due to variable ionisation and ion suppression 
effects (Lindon & Nicholson, 2008b).   
2.6.12.4 Why environmental metabolomics? 
The most important characteristic which sets environmental metabolomics apart from the 
other omics techniques, which makes it particularly suited to characterising organism 
stressor response, is the degree to which the metabolome varies under normal and 
stressed conditions (Viant, 2007).  It is the first to respond to stressors often when no 
changes in the transcriptome or proteome occur.  The metabolome therefore can act as 
an indicator of organism’s energetic, oxidative and reproductive state.  Genes and 
transcripts do not manifest functional changes at the organismal level and are much 
more suited to characterising population structure and genealogy.  This dynamism and 
responsiveness is a key advantage but also one the major obstacles when it comes to 
producing useable data.  This is due to high levels of metabolic ‘noise’ as metabolite 
concentrations vary due to differences in individual genetics, fluctuating environmental 
and stressor conditions, diet, age and sex (Viant, 2007).  Separating differences between 
stressed and healthy individuals from this noise is the biggest challenge to using 
metabolomics as an indicator of toxicity.  Controlling for such traits as strain, sex and 
age (known as genotypic or phenotypic anchoring) may play a part in addressing this 
(Viant, 2007).  For example, studies with marine mussels have shown that variability in 
the metabolome was more pronounced in species transferred from the laboratory and 
that gender was the principal source of variation (Hines et al., 2007).  They 
recommended the use of directly field-sampled individuals to reduce metabolic variability 
for toxicological testing. 
Despite such ‘noise’ metabolomics has been applied to a range of organisms and 
has demonstrated considerable success in identifying aspects of biological, chemical 
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and temperature stress (Viant et al., 2003; Viant, 2007).  Viant et al. (2003a) were the 
first to apply metabolomics techniques (1H NMR) to aquatic organisms which was 
successful in distinguishing between healthy and diseased groups of the marine 
gastropod red abalone (Haliotis rufescens).  Williams et al. (2009) exposed a freshwater 
fish to low levels (50 000 ng L-1) of the polycyclic aromatic hydrocarbon 
dibenzanthracene for four days and were able to detect very small (6-24 %) but 
significant changes in four metabolites (taurine, malonate, glutamate and alanine).  
Similar techniques have been successful in identifying toxic effects of pesticides and 
industrial solvents on freshwater fish (Viant, 2005; Viant et al., 2006; Viant et al., 2006).  
Numerous studies have also demonstrated significant effects of low-level exposure to 
EE2 (Samuelsson et al., 2006; Ekman et al., 2008).  Short-term exposure of fathead 
minnow (Pimephales promelas) to 10 ng L-1 caused perturbations in energy metabolism 
and liver toxicity (Ekman et al., 2008).  A study by Bundy et al. (2007) sampled 
earthworms from a range of UK sites and found that NMR metabolomics could resolve 
individual sites and that certain specific metabolites correlated with zinc contamination 
of soils across all the sites.  This conclusion lends support to the use of environmental 
metabolomics as a diagnostic tool in ecotoxicology.   
Viant et al. (2008) conducted an inter-comparison exercise between NMR 
laboratories in the USA, Canada, UK and Australia and concluded that NMR 
metabolomics produces sufficiently reproducible results to justify its continued use in 
environmental science and regulation.  Despite the progress in recent years, 
environmental metabolomics is still a growing field and researchers are still a long way 
from being able to routinely infer underlying biochemistry from metabolic profiles.  This 
linking of metabolomics to clear physiological endpoints should be seen as a priority for 
future work in this area (Bundy et al., 2007). 
Biomarker profiles from metabolomics would be able to directly distinguish 
metabolic effects of pharmaceutical compounds or mixtures from other confounding 
factors in waters receiving complex STP effluents.  However, these techniques have not 
yet been widely applied to the problem of pharmaceutical pollution in freshwaters. Their 
application to aquatic invertebrates (even widely used species such as D. magna) is 
almost entirely absent (Bundy et al., 2009).  Only two studies have addressed this issue 
with the effects of the antibiotic oxytetracycline on red abalone (Viant et al., 2003a) and 
propranolol on D. magna (Taylor et al., (2010).  However, neither of these studies 
includes exposure concentrations that are representative of the very low concentrations 
present in freshwater ecosystems nor did they consider the effects of pharmaceutical 
mixtures. 
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2.6.13 Potential human health impacts of pharmaceuticals in rivers 
This thesis is concerned with the occurrence and toxicological effects of pharmaceuticals 
in freshwater ecosystems but this brief section will provide a wider context by outlining 
some of their known and potential impacts on human health. 
2.6.13.1 Drinking water 
Low levels of some active pharmaceutical ingredients or their metabolites have been 
found in drinking water supplies (Huerta-Fontela & Ventura, 2008).  For example, 
Stackelberg et al. (2004) detected a number of prescription and OTC drugs, cosmetics 
and fragrances in finished drinking water from a US treatment plant with carbamazepine 
present at a maximum concentration of 258 ng L-1.  Heberer & Stan (1997) detected 
clofibric acid in Berlin tap water at concentrations up to 270 ng L-1 but the study by 
Stackelberg et al. (2004) suggests that drinking water treatment reduces the levels of 
most pharmaceuticals below the current limits of detection.  The drinking water treatment 
process itself has been linked with the creation of potentially harmful transformation 
products.  For example the chlorination of the antibacterial triclosan (used in many hand 
soaps and disinfectants) has been found to form chloroform and other harmful by-
products (Farré et al., 2008) which can increase a person’s annual chloroform exposure 
by 40 % over background levels.  At the concentrations of carbamazepine measured in 
US finished drinking water, Stackelberg et al. (2004) estimated that a lifetime intake 
(assuming 2 litres of water per day for 70 years) would be just 13 mg compared an 
average DDD of up to 100 mg.  Despite such low concentrations the presence of 
pharmaceuticals in drinking water does raise potential human health concerns, 
particularly related to low-level chronic exposure, transformation products and mixture 
toxicity.  These potential effects are poorly understood and more research is required 
(Guo et al., 2009).  Rowney et al. (2009) estimated the potential human health 
consequences of cytotoxic (anti-cancer) drugs in UK drinking water to be of low risk to 
healthy adults but that certain vulnerable subgroups (e.g. pregnant or breast-feeding 
women, infants and the elderly) may have cause for concern. 
2.6.13.2 Antibiotic resistance 
The fostering of antibiotic resistance (ABR) amongst bacteria is considered to be one of 
the major current public health concerns as many antibiotics are becoming less effective 
and there is a paucity of new antibiotics being developed (APUA, 2010).  Harrison & 
Lederber (1998) describe it as a worsening phenomenon with our tools to combat it 
decreasing in power and number.  Indeed, a Royal Commission was established in 1969 
which looked at the potential for environmental ABR from pharmaceuticals (Swann et al., 
1969). Perhaps the most prominent recent example of a resistant strain is methicillin-
resistant Staphylococcus aureus (MRSA) but many other resistant strains have been 
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widely found in the aquatic environment and in drinking water (Kümmerer et al., 2004b; 
Kümmerer, 2008b).  Resistance is fostered amongst bacterial communities that are 
exposed to sub-inhibitory concentrations, particularly in areas of high bacterial density 
such as biofilms (Kümmerer, 2008b).  There are two possible mechanisms of resistance 
in the environment: the in-situ fostering of resistance due to the environmental release 
of antibiotics or the transport of already resistant bacteria via the sewage network from 
domestic households and hospitals.  The second mechanism is generally considered to 
be the most important as there is a strong correlation between resistant bacteria and the 
input of urban waste water (Edge & Hill, 2005).  A study by Akiyama & Savin (2010) in 
the United States demonstrated significantly elevated levels of resistance to the 
antibiotics sulfamethoxazole and trimethoprim downstream of an advanced residential 
STP.  However, this relationship was more variable for two other antibiotics (ofloxacin 
and tetracycline) and resistance to all four compounds began decreasing further than 
640 metres downstream of the STP input.   
Antibiotic resistant strains of bacteria are proliferating globally and are 
increasingly being encountered outside of hospitals and long-term care facilities 
(Taubes, 2008). Densely populated areas of China have a particularly high prevalence 
of resistance perhaps driven by the linking of doctor’s salaries with prescription and sale 
rates of antibiotics (Hvistendahl, 2012).  Bacteria demonstrating up to 58 % resistance 
to multiple antibiotics have been detected downstream of a freshwater aquaculture 
effluent discharge (Lim et al., 2013).  River biofilms, sediment and ‘floc’ have been shown 
to be key reservoirs of concentrated ABR (Drudge et al., 2012; Winkworth, 2013).  
Increased resistance to most classes of antibiotic have been demonstrated in rivers 
including ampicillins, quinolones, tetracyclines, beta-lactams (Ash et al., 2002; Goñi-
Urriza et al., 2000).  Crucially, levels of ABR have in some cases been shown to increase 
markedly downstream as rivers become more influenced by STP effluent (Lupo et al., 
2012). 
The acquisition and exchange of ABR in the environment is likely a natural 
phenomenon but water pollution may be a key factor in forcing the speed of its evolution 
(Lupo et al., 2012).  This proliferation is of particular concern considering only five of the 
major global pharmaceutical companies now have significant antibiotic development 
research programmes underway.  The lack of research is perhaps due to lower success 
rates of antibiotic compound discovery and reduced rates of financial return when 
compared with other classes such as antidepressants or cardiovascular drugs.  There is 
likely no easy solution to this problem but newly discovered antibiotics need to be 
combined with more intelligent and prudent use of existing drugs alongside more 
rigorous infection control procedures within hospitals (Taubes, 2008). 
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2.7 Legislative context and future research needs 
2.7.1 The Water Framework Directive and other relevant legislation 
The primary piece of legislation now driving catchment management and water quality 
improvements in European rivers is the Water Framework Directive (2000/60/EC).  This 
requires member states to achieve good status in the chemical and biological quality of 
surface waters by 2015.  UK rivers saw a steady improvement during the 1990s in 
chemical and biological quality but recent years have seen a slowing in this, particularly 
in biological quality (EA, 2012; Vaughan & Ormerod, 2012).  It is likely that 
pharmaceuticals and the myriad other domestic chemicals and emerging contaminants, 
alongside channel modifications and nutrient enrichment are partly responsible. 
In response to this concern, the European Union is currently in the process of 
adding diclofenac and EE2 to its list of Priority Substances (EC, 2012) which list 
substances that member states must maintain mean and maximum concentrations 
below a defined Environmental Quality Standard (EQS) (2008/105/EC).  The Annual 
Average EQS was proposed at 10 ng L-1 for diclofenac and 0.4 ng L-1 for EE2 although 
these were subject to significant opposition raised on cost grounds by the pharmaceutical 
and water industries (UK Parliament, 2012) with the UK leading successful opposition to 
the EQS at the European Commission (SCHER, 2013).  The estimated cost to the UK 
water industry for additional advanced waste water treatment in order to meet the EQS 
was £ 27 billion although the evidence base for these costs was not presented to the UK 
Parliament and is therefore not publicly available (UK Parliament, 2012).  Despite the 
removal of the mandatory EQS it is refreshing to see emerging contaminants coming 
onto the policy agenda and regulators, researchers and other stakeholders should see 
this as an opportunity to expand  understanding beyond diclofenac to the myriad other 
pharmaceuticals and chemicals that routinely enter rivers via STPs. 
2.7.2 Environmental Risk Assessment (ERA) of pharmaceuticals  
EC Directives 2001/82/EC and 2001/83/EC amended earlier EEC directives 
(81/851/EEC and 93/39/EEC) and set out the legal requirement for environmental risk 
assessments of new veterinary and human use pharmaceuticals seeking market 
approval.  These were in turn amended by EC Directives 2004/27/EC and 2004/28/EC 
to include extensions of existing approvals in 2004.  In addition, there are guidance 
documents available to aid applicants in the ERA procedure and although these are non-
legally binding, they are widely adopted across the industry (Koschorreck & Hickmann, 
2008).  These documents are published by the International Cooperation on 
Harmonisation of Technical Requirements for Registration of Veterinary Products (VICH, 
2000; VICH, 2004) for veterinary drugs and the European Agency for Evaluation of 
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Medicinal Products (EMEA, 2006) for human drugs.  The EC Directives and guidance 
documents help the applicant to demonstrate that use of their product is safe for the 
environment and that any potential adverse effects will be mitigated or managed.  There 
are numerous summaries and examples of the ERA procedure (Carlsson et al., 2006) 
for human pharmaceuticals and only a brief outline flow chart is presented here (Figure 
2-12). 
There is one fundamental distinction between the human and veterinary ERA 
procedures.  Potentially serious environmental risks can prevent the authorisation of a 
veterinary drug if no mitigation is possible but this cannot happen for human 
pharmaceuticals where legislation can stipulate risk reducing measures only 
(Koschorreck & Hickmann, 2008).  This distinction between veterinary and human 
pharmaceuticals is purely a political and legislative one and there is no scientific 
justification for a differing approach between the two particularly as some compounds 
are used in both veterinary and human applications (e.g. amoxicillin).  However, the 
environmental risks of pharmaceuticals should be rightly weighed against their significant 
health benefits to humans (Jones et al., 2002).   
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Figure 2-12: Flow chart summary of the environmental risk assessment procedure for human-use pharmaceuticals  
(EMEA, 2006) 
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CAN NOT prevent market approval.
PHASE II: TIER B
Data refinement options:
•Additional chronic toxicity studies;
•Bioaccumulation studies;
•Specific micro-organism testing;
•Major metabolite testing (any metabolite > 20% parent compound 
concentration);
•Reduce AF with additional toxicity tests
•Refinement of PEC 
PHASE I
Determine logKow and PECSURFACEWATER
PECSURFACEWATER = (DOSE a.i * F)  / (Wp * 
Dilution)
DOSE a.i. = maximum recommended dose (mg/person/day)
F = expected market penetration factor (standard 0.01)
Wp = wastewater production (standard 200L/person/day)
D = dilution factor (standard 10)
PECSURFACEWATER < 0.01µg/l
and logKOW < 4.5
PBT testing
Persistence, bioaccumulation and toxicity testing.  Particularly 
bioaccumulative compounds or those that demonstrate toxicity at 
very low concentrations (e.g. Endorcrine disruptors ) must undergo 
this additional testing
RQ < 1Predicted No Effect Concentration (PNEC)
PNEC = lowest toxicity value (mg/l) * AF
AF = Assessment Factor (standard 1000 but lower if chronic toxicity 
data available e.g. 50-100).  AF is designed to extrapolate acute 
toxicity data to a PNEC from chronic exposure.
Risk Quotient (RQ)
RQ = PEC / PNEC
PHASE II: TIER A
Fate and treatment removal studies:
•OECD 106 (Adsroption-desorption);
•OECD 308 (Water-sediment study);
•OECD 301 (Biodegradation)
Effects on aquatic organisms studies:
•OECD 201 (Algal growth inhibition);
•OECD 211 (Daphnia reproduction);
•OECD 210 (Fish early life stage test);
•OECD 209 (Activated sludge respiration inhibition)
Refined RQ > 1 Refined RQ < 1
RQ > 1
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2.7.2.1 Limitations of environmental risk assessment 
Perhaps the major limitation of current procedures is that ERAs are only required for new 
substances or those seeking a variation of an existing approval.  This means that the 
thousands of pharmaceuticals already approved for use will not be subject to a formal 
ERA.  Cooper et al. (2008) used a variety of data combinations (including prescriptions, 
toxicity, solubility and persistence) to rank over 300 APIs for environmental risk and place 
their findings in a publicly accessible database (available at 
http://www.chbr.noaa.gov/peiar/default.aspx).  This study found that central nervous 
system (CNS) drugs (which includes NSAIDs) were most frequently high ranking 
followed by cardiovascular drugs and then antibiotics.  Sanderson et al. (2003) used 
QSAR models (Quantitative Structure Activity Relationships), log KOW and treatment 
removal data to predict hazards towards algae, Daphnia and fish.  The study concluded 
that cardiovascular and gastrointestinal drugs were the most hazardous.  Other studies 
(Jones et al., 2002) have used prescription volumes to prioritise compounds for ERA; 
they found that four compounds (paracetamol, amoxicillin, oxytetracycline and 
mefenamic acid) have the potential to illicit acute toxic effects at environmental 
concentrations.  A cause for concern was that all of the assessed compounds exceeded 
the 10 ng L-1 threshold requiring Phase II assessment (Figure 2-12).  These examples 
demonstrate that priority and ranking of pharmaceuticals based on risk is dependent on 
the type and quality of data used.  Koschorreck & Hickmann (2008) estimate that at the 
current rate of progress it will take approximately 100 years to evaluate all currently 
approved compounds. Hemminger (2005) highlights the problem of who should conduct 
retrospective testing as many of the drugs originators are no longer the main 
manufacturers.  Furthermore, Carlsson et al. (2006) suggest that ERA and effects data 
be reviewed and updated in the light of new information during the life cycle of an API 
after it has achieved market approval. 
There are other limitations with this risk assessment methodology, particularly for 
the initial PEC calculation which is based on broad assumptions of market penetration, 
metabolism, dilution and treatment removal.  The assumption of 1 % market penetration 
may be too low for very popular drugs.  For example, the rapid rise of simvastatin from 
the mid-1990s to being the most widely prescribed drug in the UK in 2008 (Table 2-2).  
Also, as mentioned in the previous section, there may be no lower toxic threshold for 
some compounds (e.g. anti-cancer drugs) and the 10 ng L-1 for Phase II analysis would 
be inappropriate.  There are counter arguments from the pharmaceutical industry that 
the PEC values are overly conservative whereas some scientists have suggested they 
may be too low as the assumed 1:10 dilution factor may not be achieved in some areas 
particularly during low flows (Hemminger, 2005) or in ‘effluent dominated streams’ 
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(Waiser et al., 2010).  However, Schmitt et al. (2010) took a critical approach to the  10 
ng L-1 threshold for effects testing and they recommend that such tests be mandatory for 
all compounds (regardless of PEC) under certain circumstances.  For example, where 
drugs target biological functions known to be strongly conserved across species, high 
potency drugs or those structurally similar to other drugs known to have an effect and 
particularly for drugs in new therapeutic classes.  Furthermore, the threshold may 
become increasingly inappropriate as drug development progresses yielding much more 
potent drugs requiring lower doses (and hence lower PECs) which may have effects at 
much lower aquatic concentrations (Schmitt et al., 2010).  Kostich & Lazorchak (2008) 
suggest using the minimum daily dose of a new drug as a measure of its potency and 
this approach has already been adopted in prioritisation studies by regulators (EA, 
2009b).  Another major area for concern is the treatment of compounds in isolation with 
no requirement to consider mixture toxicity.  Lienert et al. (2007b) suggest that the risk 
assessment process should also include more in depth testing of metabolites as high 
metabolism rates can both reduce or increase overall toxicity.  Considering mixtures and 
metabolites in more detail may prevent overly conservative toxicity estimations for some 
drugs and highlight those with higher toxic potential.   
Von der Ohe et al. (2011) tested a new form of risk assessment methodology 
using decision trees to classify 500 emerging contaminants in terms of the availability of 
analytical methodologies and effects and occurrence data.  Comparisons were made 
against maximum measured concentrations and LOECs from chronic effects testing.  
These results were then ranked based on both the probability of exceedance of effects 
concentrations and the extent of exceedance.  The majority of high risk compounds 
identified during this process were pesticides and some industrial products (von der Ohe 
et al. 2011).  Such a risk assessment methodology which relies first and foremost on 
measured effects and occurrence values may prove useful for pharmaceuticals in the 
future as increased research efforts begins to expand the amount of data available.  
Despite the above requirements, the majority of pharmaceuticals assessed in the USA 
do not pass beyond Tier A although more are expected to enter this stage of testing in 
the EU due to lower threshold values (Hemminger, 2005).  The toxicological testing 
procedures recommended in the EMEA guidelines have also come under criticism for 
being inappropriate, poorly replicated and insufficient to detect very low level effects 
(Enick & Moore, 2007).  Also, the continued use of single species laboratory tests will 
mean that the ERA procedure will be unable to predict the potential for indirect effects 
manifesting at community or ecosystem level.  These authors also suggest that the 
conservative burden of proof required by the scientific community (i.e. 95 % statistical 
significance) is increasing the number of false negatives and that substances are 
deemed to pose no risk when in fact they do.  Indeed, the over reliance on significance 
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thresholds at the expense of effects size and R2 in ecology has long been acknowledged 
(Yoccoz, 1991). False negatives arising from inappropriate testing has been blamed for 
the diclofenac induced reduction in Indian vulture populations (Oaks et al., 2004).   This 
requirement for a heavy burden of proof can be reversed using the Precautionary 
Principle when there is plausible but limited evidence of an environmental risk so that 
evidence is required to indicate the absence of risk rather than its presence.  For 
example, this stance has been adopted by the EU in imposing the 2006 ban on the use 
of antibiotics as growth promoters in livestock (Enick & Moore, 2007; Kemper, 2008). 
2.7.3 Strategies for reducing pharmaceutical inputs to the aquatic environment 
When considering the environmental risks associated with pharmaceuticals the human 
health benefits for which they were derived must take precedence; this means that 
banning or restricting usage is not a viable option unless an alternative compound is 
readily available and alternative strategies for reducing environmental input must be 
developed (Jones et al., 2002).  Kümmerer (2008c) splits proposed strategies for 
reducing the input of pharmaceuticals into the aquatic environment into three broad 
categories: 
 Short-term: advanced effluent treatment and end-of-pipe technologies; 
 Medium-term: altering disposal, consumption and prescription practices and the 
collection of detailed consumption and disposal data; 
 Long-term: adoption of ‘green pharmacy’ principles that all drugs should achieve 
their therapeutic purpose and then readily degrade and other developments such 
as improved targeting of MOAs or improved delivery mechanisms to reduce 
dosage levels (Daughton, 2003). 
Short-term measures could include source control (e.g. additional treatment of highly 
contaminated hospital effluent) or source separation (urine separation) in households 
which would yield a waste source that is much more amenable to treatment, particularly 
as the majority of metabolites are in a water-soluble form (Larsen et al., 2004; Lienert et 
al., 2007a; Lienert et al., 2007b).  End-of-pipe technologies such as ozone treatment and 
granular activated carbon have demonstrated increased removal rates at STPs but these 
do not work for all compounds and carry additional capital and energy costs (Larsen et 
al., 2004).  Increased HRT of sewage within a STP can improve removal rates by 
increasing biodegradation and sorption to the sludge phase but the ultimate fate of 
sorbed compounds depends on the disposal route of the sludge i.e. whether it is 
incinerated or applied to agricultural land (Boxall et al., 2002).  Williams (2005) estimated 
that the cost to completely remove oestrogenic substances from UK STP effluent would 
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be £ 20 million per plant, a cost that would easily run into billions of pounds for all STPs 
in the UK.  However, it may only be necessary to apply these additional treatment steps 
to a small number of particularly affected plants whilst others would be satisfactorily 
controlled by more traditional technologies. 
Daughton & Ruhoy (2009) suggest the concept of ‘personalised medicine’ where 
each patient (human or animal) would receive exactly the type, degree and duration of 
treatment they require thus reducing residues from both waste and excretion.  The 
environmental benefits from such a perfectly working healthcare system could have 
additional health benefits for humans, for example by reducing the fostering of ABR in 
the environment.  The longer-term aim of ‘benign by design’ drugs will require the co-
operation of the pharmaceutical industry and the scientific community.  Such co-
operation in response to legislative, ethical and socio-economic concerns has already 
produced positive results.  For example the increased biodegradability of many 
household washing powders (Larsen et al., 2004).  The principles of ‘green chemistry’ 
(Anastas & Warner, 1998) have been successfully applied to the pharmaceutical 
sildenafil citrate (Viagra) in reducing the manufacturing process waste from 1300 L kg-1 
in 1990 to just 7 L kg-1 in 2004 (Williams, 2005).  However, green chemistry is a relatively 
recent strategy in the pharmaceutical industry which has understandably focused much 
of its efforts on achieving therapeutic benefits in humans with only secondary 
consideration of environmental consequences.  A recent EEA workshop (2010) 
suggested benign by design drugs be incentivised by extending their patent duration 
therefore encouraging pharmaceutical companies to consider environmental impacts at 
the earliest stages of drug development.  One other possibility is the consideration of 
environmental factors when prescribing or recommending drugs for use; this approach 
has been piloted with some success in Sweden (Daughton & Ruhoy, 2009a; Roig, 2010).  
Pharmaceutical take-back schemes for unwanted or unused medicines may also play a 
role in reducing the flow of drugs to the environment via disposal to solid or liquid waste 
streams (Roig, 2010). 
2.7.4 Research needs and data gaps 
A recent review of global threats to human water security and biodiversity (Vorosmarty 
et al., 2010) highlighted the lack of knowledge on occurrence, fate and effects of 
emerging contaminants such as pharmaceuticals as a major limitation to fully 
understanding global threats to freshwater resources.  The above review of literature has 
highlighted three key areas for future research required to understand and mitigate the 
consequences of pharmaceuticals in the aquatic environment: 
1. Continued research into analytical techniques and sampling of surface water 
and STP effluent to better quantify the presence of pharmaceuticals in the 
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environment.  Further sampling will assist in understanding the spatial and 
temporal variation in surface water concentrations, the relationship between 
PECs and MECs during risk assessment and the occurrence of particular 
mixtures and metabolites of pharmaceuticals in surface waters.  Additional 
work to reliably validate models such as GREAT-ER for pharmaceuticals may 
help to prioritise rivers for more detailed sampling and analysis; 
2. Continued research into treatment removal efficiencies and the development 
of new treatment technologies to prevent or reduce the input of 
pharmaceuticals to surface waters; 
3. A shift in focus of ecotoxicological testing to more ecologically relevant 
endpoints which focus on higher levels of organisation and assess the effects 
of pharmaceuticals on ecosystem structure and functioning and attach more 
importance to mixture toxicity.  Bound & Voulvoulis (2004) and Länge & 
Dietrich (2002) suggest adopting a more flexible toxicity screening process 
during risk assessment to allow the use of bespoke tests tailored to known 
MOAs or toxic endpoints.  However, it is important to continue some 
standardised testing to maintain reproducibility and allow comparisons 
between different drugs to be made. 
This thesis will focus on numbers 1 and 3.   Detailed sampling in catchment areas ranging 
from the highly urbanised to semi-rural will be undertaken.  Urban catchments are likely 
to represent a worst-case scenario due to high population density and large STPs 
although smaller works (i.e. those serving small semi-rural communities) may be 
problematic as they are less regulated under the UWWT Directive and may not have 
such comprehensive treatment systems. It will add substantially to the existing small 
dataset of pharmaceutical occurrence in England and will widen the geographical spread 
of such data beyond the current focus in SE England and Wales. The work will also be 
of global relevance given the similar patterns of consumption and environmental 
occurrence observed in other countries.  
The review of literature has highlighted the current weaknesses in the 
ecotoxicological testing of pharmaceuticals where the focus is on acutely toxic effects to 
individuals at concentrations unlikely to be encountered in the environment.  Focusing 
on higher levels of ecological organisation (population, community and ecosystem level), 
considering aspects of ecosystem functioning and mixture toxicity will help to make 
conclusions about pharmaceutical toxicity much more relevant to actual environmental 
conditions.  The use of in situ field techniques will also help to bridge the relevance gap 
between laboratory studies and environmental conditions.  These studies are particularly 
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important as toxic effects to individuals seen in the laboratory may not manifest at 
population level or above due to phenomena such as functional redundancy, stress 
response (hormesis), adaptation, migration and availability of alternative resources 
(Moss, 1988; Giller & Malmqvist, 1998; Hauer, 2006).  Furthermore, using ecosystem 
service or functional endpoints for ecotoxicological testing may provide a better basis 
and justification for the decisions of environmental managers, policy makers and 
regulators as these can have obvious socioeconomic values. 
2.8 Thesis aims and objectives 
2.8.1 Aims 
The review of literature highlighted numerous knowledge gaps both in terms of the 
occurrence of human-use pharmaceutical compounds in STP effluent and receiving 
waters and in their effects on freshwater ecosystems.  Thus, the broad aim of this thesis 
is to examine the occurrence of pharmaceuticals in typical UK catchments and consider 
the effects of such pharmaceuticals on important freshwater taxa and aspects of 
ecosystem structure and functioning.  This aim can be separated into the following four 
sub-questions: 
1. What is the current spatial and compound coverage of existing pharmaceutical 
pollution research and how reliable/representative are data obtained from these 
studies? 
2. How do pharmaceutical concentrations in STP and CSO effluent and receiving 
waters vary over diurnal, seasonal, reach and catchment scales? 
3. What lethal and sublethal impacts does extended exposure to environmentally 
relevant concentrations of pharmaceuticals have on important freshwater taxa? 
4. What impact does exposure to pharmaceuticals have on important aspects of 
ecosystem functioning? 
2.8.2 Objectives 
The research gaps identified in the literature review and the research questions outlined 
above can be divided into five key objectives which this thesis will address: 
1. Synthesise and critically evaluate current pharmaceutical pollution research by 
means of a systematic review examining spatial and compound coverage, 
sampling strategies and comparisons between measured environmental 
concentrations and ecological effect thresholds; 
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2. Quantify the temporal and spatial dynamics of the occurrence of five human-use 
pharmaceutical compounds in STP effluent, CSO effluent and receiving waters 
across two densely populated catchments over an 18 month period; 
3. Examine the effects of extended exposure to erythromycin, propranolol and their 
mixture on the functionally important freshwater amphipod Gammarus pulex 
through assessment of growth, feeding, mortality and NMR environmental 
metabolomics; 
4. Assess the impact of extended exposure to low and high levels of 
pharmaceuticals on leaf litter decomposition in the laboratory and in situ and how 
exposure to pharmaceuticals affects colonisation of leaf litter by freshwater 
macroinvertebrates; 
5. Examine the effect of pharmaceutical exposure in the laboratory on sediment 
metabolism and nutrient exchange with overlying waters. 
It is anticipated that this thesis will add substantially to the relatively small body of data 
examining the occurrence of pharmaceuticals in freshwater systems and provide novel 
information on the effects of extended exposure to environmentally relevant 
concentrations of pharmaceuticals on important freshwater taxa and aspects of 
ecosystem structure and function. 
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3 GLOBAL SYNTHESIS AND CRITICAL EVALUATION OF 
PHARMACEUTICAL DATASETS COLLECTED FROM RIVER SYSTEMS  
This chapter is comprised entirely of material included in the below paper.  It provides a 
global-scale critical review of research into the pharmaceutical pollution of rivers.  The 
aim of this chapter was to highlight spatial, temporal and methodological gaps in current 
research in order to inform the monitoring and experimental chapters presented later in 
this thesis. 
Hughes, S. R., P. Kay and L. E. Brown (2013). "Global Synthesis and Critical Evaluation 
of Pharmaceutical Data Sets Collected from River Systems." Environmental Science & 
Technology 47(2): 661-677. 
3.1 Introduction 
Pharmaceuticals have been used by humans for centuries with commercialisation 
beginning in the late 19th Century. Aside from pioneering studies in the 1970s and 1980s 
(Hignite & Azarnoff, 1977; Aherne et al., 1985; Richardson, 1985) pharmaceuticals have 
only emerged as a major group of environmental contaminants over the last 15 years 
(Wall & Strong, 1987; Oaks et al., 2004; Schwarzenbach et al., 2006; Kidd, 2007). Their 
presence in numerous environmental compartments including surface and ground 
waters, soils and biota is now well established (Daughton & Ruhoy, 2009b) and the 
predominant pathway of entry to the environment is considered to be post-consumption 
excretion to the sewer network and subsequent passage to rivers via straight piping, 
STPs (Tambosi et al., 2010) or sewer overflows (Heberer, 2002; Daughton, 2004c; Jones 
et al., 2005).  Pesticide research in the 1990s identified clofibric acid as a widespread 
aquatic contaminant (Heberer et al., 1995), which in turn sparked an expansion of 
method development and pharmaceutical research in subsequent years (Stan, 1992; 
Petrovic et al., 2010). These studies have vastly improved the reliability, availability and 
precision of pharmaceutical detection methods (Petrovic et al., 2010).   
The shift from gas to high-performance liquid chromatography with tandem mass 
spectrometry (HPLC-MS/MS) has been a key driver in improving knowledge in recent 
years (Kümmerer, 2009a).  Despite the availability of these methods, analysis and 
monitoring of pharmaceuticals in freshwaters remains far from routine and research is 
often sporadic and isolated. This is despite an increased awareness of the potential 
effects of pharmaceuticals on ecosystems and the services they provide (Fent et al., 
2006; Kümmerer, 2008a; Kümmerer, 2009a; Kümmerer, 2009b; Santos et al., 2010).  
Existing research indicates that pharmaceuticals are generally present in freshwaters 
within the ng L-1 range and, at these sub-therapeutic levels, the risk of acute toxicity is 
thought to be negligible (Enick & Moore, 2007).  However, there are substantial 
knowledge gaps in terms of chronic, long-term exposure of non-target aquatic organisms 
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and the effects on ecosystem functioning (Kümmerer, 2009a).  Data are available to 
suggest that some compounds may display chronic effects at or close to the levels 
detected in the environment (Fent et al., 2006; Santos et al., 2010).  Moreover, the 
development of antibiotic resistant bacteria is a major public health concern; the prudent 
use of pharmaceuticals in the future, is seen as key to reducing risks to public health and 
the environment (Kümmerer, 2009b; Kümmerer, 2009c).   
It is likely that pharmaceutical consumption will increase in coming years, 
particularly in developing countries and those with ageing human demographics 
(Daughton, 2003; EEA, 2010). Nevertheless, pharmaceutical compounds currently 
receive minimal consideration by regulators, policy makers and managers (Farré et al., 
2008), perhaps because there have been few attempts to amalgamate research findings 
from disparate spatial and temporal studies. However, the status quo is unlikely to remain 
in future, and the European Union has already started the process of adding the anti-
inflammatory drug diclofenac to its list of Priority Substances (EC, 2012). This change 
would mean member states must maintain concentrations below a defined 
Environmental Quality Standard in an attempt to meet the requirements of good 
ecological status under the Water Framework Directive (EC, 2000).  
This chapter synthesises the disparate research on pharmaceutical occurrence 
in freshwaters at national, regional and global scales but goes much further than a review 
by providing a critique of current research effort by compound class and individual 
substance.  A critical review of sampling strategies and methods adopted by researchers 
in this field is also provided, a crucial factor in considering how reliable and 
representative data are.  Moreover, a brief summary of the environmental effects of 
pharmaceuticals in freshwater ecosystems is given in order to highlight potentially high 
risk compound classes.  The substantial assembled database is provided as a tool to 
better inform future research on the occurrence and effects of pharmaceuticals in 
freshwaters, and to identify key areas where future research should be focused. A 
number of regulators and researchers have already accessed the database to inform 
their own work. Finally, the benefits of meta-analyses such as this is discussed in support 
of policy development to target the highest risk and most widespread compounds.   
3.1.1 Aims and objectives 
The aim of this chapter was to synthesise and critically evaluate current research into 
pharmaceutical pollution of receiving freshwaters.  Specific objectives were: 
1. Through the use of systematic review techniques, evaluate spatial coverage of 
current monitoring research at global, national and provincial levels and identify 
areas where research is sparse or absent; 
102 
 
2. Quantify the number of compounds currently detected in receiving waters and 
synthesise data to provide median and maximum measured concentrations at 
global, national and provincial level; 
3. Critique the sampling strategies adopted by researchers in this field and use this 
to inform future research; 
4. Compare synthesised receiving water concentrations with known ecological 
effects data in order to provide an indication of environmental risk posed by 
pharmaceuticals in freshwaters. 
3.2 Methodology 
A systematic review was conducted via a search of the Web of Knowledge (WoK) 
publications database (http://apps.isiknowledge.com/) on 6th March 2011. The search 
term below was applied to the title, abstract and keywords of articles: 
 
(((((pharmaceutical* OR API* OR drug* OR PPCP* OR PhAC*) AND (aquatic* OR river* 
OR stream* OR "surface water*" OR freshwater* OR effluent* OR wastewater* OR 
"waste water*"))))) 
Refined by: Document Types=( ARTICLE OR REVIEW OR ABSTRACT ) AND Research 
Domains=( SCIENCE & TECHNOLOGY ) AND Languages=( ENGLISH ) AND Subject 
Areas=(ENVIRONMENTAL SCIENCES & ECOLOGY OR PUBLIC, ENVIRONMENTAL 
& OCCUPATIONAL HEALTH OR MARINE & FRESHWATER BIOLOGY OR WATER 
RESOURCES OR BIODIVERSITY & CONSERVATION) 
 
This was intended to identify all studies that analysed for pharmaceuticals in either STP 
effluent or receiving waters; there was no restriction on time span for this query.  
Research conducted by governmental departments or reported in the ‘grey’ literature is 
also available; for example the US Environmental Protection Agency 
http://www.epa.gov/ppcp/but such work was not included here. The acronyms API 
(active pharmaceutical ingredient), PPCP (pharmaceuticals and personal care products) 
and PhAC (pharmaceutically active compound) are the most widely used by researchers 
in this field.  This initial search yielded 57 289 results which were sorted by their 
relevance to the search term (using the in-built WoK algorithm) and refined using the 
criteria above. 
The refined search criteria yielded 18 245 results and consequently the study 
was constrained further to the 28 most common journals returned by the search; which 
accounted for ~50 % of results (9072 records) and included most major environmental 
and analytical chemistry journals.  The remaining records were sorted by relevance and 
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the first 1000 results were examined individually. The cut-off of 1000 and top 28 journals 
results was deemed necessary due to the time taken to assess each individual data 
source for the meta-analyses, versus the ‘success rate’ for inclusion.  The criterion for 
inclusion in the database was that a study explicitly analysed for, detected and quantified 
at least one human-use pharmaceutical compound in either STP effluent or receiving 
waters.  From these 1000 studies, only 236 met the inclusion criterion (Table 3-1).  While 
a more exhaustive search may have improved coverage, the assembled database 
represents the broadest review of the most detailed research studies to date.  
Table 3-1: Summary of journal sources for the 236 studies included in the full database 
Journal Record Count % total (236) 
Journal of Chromatography A 42 17.80 
Environmental Science & Technology 34 14.41 
Water Research 34 14.41 
Science of the Total Environment 33 13.98 
Chemosphere 27 11.44 
Environmental Toxicology and Chemistry 23 9.75 
Analytical and Bioanalyitcal Chemistry 11 4.66 
Environmental Pollution 9 3.81 
Journal of Hazardous Materials 9 3.81 
Water Science and Technology 8 3.39 
Aquatic Toxicology 1 0.42 
Environmental Science and Pollution Research 1 0.42 
Environmental Health Perspectives 1 0.42 
Talanta 1 0.42 
Archives of Environmental Contamination and Toxicology, 1 0.42 
Ecotoxicology and Environmental Safety 1 0.42 
 
Analysis of publication dates of the 236 studies showed a clear upward trend from the 
late 1990s onwards (Figure 3-1). The majority of studies included (>80%) were published 
between 2005 and 2010, a trend most likely driven by the advancement of analytical 
techniques such as HPLC-MS/MS and increased interest in pharmaceutical pollution 
(Kümmerer, 2009a).  This is reflected in the relatively high number of studies published 
in analytical chemistry journals such as Journal of Chromatography A and Analytical and 
Bioanalytical Chemistry (Table 3-1) despite neither of these journals having a specific 
environmental focus. 
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Figure 3-1: Number of publications per year for 236 studies included in the database 
 
For each of the 236 studies the following data were extracted from the main report body 
or supplementary material: compound(s) detected; country; median and maximum 
concentration(s); sampling technique(s) adopted; sampling period; analytical 
methodologies; number of samples; number of detections; number of no detections; 
frequency of detection; referencing information and any pertinent information (e.g. raw 
drinking water or estuarine sampling).  Median and maximum concentrations were 
recorded when explicitly stated by authors or in some cases were calculated using data 
tables and in a small number of cases, concentrations had to be derived from graphical 
representations such as boxplots. Other concentrations stated in the studies were not 
recorded as it was felt that median levels were appropriately representative of ‘normal’ 
conditions and maxima represent peaks in concentrations indicative of a worst-case 
scenario in terms of ecological effects.  
The ratio of maximum: median concentration was also calculated and recorded 
and available for 74 % of the studies. For the purposes of this review only data 
concerning receiving waters (and not treated effluent) were subjected to meta-analysis 
because these were the most relevant indicators of potential effects in freshwater 
ecosystems.  Effluent concentrations are inherently variable (Kanda et al., 2003) and are 
less reliable as indicators of effects given the broad range of dilution factors and chemical 
transformations to which they are subjected when entering receiving waters.  When 
published studies reporting only treated effluent concentrations were excluded, a total of 
156 studies were retained. Fifty studies (26.8 %) contained samples of a non-riverine 
source (marine, estuarine, groundwater, raw drinking water or sediment samples); from 
which lentic and raw drinking water samples were included as these were deemed 
relevant.  Five studies contained samples extracted from freshwater sediments and 
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although these are relevant, the small number of studies was deemed insufficient to merit 
inclusion.  The full database containing all receiving water records is freely available 
upon request from http://www.wateratleeds.org (further details are given in Appendix A). 
All concentrations were recorded in the database as nanograms per litre (ng L-1) 
to enable direct comparison.  Individual compounds were then grouped into the following 
classes: antibiotics; antidepressants; antiepileptics; antivirals; blood lipid regulators; 
cancer treatments; contrast media; endocrine drugs; gastro-intestinal drugs; illicit drugs; 
other cardiovascular drugs; other CNS (central nervous system) drugs; others; 
painkillers and  respiratory drugs. 
3.3 Results 
The full database containing pharmaceutical occurrence records from the 156 published 
studies with data for 203 compounds across 41 countries is available in Appendix A. 
Median concentrations ranged from 6.2 ng L-1 for the antibiotic sulfathiazole to 163 673 
ng L-1 for the antibiotic ciprofloxacin which also had the highest maximum concentration 
of the entire database at 6 500 000 ng L-1.  Of the 61 (=50th) most frequently detected 
compounds, 39 % were antibiotics, 21 % painkillers, 20 % cardiovascular drugs or blood 
lipid regulators and 3 % antidepressants. 
3.3.1 Spatial coverage of research 
Pharmaceutical compounds were identified in receiving waters across 41 countries on 
all continents except Africa and Antarctica (Figure 3-2). The database included 1417 
records representing 67 903 analyses and median/maximum concentrations from >14 
155 samples (nb. 27 studies did not state sampling numbers) and >24 989 positive 
detections of pharmaceuticals; equating to an overall detection frequency of 37 %.  The 
results illustrated a heavy bias towards research in Europe and North America which 
accounted for 80 % of studies, with a further 16 % in Asia (predominantly China). Only 
three studies reported from South America and just one from the Middle East (Israel).  
The USA had the most studies (34) and Spain, China, Germany, Canada and the UK 
were the only other countries to have >10 studies.  Seventy one percent of nations in the 
database had three or fewer studies conducted, including very large or populous nations 
such as Japan, Brazil, Mexico, Pakistan and Australia. 
When examining data at the 'continental' scale strong biases are again evident 
(Figure 3-3).  For example, just 6/176 provinces in Asia accounted for >50 % of published 
studies in that region, with the most populous province in China (Guangdong) having the 
highest number (six).  In Europe most studies have been undertaken in Germany, Spain 
and Switzerland (in the Elbe, Rhine, Ebro and Llobregat basins).  The UK has a relatively 
good spread of research, covering most countries except South West England and 
Northern Ireland.  However, studies are generally isolated, with the only repeated work 
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undertaken in Wales, Greater London and the North East.  A similar story is evident in 
North America with nine Canadian provinces (69 %) and 28 US states (55 %) having one 
or no studies. 
Globally, painkillers were the most frequently detected compounds accounting 
for 31 % of records with a median concentration of 230 ng L-1 followed by antibiotics (21 
%, 8128 ng L-1; Figure 3-4 a).  The remaining compound classes each demonstrated 
medians of <100 ng L-1 except for Others (830 ng L-1 incl. antiepileptics and contrast 
media).  The picture changes when data are examined regionally (Figure 3-4 b-d). For 
example, the most commonly encountered pharmaceuticals were painkillers in Europe 
(34 %, median concentration 261 ng L-1) and antibiotics in North America (38 %, 71 ng 
L-1) and Asia (42 %, 33 446 ng L-1).  Contrast media and respiratory drugs had particularly 
high median concentrations in Asian waters of 1257 and 50 023 ng L-1 respectively, 
although these were from a small number of studies contaminated by effluent from 
pharmaceutical manufacturing facilities (Li et al., 2008; Fick et al., 2009).  Additionally, 
antidepressants are more frequently detected in North America (9 %, 25 ng L-1) 
compared to Europe and Asia where they account for <1 % of records. 
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Figure 3-2: Global-scale distribution of the number of published studies identifying pharmaceuticals in inland surface waters 
Number of studies 
detecting one or 
more 
pharmaceutical 
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Figure 3-3: Number of published studies detecting at least one pharmaceutical 
compound in (a) European regions (b), North American states and (c) south Asian 
provinces 
109 
 
 
Figure 3-4: Relative frequency of detection, and median concentration, of pharmaceuticals in receiving waters: 
(a) global, (b) Europe, (c) North America and (d) Asia.  
[The circumference of each fan is scaled by the relative proportion of detections. Each point outwards on the 
radial axis represents 10y of the median concentration in ng L-1. For example, the innermost circle represents 
101 ng L-1; the second represents 102 ng L-1, etc. 
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3.3.2 Concentrations of pharmaceuticals in receiving waters 
A striking result from mean concentrations in the top 10 most studied countries was that 
all except China demonstrated very low proportions of the global mean (<2 %) for 
antibiotics (Figure 3-5); this was due to the very high concentrations detected in a small 
number of Asian studies.  Interestingly, China displayed values well below the global 
means for all other compound classes ranging from 2 to 25 %.  Spain was above the 
global mean (171 to 441 %) for all classes except Antibiotics and Others compared to 
Italy, Switzerland, Japan and the UK which were below the global mean for all classes.  
No single country in the top 10 demonstrated mean concentrations above 40 % of the 
global mean for Others.  This is due to there being only seven countries within this group 
which are heavily skewed by one study in India detecting very high concentrations (15 
000 ng L-1) of the antifungal terbinafine (Fick et al., 2009). 
The top 20 most frequently studied compounds in Europe included eight 
painkillers, six cardiovascular drugs and four antibiotics with median concentrations for 
all compounds below 100 ng L-1 except aspirin and paracetamol (median 190 ng L-1; 
Figure 3-6).  A similar picture was evident in North America and Asia with mostly 
antibiotics, cardiovascular drugs and painkillers present in the top 20 compounds with 
median concentrations generally <100 ng L-1.  A small number of compounds (six in 
Europe and Asia and two in North America) had maxima >10 000 ng L-1.  Of particular 
note was carbamazepine which was the most frequently studied and detected compound 
in both North America and Europe and third in Asia.  The minimum detection frequency 
for all compounds studied (Figure 3-6) was 9 % (diclofenac in North America) but 
average detections frequencies were 70 % (Europe), 27 % (North America) and 65 % 
(Asia). 
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Figure 3-5: Comparison of national mean of pharmaceuticals concentrations to the 
global mean for (a) the 1st to 5th and (b) the 6th to 10th top countries  
[as determined by number of entries in the database; represented by the number in 
brackets.  Global mean is the mean concentration for all records of that compound 
group. Values exceeding 200% of global mean: Spain (blood lipid regulators 441%, 
other cardiovascular drugs 213%, and painkillers 209%), Germany (antidepressants 
246%), and South Korea (other cardiovascular drugs 404%)] 
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Figure 3-6: Boxplots of the 20 most commonly encountered pharmaceuticals in (a) 
European, (b) North American, and (c) Asian receiving waters.  
[n values represent total number of records for the respective region and values above 
the x axes represent records for each of the 20 specific compounds. Boxes represent 
interquartile ranges with median concentration represented by the horizontal line. 
Whiskers show the range of data and asterisks represent outliers]. 
3.3.3 Sampling strategies adopted in pharmaceutical monitoring studies 
A major finding from this analysis was that 45 % of European and Asian and 23 % of 
North America studies failed to provide any details of the sampling regime and 
techniques adopted (Figure 3-7). Isolated and non-repeated grab sampling was by far 
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the most common technique and was adopted in 31-34 % of studies.  Slightly more 
representative repeated grab sampling over periods ranging from days to years was 
undertaken in just 12 % of studies. Additional techniques are available including 
composite sampling and the use of passive samplers (e.g. polar organic contaminant 
integrative sampling, POCIS) which give an integrated sample over a period of days to 
weeks.  However, these were adopted by just 11 % of European and 9 % of North 
American studies and not at all elsewhere.  
 
Figure 3-7: Summary of sampling methodologies employed in detection of 
pharmaceutical compound(s) in rivers.  
[n =  number of records in the database; POCIS = polar organic contaminant 
integrative sampler] 
3.3.4 The effects of long-term exposure to pharmaceuticals in receiving waters 
Chronic effects data for the six main compound classes were collated from four major 
reviews (Crane et al., 2006; Fent et al., 2006; Enick & Moore, 2007; Santos et al., 2010) 
and any duplicate results were removed manually.  Chronic (i.e. long-term) data (rather 
than short-term, acute studies) were chosen as these were deemed to be more 
representative of actual low-level exposure of aquatic organisms (Newman & Unger, 
2003).  The endpoints assessed included lethal and sub-lethal indices (e.g. feeding, 
growth, behaviour and reproduction).  The data included here are not intended as a direct 
assessment of particular compound toxicity but rather to highlight where overlaps 
between measured environmental concentrations and chronic toxicity indicate potential 
environmental risk. 
The ranges of long-term toxicity vary markedly across compound types and taxa 
(Figure 3-8).  From these data antidepressants appear to pose a particular risk to all taxa 
except bacteria with effective concentrations ranging from low µg to mg L-1.  Invertebrates 
and fish show chronic toxic effects at sub mg L-1 levels for cardiovascular drugs and 
Others.  Fish also appear susceptible to painkillers with effects manifesting at 40 000 ng 
L-1.  This summary highlights where research is lacking; in particular there were no 
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studies examining the effects of antibiotics on fish, antidepressants on aquatic plants or 
cardiovascular drugs on bacteria.  Overall, bacteria and aquatic plants appear to be the 
least well studied whereas research on chronic effects in aquatic invertebrates is 
relatively abundant. 
3.4 Discussion 
3.4.1 Spatial distribution of research 
This study shows that knowledge of pharmaceutical occurrence is poor or absent for 
large parts of the globe, particularly in developing countries.  The research that has been 
undertaken displays a heavy bias towards North America, Europe and the more 
populous parts of China.  Given that the consumption of pharmaceuticals is ubiquitous 
across the globe (Daughton, 2001), there is clearly a pressing need to expand research 
into their occurrence particularly in Russia, southern Asia, Africa, the Middle East, South 
America and Eastern Europe.  As more data become available, the better able 
researchers will be able to highlight the scale of the problem and inform management 
decisions. Moreover, even where studies have been relatively numerous knowledge is 
still minimal compared to that for other stressors such as nutrients (Smith & Schindler, 
2009; Woodward et al., 2012), acidification (Evans, 2001), river regulation (Nilsson et al., 
2005) and sedimentation (Viers et al., 2009). 
When looking at the spread of research it is apparent that the spatial biases 
manifest at multiple scales. In Europe, an obvious cluster of research is evident around 
central Europe particularly and to a lesser extent in the UK and Spain. Research effort 
appears to be clustered around the high population areas of (London, Paris, Hamburg, 
Frankfurt, California and the North American eastern seaboard and Beijing and 
Guangdong province in China).  This is understandable given that pharmaceutical 
pollution can be expected to be at its greatest in densely populated areas and a risk 
based approach (Borja et al., 2006) should target these receiving waters first.  However, 
this leaves substantial proportions of Europe and North America with insufficient 
research.  For example, in the UK no research has been conducted in the major urban 
areas of the West Midlands, Greater Manchester or West Yorkshire which have a 
combined population of 6 million people (Pointer, 2005).  Researchers should expand 
monitoring efforts to previously unstudied catchments whilst at the same time increasing 
the length/breadth and temporal resolution of monitoring campaigns if the dynamics of 
pharmaceutical pollution are to be fully understood.  Research in less densely populated 
and rural areas should also be a priority as it is probable that STPs in such locations are 
smaller and less advanced when compared to their larger counterparts serving urban 
areas and septic tanks may also represent a risk (Neal et al., 2005). 
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Figure 3-8: Summary of chronic ecotoxicological data for pharmaceuticals and freshwater organisms across (a) antibiotics, (b) 
antidepressants, (c) blood lipid regulators, (d) other cardiovascular drugs, (e) others and (f) painkillers 
data summarised from (Crane et al., 2006; Fent et al., 2006; Enick & Moore, 2007; Santos et al., 2010) 
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3.4.2 Coverage of compound classes 
When viewed globally, antibiotics, antiepileptics, cardiovascular drugs (including blood 
lipid regulators) and painkillers accounted for 86 % of all database records with 
carbamazepine being the single most commonly identified compound. A likely reason for 
this bias is that these drug types are the most widely prescribed and purchased over-
the-counter (NHS, 2009b; Gu, 2010).  For example, cardiovascular drugs and painkillers 
were amongst the top three compound types prescribed to adults in the USA during 2007 
(Gu, 2010) and as such could be expected to enter the environment in the highest 
concentrations. However, this leaves major groups of potentially toxic pharmaceuticals 
being poorly studied.  For example, antidepressants, antivirals, cancer treatments, 
tranquilisers and antifungals combined accounted for just 6.3 % of records. A reason for 
this imbalance in detections could be that researchers have not been analysing these 
compounds in environmental samples, rather than them being genuinely scarce.  It may 
also be possible that less frequently detected compounds are less refractory and are 
more efficiently removed during sewage treatment (Tambosi et al., 2010). Further studies 
on these ‘rarer’ compounds are particularly necessary given documented effects on 
microalgal communities even at very low concentrations (Porsbring et al., 2009).  
Interestingly, antidepressants were the most widely prescribed compounds amongst 
young American adults (Gu, 2010), and this is reflected in the relatively high number of 
North American studies analysing these compounds (9 %) when compared to Asia and 
Europe (1 %). 
The analysis confirmed that knowledge of some pharmaceutical groups is almost 
completely lacking with >50 % of entries in the database represented by just 14 
compounds (all of which are antibiotics, antiepileptics, cardiovascular drugs or 
painkillers).  The entire database represents only a snapshot (203) of all pharmaceuticals 
approved for use, which is estimated to be well over 5000 in Europe alone (Pascoe et 
al., 2003). This gives a conservative estimate that fewer than 4 % of pharmaceuticals 
have been analysed for and detected in freshwaters. It demonstrates a clear need for 
future research to be expanded across the less well studied compounds, particularly 
those identified as posing environmental risk. 
3.4.3 Pharmaceutical concentrations in freshwaters 
One of the most striking results from the data was the relatively high concentrations for 
antibiotics and Others (comprising just the respiratory drug ceterizine and the contrast 
medium ioprimide in Asia) compared to other classes.  However, these very high 
concentrations were skewed by a small number of studies which analysed waters 
receiving pharmaceutical manufacturing effluent (Li et al., 2008; Fick et al., 2009).  Up 
until recently pharmaceutical manufacturing facilities (PMFs) were considered a low 
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priority given the high value of pharmaceutical products and the adoption of 'good 
management practice' by the industry intended to reduce wastage and loss to the 
environment (USEPA, 1997).  However, PMFs can be a source of pharmaceuticals to 
receiving waters both within developed (Phillips et al., 2010) and developing countries 
(Larsson et al., 2007; Li et al., 2008); these should be considered a priority for future 
research effort given the potential for strong localised effects. 
National means were compared to global means to evaluate the appropriateness 
of local studies as indicators of concentrations at larger spatial scales.  The differences 
shown in these comparisons highlight the importance of local studies to inform 
stakeholders and regulators, and emphasise a need for caution when scaling up to larger 
spatial scales, or vice-versa.  Given the relative paucity of data it is possible for a small 
number of studies at particularly polluted locations to have a disproportionate influence 
on national and even global mean concentrations.  The very high concentrations for 
antibiotics in Asia and globally are an example of this problem  The global median 
antibiotic concentration of 8135 ng L-1 reduces to 58 ng L-1 if just two Chinese and Indian 
studies are excluded (Li et al., 2008; Fick et al., 2009). 
3.4.4 Frequently studied compounds 
Ibuprofen and sulfamethoxazole were consistently within the top five most studied 
compounds across all regions and had similar concentration ranges (1 to 10 000 ng L-1). 
Notably though, very high concentrations (up to a maximum of 10 000 000 ng L-1) of 
ciprofloxacin, erythromycin, norfloxacin and ofloxacin were evident in Asia; this is of 
concern because these are well within the range known to cause acute and chronic toxic 
effects to aquatic organisms (Santos et al., 2010). Also of note was the presence of the 
antidepressant fluoxetine in the top 20 North American compounds; this type of 
antidepressant causes chronic effects at the low ng L-1 range (Flaherty & Dodson, 2005; 
Painter et al., 2009), well below the median and maximum concentrations detected in 
the environment. Carbamazepine is the single most widely studied and detected 
compound in Europe and North America but is not generally considered to pose a risk of 
acute or chronic toxicity to freshwater organisms (Quinn et al., 2008).  However, its 
refractory nature and generally ubiquitous presence in STP effluent may make 
carbamazepine a useful source-specific tracer of domestic wastewater contamination 
(Gasser et al., 2011). 
3.4.5 Sampling strategies 
Perhaps the most crucial step in reliably quantifying the presence of pharmaceuticals in 
freshwaters is the collection of a representative sample using appropriate strategies and 
methodologies (Ort et al., 2010a; 2010b).  Sampling uncertainty can often exceed that 
during the analytical procedure (Ramsey & Thompson, 2007).  Large sample numbers 
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and sophisticated analytical techniques, although important, should not be seen as a 
substitute for the collection of a representative sample (Ort et al., 2010a) and poor 
sampling regime can be the dominant source of error in water quality data (Martin et al., 
1992).  Some exponents of sampling theory have gone so far as to argue that “nothing 
good (certainly nothing representative) has ever come from grab sampling" (Petersen et 
al., 2005) due to the fact that it provides a mere snapshot in time.  Grab sampling does 
have a part to play in furthering our understanding of pharmaceutical occurrence 
particularly for extensive spatial or long-term studies where the equipment and set-up 
costs of more representative techniques may be prohibitive. However, efforts should be 
made to adopt more representative techniques wherever possible. For pharmaceuticals 
in particular, non-repeated grab sampling is unlikely to be representative as 
concentrations have been shown to vary considerably over time (Kanda et al., 2003).  
A possible explanation for the lack of robust sampling is the relatively high 
proportion of studies published in journals with a focus on analytical chemistry (namely 
Journal of Chromatography A, Analytical and Bioanalytical Chemistry and Talanta).  The 
main thrust of these journals is method development rather than the collection of large, 
representative datasets and this is borne out by the fact that 64 % of these papers did 
not state the sampling methodologies adopted (c.f. 44 % across all journals) and only 11 
% of studies adopted repeated grab or composite sampling strategies (c.f. 21-23 % 
across all journals).  This propensity of analytical studies to collect fewer samples for 
shorter periods is probably due to analytical chemists needing to validate methods on 
‘real’ samples which requires only minimal numbers to be collected.  The contribution of 
these papers should not be understated, as they provide reliable and sophisticated 
analytical methods that can be adopted as part of more representative sampling studies. 
The occurrence data alone provided by these studies covers 94 compounds in 34 
countries, so minor modifications to sampling strategies and subsequent reporting by 
these scientists could benefit the field substantially.  
In addition to the techniques adopted, appropriate sampling numbers, duration 
and frequency are crucial to obtain a reliable quantification of variable water quality 
parameters.  Most studies collected a relatively small number of samples (1-50) with only 
13 % of studies collecting for >12 months.  This indicates a dearth of long-term 
monitoring which may be crucial in understanding seasonal and annual dynamics.  
Conversely, sampling at an appropriately high temporal resolution over the short-term is 
equally important if we are to fully quantify variability over the periods of minutes to days 
(Kanda et al., 2003; Ort et al., 2010a; Ort et al., 2010b).  Studies on other aquatic 
contaminants have shown the importance of a robust sampling strategy; Rabiet et al. 
(2010) demonstrated that fixed time interval grab sampling underestimated pesticide 
fluxes from a small catchment by as much as a factor of five.  One study (Robertson, 
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2003) recommended tailoring sampling strategies to the variable of interest and the 
duration of the study when monitoring in small streams. An interesting research task 
would be the systematic comparison of measured concentrations using grab sampling 
and continuous or composite techniques; the database assembled here may prove 
useful in such a study. 
These data clearly highlight the importance of adopting flexible, appropriate 
sampling strategies in order to supply reliable and representative data.   Furthermore, 
researchers should explicitly state the techniques employed in addition to sample 
numbers, frequencies and locations so that other researchers can fairly evaluate the 
results presented and use them to inform their own research.   
3.4.6 Effects of pharmaceuticals on freshwater ecosystems 
Despite the widespread presence of many pharmaceuticals in freshwaters, some risk 
assessments have suggested that they pose little risk of acute or chronic toxicity at 
environmentally relevant concentrations (Jones et al., 2002; Fent et al., 2006).  The data 
summaries presented here and elsewhere indicate potential overlap between chronic 
effects levels and the concentrations detected within freshwaters however.  In particular, 
potential risks are evident for invertebrates and fish from antibiotics and cardiovascular 
drugs in Asia and from the contrast media, tranquilisers and antiepileptics 
(carbamazepine) across all regions.  Additionally, invertebrates and fish are potentially 
at risk (i.e. low margin of safety) from antidepressants and painkillers in North America.  
While this may suggest that future research should shift towards less well studied but 
more ‘toxic’ compounds, particular care needs to be taken with these conclusions 
because many effects studies on aquatic ‘ecosystems’ have been undertaken using 
ecologically unrealistic (i.e. single species) laboratory experiments. Additionally, such 
studies tend to test at concentrations that are orders of magnitude above those detected 
in the environment and be run over short time-scales, and as such do not adequately 
address the issue of low-level, chronic exposure.  Studies which have examined the 
effects of low-level pharmaceutical exposure on aquatic ecosystem structure and 
functioning are rare but have indicated that pharmaceuticals can display significant 
effects on important ecosystem services (Wilson et al., 2004; Näslund et al., 2008; 
Bundschuh et al., 2009; Painter, 2009). 
The data presented here are a useful indicator of particular compound classes 
exhibiting some kind of toxic effect at the levels stated.  As such, the combined 
occurrence and effects datasets can serve as a guide for future ecotoxicological 
research.  However, they should be treated with caution as they integrate a variety of 
toxicological tests which employ a range of exposures and endpoints across a variety of 
species.   The exposure regime of any testing should attempt to cover both the median 
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as a measure of frequently encountered concentrations, and the maximum concentration 
as an indicator of worst-case exposure. Furthermore, standard assessments of toxicity, 
whilst useful in producing comparable results, suffer from low bio complexity and 
environmental relevance and so researchers need to adopt a more flexible, knowledge 
based approach tailored to specific risks (Länge & Dietrich, 2002).  A problem with 
undertaking research in ‘natural’ freshwaters is that there will probably be myriad other 
compounds in addition to the one of interest, meaning a high potential for confounding 
effects. More realistic controlled experiments need to be designed and undertaken 
(Brown et al., 2011) before researchers can make better predictions about ecosystem 
response to pharmaceutical pollution. Researchers and regulators must therefore be 
wary of dismissing particular pharmaceuticals as ‘low risk’ on the basis of isolated and 
overly simplified laboratory studies. 
3.5 Conclusions 
This study is the first to assemble a comprehensive database of widely distributed 
information on pharmaceutical concentrations at global, continental, national and 
provincial scales. In doing so it has highlighted large parts of the globe where knowledge 
of pharmaceutical occurrence is minimal or non-existent.  In particular, large parts of 
Asia, Africa, South America and Australia should be seen as a priority for future research.  
Additionally, the majority of countries where research is sparse or absent are developing 
nations, and as such it is possible that the pharmaceutical consumption (and hence 
pollution) profile may differ markedly from developed nations.  It could be the case that 
in developing countries water resource management has not yet progressed to the stage 
where environmental monitoring and regulation of pollutants typically start to be taken 
seriously (Wescoat & White, 2003).   
Even within the developed nations of Europe and North America there is a 
pressing need for better spatial coverage across all provinces and states.  Future 
research should learn lessons from other fields and use appropriate, representative 
sampling strategies to give much more reliable estimates of the pollution problem.  The 
current proposal for statutory monitoring of diclofenac in European waters (EC, 2012) 
will provide a substantial boost to our knowledge but researchers and regulators should 
also see this as an opportunity to increase our understanding of the thousands of other 
pharmaceuticals and domestic chemicals that routinely enter freshwaters via STPs. 
The most striking results of this study were the very high concentrations reported 
(particularly antibiotics, painkillers and antidepressants) that are within the range known 
to cause acute or chronic toxicity in aquatic systems. This challenges the assumption 
that pharmaceuticals in rivers generally pose little risk (Kanda et al., 2003) and highlights 
the need for an expansion of robust monitoring and the adoption of more realistic 
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ecotoxicological experiments. Expanding research effort to previously understudied 
compounds (some antibiotics, antidepressants, respiratory drugs and contrast media) 
and areas of the globe where research coverage is poor should be a priority.  This is 
particularly important as in coming decades it is anticipated that pharmaceutical use will 
increase substantially, partly due to the ageing population structure in developed 
countries, and with ongoing increases in the standard of living in developing countries.  
These improvements in quality of life are accompanied by an increase in meat 
consumption in developing countries (Stokstad, 2010) which in turn may boost the 
consumption of veterinary pharmaceuticals, posing additional environmental risk.  
The database assembled in this study should serve as a useful tool for industry 
professionals, academics, regulators and water managers in prioritising future work on 
both pharmaceutical occurrence and the effects of such compounds on aquatic 
ecosystems. Ultimately, the results indicate that despite almost two decades of research 
effort, our knowledge of pharmaceutical occurrence and effects in the environment is still 
substantially lacking when compared to other aquatic pollutants.   
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4 PHARMACEUTICALS IN SEWAGE EFFLUENT, COMBINED SEWER 
OVERFLOWS AND RECEIVING WATERS 
4.1 Introduction 
An increasing global population is placing great strain on over 65 % of the Earth’s rivers 
with chemical pollution one of the main causes of degradation and biodiversity loss in 
aquatic ecosystems (Vorosmarty et al., 2010).  In chemical pollution research there has 
been an increasing focus on emerging contaminants over recent decades (Daughton & 
Ternes, 1999) which enter the aquatic environment following excretion to the sewer 
system and passage through STPs (Kolpin et al., 2002).  The technologies employed in 
most STPs are designed to reduce organic pollution and excess nutrients but they are 
often poor at removing pharmaceutical compounds (Halling-Sørensen, 1998).  Removal 
rates are highly variable between compounds and individual STPs but it is now widely 
considered that STP effluent is the dominant source of pharmaceuticals entering the 
aquatic environment (Heberer, 2002; Daughton, 2004c; Jones et al., 2005; Tambosi et 
al., 2010).  The presence of pharmaceuticals in continually discharged effluent is a major 
concern due to ‘pseudo-persistence’ resulting in continuous, low-level and 
multigenerational exposure of aquatic organisms (Daughton, 2001).  The ultra-trace 
concentrations of pharmaceuticals in rivers mean that the risk of acute toxicity and 
human health impacts are low but there is increasing evidence of chronic, longer-term 
effects on aquatic biota and important ecosystem processes (Fent et al., 2006; 
Kümmerer, 2009a; Santos et al., 2010).  The potential for effects at very dilute 
concentrations and the effects of mixture toxicity must also be considered (Cleuvers, 
2003; Cleuvers, 2004; Caliman & Gavrilescu, 2009). 
Research into pharmaceutical pollution is expanding largely due to increased 
concern over potential adverse effects and advancements in the analytical techniques 
necessary to detect such compounds at extremely low concentrations (Daughton, 2001; 
WIlliams, 2005).  Research to date has been overwhelmingly biased towards certain 
European countries (Germany, Italy, Spain, Sweden, Switzerland and the UK), the USA, 
Canada and China (Petrovic et al., 2004; Caliman & Gavrilescu, 2009).  Very little 
research has been conducted in large parts of Africa, Asia, the Middle East and South 
America (Hughes et al. 2013).  Even within those countries with a relatively high level of 
research, studies are spatially biased around a small number of densely populated urban 
areas or around key research institutions.  For example, UK pharmaceutical pollution 
research is heavily clustered around south east England and parts of north Wales with 
very few studies in central, western and northern England or Scotland and where such 
studies are present they are often single, non-repeated studies (Hughes et al. 2013). 
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When compared to other aquatic stressors such as nutrients, acidification and 
sedimentation (Evans, 2001; Smith & Schindler, 2009; Viers et al., 2009; Woodward et 
al., 2012) relatively little is known about pharmaceutical pollution and there remains a 
pressing need for more widespread and reliable monitoring studies (Hughes et al., 2013).   
Furthermore, existing studies have typically provided very few details on the adopted 
sampling regime, making it difficult to draw conclusions about the reliability or 
representativeness of the data presented.  Hughes et al. (2013) showed that 45 % of 
European studies provided no details of sampling techniques, numbers, frequency or 
duration.  Of those studies which did provide such data, isolated and non-repeated grab 
sampling was by far the most common technique adopted with more representative 
composite techniques used in just 11 % of studies.  
Combined sewer overflows (CSOs) and storm water discharges have been 
identified as potential sources of pharmaceutical pollution under differing flow conditions 
which can potentially discharge untreated sewage effluent to receiving waters.  Despite 
this, there are very few studies which attempt to examine the contribution they make to 
overall pharmaceutical loads in rivers (Boyd et al., 2004; Kolpin et al., 2004).  This is of 
concern as it has been hypothesised that such non-STP point sources may be the key 
contributor of high pharmaceutical concentrations in reaches far from STP effluent 
outfalls (Ellis, 2006). 
Examinations of the longitudinal (up-downstream) profile of pharmaceutical 
pollution in rivers generally present the same view of relatively uncontaminated upper 
reaches with increasing concentrations moving downstream through more urbanised 
areas (Glassmeyer et al., 2005; Kasprzyk-Hordern et al., 2008; Tamtam et al., 2008; 
Schultz et al., 2010; Waiser et al., 2010).  In some cases, residual low levels of 
pharmaceuticals have been detected tens or hundreds of kilometres downstream of STP 
outfalls (Waiser et al., 2010) demonstrating the potential for much wider, catchment-level 
impacts.   However, only 16 % of studies included in a recent review collected samples 
more than 1 km downstream of STP outfalls indicating a tendency of research to focus 
on the effluent dominated reaches immediately downstream (see Appendix A; Hughes 
et al., 2013).  This is understandable given the likelihood that these areas are most 
affected by pharmaceutical pollution but this leaves long reaches of even well studied 
catchments with little or no monitoring data available. 
The degree of attenuation of pharmaceuticals over reaches of several kilometres 
is also highly variable and dependent on local and compound specific factors (Packer et 
al., 2003; Radke et al., 2010).  Furthermore, it is likely that in highly urbanised reaches 
with many STP and CSO outfalls that at least some pharmaceutical attenuation over 
such distances is replaced by additional inputs (Ellis, 2006).  However, the number of 
field studies examining the longitudinal profiles across the reach scale is small (Radke 
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et al., 2010) and this is a pressing research question given the potentially unsafe 
assumption in many risk assessment models of first-order in-stream decay of 
pharmaceuticals (e.g. GREAT-ER; Schowanek et al., 2001). 
Research examining temporal variation in pharmaceutical concentrations over 
the short-term (daily) is also relatively rare.  This is despite evidence demonstrating high 
degrees of variation in STP effluent pharmaceutical concentrations over hourly and daily 
periods (Kanda et al., 2003).  Given the tendency towards non-repeated grab sampling 
it is unlikely that such variation has so far been adequately captured in existing 
monitoring datasets (Ort, 2006; Ort et al., 2010a; Ort et al., 2010b).  Monitoring over 
longer, seasonal timescales is well represented with 50 studies in a recent review having 
collected samples for a period of greater than six months (Hughes et al., 2013).  There 
are no general seasonal trends in pharmaceutical concentrations in either effluent or 
receiving waters (Kasprzyk-Hordern et al., 2008) as these are dependent on a number 
of factors including seasonal consumption trends, flow/dilution, temperature and site 
specific factors (Goossens et al., 2005; Ort et al., 2010b).   However, Conkle et al. (2008) 
suggest that due to catchment retention effects and the tendency of many drugs to be 
prescribed for longer-term (monthly) usage, the majority of variation in pharmaceutical 
concentrations will be at the seasonal scale.  For example, Lorraine & Pettigrove (2006) 
showed markedly higher emerging contaminant concentrations during the dry season in 
southern California, USA.  However, this was largely caused by higher summer 
consumption of certain compounds and the import of water from adjacent effluent-
dominated catchments during the summer months.  This highlights the importance of 
local monitoring data and demonstrates the pitfalls of using even nearby proxy sites as 
an indicator of the likely pollution extent in a particular catchment.  Therefore, there is a 
pressing need to further expand the temporal and spatial coverage of pharmaceutical 
monitoring to previously unstudied catchments. 
In the UK, to date 19 published studies have analysed for pharmaceuticals in UK 
STP effluent or receiving waters, and in total 73 different compounds have been 
monitored.  Chapter 3 showed that although there was a good spread of research across 
the UK, most of the studies were isolated with repeated work only conducted in small 
clusters throughout the country (Figure 4-1).  The Thames is by the far the most studied 
catchment with eight different published papers.  Substantial parts of the UK have little 
or no existing data on pharmaceutical pollution in rivers.  For example, in England no 
published research has been conducted in the major urban areas of the West Midlands, 
Greater Manchester or West Yorkshire which have a combined population of 6 million 
people (Pointer, 2005).  Research is also lacking in much of Wales, south west England, 
Scotland and Northern Ireland.  The region of Yorkshire has been subject to only one 
published study (Loos et al., 2009) despite being home to a population of 5.3 million 
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people and the fifth most populous region outside of London (ONS, 2012).  There is a 
need to expand pharmaceutical pollution research in the UK beyond London and the 
South East to densely populated areas where the risk of pollution is also high.    
The contribution of CSOs to reductions in water quality are well acknowledged 
(Muliss et al., 1997; Old et al., 2003; Saul, 1989) and some recent research has 
highlighted their capacity to contribute significant loads of pharmaceuticals to rivers 
under differing flow conditions in the USA (Boyd et al., 2004).  Despite this no such 
research has been conducted in the UK and CSOs represent an unquantified but 
potentially significant source of pharmaceutical pollution.  The above studies indicate 
that emerging contaminants are present and potentially eliciting negative effects on the 
freshwater ecosystems in the UK.  However, the relative paucity of data for large parts 
of the UK means a substantial monitoring study is required to broaden the spatial 
coverage of research and add to the global knowledge base on temporal and spatial 
variation, in-stream degradation and the contribution of CSOs to pharmaceutical 
pollution.   
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Figure 4-1: Pharmaceutical pollution research in the UK from Hughes et al. (2013) 
Boundaries are major UK river catchments, and the total no. studies reporting 
sampling locations = 14) 
4.1.1 Aims and objectives 
The aim of this study was to build on existing pharmaceutical occurrence research by 
improving spatial coverage to previously unstudied catchments, considering a 
substantial range of sites from semi-rural to urban and including both nested temporal 
monitoring (diurnal-seasonal).  Compounds posing a high risk to the environment were 
selected for monitoring and pollution from combined sewer overflows was also 
considered.  Specific objectives were to:  
1. Carry out repeated monthly grab sampling of effluent and receiving waters 
downstream of several STPs to examine seasonal trends in pharmaceutical 
concentrations; 
2. Quantify short-term diurnal variations in receiving water pharmaceutical 
concentrations by carrying out intensive sampling of the receiving waters from 
two STPs; 
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3. Use the seasonal dataset to compare concentrations between different STPs of 
differing treatment technologies and populations served throughout the 
catchments; 
4. Sample along a 5 km stretch of the River Aire downstream of a large STP to 
examine longitudinal concentration profiles; 
5. Collect samples from combined sewer overflows to examine the contribution 
these sources make to overall pharmaceutical pollution of rivers. 
The following specific hypotheses were tested: (H1) that pharmaceuticals will be 
consistently present in STP effluent at concentrations greater than receiving waters and 
that concentrations would show significant temporal variation across both seasonal and 
diurnal timescales (H2).  It was also hypothesised that differences in concentrations 
would be present between different STP sites based on the treatment technologies 
employed within (H3) and that significant attenuation along the 5 km study reach of the 
River Aire would take place (H4).  Finally, it was hypothesised that pharmaceuticals would 
be present in CSO effluent at reduced concentrations and frequencies when compared 
to STP effluent (H5). 
4.2 Methods 
4.2.1 Study area 
The Aire and Calder catchments are ideal for studying the occurrence of pharmaceuticals 
in rivers given the 105 STPs that discharge effluent into them (Yorkshire Water, pers. 
comm.).  Within Yorkshire the major conurbation known as the West Yorkshire Urban 
Area (WYUA) comprises the cities of Leeds, Bradford, Wakefield and Huddersfield 
alongside the adjacent large towns of Castleford and Halifax, with a combined population 
of 2.2 million.  Two major rivers, the Aire and Calder, flow from west to east through the 
WYUA and they have a long history of receiving runoff affected by textiles manufacturing, 
heavy industry and coal mining, as well as agricultural production.  The River Aire rises 
at Malham Tarn in North Yorkshire whilst the Calder rises at Heald Moor close to 
Todmorden, West Yorkshire. The upper reaches of these rivers are dominated by 
Carboniferous Limestone with some overlying Millstone Grit in the south progressing 
through Coal Measures around Leeds, Wakefield and Huddersfield into Magnesian 
Limestone in the lower reaches, which are subject to groundwater abstraction in parts of 
the catchment (Aldrick, 1978).  Soil cover ranges from blanket peat bog and acid loams 
in the upper reaches in the southern Pennines through more freely draining acid loams 
and clays in the lower reaches of both catchments.  Freely draining, lime-rich loams 
dominate the lower extremes of the catchments east of Leeds and Wakefield 
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(Soilscapes, 2013).  Average air temperatures across the catchments vary from 3.1 °C 
in winter to 15.2 °C in July although these are generally much lower in the Pennine 
headwaters.  Average rainfall can exceed 1500 mm in parts of the Pennines and drops 
to approximately 660 mm in the lower eastern parts.  Rainfall is distributed relatively 
evenly across the year although there is a seasonal trend of dry springs and wet 
autumn/winter period which is much more prevalent in upland areas (Met Office, 2008). 
The Aire flows for 114 km prior to joining the Yorkshire Ouse at Airmyn in the 
East Riding of Yorkshire with the River Worth (a major tributary) joining at Keighley.  The 
Calder flows for approximately 72 km prior to joining the Aire east of Castleford with its 
major tributaries being the Rivers Hebble and Colne which join at Halifax and Brighouse, 
respectively.  Both rivers are canalised along parts of their length forming part of the Aire 
& Calder and Calder & Hebble Navigations and the Calder in particular is heavily 
reservoired for drinking water supply (Jarvie et al., 1997).   
Generally speaking the water quality in these two catchments has improved over 
recent years due largely to declines in heavy industry and developments in sewage 
treatment.  However, the improvement has been much slower in reaches downstream of 
the major population centres of Bradford, Wakefield and Leeds (EA, 2009a).  In 
particular, biological water quality was much slower to improve when compared to 
chemical indices and the UK Environment Agency have identified toxic discharges from 
storm systems and STPs as the main reasons for this lack of improvement (EA, 2009a).  
These problems may be exacerbated by the abundance of small and medium-sized 
STPs discharging to smaller tributaries where dilution factors of effluent can be as low 
as 2:1 (Fox et al., 2000).  In addition to the 105 operational STPs currently discharging 
in the Aire and Calder catchments, there are estimated to be at least 70 CSOs spread 
across the entire catchment (EA, 2010) representing significant potential point sources 
of pharmaceutical pollution during heavy rainfall events (Figure 4-2).   
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Figure 4-2: Map of combined sewer overflow (CSO) and sewage treatment plant 
(STP) locations in the Aire and Calder catchments 
[Based on data supplied by the Environment Agency and Yorkshire Water] 
 
4.2.2 Monitoring sites 
Seven STP sites were identified for monthly monitoring over an eighteen month period 
(September 2010 to March 2012) which comprised four in the Aire and three in the Calder 
catchments (Table 4-1; Figure 4-3).  Sites were chosen based on access via public rights 
of way and where it was possible to sample both the effluent and receiving waters 
directly.  These STPs represented a range of sizes and treatment technologies and they 
also discharged to receiving waters of various sizes ranging from the relatively small 
Sheffield Beck to the main channels of the Aire and Calder themselves.  Furthermore, 
they were distributed throughout the catchments from the semi-rural upper reaches down 
to the urbanised lower reaches.  
In addition, five CSO monitoring sites were selected in the Aire catchment (Figure 
4-3) where it was possible to directly sample the effluent.  Furthermore, it was necessary 
for sites to be in relatively close proximity to the University of Leeds to allow responsive 
grab sampling during rainfall events.  CSOs were grab sampled during periods of 
intensive rainfall from March 2010 to August 2012 and sites were chosen based on 
access, safety and ease of sampling.   
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4.2.2.1 River Aire reach sampling 
The stretch of the River Aire between two large STPs at Knostrop and Oulton/Lemonroyd 
(Figure 4-4; Table 4-1) was chosen for monitoring of a river reach based on the absence 
of any additional known point sources of pharmaceutical pollution.  During the period 
from February to July 2011 (seven sampling occasions) receiving waters were collected 
at five sites between the two STP outfalls.  Sampling across winter, spring and summer 
periods was conducted to capture a range of flow conditions in the River Aire.  The 
presence of a large and reliable flow gauging structure (Fleet Weir; EA Station Number 
8079) approximately 30 m upstream of sampling point 5 meant it was possible to obtain 
accurate flow information for the whole sampling campaign.  Although not a fully synoptic 
survey, this sampling campaign still gave an informative indication of the longitudinal 
concentration profiles of the study compounds across a range of flow conditions. 
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Table 4-1: Summary of pharmaceutical sampling sites 
Location * 
Channel, catchment 
and  catchment area 
(km2) Sample type 
Treatment type, 
population  
(design dry 
weather flow, m3 
d-1) OS NGR 
Garforth Owlwood 1 
A  
Sheffield Beck (Aire) 
15.6 
STP effluent and 
receiving water 
Secondary BF 
36 868 
(10 204) 
SE 41683 
28738 
Heaton LodgeB River Calder 
393.4 
STP effluent and 
receiving water 
Secondary BF 
Unknown 
SE 17652 
20677 
Horbury Junction C River Calder 
779.5 
STP effluent and 
receiving water 
Secondary BF 
15 842 
(3974) 
SE 29992 
17362 
Knostrop 1 D River Aire 
847.5 
STP effluent and 
receiving water 
Unknown SE 34177 
30982 
Oulton/Lemonroyd 
E 
River Aire 
890.5 
STP effluent and 
receiving water 
Tertiary A1 
33 262 
(6178) 
SE 37869 
27952 
Oxenhope No. 2 F Bridgehouse Beck (Aire) 
14.9 
STP effluent and 
receiving water 
Secondary AS 
2204 
(1632) 
SE 03496 
35565 
Ripponden G River Rybrun (Calder) 
37.9 
STP effluent and 
receiving water 
Secondary BF 
4995 
(1150) 
SE 04460 
20558 
Canal Road V River Aire 
684.5 
CSO effluent n/a SE 27685 
34037 
Commercial Road W River Aire 
678.5 
CSO effluent n/a SE 26497 
35079 
Cotton Mill Beck X Cotton Mill Beck (Aire) 
3.3 
CSO effluent n/a SE 28233 
28655 
Oulton Park Y Oulton Beck (Aire) 
22.48 
CSO effluent n/a SE 34700 
28307 
Newlay Lane Z River Aire 
655.5 
CSO effluent n/a SE 23852 
36963 
Fishpond Lock weir River Aire 
854.5 
Receiving water n/a SE 35409 
30090 
Woodlesford Lock 
weir 
River Aire 
857.3 
Receiving water n/a SE 36695 
29519 
Fleet weir River Aire 
861.4 
Receiving water n/a SE 38021 
28539 
* For site locations see Figure 4-3 and 4-4 
Effluent samples collected from an effluent channel downstream of the STP outfall.  Approximate 
downstream distance of 15m at Garforth and 600m at Knostrop. 
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Figure 4-3: Map of sewage treatment plant (STP) and combined sewer overflow (CSO) 
sampling sites monitored during the period September 2010 to March 2012 
For site details see Table 4-2 
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Figure 4-4: Locations of the River Aire reach sampling sites monitored during the 
period February to November 2011 
1. Knostrop outfall, 2. Fishpond Lock weir, 3. Woodlesford Lock weir, 4. Fleet weir, 5. 
Upstream of Oulton/Lemonroyd outfall 
4.2.2.2 Intensive diurnal sampling 
Garforth Owlwood and Oulton/Lemonroyd were selected for intensive 24 h sampling 
given their close proximity to one another and relative ease of sample collection which 
allowed for the collection of samples from both sites within one hour.  Furthermore, the 
differing treatment technologies in place at these two STPs provided a useful 
comparison. 
4.2.3 Sample collection procedure 
Samples of treated effluent and receiving channel water (0.8 L) for all field surveys were 
collected in 1 L amber glass bottles with Teflon® lined caps (Fisher Scientific, 
Leicestershire, UK) and kept in the dark on ice during transit. Samples were collected 
from the centre of the stream at 50 % depth in line with established guidelines (USGS, 
2006) where possible although the size of the channel and bank topography meant it 
was necessary at some sites to collect samples at bankside (Heaton Lodge, Horbury 
Junction, Oulton/Lemonroyd, and Knostrop).  Once returned to the laboratory, samples 
were stored in the dark at 4 °C before extraction within 48 hours.  Solid phase extraction 
recoveries indicated no appreciable change in pharmaceutical concentrations when 48 
h stored samples were compared to those extracted immediately.  Other studies have 
also shown that extended periods of storage (up to 6 months) even at 4 °C caused no 
appreciable change in spiked concentrations. All apparatus and glassware used during 
sample collection and preparation were thoroughly washed with 100 % methanol (1 x) 
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and de-ionised water (3 xs) prior to each use to remove potential contamination.  For all 
samples collected, field measurements of pH, dissolved oxygen and electrical 
conductivity were recorded using an Intellical LDO probe and HACH HQ30d multi-meter 
(HACH Company, CO, USA). 
Routine STP samples were collected each month at the same time of day to 
minimise errors associated with diurnal fluctuations in pharmaceutical concentrations 
(Kanda et al., 2003).  At Garforth Owlwood and Knostrop access to the immediate STP 
outfall was not possible and at these two sites it was necessary to sample from undiluted 
effluent channels 15 m and 600 m downstream, respectively.  Receiving water samples 
were collected at a point of five times the stream width downstream of the effluent outfall 
to allow for mixing (Morris, 2013). Grab samples of CSO effluents were collected directly 
from the outfall.   
4.2.4 Study compounds 
An initial set of five study compounds was chosen based on potential environmental risk 
in previously published studies (Table 4-2).  Environmental risk was assessed using 
published estimated risk quotients (RQ) (which is the ratio PEC: PNEC or MEC: PNEC).  
A RQ≥1 indicates the potential for impacts on aquatic organisms so this was used as the 
basis for selection.  In addition only compounds with a published analytical method and 
which had previously been detected in UK rivers were selected for monitoring (Table 4-
2).  
  
135 
 
 
 
Table 4-2: Structure and properties of the five study compounds 
Compound  
Therapeutic 
use 
Structure  
Physico-chemical 
properties and risk 
quotients 
Diclofenac 
Non-
steroidal 
anti-
inflammatory 
drug 
(NSAID) 
 
 
MW = 296.15 
Solubility (mg/L) = 
2430 
pKa = 4.0 
log KOW = 4.02 
Excretion rate = 15% 
parent, <1% 
conjugates 
RQmin = 0.01  
RQmax = 1.13  
Erythromycin 
Macrolide 
antibiotic 
 
 
MW = 733.95 
Solubility (mg/L) = 1.44 
pKa = 8.9 
log KOW = 2.48 
Excretion rate = 5% 
parent 
RQmin = 0.01  
RQmax = 1.25  
Ibuprofen NSAID 
 
 
MW = 206.29 
Solubility (mg/L) = 
21.00 
pKa = 4.91 
Excretion rate = 1% 
parent  
log KOW = 3.79 
RQmin = 0.55  
RQmax = 4.20  
Mefenamic 
acid 
NSAID 
 
 
MW = 241.29 
Solubility (mg/L) = 
20.00 
pKa = 4.2 
Excretion rate = 52% 
conjugates 
log KOW = 5.12 
RQmin = 1.03  
RQmax = 8.31 
Propranolol 
Non-
selective 
beta-blocker 
 
 
MW = 259.35 
Solubility (mg/L) = 31.7 
pKa = 9.4 
log KOW = 2.60 
Excretion rate = <0.5% 
parent, 20% active 
conjugates 
RQ=0.21 
Notes:  
MW= molecular weight; pKa = dissociation constant; log KOW = octanol: water partition coefficient 
RQ data from: (Jones et al., 2002; Thompson, 2006; Yamamoto et al., 2009) 
Physicochemical data from: (Ternes, 1998; Kasprzyk-Hordern et al., 2007), ChemIDplus 
(http://chem.sis.nlm.nih.gov/chemidplus/), DrugBank (Knox et al., 2010) and ECOSAR v1.00a 
(http://www.epa.gov/oppt/newchems/tools/21ecosar.htm) 
 
There was some variation between RQs calculated by Thompson (2006) and Jones et 
al. (2002), the major reason for which is the assumed dilution factor; Jones assumed 
1:10 dilution whereas Thompson assumed none.  Thompson’s estimates are 
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conservative but 1:10 dilution factor may not be achieved in some rivers, particularly 
during low summer flows (Hemminger, 2005).  It is likely that actual RQs will fall 
somewhere between the two estimates.   
4.2.5 Collation of flow data 
Flow data (15 min) from the closest relevant river gauge to each sampling location were 
obtained from the Environment Agency (see Appendix B1) to compare receiving water 
concentrations with flow.  Flow or stage duration curves were therefore available at or 
close to all but one sampling site (Garforth Owlwood). 
4.2.6 Analysis of receiving water and effluent samples 
4.2.6.1 Chemicals and materials 
Pharmaceutical standards were used to create working and stock solutions in dilution 
series for calibration of analytical instruments.  All pharmaceuticals were supplied by 
Sigma-Aldrich Company Ltd. (Dorset, UK) and were of the highest purity available (>99 
%).  Individual stock standard solutions were prepared on a weight basis in 100% 
methanol and stored in the dark at -20 °C until used.  A fresh working mixture solution of 
all pharmaceuticals was prepared by appropriate dilution of the individual stocks in 
methanol-water (20:80, v/v) immediately before each analytical run and used as working 
standard solutions.  Working standards were also stored in the dark at -20°C between 
uses.  HPLC-grade methanol was supplied by Fisher Scientific UK Limited 
(Loughborough, UK).  Deionised water was supplied by a Purite Select HP160/BP/IT 
deioniser. 
4.2.6.2 Solid phase extraction (SPE) 
The SPE procedure and subsequent analysis by HPLC and Q-TOF MS/MS used during 
this study followed that of Petrovic et al. (2006). A total of 800 mL of unfiltered sample 
was accurately measured for SPE.  For the SPE, a 20-position Waters vacuum extraction 
manifold was used in conjunction with Oasis HLB SPE cartridges (6 cc, 150 mg; Waters 
Corporation, Milford, MA, USA).  First the SPE cartridges were conditioned with 5 mL 
100% methanol followed by 5 mL de-ionised water at a flow rate of 1 mL min-1.  The 800 
mL river and effluent samples were then loaded onto the SPE cartridge at a flow rate of 
10 mL min-1 during which care was taken not to let the sorbent material dry out.  The 
cartridges were then rinsed with 5 mL de-ionised water at a flow rate of 1 mL min-1 prior 
to being thoroughly air dried under vacuum for 15 minutes to remove excess water.  
Elution of the cartridges was then performed with 2 * 4 mL of 100 % methanol at a flow 
rate of 1 mL min-1 directly into glass centrifuge tubes.  The eluent was evaporated to 
dryness under vacuum centrifugation and reconstituted in 0.5 mL of methanol: water 
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(20:80, v/v).  Sample extracts were stored in the dark at -20 °C prior to analysis.  Data 
reported are for extractions from unfiltered samples and as such will potentially include 
pharmaceuticals sorbed to suspended particulate material.  However, previous studies 
have shown that this fraction only represents a small proportion of the total load (Miao & 
Metcalfe, 2007) and observations during SPE showed very little suspended particulate 
material was present in the samples. Sample extracts were stored for periods up to six 
months as tests have shown that storage of samples at frozen (-20 °C) and chilled 
temperatures (up to 4 °C) caused no significant change in sample concentration (Radke 
et al., 2010). 
4.2.6.3 HPLC-Q-TOF-MS/MS 
Liquid chromatography was performed using an Ultimate 3000 nanoLC system (Dionex) 
on a 2.1 * 100mm Acclaim RSLC 120 C18 2.2 µm particle silica column.  In positive ion 
(PI) mode analysis a solvent system of 5 mM ammonium acetate/acetic acid (pH 2.4; 
buffer A) and methanol-acetonitrile (2:1, v/v, buffer B) was used at a flow rate of 0.3 mL 
min-1 and the column held at constant temperature (30 °C).  In negative ion (NI) mode 
analysis a solvent system of 2 mM ammonium acetate (buffer A) and 2mM ammonium 
acetate in methanol-water (95:5, v/v, buffer B) was used at a flow rate of 0.3 mL min-1 
and the column held at constant temperature (30°C).  After injection the gradient was 
held at 5 % B for 5 minutes followed by 5-80 % B over 20 minutes.  A 15 minute column 
wash at 95 % B and an equilibration of 5 min at 5 % B was performed between each 
sample injection. 
The LC eluent was directly infused into the Z-spray electrospray source of a 
quadrupole-ion mobility-orthogonal time of flight (Q-TOF) mass spectrometer (Synapt 
HDMS, Waters UK).  Electrospray desolvation temperature was 150 °C and desolvation 
gas was 500 L h-1, capillary and cone voltages were 3.2 kV and 30 V respectively.  
Backing pressure was 2.1 bar, the argon pressure in the trap and transfer region of the 
IMS cell was 2.17 mbar.  MS/MS analysis was performed only on the target 
pharmaceutical compounds when their intensity was greater than 10 counts per second 
and their retention time was within ±1 min of that of the corresponding standards.  Trap 
collision energy used for each compound was optimised individually between 15 and 30 
V.  The lockspray frequency was set to one 1 s scan every 10 s.  For PI mode a 5 µM 
solution of Glu fibrinopeptide in methanol/0.1 % formic acid (50:50, v/v) was used as the 
lock mass, in NI mode the m/z 276 peak of a 2 ng µL-1 of sodium iodide in methanol 
water (50:50, v/v) was used as the lock mass. 
4.2.7 Data analysis and method validation 
All data analysis was performed in MassLynxTM (v4.1, Waters Ltd.).  Positive 
identification of the target pharmaceuticals was based on: accurate mass measurement 
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of the parent ion within an error of ±20 ppm, accurate mass of at least one product ion 
also within an error of ±20 ppm and LC retention time of the target analyte with reference 
to that of a standard (±5 %).  Quantitation was performed by constructing extracted ion 
chromatograms (XICs) of the protonated (PI mode) and deprotonated (NI mode) ion 
using a 20 mDa window centred on the theoretical m/z of the compound and taking the 
area of the resulting peak using MassLynx’s inbuilt integration algorithms. 
Reproducibility of the method was tested with repeated injections of a standard 
solution both sequentially and day-to-day.  Instrumental detection limits (IDLs) were 
estimated using a standard solution in dilution series until reaching a concentration 
yielding a signal: noise (S: N) ratio of three.  Linear dynamic ranges were determined for 
each compound by injecting a dilution series of the working standard mixture solutions 
across a wide concentration range (2-1000 ng L-1).  Calibration curves of peak area (from 
XICs) vs. concentration were created using linear regression analysis and the linear 
range that gave good fit (r2>0.95) was established for each compound. 
4.2.8 Matrix effects and signal suppression 
Ion suppression (and occasionally enhancement) due to matrix effects is a phenomenon 
in LC-MS whereby components of a complex matrix sample co-elute from the LC column 
with the analyte(s) of interest and influence the ionisation process at the beginning of the 
MS stage.  This can lead to a reduced (or enhanced) analyte signal and reduce 
reproducibility.  The mechanisms are not fully understood but it is believed that co-eluted 
compounds compete with the analytes for space and charge on the surface of the small 
droplets formed during electrospray ionisation (ESI) (Jessome, 2006).  The source of the 
interfering components may be endogenous within the sample (e.g. a complex river or 
effluent sample) or may be due to contamination during sample preparation.  A common 
method to attempt to separate the analyte(s) of interest from interfering matrix 
components is to use sample preparation techniques such as solid phase extraction 
(SPE). 
SPE recovery and signal suppression due to matrix effects were evaluated by 
spiking  known concentrations of all five pharmaceuticals into replicates of deionised 
water and a sample matrix, in this case a sample of ‘clean’ river water from Silsden Beck 
immediately downstream of Silsden Reservoir (OSNGR SE 0446147504).  This location 
is upstream of all STP inputs.  Three replicates each of both deionised and river water 
were spiked at the following concentrations: 20, 100 and 200 ng L-1 for a total of 18 
samples.  The pharmaceutical standards (in the form of working solutions dissolved in 
100 % methanol) were added prior to SPE and handled in the same way in order to 
account for losses during the sample preparation and extraction and that due to matrix 
assisted signal suppression (Kasprzyk-Hordern et al., 2007).  
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4.2.9 Data analysis 
Detection frequencies were calculated by dividing the total number of samples by the 
number of samples containing a detectable pharmaceutical concentration.  All 
pharmaceutical concentration values were tested for normality using the Anderson-
Darling normality test and were found to be generally non-normal; therefore non-
parametric techniques were used throughout.  
Flows at sampling dates were classified based on the daily mean flow from 
individual site flow duration curves as follows: <Q25 high flow, Q25 to Q75 normal flow, 
>Q75 low flow.  Comparisons of receiving water concentrations between flow categories 
were tested using the Kruskal-Wallis H test.  Pairwise comparisons between CSO and 
STP effluent were performed using the non-parametric Mann-Whitney U test. 
Differences between concentration based on sampling site and date were tested 
using a General Linear Model (GLM) which also tested for interaction between site and 
date.  Any subsequent pairwise comparisons between categories were performed with 
a Tukey's family error rate of 0.05 to correct for multiple comparisons. 
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4.3 Results 
4.3.1 Total sample numbers and frequency of detection 
A total of 317 samples were collected across all campaigns representing 121 STP 
effluent, 185 receiving water and 11 CSO effluent samples (Table 4-3).  Detection 
frequencies were high in STP effluent and receiving waters (≥51 % overall) although 
detection frequencies in CSO effluent were usually lower (Table 4-4).  Diclofenac (≥67 
%), erythromycin (≥78 %) and ibuprofen (≥83 %) were detected at particularly high 
frequencies.  Notably, several compounds were detected at 100 % frequency in certain 
sampling campaigns, particularly during the intensive diurnal sampling (Table 4-4).  
Furthermore, detection frequencies were comparable between channel and effluent 
samples. 
Table 4-3: Summary of sample numbers collected from September 2010 to March 2012 
Campaign 
No. effluent 
samples 
No. receiving 
water samples 
No. CSO 
samples 
TOTAL 
Monthly STP and 
receiving water 
121 125 - 246 
Intensive diurnal - 28 - 28 
River Aire reach - 32 - 32 
CSO - - 11 11 
TOTAL 121 185 11 317 
Aire 71 131 11 
 
Calder 50 54 - 
 
Table 4-4: Summary of detection frequency (%) of pharmaceutical compounds in 
samples from the Aire and Calder catchments 
Monthly sampling 
 Erythromycin Propranolol 
Mefenamic 
acid 
Ibuprofen Diclofenac 
Secondary AS 
Channel 
77.8 44.4 27.8 83.3 66.7 
Secondary AS 
Effluent 
88.9 77.8 16.7 83.3 88.9 
Secondary BF 
Channel 
95.5 71.9 68.5 94.4 96.6 
Secondary BF 
Effluent 
89.4 75.3 52.9 89.4 94.1 
Tertiary Channel 94.4 77.8 94.4 94.4 100.0 
Tertiary Effluent 100.0 88.9 77.8 100.0 100.0 
Intensive diurnal sampling 
Garforth Owlwood 100.0 100.0 100.0 100.0 100.0 
Oulton/Lemonroyd 100.0 92.9 100.0 100.0 100.0 
River Aire reach samples 
 93.8 84.4 96.9 96.9 100.0 
CSO effluent samples 
 64.3 35.7 21.4 100.0 85.7 
TOTAL CHANNEL 94.6 76.2 76.8 94.6 95.1 
TOTAL EFFLUENT 90.9 77.7 51.2 90.9 94.2 
Notes: AS = activated sludge, BF = biological filter 
4.3.2 Method performance 
Overall the performance of the HPLC-MS/MS method was very good (Table 4-5) with a 
detection limit of 5 ng L-1 for all study compounds except ibuprofen (25 ng L-1).  Precursor 
ion mass accuracies were within acceptable ranges for all five compounds although 
product ion mass accuracies fell outside the 20 ppm range for three compounds (EC, 
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2002).  Overall, SPE recovery in both deionised water and matrix samples compared 
favourably with a similar study (Petrovic et al. 2006).  All data presented below represent 
values corrected for SPE recovery in matrix samples. 
Table 4-5: Performance of the HPLC-MS/MS method and SPE recovery for receiving 
water and STP effluent samples 
Compound 
Mean 
tR 
(mins
) 
Instrumenta
l detection 
limit  
(ng L-1) 
Linear 
dynami
c range 
(ng L-1) 
Mean 
R2 
Mean 
precurso
r mass 
accuracy 
(ppm) 
Mean 
(product(s)
) mass 
accuracy  
(ppm) 
SPE 
recover
y DI H2O  
 
(%) 
SPE 
recover
y matrix 
H2O 
 (%) 
Diclofenac 
19.5 5 
0 - 
1000 
0.99
1 -16.6 6.1 
65.8 
(±12.9) 
105.2 
(±33.2) 
Erythromyci
n 19.4 5 
0 - 
1000 
0.98
3 6.5 
-39.1 
-33.6 
93.8 
(±11.0) 
71.8 
(±26.3) 
Ibuprofen 
20.1 25 
0 - 
1000 
0.98
3 3.5 365.1 
84.9 
(±18.3) 
61.2 
(±17.6) 
Mefenamic 
acid 20.7 5 
0 - 
1000 
0.99
2 -8.1 18.7 
87.0 
(±14.5) 
70.7 
(±25.8) 
Propranolol 
16.2 5 
0 - 
1000 
0.98
5 0.2 
-20.2 
-130.5 
92.9 
(±21.1) 
81.2 
(±24.2) 
4.3.3 Monthly sampling 
A total of 121 effluent and 125 receiving water samples were collected during the monthly 
sampling campaign (Tables 4-6 and 4-8 for summaries; Appendix B for raw data).  The 
physicochemical data suggest that the rivers Aire and Calder were at moderate to good 
status based on Water Framework Directive criteria for pH and dissolved oxygen (DO) 
during the sampling campaign (Table 4-6).  Notably, DO was elevated and electrical 
conductivity reduced at the two upstream semi-rural sites (Oxenhope and Ripponden) 
when compared to the more urbanised downstream locations.  Overall, test substances 
demonstrated a trend of maximum pharmaceutical concentrations during the winter 
period, particularly in the winter 2010/11 (e.g. Figure 4-5).  This trend was evident at all 
sites but was less pronounced at Oxenhope and Ripponden.  Furthermore, propranolol 
differed from the other study compounds by demonstrating peak concentrations during 
winter 2010/11.   
Table 4-6: Mean (±1 SD) physicochemical data during the monthly sampling campaign 
Site Channel pH 
Dissolved 
oxygen (mg L-1) 
Electrical 
conductivity  
(µs cm-1) 
Garforth Owlwood 
Channel 7.7 ± 0.3  9.3 ± 0.5 1234.0 ± 465.3 
Effluent 7.4 ± 0.5 8.7 ± 0.6 1300.6 ± 318.3 
Heaton Lodge 
Channel 7.5 ± 0.1 9.9 ± 0.8 839.9 ± 183.6 
Effluent 7.0 ± 0.1 9.5 ± 0.5 2779.6 ± 556.1 
Horbury Junction 
Channel 7.5 ± 0.1 9.2 ± 1.0 959.6 ± 158.8 
Effluent 7.3 ± 0.1 7.4 ± 2.1 1068.0 ± 82.8 
Knostrop 
Channel 7.4 ± 0.2 9.8 ± 0.7 1520.1 ± 224.2 
Effluent 7.3 ± 0.2 9.5 ± 0.5 1534.7 ± 229.7 
Oulton 
Channel 7.8 ± 0.2 9.3 ± 1.0 1274.4 ± 229.7 
Effluent 7.6 ± 0.5 9.4 ± 0.5 1231.7 ± 180.4 
Oxenhope 
Channel 7.6 ± 0.1 10.4 ± 0.8 236.4 ± 22.2 
Effluent 6.8 ± 0.2 8.2 ± 0.6 718.9 ± 71.0 
Ripponden 
Channel 7.4 ± 0.2 10.3 ± 0.7 288.1 ± 19.5 
Effluent 6.5 ± 0.1 8.1 ± 1.5 622.4 ±  42.1 
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Table 4-7: Mean (±1 SD) receiving water pharmaceutical concentrations during the 
monthly sampling campaign 
Site Diclofenac1 Erythromycin Ibuprofen 
Mefenamic 
acid 
Propranolol 
Garforth 
Owlwood 
589.6 ± 887.4 
(100.0) 
393.5 ± 475.7 
(100.0) 
779.6 ± 828.5 
(93.8) 
11.3 ± 7.7 
(87.5) 
37.1 ± 38.8 
(68.8) 
Heaton Lodge 
156.9 ± 318.3 
(100.0) 
249.0 ± 278.9 
(88.2) 
320.2 ± 284.9 
(82.4) 
31.5 ± 32.6 
(58.8) 
10.5 ± 5.6 
(70.6) 
Horbury 
Junction 
173.4±196.6 
(94.1) 
199.7 ± 251.2 
(100.0) 
1146.5 ± 863.8 
(94.1) 
4.5 ± 4.9 
(35.3) 
12.5 ± 10.3 
(88.2) 
Knostrop 
272.8 ± 265.8 
(100.0) 
184.6 ± 302.2 
(100.0) 
302.2 ± 223.2 
(100.0) 
7.9 ± 8.6 
(82.4) 
15.9 ± 13.0 
(94.1) 
Oulton 
231.3 ± 237.5 
(100.0) 
249.1 ± 287.9 
(100.0) 
793.7 ± 1035.4 
(100.0) 
6.9 ± 8.2 
(77.8) 
14.3 ± 11.5 
(88.9) 
Oxenhope 
60.8 ± 93.5 
(88.9) 
398.8 ± 480.3 
(88.9) 
363.0 ± 318.7 
(88.9) 
2.5 
(16.7) 
14.5 ± 10.7 
(77.8) 
Ripponden 
110.5 ± 148.1 
(100.0) 
240.4 ± 257.6 
(78.6) 
524.4 ± 585.6 
(100.0) 
107.8 
(7.1)  
9.7 ± 5.1 
(71.4) 
Detection 
frequency (%) 90.9 77.7 51.2 90.9 94.2 
 
Table 4-8: Mean (±1 SD) effluent pharmaceutical concentrations during the monthly 
sampling campaign 
Site Diclofenac1 Erythromycin Ibuprofen 
Mefenamic 
acid 
Propranolol 
Garforth 
Owlwood 
649.3 ± 957.5 
(100.0) 
402.8 ± 307.4 
(94.1) 
812.2 ± 848.9 
(100.0) 
10.6 ± 11.1 
(94.1) 
19.1 ± 11.6 
(88.2) 
Heaton Lodge 88.1 ± 86.6 
(94.4) 
143.4 ± 126.7 
(94.4) 
6165.1 ± 
23388.8 
(88.9) 
21.8 ± 19.8 
(61.1) 
5.3 ± 6.1 
(55.6) 
Horbury 
Junction 
103.4 ± 121.5 
(100.0) 
121.1 ± 108.4 
(100.0) 
3741.1 ± 
13316.1 
(88.9) 
23.8 ± 28.5 
(72.2) 
4.1 ± 2.0 
(77.8) 
Knostrop 
323.1 ± 307.3 
(100.0) 
229.5 ± 254.2 
(100.0) 
719.9 ± 1090.8 
(100.0) 
11.6 ± 11.1 
(88.9) 
30.0 ± 38.0 
(94.4) 
Oulton 
187.1 ± 169.6 
(100.0) 
138.2 ± 132.1 
(100.0) 
456.5 ± 639.3 
(94.4) 
10.7 ± 8.0 
(94.4) 
8.4 ± 17.0 
(83.3) 
Oxenhope 
39.0 ± 37.8 
(66.7) 
49.2 ± 40.1 
(77.8) 
99.7 ± 56.8 
(83.3) 
3.8 ± 2.8  
(27.8) 
2.9 ± 1.2 
(44.4) 
Ripponden 
25.1 ± 18.2 
(94.1) 
33.7 ± 43.0 
(94.1) 
123.6 ± 96.9 
(100.0) 
6.3 ± 5.5 
(29.4)  
2.9 ± 1.2 
(47.1) 
Detection 
frequency (%) 92.8 93.6 92.8 66.4 69.6 
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Figure 4-5: Example of seasonal trend in pharmaceutical concentrations  
[Values are erythromycin concentrations in receiving waters at 7 sites from the Aire 
and Calder catchments] 
4.3.3.1 Relationship between flow and receiving water concentrations 
Flow at the time of sampling was classified into low, normal or high flow based on flow 
duration curves which were available at all but one site (Garforth Owlwood).  Significant 
differences between receiving water concentrations at different flows were present for all 
compounds except mefenamic acid (Table 4-9; Figure 4-6).  Receiving water 
concentrations during moderate and low flow were consistently higher than those during 
high flow.  However, frequencies of detection were consistently greatest during high flow 
for all compounds except mefenamic acid (Figure 4-7).  During moderate and low flow 
compounds were detected less frequently but when present were at higher 
concentrations. 
Table 4-9: Summary of statistical analysis comparing pharmaceutical concentrations 
from monthly sampling in the Aire and Calder catchments during differing flow 
conditions 
Compound 
Kruskal-Wallis H 
results 
Median concentrations (ng L-1)1  
Low flow 
(n=39) 
Moderate flow 
(n=54) 
High flow 
(n=13) 
Erythromycin 
H=10.01, DF=2 
p<0.01 
45.5B 92.9A 29.8B 
Propranolol* 
H=7.26, DF=2 
p=0.03 
6.1A 5.5A 2.5A 
Mefenamic acid 
H=1.79, DF=2 
p=0.41 
7.9A 8.2A 4.6A 
Ibuprofen* 
H=10.79, DF=2 
p<0.01 
132.9A 257.6A 96.6A 
Diclofenac 
H=7.75, DF=2 
p=0.02 
43.4A B 96.5A 33.7A 
Notes: 
1. Results of pairwise comparisons between flow categories (Tukey’s family error rate: 0.05).  
Categories that do not share a letter are significantly different.   
* Note that Kruskal-Wallis H test for ibuprofen and propranolol indicated significant differences but 
pairwise comparisons did not. 
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Figure 4-6: (a) example flow duration curve for Oulton Beck and (b) frequencies of 
detection for pharmaceutical compounds in the Aire and Calder catchments during 
low, moderate and high flow conditions 
 
 
(a) 
(b) 
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Figure 4-7: Boxplots of receiving water concentrations from the monthly sampling campaign classified by low, moderate or high flow 
for (a) erythromycin, (b) propranolol, (c) mefenamic acid, (d) ibuprofen and (e) diclofenac 
(Note: two extreme outliers of ibuprofen (93 863 and 53 633 ng L-1) were excluded from this image for clarity but were included in 
statistical analyses. Asterisk markers in the x-axis represent significant differences between flow categories; see Table 4-13 for 
statistical analyses) 
(a) (b) (c) 
(d) (e) 
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4.3.3.2 Comparison of treatment technologies 
Significant differences in concentrations between different STP treatment technologies 
were present for propranolol, ibuprofen and diclofenac (Table 4-10).  Secondary BF and 
Tertiary A1 samples demonstrated median concentrations that were generally 2 to 3xs 
greater than respective concentrations from the Secondary AS STP in both receiving 
waters and effluent (Figure 4-8; 4-9). 
Table 4-10: Summary of statistical comparisons of pharmaceutical 
concentrations between different STP treatment technologies 
Compound Channel Effluent 
Erythromycin H=4.51  DF=2   
P=0.11 
H=3.08  DF=2   
P=0.21 
Propranolol H=7.26  DF=2   
P=0.03 
H=0.04  DF=2   
P=0.98 
Mefenamic acid H=3.75  DF=2   
P=0.154 
H=5.18  DF=2   
P=0.08 
Ibuprofen H=11.86  DF=2   
P<0.01 
H=2.91  DF=2   
P=0.23 
Diclofenac H=9.93  DF=2   
P<0.01 
H=11.36  DF=2   
P<0.01 
Note: pairwise comparisons with Tukey's family error rate of 0.05 did not reveal any 
significant differences 
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Figure 4-8: Comparison of pharmaceutical concentrations in 
receiving waters downstream of STPs with differing treatment 
technologies 
[(a) diclofenac, (b) erythromycin, (c) ibuprofen, (d) mefenamic acid 
and (e) propranolol.   
Sample numbers: secondary AS (18), secondary BF (89) and tertiary 
A1 (18).  Sites: secondary AS (1), secondary BF (5) and tertiary A1 
(1).] 
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Figure 4-9: Comparison of pharmaceutical concentrations in 
effluent of STPs with differing treatment technologies 
[(a) diclofenac, (b) erythromycin, (c) ibuprofen, (d) mefenamic acid 
and (e) propranolol.  Sample numbers: secondary AS (18), 
secondary BF (85) and tertiary A1 (18).  Sites: secondary AS (1), 
secondary BF (5) and tertiary A1 (1).] 
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4.3.3.3 Comparison of sample matrix 
Effluent samples demonstrated greater concentrations than receiving waters for all 
compounds except mefenamic acid.   This relationship was highly significant for 
erythromycin (H=6.53, DF=1, p=0.01), propranolol (H=9.91, DF=1, p<0.01) and 
ibuprofen (H=10.81, DF=1, p<0.01) with effluent concentrations approximately 2 x 
greater than channel concentrations.  This confirms STP effluent as a major source of 
pharmaceuticals to rivers. 
4.3.4 CSO sampling 
All five pharmaceutical compounds were present in CSO effluent albeit at generally lower 
detection frequencies compared to STP effluent and associated receiving waters (Table 
4-11).  Erythromycin concentrations in CSO effluent were significantly less than those in 
STP effluent (17.3 ng L-1 vs. 139.7 ng L-1) but this was not the case for the other four 
compounds where concentrations were broadly similar between the two sample types.   
Table 4-11: Results of pharmaceutical monitoring in combined sewer overflow effluent 
Site 
No. 
samples Diclofenac Erythromycin Ibuprofen 
Mefenamic 
acid Propranolol 
Newlay Lane 1 160.7 1602.7 75.5 - - 
Canal Road 2 
186.8 ± 
123.2 
- 
143.4 ± 
190.3 
18.8 ± 23.0 - 
Commercial 
Road 
4 74.0 ± 68.4 256.0 ± 407.5 
2734.1 ± 
4887.8 
19.2 10.2 ± 10.9 
Oulton Beck 7 
388.3 ± 
791.9 
98.0 ± 128.6 
2207.0 ± 
5303.2 
- 11.3 ± 15.2 
CSO vs. STP 
effluent 
- 
H=1.88 
p=0.17 
H=5.55 
p=0.02 
H=1.37 
p=0.24 
H=0.92 
p=0.34 
H=1.86 
p=0.17 
Detection 
frequency (%) 
- 85.7 64.3 100.0 21.4 35.7 
4.3.5 Intensive diurnal sampling 
Concentrations of all five pharmaceutical compounds sampled from Sheffield Beck 
(downstream of Garforth STP) and the River Aire (downstream of Oulton/Lemonroyd 
STP) varied by up to a factor of four within the same day (Table 4-12). Detection 
frequencies amongst these samples were 100 % for all compounds except for 
propranolol on the first sampling day (86 %).  Mean channel concentrations were 
significantly greater at Garforth Owlwood for all compounds except propranolol.  
Although concentrations varied throughout the day there were no statistically significant 
temporal trends.  Note that there was no rainfall for several days prior to or during the 
sampling campaign at either site.  A check of the flow gauge record before and during 
the sampling campaign revealed flow conditions were stable. 
4.3.6 River Aire reach monitoring 
The data indicate no appreciable reduction in pharmaceutical concentrations along the 
5 km study reach and in some cases mean concentrations fluctuate and increase slightly 
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along the reach (Figure 4-10).  However, none of these concentration changes were 
statistically significant.  The general trend amongst the sampling campaign was for 
reduced River Aire concentrations later in the year (October to November) when 
compared to spring and summer samples. 
  
  
 
 
 
Figure 4-10: Downstream concentration profiles of (a) erythromycin, (b) propranolol, 
(c) mefenamic acid, (d) ibuprofen and (e) diclofenac along a 5 km stretch of the River 
Aire between two major STPs (Knostrop and Oulton) 
[values are means of seven replicates and bars represent ± 1 SD; samples collected 
Spring-Autumn 2011] 
 
 
(a) (b) 
(c) (d) 
(d) 
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Table 4-12: Mean (±1 SD) concentrations of pharmaceuticals (ng L-1) in receiving water of two STPs during intensive diurnal sampling 
Time 
Garforth Owlwood Oulton/Lemonroyd 
Erythromycin Propranolol 
Mefenamic 
acid 
Ibuprofen Diclofenac Erythromycin Propranolol 
Mefenamic 
acid 
Ibuprofen Diclofenac 
0500 133.7 ± 1.6 2.5 30 ± 16.1 
743.1 ± 
68.02 
1747.5 ± 
407.4 
66.1 ± 16.5 4.5 ± 2.8 8.2 ± 8.0 
261.7 ± 
29.3 
479.6 ± 
186.9 
0800 146.3 ± 25.5 5.9 ± 4.8 58.2 ± 46.1 
829.8 ± 
31.7 
2228.7 ± 
196.6 
51.2 ± 4.7 11.9 10.5 ± 1.6 
464.7 ± 
280.5 
316.4 ± 
34.5 
1100 210.6 ± 38.04 13.4 ± 6.2 53.1 ± 6.4 
1424.4 ± 
734.8 
3583.3 ± 
1139.4 
61.2 ± 1.7 4.5 ± 2.8 9.4 ± 0.3 
362.5 ± 
145.0 
947.7 ± 
240.1 
1400 155.3 ± 8.4 7.35 ± 6.9 29.5 ± 4.7 
1312.9 ± 
903.7 
2697.6 ± 
947.5 
68.8 ± 5.4 2.5  10.6 ± 2.4 
449.0 ± 
76.2 
359.6 ± 
243.7 
1700 128.9 ± 20.6 7.2 ± 6.6 60.4 ± 39.1 
1263.6 ± 
14.1 
2732.5 ± 
737.0 
67.3 ± 22.5 6.8 ± 1.9 18.5 ± 8.7 
476.5 ± 
314.5 
438.4 ± 2.4 
2000 202.1 ± 63.9 11.2 ± 0.8 72.4 ± 64.1 
1300.7 ± 
494.4 
2912.1 ± 
869.5 
61.2 ± 9.6 2.5 16.8 ± 0.4 
746.9 ± 
431.1 
557.7 ± 
110.0 
2300 162.7 ± 12.9 6.8 ± 6.1 42.5 ± 27.4 
1796.4 ± 
754.9 
2848.0 ± 
746.6 
62.5 ± 9.1 2.5 13.1 ± 2.3 
776.9 ± 
491.9 
206.9 
Statistical comparison between sampling site and time1 
 Erythromycin Propranolol Mefenamic acid Ibuprofen Diclofenac 
 
Time: F=1.75, p=0.18 
Site: F=125.33, p<0.001 
Interaction: F=2.04, p=0.128 
Time: F=1.03, p=0.45 
Site: F=3.07, p=0.10 
Interaction: F=1.62, p=0.22 
Time: F=0.56, p=0.75 
Site: F=14.94, p<0.01 
Interaction: F=0.30, p=0.93 
Time: F=1.27, p=0.33 
Site: F=18.75, p<0.01 
Interaction: F=0.37, p=0.89 
Time: F=1.69, p=0.20 
Site: F=105.32, p<0.001 
Interaction: F=0.68, 
p=0.67 
Notes:  
1. General linear model: Concentration vs. Time Site (Time*Site) 
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4.3.6.1 Comparison of reach samples during differing flow conditions 
Low and moderate flow samples demonstrated the highest median concentrations for all 
compounds except mefenamic acid and ibuprofen (Table 4-13).  The difference between 
concentrations at the upstream and downstream sampling points were compared against 
daily mean flow (m3 s-1) on the day of sampling to analyse whether stream flow conditions 
had any effect on in-channel fate of each pharmaceutical compound.  Low flow 
conditions demonstrated the greatest downstream reductions in concentrations for all 
compounds except ibuprofen (which demonstrated an increase) although these 
differences were not significant (Table 4-13). 
Table 4-13: Summary of statistical analysis comparing pharmaceutical concentrations 
sampled along a 5km stretch of the River Aire during different flow conditions 
Compound 
Kruskal-Wallis H 
results 
Median concentrations (ng L-1)1 
Low flow Moderate flow High flow 
Erythromycin 
H=7.07, DF=2 
p=0.03 
30.4A 86.4A 17.5A 
Propranolol 
H=2.12, DF=2 
p=0.35 
17.0A 5.1A 2.5A 
Mefenamic acid 
H=7.38, DF=2 
p=0.03 
36.5A B 12.0B 22.8A 
Ibuprofen 
H=1.48, DF=2 
p=0.48 
1506.7A 553.7A 582.7A 
Diclofenac 
H=6.23, DF=2 
p=0.04 
454.3A 143.3A B 83.2B 
Compound 
Kruskal-Wallis H 
results 
Downstream concentration change (ng L-1)2 
Low flow Moderate flow High flow 
Erythromycin 
H=2.89, DF=2, 
p=0.24 -288.9 -5.9 -112.7 
Propranolol 
H=2.25, DF=2 
p=0.33 -27.4 -1.4 -1.5 
Mefenamic acid 
H=2.14, DF=2 
p=0.34 -19.8 +3.4 -11.5 
Ibuprofen 
H=2.41, DF=2, 
p=0.30 +938.2 -134.5 +133.5 
Diclofenac 
H=2.25, DF=2 
p=0.33 -409.2 -32.2 -49.7 
Notes: 
Results of pairwise comparisons between flow categories (Tukey’s family error rate: 0.05).  Categories 
that do not share a letter are significantly different. 
Difference between farthest upstream and farthest downstream concentration (positive value indicates 
an increase in concentrations along the study reach, 5 km) 
4.4 Discussion 
4.4.1 HPLC-MS/MS method performance 
Overall, the HPLC-MS/MS method performed well and compared favourably with a 
similar method also developed for UK STP effluent and receiving water samples 
(Petrovic et al., 2006).  The precursor mass accuracies reported here compare well with 
those of Petrovic et al. (2006) which ranged from 1.4 ppm for erythromycin to 3.1 ppm 
for mefenamic acid.  Product ion mass accuracies were generally poorer although still 
within acceptable ranges (≤20 ppm; EC (2002)).   The slightly reduced product ion mass 
accuracy compared to Petrovic et al. (2006) may be explained by their use of ultra-
performance liquid chromatography compared to HPLC in this study (Swartz, 2005).  
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SPE recoveries from de-ionised water and environmental samples compare favourably 
and fall within the range (≥60 % effluent; ≥80 % river) reported by Petrovic et al. (2006) 
for similar samples.  These results further confirm that tandem MS detection coupled 
with effective HPLC separation is suitable for detecting trace levels of pharmaceuticals 
in complex aqueous environmental samples and is less susceptible to matrix effects. 
4.4.2 Frequencies of detection 
The dataset presented here represents a substantial contribution to the knowledge base 
of pharmaceutical occurrence in rivers at the UK and global scales. Pharmaceuticals 
were detected at very high frequencies in both receiving waters and STP effluent and to 
a lesser extent in CSO effluent across the Aire and Calder.  The reduced detection 
frequencies in CSO effluent agree with the original hypothesis (H5).  The high detection 
frequencies confirm that STP and CSO effluent are the major source of pharmaceutical 
pollution in the Aire and Calder and that such pollution is ubiquitous in semi-rural and 
urban areas.   Similarly high detection frequencies have been detected in the USA by 
Kolpin et al. (2002) at up to over 80 % for non-prescription drugs.  They hypothesised 
that the high detection frequencies were due to high annual consumption values.   This 
may also be the dominant cause in this study as diclofenac and ibuprofen are available 
over the counter in the UK.  Furthermore, erythromycin, mefenamic acid and propranolol 
are widely prescribed in the UK with annual consumption volumes up to several tonnes 
(Ayscough et al., 2000; Jones et al., 2001; Webb, 2001; Jones et al., 2002; Sebastine & 
Wakeman, 2003). 
Detection frequencies for the compounds monitored here were highly variable across 
other published studies.  They ranged from 5 to 100 % for diclofenac (Comeau et al., 
2008; Zhou et al., 2009), 3 to 100 % for erythromycin (Kolpin et al., 2004; Kasprzyk-
Hordern et al., 2009), 1 to 100 % for ibuprofen (Bound & Voulvoulis, 2006; Focazio et 
al., 2008), 14 to 88 % for mefenamic acid (Kasprzyk-Hordern et al., 2009; López-Roldán 
et al., 2010) and 37 to 100 % for propranolol (Ashton et al. 2004). 
Detection frequencies in the present study were broadly similar except for ibuprofen 
and erythromycin which were detected in the Aire and Calder at higher frequencies than 
previously reported.  One explanation for this was the unfiltered samples used in this 
study which have previously been shown to yield greater detection frequencies (Kolpin 
et al., 2004).  However, data collected by Hughes et al. (2013; Appendix A) showed that 
25 % of studies used unfiltered samples but no obvious relationship between filtration 
and detection frequency or measured concentrations was present.  Furthermore, direct 
comparisons between this study and others are not straightforward given differences in 
sampling sites, sample preparation and analytical techniques.  Kolpin et al., 2002).  In 
this study ibuprofen demonstrated similar detection frequencies to the other compounds 
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despite having a detection limit five times greater at 25 ng L-1.  Overall, pharmaceuticals 
were detected in the vast majority of samples for four compounds at frequencies similar 
or greater than previous UK and global studies highlighting the consistent presence of 
pharmaceuticals in effluent impacted rivers.  Therefore, pharmaceuticals should be 
considered a ubiquitous pollutant in freshwater ecosystems receiving waste material 
from domestic settings. 
4.4.3 Pharmaceutical concentrations in effluent and receiving waters 
This study successfully identified all five study compounds in the effluent and receiving 
waters of seven typical UK STPs in the Aire and Calder catchments.  Effluent 
concentrations were greater than receiving water concentrations for all compounds 
except mefenamic acid (6.4 ng L-1 effluent vs. 7.4 ng L-1 river) in agreement with the 
original hypothesis (H1).  Notably, the results identified new UK maximum concentrations 
for diclofenac, erythromycin and ibuprofen in receiving waters and diclofenac in STP 
effluent.  Furthermore, it is believed this study was the first to quantify the presence of 
pharmaceuticals in UK CSO effluent.  Median concentrations were lower than those 
reported by other UK studies for all compounds (Table 2-6; 2-7) apart from diclofenac.  
Contrastingly, the median receiving water concentrations reported here were greater 
than global medians for diclofenac, erythromycin and ibuprofen (Hughes et al., 2013; 
Appendix A) suggesting these are pollutants of particular concern in the UK.  One 
possible reason for this is that these three compounds are very frequently prescribed in 
the UK up to 163 tonnes per year (Table 2-3). 
One other possible reason for the identification of new maxima and elevated 
median concentrations is simply the number and type of samples collected as part of this 
study.  From the 11 previous UK studies identified by Hughes et al. (2013), total sample 
numbers ranged from 142 to 348 for compared to 317 collected during this single study.  
Furthermore, the majority of UK studies conducted sampling over relatively short 
timescales (Ashton et al., 2004; Roberts & Thomas, 2006) whilst only two studies 
monitored for longer than six months (Kasprzyk-Hordern et al., 2008; 2009).  As such, 
they are unlikely to capture the inherent temporal variability at short-term and seasonal 
time scales that has been captured as part of this study.  Were the bulk of sample 
collection to be conducted during summer months then it is possible that winter maximum 
concentrations as identified in this study (Section 4.4.4) would be missed.  The data 
presented here suggest that much further monitoring is required in similar heavily 
urbanised catchments in the UK such as those around Greater Manchester and the 
Midlands which have until now received little or no pharmaceutical monitoring effort.  This 
monitoring may highlight certain catchments or locations that have particularly high levels 
of localised pollution that until now have not been accounted for. 
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Of further concern is the contamination of STP effluent and receiving waters with 
the metabolites and transformation products of pharmaceutical compounds.  All five of 
the study compounds are excreted largely in the form of metabolites or conjugates (Table 
4-3).  Consequently, it is likely that substantial volumes of metabolites will also be present 
in the Aire and Calder at concentrations likely similar or in excess of the parent 
compounds measured here.  This is a major concern given that certain metabolites have 
demonstrated increased toxicity compared to their parent compounds (Bedner & 
MacCrehan, 2005; La Farré et al., 2008; Lienert et al., 2007).  Furthermore, some 
conjugated metabolites have the potential to be re-transformed into parent compounds 
under environmental conditions (Warman, 1981) representing a further potential sink for 
pharmaceutical pollution. 
4.4.4 Seasonal trends in pharmaceutical concentrations 
The data presented here show seasonal trends in concentrations with higher 
concentrations of all compounds during the winter months.  This is in partial agreement 
with the original hypothesis (H2).  Similar winter peaks have been detected in Spanish 
rivers (Valcárcel et al., 2013) attributed to reduced solar radiation and degradation at 
lower temperatures.  However, Loraine & Pettigrove (2006) identified summer maximum 
concentrations in wastewater and raw drinking water for a range of effluent associated 
contaminants in Southern California.  This was explained by the complex nature of 
drinking water supply relying on the import from an adjacent effluent dominated 
catchment during the summer months (Loraine & Pettigrove, 2006).   No such imports 
are present in the Aire and Calder and so any seasonal trends must be caused by 
processes occurring within the catchments. 
Winter peaks have also been observed for ibuprofen in the effluent of a 
Californian STP (Yu et al., 2013).  Sui et al. (2011) demonstrated winter peak 
concentrations for three different STP technologies in China.  These authors attributed 
the reduced summer concentrations to a more efficient treatment process under warmer 
temperatures.  MacLeod & Wong (2010) used passive samplers to monitor temporal 
trends in concentrations from a small STP.  As in this study, winter concentrations were 
peaks were present.  These were attributed to reduced attenuation at lower temperatures 
and changes in use patterns.   Similar processes such as these may be operating in the 
Aire and Calder which would explain the higher winter concentrations. 
MacLeod & Wong (2010) also highlight the susceptibility of smaller STPs (2000 p.e) to 
small changes in use patterns amongst the served population.  They estimated that a 
single additional 200 mg dose of a compound would result in an effluent increase of 100 
ng L-1 if the compound was un-metabolised.  This is clearly an oversimplification but 
emphasises the importance of considering local factors when designing pharmaceutical 
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monitoring campaigns.  The two smaller STPs monitored in this study should be 
considered a monitoring priority given their relatively small population equivalents 
(Oxenhope: 2295 p.e. and Ripponden 4495 p.e.). 
A key finding of this study was winter peak concentrations in pharmaceuticals, 
particularly erythromycin.  The macrolide group of antibiotics (including erythromycin) 
are amongst the most widely used and are consumed in greater volumes during the 
winter across Europe (Alexy et al., 2006).  Similar winter peaks in consumption have also 
been demonstrated for antibiotic consumption across the UK (Davey et al., 2008).  The 
consumption of newer broad-spectrum antibiotics (including macrolides) is increasing 
across Europe (Goossens et al., 2005) which may be an additional driving factor of 
pharmaceutical pollution in rivers.  One theory for the strong seasonal trends in antibiotic 
consumption is the winter prevalence of upper respiratory tract infections (Deschepper 
et al., 2002).  Metoprolol (a beta-blocker similar to propranolol) has demonstrated winter 
peak concentrations in STP effluent (Sui et al., 2011) which could be explained by the 
prevalence of higher blood pressure during the winter months (Brennan et al., 1982).  
These increased rates of consumption during winter will lead to greater excretion to the 
sewer network and subsequent release to rivers which may partly explain the winter 
peaks found in this study.  The above studies highlight the importance of considering 
prescription or consumption datasets when designing monitoring strategies for 
pharmaceuticals. 
4.4.5 The relationship between pharmaceutical concentrations and flow 
Kolpin et al. (2004) examined the relationship between flow and pharmaceutical 
concentrations around ten cities in Iowa, USA with similar population ranges to the Aire 
and Calder catchments (populations 2000 to 200 000).  The frequency of detection was 
greatest in low flow samples for prescription drugs and antibiotics.  Additionally, the 
urban contribution to pharmaceutical concentrations in rivers was dependent on flow with 
upstream-downstream concentrations only demonstrating significant differences during 
low and normal flow conditions (Kolpin et al., 2004).  The data presented in this study 
show an opposite trend for greater detection frequencies during high flow conditions.  
One possible explanation is the additional input of unknown point sources (such as CSOs 
or sewer misconnections) which may be more active during such events (Ellis, 2006).  
Another possible explanation is reduced hydraulic retention time (HRT) within STPs 
during high flow/rainfall events or the activation of overflow/bypass mechanisms within 
the STPs themselves (Phillips et al., 2012).  Numerous studies have confirmed reduced 
removal efficiencies of hormones and other emerging contaminants during high flow 
(Fono & Sedlak, 2005; Johnson et al., 2005) which may explain the greater detection 
frequencies found during high flows in this study.   
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Although Kolpin et al. (2004) found the greatest detection frequencies at high 
flow, the greatest measured concentrations were found during low flow conditions.  The 
same was true in this study with concentrations up to 3 x greater during moderate or low 
flows.  Higher concentrations in rivers during low flow events are likely to be a function 
of reduced dilution of STP effluent (Daughton, 2001) although this is further complicated 
by the dependence of in-stream degradation on flow conditions (Kunkel & Radke, 2011).  
Clearly, any future monitoring should seek to include periods of both low and high 
rainfall/flow.   
4.4.6 Comparisons of STP treatment technologies 
Effluent samples demonstrated greater concentrations than their respective channel 
samples further confirming that STP effluent is a major source of pharmaceutical 
pollution to rivers.  The secondary AS STP displayed the lowest concentrations 
compared to secondary BF and Tertiary A1 for all compounds in both receiving waters 
and effluent.  This trend was particularly prevalent in receiving waters where secondary 
AS concentrations were lower by up to 2 to 3xs.  These results were in partial agreement 
with the original hypothesis (H3) and with Kasprzyk-Hordern et al. (2009) who found 
concentrations in effluent and receiving waters from a Welsh secondary AS STP 
displayed consistently lower concentrations for all compounds except diclofenac 
compared to a secondary BF works.  The results presented here agree with the wider 
research which shows variable but often poor removal of the study compounds during 
secondary BF treatment; the effects of additional tertiary treatment steps are variable 
often resulting in slight reductions in removal efficiency (Ternes, 1998; Kanda et al., 
2003; Carballa et al., 2004; Jones et al., 2005; Castiglioni et al., 2006; Jones et al., 2006; 
Spongberg & Witter, 2008; Terzic et al., 2008; Lundström et al., 2010; Tambosi et al., 
2010). 
Given the absence of influent samples collected during this study it was not 
possible to make comparisons in removal efficiencies between STPs and as such any 
observed differences may be the result of site-specific factors.  Notably, the 
comparatively low concentrations observed at the single secondary AS STP sampled 
may be explained by this works having the lowest population equivalent (2205 p.e.) of 
all the sampling sites.  Influent concentrations have been shown to be strongly 
dependent on the contributing sewer catchment including the age demographics of the 
population served and the relative contribution of domestic vs. commercial and industrial 
wastewater (Yu et al., 2013).  The presence of hospitals within the catchment of a STP 
can have a significant influence on the characteristics of the influent, effluent and 
receiving waters (Escher et al., 2011).  Indeed, Yu et al. (2013) found significantly 
different influent concentrations of a range of pharmaceuticals (including diclofenac and 
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ibuprofen) in two apparently similar STPs, one serving three hospitals and the other just 
one.  No data are available on hospitals or long-term care facilities within the STPs 
studied here although it is likely that the large STP downstream of Leeds (Knostrop) 
receives effluent from the major hospitals (Leeds General Infirmary and St. James’ 
Hospital) which serve the large populations within Leeds and surrounding areas.  Future 
detailed monitoring of influent, effluent and receiving waters will allow researchers to fully 
quantify the effects of STP technologies and operating parameters on pharmaceutical 
pollution loads to rivers. 
4.4.7 Combined sewer overflows 
Pharmaceuticals were detected in the majority of CSO samples except for mefenamic 
acid and propranolol.  These results further confirm that CSOs are a source of 
pharmaceutical pollution to rivers and are the first to detect pharmaceuticals in the 
effluent of UK CSOs.  Published studies examining the occurrence of pharmaceutical 
compounds in CSO effluent are rare despite the widespread acknowledgement of the 
detrimental impact they can have on water quality (Balmforth, 1990; Mulliss et al., 1997; 
Lee & Bang, 2000; Lau et al., 2002; Old et al., 2003; Weyrauch et al., 2010).  Boyd et al. 
(2004) monitored canals receiving stormwater effluent in New Orleans where the majority 
of pharmaceuticals showed a positive correlation with rainfall. This which was contrary 
to the data presented by Kolpin et al. (2004).  The likely reason for the increase during 
high rainfall was raw sewage contamination and the ‘first-flush’ phenomenon re-
suspending raw sewage, which subsequently leaked into the storm water drains (Boyd 
et al. 2004).  It is possible that similar flush processes operate in the Aire and Calder 
CSOs although further detailed monitoring and continuous sampling techniques would 
be required to confirm this.  
The results presented here and elsewhere demonstrate the capacity for CSOs to 
contribute significant loads to receiving waters.  Phillips et al. (2012) found that although 
CSOs account for a small proportion of discharge volume (10 %) in a USA sewer system 
they contribute 40-90 % of annual pollution loads for wastewater-associated 
micropollutants.  They are a particularly dominant source for compounds that would be 
well removed during the sewage treatment process with CSO concentrations up to ten 
times greater than associated STP effluent values.  This difference in concentration 
between STP and CSO effluent was present in this study for erythromycin (~10 x greater 
in STP effluent) agreeing with the original hypothesis (H5) and that of Phillips et al. (2012) 
as erythromycin is generally well removed by secondary and tertiary STPs (Table 2-5).  
However, the other study compounds also demonstrate high removal rates but did not 
show significant differences in STP and CSO effluent concentrations.  One possible 
explanation is that the lack of treatment removal in STP effluent is negated by additional 
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dilution by surface water runoff (Mulliss et al., 1997).  A further factor in support of this 
hypothesis was the fact that the order of study compounds in terms of average 
concentrations was consistent across CSO and STP effluent and receiving waters with 
ibuprofen consistently detected at the highest concentrations and propranolol at the 
lowest.  This same pattern was also evident across the various CSO monitoring sites.   
Given their proven contribution to pharmaceutical pollution of rivers, CSOs should 
be seen as a major concern for water quality in the UK and across the world.  It is 
estimated that there may be over 25 000 CSOs in the UK with up to a third of these 
classed as unsatisfactory under the terms of the Urban Waste Water Treatment Directive 
(Thompson RPM, 2006).  There are at least 100 such CSOs within the Aire and Calder 
catchments alone (Yorkshire Water, pers. comm.).  Furthermore, recent campaigns in 
the popular media have shown that a number of CSOs can discharge at very high 
frequencies, sometimes hundreds of times per year (BBC, 2009).  There are suggestions 
that CSO effluent and other cross-connections or poorly operating sewer systems are 
the major contributor of pharmaceutical pollution in areas far from the STP effluent 
discharges (Ellis, 2006).  Indeed, one of the CSOs (Oulton Beck) sampled as part of this 
study was observed to be active even during periods of dry weather suggesting that 
cross-connections in the sewer system may be contributing pharmaceutical pollution to 
rivers even when CSOs should be inactive.  Furthermore, such non-STP point sources 
are not represented in the widely used risk assessment models such as GREAT-ER 
which may in turn underestimate receiving water pharmaceutical concentrations 
(Schowanek et al., 2001; Schowanek & Webb, 2002).  The poor performance of CSOs 
in the UK is a major concern to the UK water regulator Ofwat who in 2009 required the 
water industry to invest £ 985 million in reducing unsatisfactory discharges during 
overflow events (Ofwat, 2009).  Despite such investment and attention, research into the 
contribution of CSOs to pharmaceutical pollution is still in its infancy and much more 
monitoring is required if the effects are to be fully understood. 
4.4.8 Short-term temporal variations in pharmaceutical pollution 
Data from this campaign demonstrated high degrees of diurnal variation with consistent 
peaks at late morning (8-11 am) and late evening (8-11 pm) for all five compounds at 
both STPS in agreement with the original hypothesis (H2).  The peak towards midday is 
in agreement with sampling conducted by Kanda et al. (2003) which found ibuprofen 
peaked in the middle of the day.  This peak could be explained by the combination of 
individual wastewater pulses from households (i.e. flushing of toilets, showers, emptying 
of sinks etc.) in the morning coupled with a 3-4 hour delay due to passage through the 
sewer system and STP.  Such a delay would yield maximum receiving water 
concentrations at approximately 11am (Ort et al., 2010b).  The same processes and 
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delays could also explain the peaks in late evening as people arrive home from work 
although to fully test this hypothesis then detailed sampling of influent, effluent and 
receiving waters would be required. 
STP effluent concentrations are known to be highly variable over time due to 
fluctuating influent concentrations, release rates, retention times and operating 
conditions (Kanda et al., 2003).  Raw influent entering STPs is known to be even more 
variable due to potentially thousands of wastewater pulses per day, connectivity, storage 
and dispersion within the sewer system (Ort, 2006) which can result in large fluctuations 
(Ort, 2005).  Typical peak sewer flow rates in a similar gravity based system as the ones 
studied here were at mid-morning (10 am to 12 pm) and late evening (8 to 10 pm) 
corresponding with other studies (Ort et al., 2010b).  Hydraulic pulses in the sewer 
network can propagate quickly through STPs and as such the effluent pattern of a STP 
can mirror that of its influent (Ort & Siegrist, 2009) but due to retention and mixing during 
the treatment process the variability of effluent concentrations is usually reduced (Ort et 
al., 2010a).  This was also mirrored in the variation of receiving water concentrations in 
this study which varied by up to a factor of three within 24 hours.  Furthermore, dilution 
in receiving waters, fluctuating flow conditions and in-stream degradation processes may 
also serve to smooth some of the variability once pharmaceuticals enter rivers (Kolpin et 
al., 2003, Kunkel & Radke, 2003). 
The timing of peak concentrations in late morning may have implications for 
freshwater ecosystems given that they coincide with peak photosynthetically active 
radiation and photosynthetic activity in rivers (Simonsen & Harremoës, 1978; Giller & 
Malmqvist, 1998).  Propranolol demonstrates very high specific toxicity towards the 
photosynthetic inhibition of green algae over short exposures with an EC50 of 648 000 
ng L-1 (Escher et al., 2005).   Antibiotics caused significant alterations to the 
photosynthetic pathways of plants which in turn caused reduced root growth and 
deformities at environmentally realistic concentrations (165 000 ng L-1 (Aristilde et al., 
2010)).  Such disruptions to photosynthetic activity could have important implications for 
whole ecosystem processes.  Fluctuations in photosynthetic activity influence pH and 
dissolved oxygen levels which in turn can impact on the diurnal cycling in the sorption 
characteristics of heavy metals (Bourg & Bertin, 1996; Nimick et al., 2003).  Therefore, 
much further monitoring is required to capture the short-term temporal variation in 
effluent and receiving waters which can in turn be used to inform more relevant 
ecotoxicological studies. 
The short-term temporal variation demonstrated here and elsewhere (Kanda et 
al., 2003; Sui et al., 2011) has implications for longer-term monitoring campaigns which 
utilise repeated grab sampling techniques.  If sites were sampled in the same order (and 
same approximate time) at each visit they may routinely capture or miss the daily peak 
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concentrations (Kanda et al. 2003).  Future monitoring should seek to reduce this 
possible bias through simultaneous, continuous sampling or varying the site sampling 
order randomly at each visit. 
4.4.9 Downstream profiles of pharmaceutical pollution 
The results show a consistent presence of the study compounds along a 5 km reach 
despite there being no known effluent sources between the two STPs along this stretch 
of the River Aire.  These results suggest that in-stream degradation processes along 
reaches of several kilometres are negligible and that exposure of freshwater ecosystems 
to pharmaceutical pollution will occur well beyond the locality of STP discharges.  
Therefore, the original hypothesis of significant attenuation along the study reach was 
rejected (H4). However, the in-stream fate of pharmaceuticals is relatively poorly 
understood with few laboratory studies and even fewer conducted in the field (Radke et 
al., 2010).  Sabaliunas et al. (2003) found that the antimicrobial triclosan underwent 
approximately 54 % removal along a 1500 m stretch of the River Aire.  However, direct 
comparisons between triclosan and the compounds studied here may be misleading as 
triclosan is generally more sorptive.   
Radke et al. (2010) examined the in-stream degradation of four pharmaceuticals 
along a 14 km stretch of a German river.  Diclofenac was most susceptible to direct 
photolysis, despite this, attenuation across the reach was just 5 to 15 % and of little 
quantitative relevance.  Contrary to our results, downstream concentrations were 
consistently different from upstream concentrations (339 – 381 ng L-1 upstream c.f. 279 
– 283 ng L-1 downstream) with greatest differences during dry weather.  This was due to 
a longer travel time and greater solar radiation allowing for higher in-stream degradation.  
Overall, attenuation of diclofenac in German rivers during both low and peak flow 
conditions was not significant (approximately 5 %) suggesting that photolysis, sorption 
and abiotic/biotic degradation are not relevant removal mechanisms at these temporal 
and spatial scales.  This is in agreement with the data presented here where overall 
attenuation is negligible or absent. 
Direct photolysis is the dominant removal mechanism for diclofenac but not for 
ibuprofen for which sedimentation and sorption were thought to be the most important 
(Tixier et al., 2003).  Gross et al. (2004) demonstrated significant removal (up to 97 %) 
of ibuprofen along a 11 km stretch of a shallow Californian river due to reduced flow, 
biodegradation and microbial transformation (Lin et al., 2006) and greater light 
penetration in the shallow river (Moss, 1988).  Fono et al. (2006) measured high in-
stream removal of ibuprofen along a >100 km reach of a Texan river.  However, the large 
number of STP and CSO effluent discharges to the Aire and Calder (occurring every few 
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kilometres along the channel; Figure 4-2) mean that any such removal along a 100 km 
stretch is likely to be replaced by additional pollution at other point sources downstream. 
Kunkel & Radke (2011) examined the in-stream removal of six pharmaceuticals 
(including diclofenac and ibuprofen) along a 16 km stretch of a small Swedish river.  
Ibuprofen was fully attenuated but diclofenac was not attenuated and in fact mass 
recoveries of this compound increased downstream.  The lack of attenuation of 
diclofenac, which is susceptible to photolysis (Packer et al., 2003), was attributed to high 
turbidity, riparian vegetation and cloudy weather. These factors may also explain why 
diclofenac was poorly attenuated along the Aire study reach although no such data are 
available to confirm this.  Further comparisons between the small Swedish river and the 
River Aire are problematic given vast differences in catchment size, land use (the 
Swedish brook received no STP effluent) and channel dimensions.  A similar dye tracer 
study along the River Aire would provide the best estimate of in-stream attenuation and 
would better inform environmental risk assessment for similar catchments. 
Reductions in concentration along the downstream profile were most pronounced 
when low flow conditions were compared with moderate or high flow conditions.  This is 
in agreement with Kolpin et al. (2004) who showed downstream change was most 
pronounced during low flow.  However, such changes are likely to be highly site specific 
and one possible explanation for the apparent increased in-stream removal during high 
flow may be the number of overflows from the adjacent Aire and Calder Navigation canal.  
It is likely that these overflows will discharge greater volumes of relatively 
uncontaminated canal water to the Aire during high flow conditions diluting the 
pharmaceutical pollution in the Aire. 
The results presented here and elsewhere highlight the need for caution when 
making assumptions about in-stream pharmaceutical removal with rates dependent very 
strongly on site specific factors, individual compound properties, latitude, season, 
weather, flow, turbidity, suspended sediment, hyporheic exchange, microbial 
communities and dissolved organic carbon concentrations (Kunkel & Radke, 2011).  
However, given the range of properties for the compounds studied here (Table 4-3) there 
was no appreciable difference in downstream fate between the compounds.  This 
suggests that local factors play a dominant role in ultimate compound fate and transport.  
It is clear that over relatively short travel times and distances up to tens of kilometres the 
assumption of significant in-stream removal is unsafe (Kunkel & Radke, 2011, Radke et 
al., 2010).  Furthermore, the data do not agree with the assumption in many risk 
assessments models (such as GREAT-ER) of a 1st order in-stream decay i.e. that the 
rate of in-stream decay is dependent on the concentration of the pharmaceutical 
(Schowanek et al., 2001).  Therefore, it is suggested that this assumption is revised and 
informed by laboratory or field fate data where available. 
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4.4.9.1 Physicochemical properties 
Pharmaceuticals are comprised of myriad compounds with a wide range of 
physicochemical properties which play a significant role in determining their 
environmental fate and transport (Kunkel & Radke, 2011).  All of the study compounds 
have positive pKa values (Table 4-3) indicating they are unlikely to dissociate into ionic 
components at environmental temperature and pH ranges.  This means the majority of 
the compounds will remain in their ‘parent’ form once they have entered rivers which may 
explain the high concentrations seen several kilometres downstream of the point source.  
Propranolol demonstrated the highest pKa of the study compounds (9.4; Table 4-3) which 
is contrary to this compound displaying the lowest mean concentrations in both STP 
effluent and receiving waters.  However, this may be explained by biodegradation within 
rivers as propranolol has demonstrated relatively short half-lives (0.4-1.8 days) in 
water/sediment systems (Ramil et al., 2009). 
Log KOW is variable across compounds and a log KOW > 4.5 is the threshold at 
which compounds are considered to be persistent and bioaccumulative (EMEA, 2006).  
This threshold is exceeded by mefenamic acid indicating a propensity to sorb to 
biological material.  Sorption of mefenamic acid to solid phases during STP treatment 
may explain why this compound was detected at the lowest frequency and the second 
lowest mean concentration.  Existing laboratory data appear to agree with this 
assumption showing mefenamic acid to be relatively well removed by secondary and 
tertiary STPS (87-100 %; Table 2-5).  The other study compounds demonstrate 
moderately high log KOW suggesting that accumulation within biological matter and other 
solid phases must be considered when evaluating fate and transport which can in turn 
influence their bioavailability and ultimately their toxicity to aquatic organisms (Mace, 
2002).  Conversely, ibuprofen demonstrates relatively low sorption coefficients (kd and 
kOC; Table 2-9) which may partly explain its variable but often low removal during sewage 
treatment (ranging from 0 to 100 %; Table 2-5).  Clearly, simple correlations between 
physicochemical properties and ultimate occurrence, fate and transport of 
pharmaceuticals in freshwater systems are not appropriate.  Of equal if not greater 
importance is the variable pharmaceutical consumption within the contributing sewer 
catchments and dynamic environmental conditions both during and after sewage 
treatment.  Biological uptake is also highly variable but can be significant, particularly for 
NSAIDs given their sufficient solubility to avoid sorption to sludge in STPs but high 
enough lipophilicity to bioconcentrate (Brown et al., 2007).  Therefore, biological loads 
of pharmaceuticals should also been seen as monitoring priority.   
The excretion rate of parent compounds after human consumption is generally very 
low for all compounds except mefenamic acid.  Excreted metabolites are therefore of 
concern as they may potentially be present at concentrations several fold higher than 
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parent compounds (Ayscough et al., 2000) and certain metabolites can demonstrate 
increased toxicity e.g. paracetamol (Bedner & McCrehan, 2005).  Phase II metabolism 
involves conjugation prior to excretion although some of these ‘inactive’ conjugates have 
the potential to be re-transformed into active or parent compounds after excretion 
(Warman, 1981).  Occurrence and toxicity of pharmaceutical metabolites remains poorly 
studied despite a recommendation they be considered as part of the environmental risk 
assessment process (EMEA, 2006).  Given, the variable physico-chemical properties of 
the compounds studied here it is likely that significant loads of parent and metabolised 
compounds are present within solid and biological phases of the Rivers Aire and Calder 
that were unaccounted for in this study.  Consideration of these additional pollution 
burdens should be seen a future research priority. 
4.5 Conclusions 
The results presented here highlight the consistent presence of pharmaceutical 
compounds at high concentrations in the STP/CSO effluent and receiving waters of a 
typical UK catchment encompassing both semi-rural and urban environments.  The 
results confirm STP effluent as the major source of pharmaceutical pollution to rivers.  
Concentrations were high relative to other global studies with new UK maximum 
concentrations detected for diclofenac, erythromycin and ibuprofen in receiving waters 
and diclofenac in STP effluent.  Winter concentrations were generally greater than those 
from the spring/summer period demonstrating seasonal trends that other shorter 
monitoring campaigns may have missed.  Compounds were detected more frequently 
during high flow conditions suggesting that reduced removal efficiency and overflow 
mechanisms in STPs may be contributing additional pollution loads at high flow.  During 
low and moderate flow conditions, compounds were detected less frequently but at 
significantly greater concentrations perhaps due to reduced dilution.  The high frequency 
of detection across all samples is of particular ecological concern given the potential for 
life-long, multigenerational exposure of aquatic organisms given the ‘pseudo-
persistence’ arising from continually discharging STP effluent (Daughton, 2001). 
This study also represents the first work examining the contribution of CSO 
effluent to UK rivers with concentrations up to a maximum of 10 060 ng L-1 for ibuprofen 
with variable but generally high detection frequencies.  Concentrations measured in CSO 
effluent were of the same order as those in STP effluent except for erythromycin which 
was higher in CSO effluent.  This suggests that CSOs may be a particularly important 
source for those compounds that are otherwise well removed by STP treatment (Phillips 
et al., 2012). Therefore, CSOs have the potential to be a major contributor of 
pharmaceutical pollution in rivers and much more work is needed to understand the 
implications for urban water quality.  Furthermore, the poor degradation of the study 
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compounds along a 5 km stretch of the River Aire means that the assumption of rapid 
in-stream degradation is not widely applicable and is subject to local factors such as 
weather, turbidity and flow.  Therefore, the general bias of current research to focus on 
areas immediately downstream of STP effluent discharges should be challenged.  
Concentrations have been shown to vary markedly across diurnal and seasonal 
timescales highlighting the importance of more intelligent, representative monitoring 
strategies in order to capture this variability (Ort et al., 2010a; Ort et al., 2010b; Hughes 
et al., 2013).  Continuous monitoring, composite samplers and passive integrative 
sampling techniques represent the best options to fully quantify the variable 
pharmaceutical levels in complex STP and receiving water systems (Zhang et al., 2008; 
MacLeod & Wong, 2010; Jacquet et al., 2012).   
The concentrations detected here are relatively high for a developed western 
nation and demonstrate a low factor of safety for ecological risk (Crane et al., 2006; Fent 
et al., 2006; Enick & Moore, 2007; Santos et al., 2010; Hughes et al., 2013).  
Furthermore, pharmaceutical pollution of rivers is now of major policy concern at the 
European level with the inclusion of diclofenac (and the synthetic oestrogen, EE2) on the 
'watch list' of Hazardous Substances under Annex X of the Water Framework Directive 
(EC, 2000; EC, 2012).  93 % of the receiving water samples analysed here would exceed 
the initial proposed EQS limit of 10 ng L-1 for diclofenac representing a potentially 
significant future cost and regulatory burden for the UK water industry (UK Parliament, 
2012).  These data suggest that pharmaceuticals represent a more pressing freshwater 
pollution problem than pesticides where only 6 % of samples exceeded the 100 ng L-1 
threshold (EA, 2009c) stipulated by the WFD and EU Pesticide Directive (2009/128/EC). 
Clearly, pharmaceuticals are consistent pollutants in both semi-rural and urban 
rivers and are likely to be present wherever waste from domestic consumption enters 
freshwater systems.  Despite this, there remain many significant knowledge gaps in the 
spatiotemporal aspects of their occurrence in rivers, particularly the contribution of non-
STP effluent sources such as CSOs.  The inclusion of diclofenac on the ‘watch list’ of 
Priority Substances of the Water Framework Directive should be seen as an opportunity 
to expand research across the estimated 3000 pharmaceutical compounds currently 
approved for use in the UK alone (Ayscough et al., 2000) as well as the myriad other 
chemicals consumed in domestic, commercial, industrial and hospital settings every day. 
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5 LETHAL AND SUBLETHAL EFFECTS OF PHARMACEUTICALS ON 
FRESHWATER SHRIMP (GAMMARUS PULEX) 
5.1 Introduction 
Pharmaceuticals are a major group of environmental contaminants found in soils, ground 
and surface waters and biota (Jones et al., 2001; Kolpin et al., 2002; Boxall, 2004; Ternes 
et al., 2007; Daughton & Ruhoy, 2009b).  There has been a recent focus on the effects 
of pharmaceuticals in aquatic ecosystems (Daughton, 2007) but these compounds are 
generally considered to pose minimal risk of acute toxicity to freshwater organisms given 
their low concentrations (generally ng to µg L-1; (Hughes et al., 2013).  However, most of 
the ecotoxicological studies that underpin this position have been conducted over very 
short exposure periods (≤96 hours) and at relatively high concentrations.  Although these 
tests are a good starting point and have value in producing relatively high volumes of 
reproducible and comparable data, they rarely represent exposure conditions in the 
freshwater environment. Extended exposures to more realistic concentrations are less 
common, perhaps given the associated costs and logistics.  Several review articles 
indicate a reduced margin of safety for long-term toxicity manifesting in the environment 
with effects present at the µg L-1 level (Crane et al., 2006; Fent et al., 2006; Enick & 
Moore, 2007; Santos et al., 2010; Hughes et al., 2013).  In fact, even many extended 
exposure studies do not meet the criteria to be properly classified as chronic tests (Suter, 
1993; Newman & Unger, 2003).  
Aquatic macroinvertebrates have been used widely to study toxicological effects 
of antibiotics, antidepressants, antiepileptics, cardiovascular drugs and painkillers 
(Crane et al., 2006; Fent et al., 2006; Enick & Moore, 2007; Santos et al., 2010).  
However, tests have been conducted overwhelmingly using water fleas (Cladocera: 
Daphnia magna), a commonly used standard organism in ecotoxicology (OECD, 2004; 
OECD, 2008).  D. magna has even been proposed as the sentinel aquatic invertebrate 
for future research in environmental metabolomics (Snape et al., 2004).  Despite this, 
the generic relevance of D. magna has been questioned, given its absence in most 
running waters where pharmaceutical pollution is most likely to be an issue (Koivisto, 
1995; Stark et al., 2004).  Other widespread, abundant and functionally important taxa 
such as freshwater amphipods (e.g. Gammarus pulex) are less well studied (Macneil et 
al., 1997) despite their long standing recognition as a suitably sensitive species for 
ecotoxicological research (McCahon & Pascoe, 1988). 
The vast majority of ecotoxicological tests have been conducted using single 
compounds in isolation; a situation that is clearly not representative given the myriad 
other pollutants and stressors present in the aquatic environment (Mihaich et al., 2005; 
Fent et al., 2006).  There have been a small number of studies examining the effects of 
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pharmaceutical mixtures (Cleuvers, 2003; Cleuvers, 2004; Dietrich et al., 2010) and 
these have indicated that pharmaceuticals generally follow the concept of concentration 
addition, leading to effects well below their individual thresholds (Escher & Hermens, 
2002; Escher et al., 2005).  More emphasis needs to be placed on mixture toxicity if we 
are to further our understanding of the complex effects in the aquatic environment 
(Backhaus, 2008).  There is clearly a need for a more flexible, knowledge-based 
approach towards toxicity assessment (Länge & Dietrich, 2002) and to develop tests that 
include ecologically relevant species and endpoints (Koivisto, 1995; Kümmerer et al., 
2004b). 
Given the low risk of acute or short-term toxicity, measuring endpoints such as 
growth, survival, feeding and reproduction may miss more subtle, sub-organismal effects 
(Daughton & Ternes, 1999).  Despite such long standing concerns, these endpoints are 
still the most widely assessed in both acute and chronic ecotoxicology (Santos et al., 
2010).  Daughton & Ternes (1999) and Brooks et al. (2003) recommended 
ecotoxicological testing incorporate compound or species specific biomarkers and 
bioassays to detect subtle effects.  The rapidly expanding area of environmental omics 
techniques, which allow the objective and simultaneous measurement of hundreds or 
even thousands of responses, has considerable potential to identify sub-lethal effects 
and enable biomarker development (Viant, 2007). 
Metabolomics may be able to detect minute but important disturbances that other 
techniques may miss (Daviss, 2005).  This technique can now reliably quantify a large 
number of metabolites, small products of metabolism < 2.5 kDa in size (Fernie et al., 
2004; Preti, 2005).  These can be used these to quantify an organisms baseline 
metabolic state (Viant, 2007) and in turn to contextualise physiological and metabolic 
changes caused by multiple stressors in the natural environment (Robertson, 2005).   
The first published application of metabolomics to aquatic organisms revealed an 
ability to distinguish between healthy and diseased red abalone (Haliotis rufescens) 
(Viant et al., 2003a).  The method has since been applied successfully to detect the 
effects of pesticides, solvents, polycyclic aromatic hydrocarbons and synthetic 
oestrogens in several fish species (Viant, 2005; Samuelsson et al., 2006; Viant et al., 
2006; Ekman et al., 2008; Williams et al., 2009).  Environmental metabolomics 
demonstrates significant potential for addressing current issues in aquatic ecotoxicology 
(Viant, 2008) but to date only two studies have applied metabolomics to pharmaceuticals 
and aquatic organisms, namely antibiotic effects on H. rufescens (Viant et al., 2003a) 
and propranolol on D. magna (Taylor, 2010).  Neither of these studies included exposure 
concentrations that are representative of environmental conditions nor did they consider 
the effects of pharmaceutical mixtures. 
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5.1.1 Aims and hypotheses 
The overall aim of the study was to assess the effect of extended (28 day) exposure to 
environmentally realistic concentrations of erythromycin (antibiotic), propranolol (beta-
blocker) and their mixtures on the functionally important freshwater amphipod 
Gammarus pulex (L.).  Response measurements included growth, feeding, mortality and 
the whole organism metabolic profile.  This included a first application of environmental 
NMR metabolomics to G. pulex to assess whether such techniques were applicable and 
able to differentiate between control organisms and those exposed to pharmaceuticals.  
The investigation was undertaken as a comparative study of pharmaceutical effects, and 
was not an attempt to gain a detailed biochemical understanding of the G. pulex 
metabolome.  Specific objectives were: 
 Measure the effect of extended exposures to erythromycin and propranolol on 
the growth and feeding of G. pulex; 
 Measure the effects of these pharmaceuticals on the mortality of G. pulex; 
 Apply NMR environmental metabolomics to quantify the sublethal, metabolic 
effects of extended pharmaceutical exposure; 
 Combine the above pharmaceuticals and examine the lethal and sublethal effects 
of a pharmaceutical mixture. 
It was hypothesised that (H1) low-level exposure would not have a direct lethal effect on 
G. pulex but (H2) prolonged exposure would cause significant reductions in sub-lethal 
endpoints (e.g. growth and feeding).  It was also hypothesised that (H3) these sub-lethal 
effects would be detectable via alterations to the whole organism metabolome.  Finally, 
it was hypothesised (H4) that lethal and sublethal effects of mixtures would be more 
pronounced than compounds acting in isolation. 
5.2 Methodology 
5.2.1 Experimental design 
Erythromycin and propranolol were chosen as study compounds given their high 
environmental risk quotients (Jones et al., 2002; Thompson, 2006; Yamamoto et al., 
2009) and their widespread occurrence in rivers worldwide (Hughes et al., 2013).  
Treatment concentrations were chosen as an indicator of likely exposures based on 
published maxima for UK rivers (erythromycin: 1000 ng L-1 (Hilton & Thomas, 2003); 
propranolol 215 ng L-1 (Ashton et al., 2004)) and an indicator of worst-case exposure 
based on 100x this concentration.  Low treatment concentrations were 200 and 1000 ng 
L-1 of propranolol and erythromycin respectively.  High treatment concentrations were 20 
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000 and 100 000 ng L-1 respectively.  High and low mixture treatments were binary 
combinations of the respective low and high treatments for the individual compounds. 
Six pharmaceutical treatments and a control (CON), each replicated six times, 
were established at random across 42 0.8 L flasks; treatments included low and high 
treatments of erythromycin (LT ERY and HT ERY), propranolol (LT PRO and HT PRO) 
and the equivalent binary mixtures (LT MIX and HT MIX), with 0.2 g of Beech (Fagus 
sylvatica) leaf litter provided in each flask for feeding.  F. sylvatica feed material was 
used as this was the predominant leaf species at Silsden Beck from where test 
organisms were sourced.   
The exposure matrix water was sourced from Silsden Beck, West Yorkshire (UK; 
OSNGR SE 04461 47504).  The site was chosen due to it being situated upstream of 
any STP effluent inputs, thereby reducing the potential for contamination by the study 
compounds.  A 1 L grab sample of water from Silsden Beck was analysed a priori by 
HPLC-MS/MS indicated that all five of the preliminary study compounds were below 
detection limits (5ng L-1 for diclofenac, erythromycin, mefenamic acid and propranolol 
and 25 ng L-1 for ibuprofen).   
The test was a modified static renewal exposure conducted with Gammarus 
pulex over 28 days; further details on the test organisms and laboratory acclimatisation 
are available in Appendix C.  After 28 days, each surviving individual G. pulex was flash 
frozen in liquid nitrogen, weighed and stored at -20°C prior to extraction.  Flash freezing 
to kill the individuals instantly was crucial as stress associated with a more prolonged 
death (e.g. preserving in 70% ethanol) would impact on the metabolome.  Remaining 
beech leaf feed material was immediately dried, weighed and combusted (to determine 
Ash Free Dry Mass) for analysis of feeding rates.   
5.2.1.1 Sample extraction 
The sample extraction procedure was based on that used for earthworm (Lumbricus 
rubellus) tissue by Bundy et al. (2007).  Whole organism extracts have been proven to 
be more discriminatory than specific fluid or tissue extracts such as hemolymph (Taylor, 
2010). Each individual was homogenised using an Omni TH homogeniser (Omni 
International, GA, USA) in 1.8 mL of ice-cold 60 % acetonitrile solution (v/v, D2O), 
vortexed and centrifuged (16000 g, 10 min); the supernatant was pipetted and dried in a 
vacuum concentrator. Each sample was rehydrated in 0.6 mL of an NMR buffer; this was 
100 % D2O, 100 mM phosphate buffer (30.5 mL Na2HPO4 and 19.5 mL NaH2PO4 in 50 
mL D2O), pH 7.0, and 0.25 mM sodium (trimethylsilyl)[2,2,3,3-2H4]-proprionate (TSP). 
The rehydrated samples were centrifuged (3 min, 16000 g), and 0.60 mL was transferred 
to a 5 mm NMR tube for analysis. 
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5.2.2 Data analysis 
Percentage change in G. pulex and feed material mass from day 0 to day 28 were tested 
using the non-parametric Kruskal-Wallis H test after arcsine transformation of 
proportional data.  Differences in mortality were tested using life tables and calculating 
the non-parametric Wilcoxon (Gehan) test using PASW Statistics 17.0 (SPSS Inc., IBM).  
5.2.3 NMR spectroscopy  
NMR spectroscopy was chosen for its high reproducibility and the ready availability of an 
appropriate instrument with qualified and trained operators.  Samples were analysed at 
293 K on a Varian Unity Inova 500 spectrometer (Varian Inc., Palo Alto, California, USA) 
with a field strength of 11.7 T and a proton resonance frequency of 499.97 MHz, 
equipped with a 5 mm 1H [15N - 31P] inverse detection probe. The data were acquired in 
8192 pairs data points across a spectral width of 6 kHz, with an acquisition time of 1.36 
s. Spectra were acquired with water presaturation, with an initial 1.0 s longitudinal 
relaxation delay and a 1.5 s presaturation time. A 45 0 RF pulse was used and 400 
transients were acquired for each sample.  All these delays together resulted in a total 
relaxation time of more than 3 T1 (T1 = the longitudinal spin-lattice relaxation time).  The 
spectra were processed using ACD Labs software (v.12.01, Advanced Chemistry 
Development, Inc., (ACD/Labs), Toronto, Canada). An exponential apodization function 
of 1.0 Hz was applied to the free induction decay, and the data were zero-filled to 32 768 
real points prior to Fourier transformation. The spectra were manually phase-corrected, 
baseline corrected (first-order polynomial) and referenced to TSP (0 ppm). The data were 
reduced (0.005 ppm bins) within the ACD package having first defined dark regions 
(0.000-0.180 TSP, 4.700-5.160 residual water, 7.760-7.960 histidine and 8.400-8.500 
formate), normalising to total integral sum of the remaining regions.  Spectra were 
overlaid and inspected individually; three samples were identified as erroneous and were 
removed from subsequent analysis (one each of control, high erythromycin and high 
mixture). 
5.2.4 Multivariate data analysis 
Spectral data were analysed using multivariate statistical methods in SIMCA 13 
(Umetrics Inc., Umea, Sweden).  All data were pareto scaled and partial least-squares 
discriminant analysis (PLS-DA) models were created for pairwise comparisons between 
the control and each pharmaceutical treatment (Nicholson et al., 2002).  The number of 
PLS-DA axes fitted was determined automatically in SIMCA 13. These models were 
validated using the permutation testing routine in SIMCA (i.e. 20 randomly permuted 
models were compared to the 'correct' i.e. non-random model) and those which had 
suitable permutation plots were kept for detailed scrutiny.  20 permutations were deemed 
sufficient given the relatively low number of samples in the study.  Q2 ('goodness of 
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predictability', i.e. the ability of the model to predict the class of new samples) and Y2 
('goodness of fit', i.e. the degree of variability between classes explained by the model) 
were also used to evaluate the models suitability.   
Accepted models were subjected to further internal validation by manually excluding 
each sample, rebuilding the PLS-DA model and using this to predict the class of the 
excluded sample.  The percentage of correct and incorrect classifications using these 
validation models was recorded (see (Westerhuis et al., 2008)).    1-D loadings plots for 
each PLS-DA were examined visually to identify chemical shifts of metabolites driving 
differences between the treatment groups (e.g. Figure 5-1).  Where possible these peaks 
were assigned by comparison to published chemical shifts (Viant et al., 2003a; 
Rosenblum et al., 2006) and the Human Metabolome Database (Wishart et al., 2009).  
A number of chemical shifts found to be significant could not be assigned to specific 
metabolites using these databases. However using a 2D TOCSY NMR spectrum it was 
possible to establish whether these shifts were for hydrogens in the same or different 
molecules (Table 5-2).  
 
 
Figure 5-1: Sample 1-D loadings plot for PLS-DA model of control vs. high treatment 
erythromycin 
 
Univariate analyses of the key chemical shift bins responding to treatment differences 
were conducted in Minitab 16 (Minitab Ltd.) and PASW Statistics 17.0.  Specifically, bins 
were tested for normality and subjected to either t-test, Mann-Whitney U or one-way 
ANOVA and considered significant where p<0.05.  Changes in metabolite levels relative 
to control samples were calculated by dividing the average bin intensity for the treatment 
group against the average for control samples (>1 indicated a specific treatment caused 
enrichment; <1 caused depletion) (Ekman et al., 2008). 
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5.3 Results 
5.3.1 Initial test conditions 
There were no significant differences in G. pulex mass at day 0 across treatments 
(F=0.19, DF=6, 35, p=0.98; Appendix C1).  Dissolved oxygen was maintained 
consistently at or close to saturation (≥9.8 mg L-1) throughout the exposure period and 
although there were some slight fluctuations between treatments these were not 
significant (F=2.16, DF=6, p=0.06).  pH remained within the circum-neutral range of 7.4 
– 7.9 and conductivity within 426 – 472 µs cm-1. Statistically significant differences were 
observed for pH (F=6.48, DF=6, p<0.001) although the magnitude of these (range 7.33 
to 7.95) changes was small and unlikely to affect the fitness of G. pulex.  Mean 
temperature during exposure was 7.7 ± 0.3 °C. 
5.3.2 G. pulex growth and feeding 
Based upon the average initial masses of G. pulex across all treatments (26.4 mg ±11.4 
mg), their estimated age was 150 days prior to exposure, although this is strongly 
dependent on gender (Sutcliffe et al., 1981).  However, growth differences between 
control and all treatments were not significant (Figure 5-2, H=3.18, DF=6, 162, p=0.79).  
Furthermore, there were no statistically significant differences in feeding between 
treatments (Figure 5-3, H=7.48, DF=6, 35, p=0.28). 
5.3.3 G. pulex mortality  
Mortality increased consistently over time in all six treatments compared to the control 
(Figure 5-4). Treatments started to demonstrate significantly increased mortality from the 
control at days 15-17 (HT MIX: W=4.06, p=0.04; LT ERY: W=4.33, p=0.04 and HT ERY: 
W=5.74, p=0.02) except for LT MIX which diverged at day 27 (W=3.98, p<0.05).  Neither 
of the two propranolol treatments demonstrated significant changes although they did 
follow a similar trend of increased mortality.  Mean mortality was 3-4x higher than control 
in all treatments (except LT PRO) from day 16 onwards and this was maintained until 
the end of the experiment.   
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Figure 5-2: Mean % increase in mass of G. pulex during a 28 day exposure to 
erythromycin, propranolol and their binary mixture 
[values are means (n=6; error bars are ± 1 SD)] 
 
 
 
Figure 5-3: Mean (±1 SD) % mass loss of F. sylvatica litter normalised by the number of 
‘feeding days’ 
[i.e. the total of the number of days each individual survived] 
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Figure 5-4: Cumulative % mortality of G. pulex during a 28 day static renewal exposure to (a) LT ERY, (b) HT ERY, (c) LT MIX, (d) HT MIX, (e) 
LT PRO and (f) HT PRO 
 [values are means (n=6); error bars are ± 1 SD; asterisks represent significant difference from CON (* < 0.05, ** < 0.01)] 
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5.3.4 Environmental metabolomics 
It was possible to obtain good quality NMR spectra from the whole organism aqueous 
extract of G. pulex and several metabolites were identified (Figure 5-5) enabling 
comparison between the various pharmaceutical treatments.  The whole organism G. 
pulex metabolomes were able to differentiate between controls and all treatments with 
changes in several of the assigned metabolites.  When compared pairwise with the 
controls, the PLS-DA scores plots show separation between controls and all high 
treatments and for low treatment propranolol (Figure 5-6 a-e).    Separation was also 
evident between the high and low treatments of each compound when considered apart 
from the controls (Figure 5-6 f-g).  Characteristic of all the scores plots was the greater 
variability amongst controls when compared to individual treatments. 
The model parameters showed the ability of PLS-DA to account for a significant 
proportion of the variability between treatments (R2Y generally >0.50) (Table 5-1).  R2Y 
were particularly strong for pairwise comparisons between controls and high treatment 
erythromycin/propranolol (> 0.37) and between low and high treatments of the same 
compound (> 0.50).  The goodness of predictability (Q2) indicated usable, although 
somewhat noisy, models which were particularly strong for comparing between controls 
and high treatment levels of erythromycin and propranolol (> 0.30).  Internal validation 
showed strong predictability for controls and high treatments across all compounds (> 
69 %) although this was much reduced when classifying low treatment samples (55 % 
and 0 % for low treatment propranolol and erythromycin respectively).  However, 
predictability was improved when comparing between low and high treatments without 
controls (≥ 0.77).   
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Table 5-1: PLS-DA model parameters indicating the degree of variability explained (R2Y) 
and their predictive power for ‘new’ samples (Q2) 
Model description 
No. model 
vectors 
R2Y Q2 
Prediction accuracy (%)  
(no. samples) 
CON vs. HT ERY 3 0.887 0.558 
CON 100%, HTERY 100%  
Total 100% 
 (25) 
CON vs. LT ERY  
vs. HT ERY 
1 0.282 0.198 
CON 88%, LTERY 0%, HTERY 88% Total 67% 
 (33) 
CON vs. HT MIX 1 0.375 0.172 
CON 94%, HTMIX 69%,  
Total 85% 
 (26) 
CON vs. HT PRO 1 0.569 0.300 
CON 94%, HTPRO 69%,  
Total 85% 
 (30) 
CON vs. LT PRO  
vs. HT PRO 
2 0.404 0.142 
CON 88%, LTPRO 55%, HTPRO 69%, Total 
73% 
(41) 
LT ERY vs. HT ERY 2 0.842 0.552 
LTERY 100%, HTERY 100%,  
Total 100% 
(16) 
LT MIX vs. HT MIX 1 0.537 0.259 
LTMIX 82%, HTMIX 89%,  
Total 85% 
(20) 
LT PRO vs. HT PRO 1 0.506 0.235 
LTPRO 82%, HTPRO 77%,  
Total 79% 
(24) 
Prediction accuracy was estimated using SIMCAs internal misclassification tables 
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Figure 5-5: 1H NMR spectrum from (a) control and (b) high treatment erythromycin samples G. pulex with some key 
metabolite peaks identified  
(1 lactate, 2 alanine, 3 acetone, 4 trimethyl amine N-oxide (TMAO), 5 glycogen, 6 tyrosine , 7 phenylalanine) 
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Figure 5-6: PLS-DA scores plot comparing controls to (a) high erythromycin, (b) high 
mixture, (c) low and high erythromycin, (d) high propranolol, (e) low and high 
propranolol and pairwise comparisons between high and low treatments of (f) 
erythromycin and (g) mixture 
[Models show first two model vectors; 2nd vectors were fitted manually to aid visual 
comparisons for (b), (c), (d) and (g).  Only separation along the first vector t[1] should 
be considered in these figures] 
 
Examination of the scores and loadings plots (Figure 5-1; 5-6) highlighted several 
metabolites that were driving the differences between the controls and treatment groups 
(Table 5-2).  High treatment levels of erythromycin and propranolol (200 000 and 1 000 
000 ng L-1 respectively) generally caused greater relative changes in metabolite signals 
when compared to their low treatment equivalents. 
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Table 5-2: Relative metabolite changes1 against controls from whole organism 
extracts of pharmaceutical exposed G. pulex  
Metabolite 
(chemical shifts, 
ppm) 
LT ERY HT ERY LT PRO HT PRO LT MIX HT MIX 
Leucine 
(0.875) 
 
1.02 
 
0.90 
 
1.12* 
 
1.00 
 
1.01 
 
1.06 
Unknown 1 
(0.965) 
 
0.96 
 
1.23 
 
1.01 
 
1.27 
 
1.05 
 
1.27* 
Unknown 2 2 
(1.275) 
(1.585) 
(2.595) 
 
1.07 
1.00 
0.97 
 
1.05 
0.94 
0.69*** 
 
1.19 
1.12 
1.15 
 
1.00 
1.02 
0.85 
 
1.03 
1.01 
0.99 
 
0.96 
0.95 
1.04 
Lactate  
(1.345) 
 
1.06 
 
1.27** 
 
1.05 
 
1.20** 
 
1.01 
 
0.93 
Alanine 
(1.485) 
 
1.07 
 
1.37* 
 
0.97 
 
1.34* 
 
1.04 
 
1.20 
Acetone 
(2.235) 
 
0.62 
 
0.54 
 
0.66 
 
0.60 
 
0.57 
 
0.51* 
Unknown 3 2 
(2.735) 
(4.105) 
(4.375) 
 
0.99 
1.12 
0.98 
 
0.75** 
0.89* 
0.70*** 
 
1.08 
1.06 
1.08 
 
0.67*** 
1.05 
0.83* 
 
0.99 
0.99 
0.98 
 
1.03 
1.06 
1.05 
Unknown 4 2 
(2.795) 
(4.015) 
 
1.09 
1.02 
 
0.93 
0.96 
 
1.22** 
1.11 
 
0.93 
1.05 
 
1.06 
1.02 
 
0.99 
1.05 
TMAO 
(3.275) 
 
1.05 
 
0.71** 
 
0.83 
 
1.27 
 
0.99 
 
1.12 
Unknown 5 
(4.645) 
 
1.02 
 
0.88* 
 
1.12 
 
1.04 
 
1.08 
 
1.15* 
Glycogen 
(5.325) 
 
1.67* 
 
2.39* 
 
1.49* 
 
2.00* 
 
1.46 
 
0.85 
Phenylalanine 
(7.325) 
(7.395) 
(7.425) 
 
1.00 
1.05 
0.99 
 
1.23 
1.26 
1.43 
 
1.06 
1.10 
1.07 
 
1.21 
1.33 
1.27 
 
1.13 
1.18* 
1.17* 
 
1.25* 
1.35* 
1.31* 
1. Relative changes were calculated by dividing the treatment group mean metabolite intensity by the 
mean intensity for control samples.  Changes in bold indicate a significant difference between 
treatment and control, number of asterisks denotes the degree of significance (* < 0.05, ** < 0.01, *** 
> 0.0001); 
2. 2D TOCSY NMR experiment confirmed these shifts belonged to the same unknown molecules. 
5.4 Discussion 
The aim of this experiment was to quantify the lethal, sublethal and metabolic effects of 
extended exposure to environmentally realistic concentrations of erythromycin and 
propranolol.  Overall, substantial increases in mortality of G. pulex and perturbations to 
the metabolome were found as a result of pharmaceutical exposure.  No concurrent 
effects on growth or feeding of G. pulex were evident.  Although the results indicate some 
slight differences between treatments in flask DO, pH and EC, the magnitude of these 
differences was relatively small and unlikely to affect the fitness of the G. pulex as they 
are well within the ranges of tolerance demonstrated by G. pulex in the environment 
(Meijering, 1991).  As such, this study confirms the suitability of G. pulex as an 
ecotoxicological test species that is both amenable to laboratory culture and sufficiently 
sensitive to provide reliable quantification of environmental risk.  This work represents 
the first application of an extended exposure to a simple pharmaceutical mixture using 
G. pulex and the first application of NMR metabolomics to this species allowing 
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characterisation of the lethal and sublethal effects of pharmaceutical exposure on this 
functionally important freshwater macroinvertebrate.   
5.4.1 Effects of erythromycin and propranolol on growth and feeding 
It has long been established that growth and feeding of freshwater amphipods are 
sensitive indicators of a variety of stressors including metals (Naylor, 1989; Maltby & 
Naylor, 1990), sewage effluent (Maltby et al., 1990), mine drainage (Macedo-Sousa et 
al., 2007) and nutrients (Alonso & Camargo, 2004; Alonso & Camargo, 2008).  The anti-
histamine cimetidine has been shown to reduce the growth and biomass of other 
gammarids (Gammarus fasciatus) at environmentally realistic concentrations (Hoppe et 
al., 2012).  Here the exposure to low levels of erythromycin, propranolol and their binary 
mixture for a period of 28 days indicated a similar albeit not statistically significant trend 
of reduced growth in G. pulex.  There was also some indication that exposed G. pulex 
may have been feeding at a reduced rate but this was not significant and therefore 
hypothesis H2 was rejected.  Feeding and growth of G. pulex may be strongly dependent 
on size and gender so future studies should seek to standardise by these factors 
(Willoughby & Sutcliffe, 1976; Sutcliffe et al., 1981).  However, this was not possible 
during this experiment due to the risk of excess stress and injury.  One way to remedy 
this in future studies would be to obtain pre-copulatory pairs of G. pulex or to set up large 
numbers of excess replicates and retain the genital region for post-mortem identification 
of gender. 
Sublethal effects of pharmaceuticals on the behaviour and activity of other 
amphipod species have been established at concentrations similar to those reported 
here (De Lange et al., 2006; De Lange et al., 2009), albeit with different compound 
classes (antidepressants and anti-inflammatories).  Brooks et al. (2003) showed that the 
beta-blockers reduced the heart rate and respiration of cladocerans below the 
concentrations required to affect survival or growth.  This suggests that further work is 
necessary which combines evaluations of growth and feeding with other more sensitive 
sublethal behavioural and physiological assays.   
5.4.2 Effects of erythromycin and propranolol on mortality 
Clear and consistent increases in mortality were observed for erythromycin and mixture 
treatments after 7-14 days contrary to hypothesis H1.  This compound caused a doubling 
in mortality after relatively long exposures (when compared to existing research) at 
environmentally relevant concentrations. Lethal concentrations for erythromycin (≥1000 
ng L-1) demonstrated in this study were up to four orders of magnitude below those 
demonstrated in short-term exposure tests of other aquatic invertebrates (Table 5-3).  
Other freshwater taxa such as green algae appear to be more sensitive than D. magna 
but even these effects manifest at levels 60x the nominal concentration of the lowest 
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exposure reported here.  This demonstrates that longer experimental exposures are 
likely to change the conclusions drawn from short-term experiments substantially.  As 
such future ecotoxicological testing should be conducted over longer time periods to 
better represent actual environmental exposures. However, short-term experiments 
remain useful for producing high volumes of reproducible data and may be appropriate 
in simulating a high concentration ‘pulse’ of pharmaceuticals in STP effluent. 
Furthermore, the results highlight the importance of using appropriate sensitive species 
when conducting ecotoxicological tests (Posthuma, 2002).  
Although propranolol exposed G. pulex did not demonstrate significantly 
increased mortality, the data appeared to follow the same general trend exhibited by 
erythromycin and the mixture.  This suggests that propranolol warrants further 
examination for its effects resulting from extended exposures to environmentally realistic 
concentrations. 
 
Table 5-3: Summary of published ecotoxicological data for erythromycin 
and propranolol to aquatic taxa 
Compound 
Effective 
concentration in 
other studies  
(ng L-1) 
Exposure 
duration 
(days) 
Species tested Reference 
Erythromycin 
211 000 000 2 D. magna 
(Webb, 2001; 
Kim et al., 
2009) 
60 000 4 Green algae 
>100 000 000 1 
Thamnocephalus 
platyurus 
Propranolol 
800 000 2 
Ceriodaphnia 
dubia 
(Huggett, 
2002; Ferrari 
et al., 2004; 
Kim et al., 
2009) 
1 600 000 2 D. magna 
50 000 21 D. magna 
10 310 000 1 T. platyurus 
 
The low treatment mixture exhibited a mortality increase double that of controls (and 
similar to erythromycin treatments).  The results suggest that erythromycin and 
propranolol did not interact to produce enhanced effects during this study and therefore 
hypothesis H4 was rejected.  This is contrary to previous work which has shown that the 
effects of some pharmaceuticals, when combined, can elicit even greater effects than 
when present alone (Cleuvers, 2003; Cleuvers, 2004). However the lack of interaction 
demonstrated here is probably due to the fundamentally different target receptors 
between antibiotics and beta-blockers with erythromycin targeting prokaryotic cells and 
propranolol targeting eukaryotes.  Nevertheless, some studies have shown that 
pharmaceuticals with different target receptors can interact and that these interactions 
vary with exposure (Pomati et al., 2006).  Furthermore, some pharmaceuticals 
demonstrate non-polar narcosis which is not dependent upon the presence of specific 
receptors and as such remains a concern when considering the exposure to complex 
mixtures in freshwater environments (Cleuvers, 2003).  Studies examining the toxicity of 
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simple or complex pharmaceutical mixtures are relatively sparse although there has 
been much increased attention over recent years (Brain et al., 2004a; Brain et al., 2004b; 
Brain et al., 2005).  Clearly, the issue of pharmaceutical mixtures is highly complex and 
there are many unanswered questions. Mixture studies like the one presented here and 
elsewhere are the first step in improving understanding. 
Studies examining the effects of pharmaceuticals on G. pulex are relatively 
sparse and no studies are available reporting increased mortality although non-lethal 
effects have received increased attention over recent years.  De Lange et al. (2006) 
exposed G. pulex to realistic concentrations of fluoxetine (antidepressant) and ibuprofen 
and found significant reductions in movement.  However, these experiments had very 
short exposure durations of just two hours.  A further study (De Lange et al., 2009) 
demonstrated increased ventilation at low levels of the same compounds but increased 
activity at high levels (1000 – 1 000 000 ng L-1).  Some studies have demonstrated the 
effects of metals (including copper, lead and thallium) on G. pulex mortality with acutely 
lethal concentrations in the sub mg L-1 range (Gerhardt, 1995; Ozalp et al., 2011).  
Sublethal responses in ventilation and locomotion were also present for these metals.  
Pesticides have been shown to exhibit acute lethal effects at low µg L-1 concentrations 
although the exposure periods for such studies were less than 96 hours (Taylor et al., 
1994; Crane et al., 1995).  Behavioural (e.g. invertebrate drift) and lethal effects have 
also been demonstrated over a range of time periods (<1 h to 10 days) for G. pulex 
exposed to complex industrial effluent and acidification (Taylor et al., 1994; Gerhardt, 
1996).  Generally, the concentrations required for more ‘traditional’ pollutants to cause 
lethal and sublethal effects are greater than those required for pharmaceuticals.   The 
body of research on G. pulex response to stressors suggest it is an ecologically sensitive 
indicator species for a wide range of aquatic pollutants, including pharmaceuticals.  The 
results presented here lend support to its use for detecting effects of pharmaceuticals 
with effective mortality evident at concentrations well below those reported for the much 
more widely used test species, D. magna. 
The lack of samples testing nominal concentrations in the exposure matrix means 
it was not possible to fully establish a dose-response relationship for mortality at specific 
concentrations of pharmaceuticals.  However, the experimental design allowed 
comparisons between exposures to high and low levels of each pharmaceutical and their 
comparisons against control conditions.  Further work evaluating additional exposure 
levels with measured exposure concentrations should be the next research step.  The 
three-fold increase in mortality demonstrated here may be sufficient to manifest effects 
at the population level (Brain et al., 2004a; Brain et al., 2004b).  Given the important role 
that G. pulex plays in the processing of organic matter, increased mortality may have 
serious secondary implications for leaf litter decomposition and nutrient cycling in 
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freshwater ecosystems (Macneil et al., 1997), in addition to implications for its predators 
and the wider food web.  These potential widespread negative effects on populations 
and ecosystem functioning due to pharmaceutical pollution should be seen as a future 
research priority. 
5.4.3 Effects of erythromycin and propranolol on the metabolome 
Environmental NMR metabolomics has been applied to a range of organisms and has 
shown considerable potential in the field of biomarker development (Viant et al., 2003; 
Viant, 2007).  This study represents the first application of environmental metabolomics 
in studying the effects of pharmaceuticals on G. pulex. This study has established that 
1H NMR metabolomics can successfully distinguish the whole organism metabolic profile 
of G. pulex and identify differences in individuals exposed to erythromycin and 
propranolol when compared to controls.  Therefore, hypothesis H3 was accepted.  
Furthermore, this technique has identified several metabolites which can together serve 
as potential biomarkers of pharmaceutical exposure. 
Models showed a good ability to distinguish and predict between controls and 
high treatments across all three exposures.  However, this ability was weakened when 
low treatments were included with such samples.  This suggests that any effects on the 
metabolome caused by low treatments are not distinguishable from normal metabolic 
‘noise’ in the controls.  This trend is consistent for all compounds and suggests a 
metabolic response that increases with exposure concentration i.e. dose response.  
However, further work is needed to establish a true dose-response relationship and 
nominal exposure concentrations.   
Discriminating stress effects from metabolic ‘noise’ (due to diet, age, gender etc.) 
is a major challenge in environmental metabolomics although phenotypic anchoring can 
help reduce this (Viant, 2007).  One possible explanation for this ‘noise’ is the lack of 
standardisation by gender, (Viant, 2007); however this was not possible during this study 
due to the excessive stress to which G. pulex would be subjected.  High levels of noise 
have been demonstrated in other laboratory studies even in cultured populations (Hines 
et al., 2007).  Phenotypic anchoring of G. pulex is particularly important for future studies 
because sexual dimorphism in this species can influence growth, feeding and 
metabolism (Sutcliffe et al., 1981; Greenwood & Adams, 1984).  Furthermore, changes 
in the molt and sexual stages of G. pulex may have occurred during the exposure period 
which are likely to cause changes in the metabolome.  These differing stages are known 
to have varying susceptibility to toxicants such as heavy metals (Geffard et al., 2010).  
Another possible explanation for noise is parasitism; microsporidian parasites have been 
shown to alter the activity, aggression and micro-scale distribution of Gammarids 
(MacNeil et al., 2003; Fielding et al., 2005).  However, all individuals were collected from 
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the same river to reduce the likelihood of infection/non-infection being a confounding 
factor. 
Several metabolites were found to be significantly altered by pharmaceutical 
exposure and all (except TMAO) appear to be related to fluctuations in exertion 
(anaerobic metabolism), stress response and the resultant demand on energy stores 
(glycogen).  These are perhaps indicators of a general sub-lethal stress response and 
increased energy requirements in order for G. pulex to combat the sublethal toxic action 
of pharmaceuticals.   
Exposure to erythromycin caused significant changes in the chemical shift region 
identified as TMAO; this compound has been widely identified as an osmolyte in aquatic 
crustaceans playing a crucial role in regulating fluid balance and maintaining cell volume 
(Yancey, 2005).  In addition to their roles as osmolytes, methylamines such as TMAO 
have demonstrated the ability to counteract the negative effects, such as protein 
destabilisation, of urea and salt accumulation within cells (Yancey, 2001).  Intracellular 
levels of TMAO appear to increase in the presence of a stressor, such as urea, pressure, 
temperature and possibly pharmaceuticals and this can itself be detrimental by over 
stabilising proteins and inhibiting their function (Yancey et al., 1982).   
Erythromycin displays its therapeutic bacteriostatic activity by disrupting protein 
synthesis and related processes that are critical for survival and reproduction (Tenson et 
al., 2003) but this mechanism of action is only likely to be present in prokaryotic cells.  If 
similar receptors were present in Gammarus pulex the ultimate effects may be vastly 
different making comparisons difficult.  However, freshwater amphipods such as G. pulex 
and Asellus aquaticus have been shown to have endosymbiotic relationships with gut 
bacteria which contribute to the digestive process (Harris, 1993; Zimmer & Bartholme, 
2003; Wang et al., 2007).  Were such a symbiotic relationship to be disrupted by 
antibiotics then the feeding, fitness and growth of Gammarus pulex could be negatively 
affected.  Furthermore, G. pulex selectively choose food sources based on the level of 
pre-conditioning by fungal and bacterial communities which can significantly alter feeding 
rates (Gulis & Suberkropp, 2003a; 2003b; Woodward et al., 2012).  Antibiotic compounds 
have been shown to disrupt this pre-conditioning and food selection at environmentally 
relevant concentrations (Bundschuh et al., 2009; Hahn & Schulz, 2007).  Therefore, it is 
possible that antibiotics exert an indirect effect on G. pulex metabolism by altering food 
selection, feeding rates and digestion processes within the gut.  This represents an 
interesting avenue for future research. 
One other possible explanation for the observed effect is the accumulation of the 
pharmaceutical compounds (or their breakdown products) in cells which disrupts the 
osmotic balance causing alterations in TMAO.  TMAO did not appear to be involved in 
general stress response mechanisms (associated with the other metabolites) and may 
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be responding more specifically to the pharmaceuticals. This could indicate that TMAO 
is a useful metabolite in the study of sub-lethal impacts of pharmaceuticals in freshwater 
invertebrates but further evidence from other studies would be needed to support this 
hypothesis.   
Exposure to erythromycin caused significant increases in lactate, alanine and 
glycogen.  Lactate is known to accumulate in the muscles and liver after significant 
exertion (Phillips et al., 1977). Exposure of fish to environmentally realistic 
concentrations of copper and synthetic oestrogens caused increased hepatic 
concentrations of lactate indicative of anaerobic metabolism (Ekman et al., 2008; Santos 
et al., 2009).  Alanine is produced by the muscles and transported to the liver during 
exertion (Salway, 2004).  Exposure to very high levels (1.4 mg L-1) of propranolol have 
been shown to illicit small but significant elevations (+16 %) in alanine levels from whole 
organism extracts of D. magna (Taylor, 2010); however this concentration is extremely 
high and not representative of those likely to be encountered in the environment. 
Exposure to the high and low mixtures caused an increase in phenylalanine.  
Phenylalanine is an indispensable amino acid which in humans may be involved in the 
‘fight or flight’ response and is linked with growth and metabolic processes and stress 
control via tyrosine (Lehnert & Wurtman, 1993).  This amino acid has been identified in 
the whole organism metabolome of D. magna and was shown to increase slightly (2.1 
%) upon exposure to high levels of propranolol (Taylor, 2010).  The greater enhancement 
of phenylalanine present may perhaps be explained by the longer exposure period in 
this study (28 days) compared to the above study (one day). 
Glycogen (elevated in erythromycin and propranolol exposed individuals) is a 
polysaccharide energy store and is the principle storage form of glucose in most animals 
(Sedlmeier, 1982).  Existing research presents contrasting results when examining 
glycogen storage in response to external stressors.  Exposure of dog whelks (Nucella 
lapillusi) to cadmium caused increased storage in male individuals (Leung & Furness, 
2001) but tributyltin caused a depletion in the freshwater shrimp (Caridina rajadhari) 
(Nagabhushanam et al., 1991).  It is hypothesised that depletion of energy reserves is 
caused by increased demand in response to toxic stress.  However, continuous 
availability of food (as in this study) may offset this demand on the glycogen store and 
explain why the exposed G. pulex displayed only a slight increase in glycogen levels.  
One study has shown the potential for low levels of insecticides to initially elevate 
glycogen levels in field crabs (Barytelphusa guerini) followed by significant decreases 
after 72 hours (Reddy et al., 1991).  This indicates these crabs have mechanisms to 
initially increase glycogen storage and then draw upon these excess energy stores in 
response to the stressor; a process that may be mirrored by G. pulex in this study.   
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Despite the inherent noise and lack of phenotypic anchoring, 1H NMR 
metabolomics has proved a powerful technique capable of differentiating between 
pharmaceutical treatments and identifying subtle, sublethal effects in G. pulex.  Toxicities 
of these compounds can be reliably distinguished between some treatments and controls 
with minimal classification error rates.  The next step in environmental metabolomics 
should be the continued testing of G. pulex alongside other important freshwater species 
– both individually and as part of interacting communities (e.g. within realistic food webs 
(Brown et al., 2011)).  Testing should include other pharmaceuticals and wider chemical 
pollutants in order to create extensive databases of metabolic responses (Taylor, 2010).  
However, there remain considerable obstacles in understanding the underlying 
biochemical significance of changes in the metabolome given the complex interactions 
between metabolites and the lack of knowledge of how these function in lower organisms 
(Bundy et al., 2009).   
5.5 Conclusions 
The results presented here demonstrate the potential for extended exposure to low 
levels of pharmaceuticals to cause significant sublethal effects in freshwater 
macroinvertebrates that would likely go undetected by standard short-term toxicological 
experiments.  Furthermore, they highlight the vital importance of using appropriate 
experimental design, sensitive species and sufficiently long exposures if a full 
understanding of the risk posed by pharmaceutical pollution is to be gained.  The novel 
application of 1H NMR metabolomics has demonstrated its strong potential in 
understanding the sublethal effects of emerging contaminants in aquatic ecosystems 
and in the field of biomarker development.  The demonstrated effects of pharmaceuticals 
will have implications for the water and pharmaceutical industries, managers, regulators 
and policy makers.  In particular, the low-level effects of emerging contaminants may be 
a major barrier to meeting legislative requirements such as the ‘good status’ required by 
the EU Water Framework Directive (EC, 2000).  Future policy and management 
strategies should consider pharmaceuticals as widespread and potentially damaging 
pollutants in freshwater ecosystems.  
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6 THE IMPACT OF PHARMACEUTICALS ON LEAF LITTER 
DECOMPOSITION IN RIVERS 
6.1 Introduction 
Pharmaceuticals are widely present as pollutants in the environment and have been 
detected in soils, rivers, groundwater, biota and drinking water across most of the globe 
(Daughton & Ruhoy, 2009b; Hughes et al., 2013).  Knowledge of pharmaceutical 
occurrence is growing rapidly but studies of their effects on freshwater organisms and 
ecosystems are relatively sparse (Fent et al., 2006; Kümmerer, 2009a).  In particular, 
much existing ecotoxicological research has focused on short-term exposure to high, 
environmentally unrealistic concentrations of pharmaceuticals using a small number of 
standard test species and endpoints mostly focused around organismal level metrics 
(e.g. feeding, growth, reproduction, mobility, mortality).  Such procedures are useful in 
generating high volumes of reliable and reproducible effects data but their ecological 
relevance is limited and the risk of such acute toxicity is generally low.  Even more 
recently, research effort has shifted towards understanding the effects of long-term, low-
level exposure to pharmaceuticals in freshwater ecosystems where the risk of negative 
implications is much higher (Fent et al., 2006; Kümmerer, 2008a; Santos et al., 2010; 
Hughes et al., 2013).  Despite this, most work still examines the effects at the individual 
organism level with very few studies attempting to address the complex issue of 
pharmaceutical mixtures and their implications for structural and functional aspects of 
freshwater ecosystems (Hughes et al., 2013). 
Scientists and policy makers need reliable indicators of integrity to assess the 
state of ecosystems and to alleviate negative impacts resulting from anthropogenic 
stressors (Gessner & Chauvet, 2002).  Ecosystem integrity is composed of structural 
and functional components and the two are intimately linked; pattern (structure) 
determines process (function) and vice versa and so both must be considered (Matthews 
et al., 1982; Bunn et al., 1999).  Functional measures are integrative over time, space 
and organisational levels and are much less dependent on the presence of specific 
species sets and are therefore not restricted to particular geographical settings.  
Furthermore, it is possible for changes in structure to occur with no corresponding 
change in processes and vice versa.  Despite this bioassessment is overwhelmingly 
based on structural measures alone (Matthews et al., 1982; Gessner & Chauvet, 2002).   
An often cited concern in the use of functional indicators for monitoring stressor 
impacts is that inherent environmental variability will mask stressor response (Hill et al., 
2000).  However,  Niemi et al. (1993) reviewed a variety of chemical and biological 
(structural and functional) measures of ecosystem recovery to a range of stressors 
(temperature, ammonia, heavy metals and pesticides) and found that functional 
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measures were generally more sensitive (requiring lower samples sizes and reduced 
costs) in detecting impact and recovery in stream ecosystems.  Despite this, the 
application of functional endpoints in studying the effects of pharmaceuticals and other 
emerging contaminants in freshwater ecosystems is sparse (Santos et al., 2010; Hughes 
et al., 2013).  These studies fail to draw upon the well-developed ‘tool kit’ of methods 
available in aquatic ecology (Rosi-Marshall & Royer, 2012). 
The input of allochthonous carbon in the form of coarse particulate organic matter 
(CPOM; i.e. particles >1mm in size) is a major and often dominant energy source in 
freshwater ecosystems (Conners & Naiman, 1984; Richardson, 1991; Webster et al., 
1995; Giller & Malmqvist, 1998).  The decomposition of CPOM (including leaf litter) 
involves three vital processes: direct leaching of dissolved organic carbon (DOC), 
microbial and fungal decomposition, and biological and mechanical fragmentation 
(‘shredding’) by macroinvertebrates (Webster & Benfield, 1986).  These processes are 
interrelated and mechanical shredding increases surface area of leaf litter available for 
microbial colonisation (Giller & Malmqvist, 1998).  Colonisation by microbial and fungal 
communities can in turn affect mechanical breakdown by influencing food selection by 
shredder macroinvertebrates perhaps by rendering leaf litter more palatable and by 
increasing the energy content of the food as shredders consume both leaf material and 
the microbial colonisers (Merritt et al., 1984; Graça, 1993; Giller & Malmqvist, 1998; 
Graça et al., 2001).  Studies have shown that fungi dominate over bacteria in these 
microbial communities and contribute most towards microbial decomposition rates (Gulis 
& Suberkropp, 2003a; Gulis & Suberkropp, 2003b).  Without these processes combining 
to decompose leaf litter, the associated carbon would be unavailable at higher trophic 
levels and downstream transport would be reduced (Giller & Malmqvist, 1998).  For 
example, disruptions to the input and processing of leaf litter during large experimental 
manipulations has been shown to decrease secondary production by up to 80 % 
(Wallace et al., 1997).  The decomposition of leaf litter is a key ecosystem function with 
important implications for energy flow and nutrient cycling with the potential for this 
process to act as a bottom-up control cascading to higher trophic levels (Wallace et al., 
1997; Giller & Malmqvist, 1998).  Despite this, almost nothing is known about the impacts 
of emerging contaminants, such as pharmaceuticals on this key ecosystem process. 
There are numerous studies documenting the impact of anthropogenic change 
on the decomposition rates of leaf litter in rivers (Table 6-1).  These studies demonstrate 
that leaf litter decomposition (including the colonisation by bacteria, fungi and 
macroinvertebrates) is sensitive to a wide range of environmental stressors.  In 
particular, moderate nutrient enrichment appears to stimulate decomposition whereas 
high levels of nutrients, heavy metals or specific chemical compounds (e.g. pesticides) 
can be inhibitory.  Studies have shown that leaf litter colonised under different pollutant 
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loads, but then incubated under the same reference conditions, can decompose at 
different rates (Medeiros et al., 2010).  This approach is potentially useful for examining 
the effects of stressors on microbial colonisation in controlled laboratory conditions, prior 
to transplanting leaf packs to ‘natural’ rivers to evaluate subsequent macroinvertebrate 
colonisation and breakdown. 
Laboratory studies examining the effects of pharmaceuticals on leaf litter 
breakdown are rare and have focused on food selection by shredders following 
conditioning by antibiotics (Table 6-1; (Hahn & Schulz, 2007; Bundschuh et al., 2009)). 
These studies show contradictory effects of certain antibiotic mixtures on food selection 
and decomposition but comparisons between experiments may be misleading given the 
different compounds and test species used.    Currently, there are no studies available 
examining the effects of non-antibiotic pharmaceutical compounds or mixtures of 
different compound types on leaf litter decomposition.  In addition, no studies have 
combined structural and functional aspects of this process (i.e. quantifying the impact of 
pharmaceuticals on decomposition rates and the associated colonisation of leaf litter by 
macroinvertebrates) using both laboratory and in situ techniques.  A further limitation of 
existing studies is that they have used relatively high exposure concentrations over short 
exposure periods; concentrations ≥2000 ng L-1 up to 20 days.  Therefore, further studies 
are necessary which examine frequently observed environmental concentrations over 
longer exposure periods.  This study aimed to address these knowledge gaps and further 
our understanding of pharmaceutical effects on leaf litter breakdown in rivers. 
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Table 6-1: Examples of anthropogenic stressor effects on aspects of leaf litter 
decomposition in freshwaters 
Stressor Effects Reference 
Land use 
Intensive agricultural land 
use (crops and industrial 
animal rearing) 
 
Invertebrate mediated decomposition reduced in 
most intensively farmed catchments, microbial 
decomposition unaffected 
 
(Piscart et al., 2009) 
Nutrient enrichment  
Agricultural runoff 
 
 
 
 
 
 
 
 
N and P 
 
 
 
 
 
Low level eutrophication (N 
and P) 
 
High phosphate reduced fungal diversity but 
increased decomposition 
 
Ammonium, phosphate and nitrite reduced 
invertebrate mediated decomposition but nitrate 
increased it 
 
Fungal and bacterial colonisation, biomass and 
decomposition increased at elevated nutrient 
levels,  
No effect on bacterial colonisation when fungi 
excluded but decomposition was reduced 
 
Decomposition reduced at extreme low (nutrient 
limitation) and high ends of nutrient gradient.  
Strong stimulation at moderate nutrient levels 
 
Decomposition, fungal biomass, sporulation and 
invertebrate abundance and richness elevated 
in eutrophic streams 
 
(Sridhar et al., 2009) 
 
 
(Feio et al., 2010) 
 
 
(Gulis & Suberkropp, 
2003a; 2003b) 
 
 
 
(Woodward et al., 
2012) 
 
 
 
(Gulis et al., 2006) 
Heavy metals 
Mine drainage: As, Fe, Mn 
and Zn 
 
 
 
 
 
Cu 
 
Fungal mediated breakdown unaffected but 
sporulation increased at polluted sites. 
Macroinvertebrate decomposition reduced in 
polluted sites. 
 
Fungal biomass increased in polluted streams 
but sporulation decreased 
 
Reduced decomposition rates and 
macroinvertebrate (incl. Gammarus pulex) 
abundance in polluted streams.  Fungal 
communities unaffected 
 
(Medeiros et al., 2008) 
 
 
 
(Medeiros et al., 2010) 
 
 
(Roussel et al., 2008) 
Fungicides 
Tebuconazole 
 
 
Propiconazole 
 
Reduced decomposition and microbial biomass 
 
Reduced microbial decomposition and microbial 
biomass.  Increased macroinvertebrate 
decomposition 
 
 
(Artigas et al., 2012) 
 
(Rasmussen et al., 
2012) 
Insecticides 
Alphacypermethrin 
 
Reduced macroinvertebrate decomposition 
 
(Rasmussen et al., 
2012) 
Pharmaceuticals 
Antibiotic mixture 
(erythromycin, 
clarithromycin, 
roxithromycin, 
sulfamethoxazole and 
trimethoprim) 
 
Antibiotic mixture  
(oxytetracycline and 
sulfadiazine) 
 
Increased food selection and macroinvertebrate 
(Gammarus fossarum) decomposition of 
antibiotic exposed leaves.  Increased fungal 
colonisation but microbial decomposition 
unaffected.  ≥2000 ng L1 exposure (20 days). 
 
Gammarus pulex selected non-exposed leaves.  
No effect of microbial colonisation or 
decomposition.  ≥2000 ng L-1 (10 days) 
 
(Bundschuh et al., 
2009) 
 
 
 
 
(Hahn & Schulz, 2007) 
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6.2 Aims, objectives and hypotheses 
The aim of this study was to quantify the effects of low-level extended exposure to five 
pharmaceutical compounds both in isolation and as part of a mixture on leaf litter 
decomposition during the microbial pre-conditioning phase and during subsequent in-
stream breakdown.  Specific objectives were: 
 Understand the effects of environmentally relevant concentrations of 
pharmaceutical compounds on the microbially and macroinvertebrate mediated 
decomposition of leaf litter in freshwater ecosystems; 
 Understand whether pharmaceutical exposed pre-conditioned leaf litter is 
colonised and decomposed at different rates compared to non-exposed leaf litter 
when returned to an unpolluted stream; 
 Understand the effects of different compounds acting as a combined mixture on 
the above processes; 
 Target erythromycin for detailed study using the above techniques to improve on 
previous studies showing the propensity for antibiotics to affect decomposition 
(Hahn & Schulz, 2007; Bundschuh et al., 2009).  
This study aimed specifically to test the following hypotheses: (H1) pharmaceuticals 
disrupt the colonisation and pre-conditioning of leaf material by fungal and microbial 
communities resulting in measurable changes in decomposition rates (Bundschuh et al., 
2009).  Changes to the pre-conditioning of leaf litter will alter the colonisation of leaf litter 
in streams and subsequent decomposition rates (H2).  Important macroinvertebrate 
shredder species such as Gammarus pulex and Asellus aquaticus will actively select leaf 
material colonised in the absence of pharmaceuticals (H3) (Hahn & Schulz, 2007).    
6.3 Methodology 
6.3.1 Site selection 
The site chosen for the in situ phases was Silsden Beck immediately downstream of 
Silsden Reservoir, Silsden, West Yorkshire (OSNGR SE 04461 47504; Figure 6-1).  The 
site was chosen due to it being situated upstream of any STP effluent inputs, thereby 
reducing the potential for contamination by the study compounds.  A 1 L grab sample of 
water from Silsden Beck was analysed a priori by HPLC-MS/MS indicated that all five of 
the preliminary study compounds were below detection limits (5ng L-1 for diclofenac, 
erythromycin, mefenamic acid and propranolol and 25 ng L-1 for ibuprofen).  Furthermore, 
the regulated nature of the stream made this an ideal choice for the in situ studies due 
to the stable channel platform, hydraulics and flow regime.  Wooded banks 
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(predominantly beech, Fagus sylvatica) supported a community of shredder 
macroinvertebrates (particularly Gammarus pulex and Asellus aquaticus); an initial kick 
net survey found >50 individuals per kick sample). 
6.3.2 Chemicals and materials 
Glassware and vessels were disinfected then pre-rinsed with 100 % methanol and DI 
H2O prior to the experiments.  HPLC-grade methanol was supplied by Fisher Scientific 
UK Limited (Loughborough, UK).  Deionised water was generated with a Purite Select 
HP160/BP/IT deioniser. All pharmaceuticals were of the highest purity available (>95%) 
and supplied by Sigma-Aldrich Company Ltd (Dorset, UK).  Individual stock standard 
solutions were prepared on a weight basis in 100 mL of 100 % methanol and stored in 
the dark at -20 °C until used.  A fresh working mixture solution of all pharmaceuticals 
was prepared by appropriate dilution of the individual stocks in 100 % methanol 
immediately before each experimental run and used as working standard solutions.  
Working standards were also stored in the dark at -20 °C between uses.   
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Figure 6-1: Site map of Silsden Beck downstream of Silsden Reservoir 
[highlighted area indicates location of leaf pack placement; OSNGR SE 04461 47504) 
© Crown copyright/database right 2010.  An Ordnance Survey/EDINA supplied service] 
6.3.3 Collection and preparation of leaf material 
Abscised beech (F. sylvatica) leaves were collected adjacent to Silsden Beck in 
September 2010.  After collection, these leaves were soaked in de-ionised water for 2 
days to wash off any extraneous soil or mineral matter on the surface of the leaves (which 
may affect mass loss calculations), prior to drying at 55 ºC in an oven for 48 hours 
(Benfield, 2006). The leaves were then stored in sealed polythene bags in dark, dry 
conditions at room temperature until use.  River water used in the laboratory experiments 
was collected from Silsden Beck into pre-cleaned 25 L plastic containers. Water was 
filtered through a 0.064 mm sieve to remove any coarse sediment or invertebrates and 
stored at 7.7 °C in a controlled temperature room prior to use.  Invertebrates were 
removed to ensure any breakdown in the laboratory was mediated by microbial 
communities only. 
6.3.4 Laboratory pre-conditioning phase 
6.3.4.1 Individual compound study 
The experimental setup for this study included 14 treatments (Table 6-2).  Nominal 
pharmaceutical concentrations were based on the maximum published concentrations 
in UK rivers (for LT) (Ashton et al., 2004) which were multiplied by a factor of 100 to yield 
         N 
* 
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the HT concentrations.  The rationale for these values was to ascertain whether 
environmentally realistic concentrations could affect litter breakdown and whether a 
more conservative estimate of higher concentrations (i.e. several orders of magnitude 
greater than measured maxima) would yield a more pronounced effect to gain some 
knowledge of potential dose-response relationships.  Furthermore, the evaluation of 
specific mixtures will serve to highlight any potential additive, synergistic or antagonistic 
interactions between the five study compounds. 
Table 6-2: Summary of treatment schedule for the five compound leaf litter degradation 
experiment 
Compound Re-treatment frequency (days) 1 Concentration (ng/L) 
LT2 HT3 
Diclofenac (DIC) 8 600 600 000 
Erythromycin (ERY) 11 1000 1 000 000 
Ibuprofen (IBU) 6 5000 5 000 000 
Mefenamic acid (MEF) 3 400 400 000 
Propranolol (PRO) 5 200 200 000 
Low treatment mixture (LT MIX) 3 – 11 Sum of all LT n/a 
High treatment mixture (HT MIX) 3 – 11 n/a Sum of all HT 
Methanol control (MeOH) Solvent control treated with  equivalent volume of 100% methanol 
only 
Control (CON) Untreated Silsden Beck water 
Notes: 
1. Based on conservative estimates of environmental freshwater half-lives 
2. LT: low treatment based on UK maxima  
3. HT: high treatment = 100 * LT 
Control and HT MIX tanks also contained artificial leaf packs 
 
2 g samples (±0.04 g) of dried beech leaves were weighed using a 4 d.p. analytical 
balance and placed within 1000 µm stiff mesh leaf packs (EFE UK Ltd., Cornwall, UK).  
2 g of black plastic (pre-rinsed and leached in de-ionised water for 7 days) replica leaves 
were also assembled into 12 ‘artificial’ leaf packs.    Twelve beech leaf packs were then 
randomly placed in each of 14 separate glass aquaria (total n = 168); the artificial leaf 
packs were placed in the control and HT MIX aquaria (n=6 in each).  Each aquaria 
contained 20 L of water from Silsden Beck. This water was equilibrated for temperature 
and dissolved oxygen over 7 days prior to the addition of leaf packs.  Throughout 
equilibration and exposure the aquaria received constant aeration (Hailea ACO-9602 air 
pumps, Guangdong Hailea Group Co. Ltd., Guangdong, China) at 7.7 ±0.3 °C and a 
light: dark photoperiod of 12:12 hours.  The experiments were conducted in all-glass 45 
x 38 x 30 cm Clear-seal aquaria (Clear-seal Ltd., Birmingham, UK). 
After equilibration, treatment of 12 tanks with pharmaceutical compounds was 
achieved by pipetting the appropriate volume of pharmaceutical working solution directly 
into the tank and then stirring thoroughly with a glass rod.  No further mixing was 
conducted as the aeration was observed daily and found to mix the entire tank 
adequately.  The treatment approach was a modified static-renewal design whereby 
each tank was re-treated with working pharmaceutical solutions during the 8 week 
laboratory exposure period.  This modified static-renewal approach was adopted in order 
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to simulate the ‘pseudo-persistence’ of pharmaceuticals in the environment and allowing 
for losses due to hydrolysis, photolysis, adsorption and biological uptake (Daughton, 
2001).  The re-treatment frequency was determined by examining the literature for 
relevant environmental half-lives and renewing the treatment solution at the number of 
days coinciding with each compounds half-life (Tixier et al., 2003; Castiglioni et al., 2004; 
Löffler et al., 2005; Alonso & Camargo, 2008; Yamamoto et al., 2009).  For example, 
erythromycin was found to have a half-life of approximately 11 days; on day 0 the 
erythromycin tanks were treated with the appropriate working solution.  After 11 days the 
tanks were renewed to ‘top up’ the concentration back to nominal level.  This re-treatment 
schedule is summarised in Table 6-2.     
Each tank received the same volume of working solution but with varying 
concentrations depending on treatment compound and level. A solvent-only control 
(methanol) was also established to evaluate any potential confounding effects.  The total 
treatment period in the controlled temperature room was eight weeks during the period 
August to October 2010.  The in situ treatment phase totalled an additional eight weeks 
from the period October to December 2010.  An initial pilot study under identical 
conditions showed eight weeks was sufficient to obtain small but quantifiable changes in 
leaf pack mass. 
6.3.4.2 Detailed erythromycin study 
This study focused on a single compound - the macrolide antibiotic erythromycin - as 
previous studies of other antibiotics to have significant impacts on food selection and 
decomposition (Hahn & Schulz, 2007; Bundschuh et al., 2009).  Four treatment levels 
were adopted (Table 6-3) to cover a much wider range of exposure concentrations based 
on published UK river concentrations (for VLT and LT: (Ashton et al., 2004)) and higher 
concentrations (HT and VHT) to represent worst-case exposures.  Treatment conditions, 
exposure period and leaf material preparation were identical to the individual compound 
study.  Treatment in the laboratory was carried out over eight weeks during the period 
April to May 2011 with an additional eight weeks in situ during May to July 2011. 
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Table 6-3: Summary of treatment schedule for the detailed 
erythromycin leaf litter degradation experiment 
Treatment level Nominal concentration (ng/L) 
Very low treatment (VLT) 100 
Low treatment (LT) 1,000 
High treatment (HT) 100,000 
Very high treatment (VHT) 1,000,000 
Solvent control (MeOH) 16.4 mL methanol 
Control (CON) n/a 
 
6.3.5 In situ phase 
After the eight week pre-conditioning phase the leaf packs in each tank (n=12) were 
removed.  Six (hereafter termed pre-conditioning packs) were selected randomly for 
immediate analysis in the laboratory and the remaining packs (hereafter termed in situ 
packs) were transported to the Silsden Beck site.  A total of 84 leaf packs (6 replicates 
across 14 treatments) were placed in the stream.  The packs were anchored to the 
stream bed using house bricks held in place with steel bar.  Suitable locations in the 
stream were identified (i.e. stretches that were deep enough to cover the whole pack and 
with slower flows favoured by Gammarus and other shredders) and the packs were 
randomly assigned to these locations.  The leaf packs were left in situ for a total period 
of eight weeks and a number of checks were made throughout this time to monitor for 
any loss of packs due to vandalism or high flow events.  Temperature in the stream 
during this eight week period was recorded at 15-minute intervals using a Tinytag Plus 
2 data logger (Gemini Data Loggers UK Ltd., Chichester, UK) as temperature is known 
to be a major controlling factor on leaf litter decomposition (Petersen & Cummins, 1974).  
Mean stream temperature for the individual compound study was 7.2 (±0.6) and 17.0 
(±0.5) °C for the detailed erythromycin study. 
6.3.6  Analysis of leaf packs 
This section describes the process of measuring change in leaf litter mass and organic 
matter due to decomposition processes in the laboratory and in situ. After retrieval from 
Silsden Beck, the leaf packs were opened and rinsed with deionised water onto a 0.064 
mm sieve to remove any macroinvertebrates which were then preserved with 70 % 
methylated spirit for subsequent identification of taxa to family level under stereo 
microscope.  More specifically, Gammarus pulex and Asellus aquaticus were identified 
and counted as these were found to be the most dominant shredder macroinvertebrate 
species at Silsden Beck.  The leaf packs were oven dried at 55 ºC for 48 hours.  A 0.5 g 
(± 0.1 g) subsample of the leaf pack and the 1 cm discs were combusted in the furnace 
at 550 ºC for 1 hour in order to calculate ash free dry mass (AFDM) and % organic matter 
(%OM).  This procedure was also followed for the leaf packs treated in the laboratory 
immediately after their removal from the treatment tanks.  Handling loss control packs 
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(n=6) were also made and subjected to the same transport and handling procedures to 
account for potential losses during handling of the fragile dry leaf tissue (Benfield, 2006) 
and the final mass changes for treatment packs were corrected as necessary. 
6.3.7 Statistical analysis 
All univariate and multivariate analyses were conducted in Minitab 16 (Minitab Inc., PA., 
USA) and PASW Statistics 17.0 (SPSS Inc., IBM).  All data were tested for normality 
using the Anderson-Darling test and then the most powerful appropriate parametric (t-
test, ANOVA or General Linear Model) or non-parametric (Mann-Whitney or Kruskal-
Wallis) statistical tests were used.  All proportional data were arcsine transformed prior 
to comparisons. Macroinvertebrate diversity indices (species richness, Bray-Curtis D, 
Fisher’s Alpha, Shannon H Index)  were calculated using Species Diversity and Richness 
v2.65 (Pisces Conservation, Lymington) and analysis of similarity (ANOSIM using Bray-
Curtis distance over 9999 runs) was calculated using PAST (Hammer et al., 2001).  Two-
dimensional non-metric multidimensional scaling (NMDS) plots were constructed in 
PAST using the Bray-Curtis distance measure (Rabinowitz, 1975). 
6.4 Results 
6.4.1 Individual compound study 
6.4.1.1 Mass and organic matter change 
Mass loss was greater in the in situ decomposition packs when compared to the 
laboratory pre-conditioning phase but pharmaceutical treatment caused no significant 
differences from controls in either phase.  Significant differences in AFDM change and 
%OM between the pre-conditioning and in situ phases were present (Table 6-4; Figure 
6-2).  Controls packs lost less AFDM and organic matter than all but three pre-
conditioning treatments (HT-DIC, HT-MIX and HT-PRO) and all of the in situ treatments 
but these differences were not significant.    
Table 6-4: Summary of statistical analysis of mass and organic matter change in F. 
sylvatica leaf packs exposed to diclofenac, erythromycin, ibuprofen, mefenamic acid, 
propranolol and their mixture during a 16 week laboratory and in situ  experiment 
Comparison AFDM change %OM 
Pre-conditioning vs. 
in situ 
-14% vs. -19% 
(H=61.75, DF=1, p>0.0001) 
93% vs. 87% 
(H=97.93, DF=1, p>0.0001) 
Treatment 
comparisons 
Pre-conditioning In situ Pre-conditioning In situ 
H=21.12, DF=12, 
p=0.05* 
H=11.09, 
DF=12, p=0.52 
H=18.28, DF=12, 
p=0.11 
H=15.34, 
DF=12, p=0.22 
* Statistically significant difference between treatments, pairwise comparisons against control (family 
error rate: 0.05) showed no differences. 
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Figure 6-2: Percent organic matter in F. sylvatica leaf pack mass after 8 week 
laboratory exposure to five pharmaceuticals and their additive mixtures followed by 
eight weeks in situ in a stream 
[black line represents initial %OM of untreated leaf packs at 94.1%. Bars represent 
mean from n=6 replicates; error bars are ±1 SD; CONT: control, DIC: diclofenac, ERY: 
erythromycin, MIX: mixture, MEF: mefenamic acid, PRO: propranolol, LT: low 
treatment, HT: high treatment. N indicates laboratory-only exposure, Y indicates 
additional in situ exposure] 
6.4.1.2 Macroinvertebrate colonisation 
In situ leaf packs were colonised predominantly by Chironomidae with smaller numbers 
of A. aquaticus, Oligochaeta, Plecoptera and Simuliidae (Table 6-5).  Total abundance, 
species richness, dominant taxa and numbers of individual taxa varied but were not 
significantly different between treatments.  Mean total abundance in artificial leaf packs 
(6.2) was lower than the F. sylvatica leaf packs (13.5); although this difference was not 
significant (H=18.50, DF=13, p=0.14).  The dominant taxon in all treatments was 
Chironomidae. 
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Table 6-5: Mean (±1 SD) macroinvertebrate community metrics for leaf litter packs from 
the individual compound study 
Treatment 
Total 
abundance 
Taxonomic 
richness 
Berger-
Parker D (%) 
Abundance A. 
aquaticus 
Abundance 
G. pulex 
ART 6.2 ±4.6 2.8 ± 1.6 68.5 ± 19.8 0.5 ± 0.5 0.1 ± 0.3 
CON 12.2 ± 4.1 4.2 ± 0.8 63.7 ± 10.0 0.3 ± 0.5 0.2 ± 0.4 
LT DIC 14.2 ± 7.6 3.2 ± 1.2 68.3 ± 16.9 0.5 ± 0.5 0.0 ± 0.0 
HT DIC 11.5 ± 5.1 3.7 ± 1.4 57.2 ± 11.4 1.0 ± 1.7 0.0 ± 0.0 
LT ERY 14.3 ± 9.3 3.2 ± 1.2 72.7 ± 16.4 0.7 ± 0.8 0.0 ± 0.0 
HT ERY 14.0 ± 3.7 3.8 ± 0.4 64.6 ± 17.4 1.2 ± 1.3 0.4 ± 0.5 
LT IBU 13.8 ± 5.3 4.0 ± 0.6 56.7 ± 11.1 1.0 ± 2.4 0.2 ± 0.4 
HT IBU 17.5 ± 4.1 4.0 ± 1.8 58.1 ± 17.4 2.8 ± 3.1 0.3 ± 0.8 
LT MEF 12.3 ± 9.0 4.2 ± 1.6 49.9 ± 13.5 1.5 ± 1.6 0.0 ± 0.0 
HT MEF 13.3 ± 2.3 3.8 ± 1.3 70.7 ± 13.8 0.8 ± 0.8 0.0 ± 0.0 
LT PRO 13.0 ± 6.3 3.7 ± 1.5 67.7 ± 19.6 0.3 ± 0.5 0.0 ± 0.0 
HT PRO 13.7 ± 5.9 3.5 ± 0.5 64.2 ± 13.7 1.2 ± 1.2 0.2 ± 0.4 
LT MIX 13.3 ± 6.3 4.8 ± 1.8 57.6 ± 9.8 1.5 ± 1.0 0.2 ± 0.4 
HT MIX 12.5 ± 7.8 3.0 ± 1.7 79.6 ± 17.2 0.3 ± 0.5 0.3 ± 0.8 
 
One-way ANOSIM showed no significant dissimilarity in macroinvertebrate colonisation 
across all treatments (R=-0.003, p=0.50) but pairwise comparisons between treatments 
did highlight some significant dissimilarities.  In particular, HT-IBU showed significant 
dissimilarity when compared to CON (p=0.02), HT-MIX (p=0.01) and LT-IBU (p=0.04). A 
two-dimensional non-metric multidimensional scaling (NMDS) plot showed no obvious 
clustering of treatments.  The calculated Kruskal’s stress value was 0.156 which is 
indicative of a good, interpretable ordination (Rabinowitz, 1975). 
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Figure 6-3: Two-dimensional NMDS plot of macroinvertebrate communities colonising 
real and artificial leaf packs exposed to (a) diclofenac and erythromycin, (b) ibuprofen 
and mefenamic acid and (c) propranolol and mixtures 
(treatment abbreviations in table 6-2; similarity measure = Bray-Curtis.  Kruskal’s 
stress for whole dataset = 0.156) 
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6.4.2 Erythromycin study 
6.4.2.1 Organic matter change 
There were significant differences in the AFDM change at the end of the pre-conditioning 
and in situ phases (H=53.22, DF=1, p<0.001) with an average reduction of 45 % after in 
situ compared to 14 % for the pre-conditioning phase.  However, there were no 
significant differences between treatments in the pre-conditioning (H=9.80, DF=5, 
p=0.08) or in situ phases (H1.08, DF=5, p=0.96). 
Differences in %OM between the pre-conditioning and in situ phases and between 
treatment levels showed clearly reduced organic matter content within in situ packs 
(88%) when compared to the pre-conditioning phase (90%) and this difference was 
significant (H=28.22, DF=1, p<0.001; Figure 6-4).  There were no significant differences 
in %OM between treatments during pre-conditioning (H=4.89, DF=5, p=0.43) but there 
were significant differences after the in situ phase (H=12.24, DF=5, p=0.03).  High 
treatment displayed significantly lower %OM than both the very low (W=34.0, p=0.04) 
and very high treatments (W=33.0, p=0.03).  Low treatment exposed leaves also showed 
significantly lower %OM than both the very low (W=24.0, p=0.02) and very high 
treatments (W=21.0, p<0.01).  There were no differences between control leaf packs and 
any of the treatments and pairwise comparison between control and the methanol 
solvent control indicated no difference (W=43.0, DF=1, p=0.58). 
 
Figure 6-4: % organic matter in F. sylvatica leaf packs after 8 week laboratory tank and 
8 week in situ stream exposure to four concentrations of erythromycin 
[line represents initial %OM of untreated leaf packs at 94.1%. Bars represent mean 
values from n=6 replicates, error bars are ±1 SD; CON: control, MeOH: methanol 
solvent control, VLT: very low treatment, LT: low treatment, HT: high treatment, VHT: 
very high treatment] 
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6.4.2.2 Macroinvertebrate colonisation 
Colonised leaf packs were dominated mostly by A. aquaticus followed by G. pulex and 
Chironomidae.  A. aquaticus was the dominant taxon in all but three of the leaf packs 
(Table 6-6).  HT showed significantly elevated species richness when compared to CON 
(H=19.14, DF=5, p<0.01).  Comparisons of individual taxa, Berger-Parker D and % EPT 
showed no significant differences between the treatments.  Across all treatments there 
was a marginal significant difference in the abundance of A. aquaticus (H=10.99, DF=5, 
p=0.05) but not G. pulex (H=5.89, DF=5, p=0.32).   
 
Table 6-6: Mean (±1 SD) macroinvertebrate community metrics for litter packs from the 
detailed erythromycin study 
Treatment 
Total 
abundance 
Species 
richness 
Berger-Parker D 
(%) 
Abundance 
A. aquaticus 
Abundance 
G. pulex 
CON 82.5 ± 22.9 4.3 ± 0.5 69.9 ± 10.1 58.3 ± 20.9 4.2 ± 1.3 
MeOH 64.7 ± 15.6 6.0 ± 0.9 48.4 ± 16.6 29.0 ± 22.8 11.7 ± 8.9 
VLT 93.8 ± 34.4 5.0 ± 0.0 64.6 ± 20.8 64.7 ± 38.4 7.8 ± 6.1 
LT 67.2 ± 18.1 6.0 ± 0.9 53.3   ± 6.5 31.8 ± 10.9 7.3 ± 5.9 
HT  79.2 ± 56.3 6.8 ± 0.4 ** 51.4 ± 15.5 47.7 ± 53.9 10.7 ± 4.8 
VHT 88.7 ± 27.3 5.8 ± 1.7 67.4 ± 13.4 62.2 ± 29.9 6.5 ± 2.2 
** indicates significant difference from control (p<0.01) 
 
One-way ANOSIM (using Bray-Curtis distance) of the whole macroinvertebrate 
colonisation dataset confirmed statistically significant dissimilarity between treatments 
(R=0.10, p=0.04).  Pairwise comparisons highlighted significant dissimilarity between 
controls and HT (R=0.49, p<0.01), LT (R= 0.19, p=0.02) and the methanol solvent control 
(R= 0.21, p=0.05). The difference between the control and solvent control packs was 
driven by G. pulex (control mean abundance: 4.2. vs. methanol abundance 11.2) and A. 
aquaticus (58.3 vs. 29.0).  The solvent control was not significantly different to any other 
treatment.  HT was also significantly different to VHT (R= 0.29, p=0.04).  Two-
dimensional NMDS showed some clustering of control packs around the origin with the 
majority of low and high treatment packs different to these (Figure 6-5) confirming the 
dissimilarities found by ANOSIM.  The calculated Kruskal’s stress value was 0.11 
indicating a useful ordination.   
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 Figure 6-5: Two-dimensional NMDS plot of macroinvertebrate communities 
colonising leaf packs exposed to four treatment levels of erythromycin 
(for treatment abbreviations see Table 6-3; similarity measure = Bray-Curtis; Kruskal’s 
stress for whole dataset = 0.1142) 
6.5 Discussion 
Pharmaceuticals are a widespread pollutant found in soils, groundwater and surface 
waters across the globe (Daughton & Ruhoy, 2009b; Hughes et al., 2013).  Existing 
research on their effects in freshwater ecosystems indicates a low risk of toxicity but the 
full implications of long-term, low-level exposure are poorly understood (Fent et al., 2006; 
Kümmerer, 2008a; Kümmerer, 2009a; Santos et al., 2010).  The margin of safety for 
long-term or chronic effects is much smaller than that for short-term effects and in some 
cases environmental concentrations are known to exceed those necessary to cause 
negative effects (Hughes et al., 2013).  However, the use of structural and functional 
indicators to quantify the effects of pharmaceutical exposure is extremely limited 
although the small amount of research already conducted has highlighted their 
usefulness and sensitivity in detecting such effects. 
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6.5.1 Leaf litter decomposition 
The loss of organic matter was generally low in both the laboratory phase (< 5 % 
decrease) and the in situ phase (< 10 % decrease).  The similarity in mass loss between 
the two phases confirms the large contribution that microbial communities make to total 
decomposition rates (Irons et al., 1994).  Decomposer microbial communities have been 
shown to grow actively on leaf litter even at temperatures close to freezing and so they 
are likely to have played a major role during in situ decomposition in both the individual 
compound and detailed erythromycin studies (Barlocher & Kendrick, 1974).  Therefore, 
the differences in decomposition rates between the two experiments in this study is 
probably due to the much lower abundance of colonising macroinvertebrates (particularly 
A. aquaticus and G. pulex) during the autumn-winter exposure of individual compound 
study packs. The results also indicate consistently higher abundances in leaf packs when 
compared to artificial packs; this suggests that macroinvertebrates (particularly 
shredders) are preferentially colonising the F. sylvatica packs for their food value above 
and beyond any value as merely a microhabitat (Richardson, 1992). 
6.5.2 Impact of individual compounds on leaf litter decomposition 
When the five compounds were tested in isolation at environmentally relevant 
concentrations no significant differences in leaf litter decomposition (whether mediated 
by microbes or macroinvertebrates) or macroinvertebrate colonisation were found.  
Therefore hypotheses H1 and H2 were rejected. This was the first study to examine such 
effects of pharmaceuticals other than antibiotics on this important ecosystem process 
and these results suggest that low levels of the study compounds do not pose a risk to 
leaf litter decomposition in freshwater ecosystems.  However, decomposition rates in this 
study were generally low both in the pre-conditioning and in situ phases. The results 
further confirm the contribution that microbial communities make to total decomposition 
(14 % mass change in 4 weeks microbial cf. 20 % changes in 8 weeks microbial and 
macroinvertebrate; (Irons et al., 1994)).  The low breakdown rates may be partly 
explained by the use of F. sylvatica leaves which are known to be one of the slowest 
degrading leaf species in temperate streams (Cummins et al., 1973; Petersen & 
Cummins, 1974).  Furthermore, the timing of in situ exposure (October to December) will 
contribute to slower decomposition rates as water temperature is known to be a major 
controlling factor on this process (Petersen & Cummins, 1974).  Seasonal cycles in 
macroinvertebrate density are well established in temperate streams not prone to 
disturbance, with peaks often present in summer and autumn due to the domination of 
particular taxa (Hynes, 1970).  Associated cycles in ecosystem functioning have also 
been observed (Stoneburner & Smock, 1979; Mulholland & Lenat, 1992) which may 
mean that leaf litter decomposition (alongside other ecosystem functions) may be more 
205 
 
 
 
or less sensitive to pharmaceutical exposure at different times of the year.  Repeated 
studies using a variety of different leaf species and at varying times throughout the year 
are needed to determine whether there are impacts in the sensitivity of 
macroinvertebrate and microbial communities across the seasons.   
Colonisation of leaf packs in this study highlighted some differences between 
pharmaceutical exposed packs and controls, particularly those exposed to higher 
treatments of erythromycin and ibuprofen.  Therefore hypothesis H3 was partially 
accepted.  The differences appear to have been driven by elevated levels of the shredder 
A. aquaticus as well as Oligochaeta sp. in ibuprofen treated leaf packs.  This broadly 
agrees with the preferential selection by shredders of antibiotic exposed leaf discs 
demonstrated previously in laboratory studies (Bundschuh et al., 2009).  G. pulex in this 
study showed a tendency to select leaf packs exposed to higher levels of erythromycin 
and ibuprofen but the tendency was not as strong as for A. aquaticus.  Gammarus 
species are selective consumers capable of differentiating between conditioned and 
unconditioned leaves of various sources (Barlocher & Kendrick, 1975; Arsuffi & 
Suberkropp, 1989; Graça et al., 2001).  This muted response by G. pulex could perhaps 
be explained by their demonstrated preference of other leaf species over beech (F. 
sylvatica); Friberg & Jacobsen (1994) showed that Fagus leaves were the least preferred 
by Gammarus in a laboratory study.  However, in this study the choice of F. sylvatica leaf 
material was justified given this species dominance in the riparian vegetation community 
at Silsden Beck.  Furthermore, there were some differences in macroinvertebrate 
communities between the controls and solvent controls which may have masked any 
response in the pharmaceutical treatments.  Further experiments may be necessary 
utilising exposure techniques which do not require carrier solvents such as methanol 
(see Dietrich et al., 2010 and Chapter 7). 
Studies examining the effects of the non-antibiotic compounds (diclofenac, 
ibuprofen, mefenamic acid and propranolol) on food selection by macroinvertebrates and 
leaf litter decomposition are not available but some work has been carried out on other 
aspects of ecosystem structure and functioning.  Brain et al. (2004a) demonstrated small 
impacts on the growth and pigmentation of two aquatic plant species caused by a mixture 
of eight pharmaceuticals over 7 and 35 days exposures.  However, lowest observable 
effects concentrations were relatively high (>30 µg L-1) compared with the concentrations 
tested during this study and the changes in growth were unlikely to be ecologically 
significant.  An examination of 25 different pharmaceuticals (including ibuprofen) was 
performed using still water mesocosms (Brain et al., 2004b) which found that a 
concentration greater than 1 mg L-1 of ibuprofen was necessary to affect the growth and 
pigmentation of Lemna gibba.  This agrees with the finding here which indicated a 
concentration greater than 5 mg L-1 was necessary to affect leaf litter decomposition.  
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However, the margin of safety is low when compared to the maximum concentration of 
0.31 mg L-1 detected in a Turkish river (Loos et al., 2009; Hughes et al., 2013). The 
results presented here and elsewhere indicate that environmentally realistic 
concentrations of diclofenac, ibuprofen, mefenamic acid and propranolol are unlikely to 
pose a risk to leaf litter decomposition in freshwater ecosystems.  However, much more 
research is necessary which examines pharmaceutical effects on ecosystem functioning 
using relevant exposure conditions.  Furthermore, margins of safety may be significantly 
reduced for the more widely used painkillers (namely diclofenac and ibuprofen) which 
have been identified in freshwaters at very high concentrations (up to 18 740 and 31 323 
ng L-1 respectively; (Hughes et al., 2013)). 
6.5.3 Impact of erythromycin on leaf litter decomposition 
The results presented here indicate that long-term exposure to environmentally realistic 
concentrations of erythromycin acting in isolation is unlikely to affect the decomposition 
of beech leaf litter in freshwater ecosystems.  However, erythromycin is most likely to be 
present in the environment as part of a complex, dynamic mixture of pharmaceuticals 
and other contaminants (Fent, 2008) and as such may still pose a risk to leaf litter 
decomposition.   
This was the first study to examine the effects of erythromycin on leaf 
decomposition in isolated detail using in situ techniques.  Two other studies are available 
which examine the effects of antibiotic mixtures on food selection and decomposition 
rates of macroinvertebrates and microbial communities although both were conducted 
solely in the laboratory (Hahn & Schulz, 2007; Bundschuh et al., 2009).  A mixture of five 
antibiotics (erythromycin, clarithromycin, roxithromycin, sulfamethoxazole and 
trimethoprim; ≥2000 ng L-1) promoted colonisation by macroinvertebrates and microbial 
communities and increased decomposition rates (Bundschuh et al., 2009).  This agrees 
with the results presented here which show that the shredder A. aquaticus actively 
preferred leaves pre-conditioned in the presence of erythromycin (100 000 ng L-1).  
However, the magnitude of these differences was low and did not manifest in changes 
at the functional level.  Direct comparisons between experiments must be performed with 
caution as differences in exposure conditions and leaf or macroinvertebrate species used 
may have a significant impact on end results.  For example, exposure of a different 
gammarid species (Gammarus fossarum) to an alternative antibiotic mixture 
(oxytetracycline and sulfadiazine) showed opposite effects on food selection and no 
overall effect on decomposition rates (Hahn & Schulz, 2007).  More work is necessary 
which combines parallel exposures of different leaf and macroinvertebrate species to a 
range of antibiotic compounds and mixtures if reliable comparisons of specific compound 
toxicity are to be made. 
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Brain et al. (2005) examined the effects of a mixture of antibiotics at similar 
concentrations to those tested here (oxytetracycline, chlortetracycline, tetracycline and 
doxycycline; ≥9000 ng L-1 for 35 days).  Significant reductions in somatic endpoints were 
found at concentrations less than 9000 ng L-1 although one species (Myriophyllum 
sibiricum) was up to 57 times more sensitive than L. gibba.  Long-term exposure (30 
days) to erythromycin in mixture with other antibiotics caused some alterations to the sex 
ratio of D. magna at concentrations ≥10 000 ng L-1.  Notably, these previous studies did 
not conduct parallel exposures to individual compounds so it is not yet impossible to say 
what contribution erythromycin had on the overall effects seen.  Furthermore the 
differences in sensitivity highlight the importance of using appropriately sensitive species 
and indices during ecotoxicological testing. 
6.5.4 Impact of mixtures on leaf litter decomposition 
Pharmaceuticals are not present in rivers in isolation but rather alongside myriad other 
chemicals and pollutants that form complex and dynamic mixtures (Fent, 2008).  Most 
studies have examined the effects of mixtures on individual organisms 
(macroinvertebrates and aquatic plants) with compounds generally demonstrating 
concentration addition (CA).  This is crucial as it allows a mixture to exert toxic effects 
below the threshold required from individual compounds (Cleuvers, 2003; Cleuvers, 
2004; Escher et al., 2005).  Despite this, only a limited number of studies have addressed 
the issue of pharmaceutical mixtures and to the best of the author's knowledge none 
have examined the effects of non-antibiotic pharmaceutical mixtures on leaf litter 
decomposition.   
Antibiotic mixtures have been shown to decrease leaf litter decomposition and 
alter food selection by invertebrates (Hahn & Schulz, 2007; Bundschuh et al., 2009) at 
concentrations similar to those tested here.  Cleuvers (2003) showed that diclofenac and 
ibuprofen acting in combination elicited much stronger effects on the immobilisation of 
D. magna and growth of the chlorophyte Desmodesmus subspicatus than when these 
compounds were tested in isolation.  A further analysis of a mixture of four non-steroidal 
anti-inflammatory drugs (including diclofenac and ibuprofen) confirmed concentration 
addition (Cleuvers, 2004). However, these studies were conducted at much higher 
concentrations (≥10 mg L-1) than those tested here and so their environmental relevance 
is limited.  Dietrich et al. (2010) found that a mixture of four pharmaceuticals 
(carbamazepine, diclofenac, metoprolol and 17α-ethinylestradiol (EE2)) at 
environmentally relevant concentrations (up to 1200 ng L-1 for pharmaceuticals and 0.1 
ng L-1 for EE2) disrupted the moulting behaviour of G. fossarum.  A similar study exposed 
freshwater snails (Lymnaea stagnalis) to a total mixture of 16 compounds of varying 
classes (antibiotics, cardiovascular, antihypertensive and psychiatric) for three days at 
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relevant concentrations (10 to 500 ng L-1) showed the potential for complex mixtures to 
disrupt their immunocompetence to a similar extent to that caused by exposure to treated 
sewage effluent (Gust et al., 2013).  Other studies have demonstrated lethal and 
sublethal effects of simple and complex pharmaceutical mixtures on aquatic mesocosms 
although generally at very high concentrations (Brain et al., 2004a; Brain et al., 2004b; 
Brain et al., 2005; Flaherty & Dodson, 2005; Laird et al., 2007).   
This and other studies represent the first vital steps in improving our 
understanding of the complex effects of pharmaceutical mixtures on aquatic organisms.  
However, further work needs to be carried out which combines the use of functionally 
important organisms (e.g. Gammarus spp.) with environmentally relevant concentrations 
and sufficiently long exposure periods to maximise the environmental realism of such 
studies.  Furthermore, many of the above studies did not conduct parallel exposures of 
mixtures and individual compounds which limited their ability to quantify the contribution 
each pharmaceutical to overall mixture toxicity.  The simple mixture tested in this study 
represents an important early step in such research although actual environmental 
mixtures are much more complex perhaps containing thousands of contaminants from a 
range of sources (Fent, 2008). 
Although the data presented here did not indicate significant effects of the tested 
mixture on leaf litter decomposition or microbial and macroinvertebrate colonisation other 
studies have demonstrated lethal and sublethal effects of pharmaceutical mixtures at 
concentrations below those caused by individual compounds.  The probable reason for 
other researchers identifying significant effects was their use of relatively simple 
organismal and sub-organismal endpoints (e.g. growth, mortality, motility etc.) compared 
to the inherently complex structural and functional endpoints employed in this study 
which can display higher degrees of variability (Hill et al., 2000).  However, structural and 
functional endpoints have distinct advantages both in terms of their ecological relevance 
and their integration an ecosystems response over time and space (Gessner & Chauvet, 
2002).  Despite the lack of effects demonstrated in this study, research elsewhere 
indicates that further studies into the effects of pharmaceuticals on leaf litter 
decomposition are necessary.   
6.5.5 Future research 
Due to analytical and cost constraints this study was unable to quantify the composition 
or change in the microbial and fungal communities colonising the leaf packs which is of 
particular importance in the degradation of leaf material in streams (Webster and 
Benfield 1986). As such, any further studies should attempt to estimate bacterial 
abundance using epifluorescence microscopy (Buesing, 2005) and fungal biomass using 
the indicator ergosterol (Mille-Lindblom et al., 2004).  This is particularly important as 
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bacterial communities have been shown to develop tolerance against certain antibiotics 
over relatively short exposure periods (Schmitt et al., 2005).  Furthermore, competitive 
release of fungal communities due to inhibition of bacteria by antibiotic compounds can 
have implications for food selection and decomposition by macroinvertebrates (Gulis & 
Suberkropp, 2003b).  Quantification of fungal and microbial communities will help in 
understanding the importance of these interactions on overall decomposition rates.  One 
promising area of research is metagenomics which allows the rapid characterisation of 
microbial diversity in environmental samples.  This work has already been applied to 
characterise the diversity and functional roles of microbial communities in large rivers 
(Ghai et al., 2011) and in understanding the effects of pollutants of microbial communities 
(George et al., 2010). 
6.6 Conclusions 
The results presented here indicate the potential for environmentally realistic 
concentrations of pharmaceuticals to alter the colonisation of leaf litter by 
macroinvertebrates in temperate, low-order streams.  However, no effects were 
observed due to exposure of the other study compounds nor were any significant or 
ecologically relevant effects seen on leaf litter decomposition rates.  This suggests that 
low levels of these five pharmaceuticals do not pose a risk to leaf litter decomposition.  
However, there remain significant knowledge gaps in understanding the effects of 
pharmaceuticals at low-levels over extended periods and as part of complex mixtures on 
this and other important aspects of freshwater ecosystem functioning. Future 
assessments of ecosystem health and their response to stressors such as 
pharmaceuticals should utilise both established structural indices as well as functional 
measures if a full understanding of the risk pharmaceuticals pose in freshwaters is to be 
obtained.  This is of particular importance as any disruptions to leaf litter degradation, 
sediment metabolism and nutrient cycling have the potential to cascade throughout the 
ecosystem causing additional indirect effects at higher trophic levels and downstream 
(Wallace et al., 1997). 
The slowing in improvement of biological water quality indices in UK rivers (EA, 
2012) may in part be due to the structural and functional disruption caused by 
pharmaceuticals (alongside the myriad other emerging contaminants and aquatic 
pollutants).  This is of concern to policy makers, catchment managers and the water 
industry across the UK and Europe if rivers are to meet the requirements of 'good 
ecological status' mandated by the European Water Framework Directive (EC, 2000).  
The focus of water quality interventions may be changing in the future with the proposed 
inclusion of diclofenac (alongside 47 other chemicals) on the list of Hazardous 
Substances (EC, 2012).  This could mean that increased attention is paid to these 
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compounds by regulators and water managers in the coming years but should be seen 
as an opportunity to broaden the research and policy focus to the thousands of other 
emerging contaminants that are present within rivers. 
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7 THE IMPACT OF PHARMACEUTICALS ON RESPIRATION AND 
NUTRIENT DYNAMICS IN RIVER SEDIMENTS 
7.1 Introduction 
The integrity of any ecosystem is measured by assessing both structural and functional 
components which are intimately linked.  Any assessment of ecosystem integrity or 
attempt to understand the impact of anthropogenic stressors must consider both of these 
aspects (Matthews et al., 1982; Bunn et al., 1999; Gessner & Chauvet, 2002).  Functional 
indices have numerous advantages over their structural counterparts such as being 
integrative over space and time and not being reliant on the presence of specific species 
sets yet despite these advantages, bioassessment is overwhelmingly based on structural 
measures alone (Matthews et al., 1982; Gessner & Chauvet, 2002).  In particular, the 
application of functional endpoints in studying the effects of emerging contaminants 
(including pharmaceuticals) is not widespread and most studies focus on single-species 
examinations of toxicity which fail to draw upon the well-developed tool kit of methods 
available in aquatic ecology (Rosi-Marshall & Royer, 2012).  Community respiration (CR) 
and sediment respiration (SR) in particular have been shown to be highly sensitive to a 
range of environmental stressors (Hill et al., 1998; Hill et al., 2000).  These functional 
endpoints, along with nutrient cycling in freshwater sediment systems show promise as 
indicators of ecosystem stress caused by emerging contaminants.  Despite this, the 
application of these indicators to pharmaceutical pollution in rivers is sparse and the 
potential effects for freshwater ecosystem functioning are poorly understood. 
Stream sediments are biologically active zones which modify the chemistry of 
water passing through them, acting as both sinks and sources of nutrients from both 
upwelling groundwater and infiltrating stream water (Rutherford & Hynes, 1987).  
Processes within stream sediments can increase overall ecosystem efficiency by 
allowing more rapid recycling of nutrients that would otherwise be lost to downstream 
transport (Battin, 1999; Battin et al., 2003).  The majority of metabolic activity in small 
streams occurs within bed sediments, either at the sediment-water interface or in the 
deeper pore waters where there is a hyporheic zone (Sobczak & Findlay, 2002).  
Therefore, the microbial processes within sediments play a major role in the cycling of 
both carbon and other nutrients in rivers with potential wider catchment impacts 
manifested through changes in the downstream fluxes of dissolved organic carbon 
(DOC) (Rutherford & Hynes, 1987).  Carbon supplied to stream sediments may come in 
the form of coarse or fine particulate organic carbon (POC) and the direct transport of 
DOC from stream or groundwater (Findlay, 1995).  POC can be directly utilised by 
invertebrates as a food source but this is not often the case for DOC where some form 
of microbial transformation into a particulate form is necessary.    This DOC represents 
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a major energy source for bacterial communities in freshwater sediments (Miller, 1987).  
These communities are responsible for significant energy fluxes and nutrient cycling both 
within the hyporheic zone and at the sediment/water interface (Giller & Malmqvist, 1998) 
and any disruptions to these communities by emerging contaminants may have 
significant impacts on ecosystem-level processes. 
The relatively slow velocity of pore waters can allow ample time for the microbial 
metabolism of bioavailable solutes.  Indeed, Sobczak & Findlay (2002) have shown that 
DOC losses along hyporheic flow paths can be as high as 50 %.  This depends 
predominantly on microbial metabolism and less so on other parameters such as dilution, 
residence time and initial DOC concentrations.  Biotic uptake, predominantly at the 
sediment-water interface, is considered to be the dominant removal mechanism for DOC 
in streams (Dahm, 1981; Findlay & Sobczak, 1996; Tank et al., 2010).  The fundamental 
importance of sediment microbial communities in retaining DOC and rendering otherwise 
refractory carbon available to higher trophic levels (via its incorporation in bacterial 
biomass) is known as the ‘microbial loop’ and is well recognised both in marine (Fenchel, 
2008) and freshwater systems (Meyer, 1994). Rosenfeld & Roff (1991) have shown that, 
alongside their role in the microbial loop, respiration by benthic microbial communities 
(particularly bacteria) can exceed whole stream primary production in forested streams.  
This is a relatively common phenomenon, where ER exceeds gross primary production 
(GPP) resulting in a net heterotrophic stream which consumes more organic carbon than 
it produces (Mulholland et al., 2001).  Smith (1973) estimated that bacteria were 
responsible for the majority of sediment respiration (accounting for 30 to 60 %) whereas 
macrofaunal respiration accounted for just 5 to 26 %.  Therefore any change in benthic 
respiration caused by disruption or inhibition of sediment microbial communities has the 
potential to significantly alter the stream production: respiration (P/R) ratio (Wilson et al., 
2004).   
The disruption of microbial cycling in sediments can cause the sediment to 
become a carbon sink rendering nutrients unavailable for secondary productivity which 
will have knock-on effects via food web interactions (Burton, 1991).  The communities 
present within sediment pore waters (particularly microorganisms) therefore play a major 
role in both the respiration of organic matter in sediments and nutrient cycling.  Therefore, 
pharmaceuticals (particularly those designed to target microorganisms such as 
antibiotics and antifungals) have the potential to alter or disrupt these sediment dwelling 
organisms which in turn may impact on the important ecosystem functions they perform 
(Likens, 2004).  However, studies examining the effects of pharmaceuticals on the 
respiration and nutrient cycling of freshwater sediments are sparse and there is a 
pressing need for further research in this area if potential disruption to the functioning of 
freshwater ecosystems is to be understood. 
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Studies comparing CR to other functional attributes in stream ecosystems have 
shown it is the most sensitive to a range of environmental stressors such as pH, heavy 
metals and organic chemicals (Matthews et al., 1982).  For example, Crossey et al. 
(1988) showed that CR was significantly increased (by a factor of 2-3) in a Montana 
stream experiencing chronic heavy metal pollution but structural indices did not show 
any difference between control and impact sites.  Bunn et al. (1999) found that both GPP 
and CR were sensitive to changes in catchment land use.  As the above studies indicate, 
the use of CR or similar endpoints as indicators of stress caused by ‘traditional’ stressors 
is relatively widespread but their use in examining the effects of pharmaceutical pollution 
is much more limited. 
Bunch & Burnot (2011) examined the effects of ibuprofen and paracetamol at 
environmentally realistic concentrations (100 to 10 000 ng L-1) on sediment respiration 
and nitrate uptake using both in vitro and in situ techniques.  The in vitro exposures 
demonstrated increased respiration rates at low levels of both pharmaceuticals and a 
slight inhibition at the highest exposure to paracetamol.  Furthermore, lower levels of 
paracetamol appeared to enhance nitrate uptake.  None of the above differences were 
evident in the more variable in situ experiments although this may be due to the long 
exposure history to pharmaceuticals at the site yielding greater adaptation and tolerance 
in the microbial community (Bunch & Burnot, 2011).   The picture is further complicated 
as different pharmaceutical compounds may be stimulatory (due to the uptake of 
pharmaceuticals as a nutritive source) or inhibitory (due to direct toxic effects), although 
this is dependent on compound-specific properties and can change depending on 
exposure concentrations (Lawrence et al., 2005).  These few studies indicate the 
potential for low levels of pharmaceutical compounds to have a significant impact on 
stream microbial activity and the cycling of nutrients which may have further implications 
for autotrophic production and algal blooms (Dodds & Welch, 2000).  Therefore, further 
research is required to fully understand the effects of environmentally relevant 
concentrations of a broader range of pharmaceutical compounds on processes within 
freshwater sediments.  Significant knowledge gaps remain, particularly in testing the 
effects of pharmaceutical classes other than antibiotics (e.g. painkillers, antidepressants, 
cardiovascular drugs and cancer treatments).  Furthermore, the majority of existing 
studies have examined pharmaceutical compounds in isolation and have not addressed 
the issue of complex, dynamic mixtures of such substances (Backhaus, 2008).  Mixture 
toxicity is a key concern in pharmaceutical pollution research as many compounds act 
additively in combination allowing them to demonstrate toxic effects at levels well below 
those shown for individual compounds (e.g. Cleuvers, 2003). 
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7.2 Aims and hypotheses 
The aim of this study was to quantify the effects of low-level extended exposure to two 
pharmaceutical compounds (erythromycin and propranolol; both in isolation and as part 
of a mixture) on respiration and nutrient cycling in freshwater sediments.  Specific 
objectives were: 
 Measure the effects of erythromycin and propranolol on the degradation of 
organic matter in artificial freshwater sediments over a 7 day period; 
 Evaluate the effects of the same pharmaceuticals on the respiration rates of 
freshwater sediments; 
 Quantify the effects of pharmaceuticals on the exchange of dissolved carbon, 
nitrogen and phosphorous between surface sediments and overlying waters; 
 Quantify the effects of the binary mixture of erythromycin and propranolol on the 
above processes. 
The following hypotheses were tested: (H1) pharmaceuticals (particularly antibiotics) 
disrupt the functioning of bacterial communities living in sediments, resulting in a 
reduction of the processing of organic matter (H2).  This disruption will also induce a 
reduction of microbial community respiration rates (H3). Changes to microbial respiration 
in sediments will in turn reduce the microbial cycling of dissolved carbon, nitrogen and 
phosphorous and subsequently their exchange with the overlying water column (H4).  
The effects will be more pronounced when sediments are exposed to a mixture as 
opposed to pharmaceutical compounds in isolation due to additive effects. 
7.3 Methodology 
7.3.1 Chemicals and materials 
All glassware and vessels were thoroughly disinfected and pre-rinsed with 100 % 
methanol and deionised water prior to each use.  HPLC-grade methanol was supplied 
by Fisher Scientific UK Limited (Loughborough, UK).   Deionised water was supplied by 
a Purite Select HP160/BP/IT deioniser. All pharmaceuticals were of the highest purity 
available (>99%) and supplied by Sigma-Aldrich Company Ltd (Dorset, UK).  Individual 
stock standard solutions were prepared on a weight basis in 100 mL of 100 % methanol 
and stored in the dark at -20 °C until used.  A fresh working mixture solution of all 
pharmaceuticals was prepared by appropriate dilution of the individual stocks in 100 % 
methanol immediately before each experimental run and used as working standard 
solutions.  Working standards were also stored in the dark at -20 °C between uses.   
215 
 
 
 
7.3.2 Preparation of sediment 
The site chosen for the collection of natural sediment and pre-conditioning of artificial 
sediment was Silsden Beck, immediately downstream of Silsden Reservoir, Silsden, 
West Yorkshire (OSNGR SE 0446147504).  An initial survey of Silsden Beck showed 
that the depth and quantity of sediment in this stretch was insufficient for experimental 
use.  However, this site was retained due to its situation upstream of any STP effluent 
inputs, thereby reducing the potential for contamination by the human pharmaceutical 
study compounds.  Furthermore, the regulated nature of the stream (i.e. directly below 
Silsden Reservoir) made it ideal for in situ studies.  A preliminary analysis of a 1 L water 
grab sample from Silsden Beck by HPLC-MS/MS indicated that all five of the preliminary 
study compounds were below detection limits (<5 ng L-1).    
25 kg sacks of gravel (<10 mm grain size) and sand (average grain size 0.2 mm) 
were purchased and leached thoroughly in deionised water for seven days (water was 
replaced daily), to minimise any potential contaminants.  After leaching, the sand and 
gravel were placed in hessian bags and anchored on the Silsden Beck stream bed for a 
period of 21 days to allow microbial communities to develop similar to previous studies 
(Hill & Perrotte, 1995).  Slower flowing areas were chosen for placement of the sediments 
(for example in deeper pools, inside edges of meanders and downstream of large 
boulders) where most deposition was likely to occur and hydraulic forces were less likely 
to dislodge the sacks.  A Tinytag temperature logger was secured alongside the hessian 
sacks which recorded temperature at 15-minute intervals.  After retrieval, the sediment 
was transported immediately to the laboratory in stream water to be used in the 
experiments.   
Six samples of streambed sediment were collected from random locations within 
the stream for quantification of organic matter content. The top 2-3 cm of natural 
sediment were sampled as this represents the biologically and hydrodynamically active 
portion (Burton, 1991).  These samples were then composited to homogenise the spatial 
variability of sediment composition across the site and obtain a more representative 
sample of mean conditions. The composite sample was sieved (Shelton & Capel, 1994) 
and washed into clean plastic bottles using stream water.  Any coarse particulate organic 
matter (CPOM) or macroinvertebrates were removed.  Natural and artificial sediment 
samples were transported back to the laboratory and stored in the dark at 4°C.  Each 
time artificial and natural sediment were collected, subsamples (n=3) of each size 
fraction were taken, dried and ashed to calculate % organic matter (%OM) and ash free 
dry mass (AFDM) following the method outlined in Hill et al. (1998).  This was done in 
order to compare %OM between the natural and artificial sediments. 
Artificial sediments were homogenised to reduce any variations in colonisation 
by microbial communities between the outer and inner areas of the sacks.  350 g (± 1.24 
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g) each of sand and gravel was then added to a 0.97 L clear glass flask and filled with 
stream water.  Flasks were aerated using air pumps (Hailea ACO-9602 air pumps, 
Guangdong Hailea Group Co. Ltd., Guangdong, China) and kept at 7.0 °C for seven 
days with a light: dark photoperiod of 12:12hrs to equilibrate the sediment samples and 
maintain dissolved oxygen concentrations at saturation. 
7.3.3 Experimental design 
Each experiment used pre-conditioned sand and gravel to simulate natural river 
sediment.  Artificial sediment was used in order to minimise inter-experimental 
differences in sediment composition and organic matter content; the preparation of this 
material is detailed in Section 7.3.2.  Four concentrations each of erythromycin, 
propranolol and their equivalent binary mixture were employed during a seven day static 
non-renewal test in order to measure changes in respiration rate, sediment organic 
matter content and dissolved nutrient concentrations (Table 7-1).  The exposure 
concentrations ranged from environmentally realistic concentrations (based on published 
UK maximum river concentrations) to much higher concentrations (2 orders of magnitude 
greater than the UK maxima) intended to simulate a worst-case exposure.  The 
experimental apparatus consisted of 0.97 L clear glass flasks containing 700 g (±5.9 g) 
of artificial sediment overlain by river water obtained from Silsden Beck (see Chapter 6 
for site details).   Each compound was tested in turn in a self-contained experimental run 
which consisted of four pharmaceutical treatments plus one sediment control and one 
water-only control, each with six replicates (n=36).  The experiment was conducted three 
times in succession, once each for erythromycin, propranolol and the mixture because 
space and equipment restraints meant it was not possible to conduct experimental runs 
simultaneously.  Due to the sequential experimental runs it was necessary to standardise 
against control values in order to make comparisons between runs.  Total exposure 
period for all runs was seven days and was conducted in the dark at a mean temperature 
of 7.0 °C (±0.6 °C).   
These study compounds and exposure levels were chosen based on previously 
published environmental monitoring and risk assessment studies which highlighted their 
potential to cause negative effects in freshwater systems (Jacobsen & Berglind, 1988; 
Jones et al., 2002; Ashton et al., 2004; Thompson RPM, 2006; Yamamoto et al., 2009).  
Furthermore, experiments have indicated their potential to readily sorb and persist in 
sediment systems and alter the structure of associated bacterial communities (Kim & 
Cerniglia, 2005; Jones et al., 2006; Ramil et al., 2009). 
Table 7-1: Exposure concentrations for sediment metabolism experiment 
Compound Concentration (ng L-1) 
VLT LT1 HT VHT 
Control (CON) n/a n/a n/a n/a 
Native-water only control (H2O) n/a n/a n/a n/a 
217 
 
 
 
Erythromycin 
(ERY) 
100 1000 100000 1000000 
Propranolol 
(PRO) 
20 200 20000 200000 
Mixture 
(MIX) 
100 + 20 1000 + 200 100000 + 20000 1000000 + 200000 
Notes:  
VLT = very low treatment (LT / 10) 
LT = low treatment (UK river max) 
HT = high treatment (LT * 100) 
VHT = very high treatment (LT * 1000) 
7.3.4 Treatment with pharmaceuticals 
After the period of equilibration a static non-renewal exposure of the overlying water to 
the target pharmaceutical compounds was conducted over a period of seven days across 
a range of four environmentally realistic and higher concentrations (Table 7-1).  Exposure 
was achieved by pipetting the appropriate amount of the relevant pharmaceutical 
working standard solution into 5 mL glass beaker and allowing the methanol to 
evaporate.  Given the very low vapour pressures of the crystalline form of both 
pharmaceutical compounds, the loss of the compounds to evaporation was deemed to 
be negligible.  This glass beaker was placed into the sediment flask and the overlying 
water thoroughly mixed.  The advantage of this exposure technique is it removes the 
need for a carrier solvent such as methanol which could be a confounding effect and 
would otherwise require a solvent control (Dietrich et al., 2010).  Empty glass beakers 
were placed into control flasks.     
After treatment with pharmaceuticals, the flasks were filled completely and PTFE 
lids fitted leaving no air-filled headspace in order to minimise the effect of oxygen 
diffusion through the free water surface.  Flasks were placed in the dark and incubated 
at a temperature of 7.1 °C (±0.3).  Measurements of dissolved oxygen (DO), water 
temperature, pH and electrical conductivity (EC) were taken twice daily for seven days 
using an Intellical LDO probe and HACH HQ30d multi-meter (HACH Company, CO, 
USA).  The LDO probe calibration was checked with a 0 % DO solution (1 % sodium 
sulphite in de-ionised water, m/v) and any minor corrections required (max. ±0.03 mg L-
1) were performed manually.  50 mL water column samples were taken immediately 
following treatment and at exposure termination for analysis of DOC and nutrients.  
Subsamples of the surface layer (top 2-3 cm) of artificial sediment were taken 
immediately prior to and after 7 days for calculation of %OM and AFDM. 
7.3.5 Analysis of dissolved organic carbon, nitrogen and phosphorous 
All water samples were filtered through a 0.45 µm membrane and analysed within 12 
hours; filtration was performed to ensure that results represent the dissolved phase only. 
Subsamples for carbon analysis were placed into 1.5 mL capped glass vials and 
analysed on an Analytik Jena Multi N/C 2100 measuring carbon by the differential 
method (Fukushima et al., 1996) with a detection limit of 5.95 mg L-1.  12 mL subsamples 
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for ammonium (NH4-N), nitrite (NO2-N), nitrate (NO3-N) and phosphate (PO4-P) were 
placed in test tubes for colorimetric analysis with a four-channel Skalar SAN++ 
autoanalyser.  Detection limits for ammonium, nitrate, nitrite and phosphate were 0.015, 
0.270, 0.017 and 0.015 mg L-1 respectively.  Dissolved nitrate was calculated as the 
difference between total N and nitrite concentrations. 
7.3.6 Statistical analysis 
All univariate and multivariate analyses were conducted in Minitab 16 (Minitab Inc., PA., 
USA).  All data were tested for normality using the Anderson-Darling test and then 
selecting the most powerful appropriate parametric (t-test or ANOVA) or non-parametric 
(Mann-Whitney, Kruskal-Wallis or Generalised Linear Model) statistical tests.  All 
proportional data were arcsine transformed prior to comparisons in order to satisfy the 
assumption of normal distribution.  Pairwise tests were corrected for multiple 
comparisons using a Tukey’s family error rate of 5 % or using Dunnett’s test to compare 
against controls where appropriate.   
Mean OM retention from each treatment was tested with linear regression vs. 
log10 exposure concentration.  Comparisons of OM retention between experimental runs 
was complicated by the differing levels of retention in each experimental control.  
Therefore, it was necessary to standardise for this variation.  This was achieved by 
expressing OM retention as a proportion of each individual experimental control.   This 
standardisation was also necessary for experimental comparisons of nutrient exchange 
as initial nutrient conditions appeared to vary between experimental runs. 
Generalised Linear Models were used to compare differences in respiration rates 
against treatment and timestep in the form: respiration rate vs. treatment, time 
(treatment*time).  The final term in this model evaluates the degree of interaction 
between the treatment and time within the statistical mode.  Following this, non-
parametric Kruskal-Wallis H tests were used to compare differences between treatments 
at individual timesteps. 
7.4 Results 
7.4.1 Characteristics of sediment 
The organic content of the artificially colonised sediment was substantially lower than 
natural in-stream sediments of all size fractions (Table 7-2).  The artificial 10mm gravel 
contained 6.4 % of the organic matter content of the nearest size fraction (natural >2mm) 
and artificial sand contained 12.1 % of the organic content of the equivalent 0.15 mm 
natural sediment.  Although organic content was significantly lower in the artificial 
sediment, it was deemed sufficient for experimental purposes and was greater than 
uncolonised artificial sediment. 
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Table 7-2: Organic matter content of artificial and 
natural sediment collected from Silsden Beck in 
summer 2011 
Size fraction Mean % OM (± sd) 
Natural >2 mm 5.81 ± 0.71 
Natural >1 mm 4.55 ± 0.74 
Natural >0.5 mm 4.53 ± 1.27 
Natural >0.15 mm 4.86 ± 1.50 
Artificial 10 mm gravel 0.37 ± 0.17 
Artificial 0.2 mm sand 0.59 ± 0.18 
Uncolonised artificial 10 mm  0.04 ± 0.01 
Uncolonised artificial 0.2 mm 0.03 ± 0.02 
Notes:  
n=3 
natural sediment collected January 2011 from Silsden Beck 
7.4.2 Sediment organic matter content 
Significant differences from control organic matter retention were observed for artificial 
sediments exposed to erythromycin (H=13.03, DF=4, p=0.01) and the mixture (H=19.41, 
DF=4, p<0.01) but not for propranolol (H=2.86, DF=4, p=0.58; Figure 7-1).  Specifically, 
slight increases in OM retention were present at the highest exposure for erythromycin 
and at all but the lowest exposure for the mixture (Table 7-3).  Furthermore, OM retention 
appeared to increase with exposure dose for the mixture treatment.  The linear 
regression of OM retention vs. log10 exposure concentration was shown to be statistically 
significant (R2=94.8, F=54.43, DF=4, p<0.01; Figure 7-2) but this same relationship was 
not present for erythromycin (p=0.29) or propranolol (p=0.71).   
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Table 7-3: Summary of statistical analysis organic matter retention of artificial 
sediments exposed to erythromycin, propranolol and mixture 
Treatment 
concentration 
Erythromycin Propranolol Mixture 
Comparison of OM retention against control value1 
VLT ↑8% 
(W=29.0, p=0.13) 
↑25% 
(W=36.0, p=0.69) 
↑11% 
(W=27.0, p=0.07) 
LT ↑11% 
(W=25.0, p=0.03) 
↓6% 
(W=44.0, p=0.47) 
↑26% 
(W=23.0, p=0.01) 
HT ↑3% 
(W=34.0, p=0.47) 
↑28% 
(W=38.0, p=0.94) 
↑49% 
(W=21.0, p<0.01) 
VHT ↑14% 
(W=23.0, p=0.01) 
↑4% 
(W=36.0, DF=0.69) 
↑46% 
(W=21.0, p<0.01) 
Treatment 
concentration 
Comparison between compounds2 
VLT ERY 145%, PRO 118%, MIX 108% 
(H=1.31, DF=2, p=0.52) 
LT ERY 145%, PRO 92%, MIX 144% 
(H=10.98, DF=2, p<0.01) 
HT ERY 111%, PRO 132%, MIX 184% 
(H=6.88, DF=2, p=0.03) 
VHT ERY 160%, PRO 105%, MIX 180% 
(H=11.59, DF=2, p<0.01) 
Notes: 
1. Values represent mean differences in OM retention relative to control mean 
2. Values represent mean OM retention standardised by the mean control OM retention for each 
compound experiment.  Bold text indicates significant difference between compound 
exposures. 
 
There was a large degree of variation in control OM retention between the three 
experiments (Figure 7-1; H=13.05, DF=2, p<0.01) and so any comparisons between the 
experiments had to be standardised for this variation (Figure 7-3).  Differences in OM 
retention between compound exposures were statistically significant at all treatment 
levels except VLT (Generalised Linear Model: F=8.46, DF=2, p<0.01; Table 7-3).  The 
mixture sediments were characterised by the highest levels of OM retention across all 
treatments except the very low exposure and propranolol generally displaying the lowest 
levels of OM retention. 
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Figure 7-1: Mean organic matter retention in artificial river sediments following a 7-day exposure to (a) erythromycin, (b) propranolol and 
(c) a binary mixture of erythromycin and propranolol 
[%OM retention = %OM at day 7 / initial %OM at day 0] 
[Bars represent mean from n=6 replicates, error bars represent ±1 SD; asterisks indicate values significantly different from control: * < 
0.05, ** < 0.01, *** < 0.001] 
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Figure 7-2: Linear regression of OM retention vs. log10 concentration of artificial 
sediment following a 7 day exposure to a mixture of erythromycin and propranolol 
[points represent mean values from 6 replicates], error bars represent ±1 SD] 
 
 
Figure 7-3: mean OM retention as a proportion of control OM retention for artificial 
sediments exposed to four treatment levels of erythromycin, propranolol and a mixture 
[Bars represent mean from n=6 replicates, error bars represent ±1 SD; asterisks 
indicate values significantly OM retention between experiments: * < 0.05, ** < 0.01, *** < 
0.001; the solid line represents 100% i.e. no change in OM during the experiment, 
values >100% indicate a gain in OM and values <100% a reduction] 
7.4.3 Sediment respiration rates 
Significant differences in respiration rates were present between erythromycin 
treatments.  Treatments were compared pairwise against the control across the whole 
exposure period which showed the very high concentration erythromycin exposed 
sediments respired at a significantly reduced rate (Table 7-4). When respiration rates 
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were examined daily, no significant differences between treatments were present.  
Overall, erythromycin exposed sediments respired at a greater rate compared to the 
propranolol and mixture sediments (Figure 7-4). 
Comparison of respiration rates for propranolol was significant between 
treatments (F=21.09, DF=4, p<0.001) with significant pairwise differences between the 
control and both low and very high treatments.  When daily rates were examined low 
treatment exposed sediments respired at a significantly reduced rate compared to the 
control at 72 hours and 96 hours.   Respiration rates between mixture treatments showed 
no significant difference from the controls either across the whole seven days or at 
individual time steps.   
 
Table 7-4: Analysis of mean (±1 SD) respiration rates of artificial sediments exposed to 
erythromycin, propranolol and mixture 
Timestep 
(hours) 
Erythromycin Propranolol Mixture 
Whole 
dataset(1) 
(F=4.63, DF=4, p<0.01) 
VHT reduced from control 
(F=22.07, DF=4, p<0.001) 
VHT increased and LT 
reduced from control 
 
 F=1.94, DF=4, p=0.11) 
24(2) H=10.15, DF=4, p=0.04 
None different from control 
H=13.20, DF=4, p=0.01 
None different from control 
 
H=2.05, DF=4, p=0.73 
32  
H=7.18, DF=4, p=0.13 
H=13.49, DF=4, p<0.01 
VHT increased from control 
 
48  
H=2.01, DF=4, p=0.73 
H=11.81, DF=4, p=0.02 
None different from control 
 
H=4.04, DF=4, p=0.40 
55  
H=1.93, DF=4, p=0.74 
H=10.70, DF=4, p=0.03 
None different from control 
 
72  
H=4.00, DF=4, p=0.41  
H=15.88, DF=4, p<0.01 
LT reduced from control 
 
H=4.58, DF=4, p=0.33 
79  
H=3.21, DF=4, p=0.52 
H=9.99, DF=4, p=0.04 
None different from control 
 
96  
H=1.62, DF=4, p=0.81 
H=11.55, DF=4, p-0.02 
LT reduced from control 
 
H=3.34, DF=4, p=0.50 
102  
H=4.33, DF=4, p=0.36 
H=11.75, DF=4, p=0.02 
LT reduced from control 
 
168 H=10.90, DF=4, p = 0.03 
None different from control 
 
H=5.84, DF=4, p=0.21 
 
H=4.60, DF=4, p=0.33 
Notes: 
Generalised Linear Model of all treatments and timesteps: respiration rate vs. treatment, time (treatment 
* time).  There was no significant interaction between treatment and time in the GLM for any of the three 
experiments. 
Kruskal-Walls H tests comparing treatments at each individual timestep (24 to 168 hours) 
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Figure 7-4: mean respiration rates of artificial sediment exposed to 4 treatment levels 
of (a) erythromycin, (b) propranolol and (c) their binary mixture over a 7 day period 
[Bars represent mean from n=6 replicates, error bars represent ±1 SD; asterisks 
indicate values significantly different from control: * < 0.05, ** < 0.01, *** < 0.001.  
Asterisks next to legend indicate differences across the whole exposure whereas 
asterisks above bars indicate differences at that specific timestep.  For further details 
see Table 7-4] 
 
Time (hours) 
Time (hours) 
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7.4.4 Dissolved organic carbon, nitrate and phosphate 
Exposure of sediments to erythromycin resulted in significant differences in nitrate, 
ammonium and phosphate exchange with overlying water.  In particular, high and very 
high treatments showed increased ammonium and decreased phosphate exchange over 
control levels (Table 7-5; Figure 7-5).  Propranolol exposed sediments showed significant 
differences in phosphate exchange with the high treatment (200 000 ng L-1) 
demonstrating increased levels compared to control.  Mixture exposed sediments at low 
treatment levels demonstrated reduced DOC exchange when compared to controls. 
Differences between experimental control values for nutrient and DOC exchange 
were present for NO2-N (H=8.02, DF=2, p=0.02), NO3-N (H=7.03, DF=2, p=0.03) and 
DOC (H=12.23, DF=2, p<0.01).  After standardisation, erythromycin exposed sediments 
demonstrated significant differences in NO2-N, NH4-N and DOC when compared to 
propranolol and mixture exposed sediments.  Propranolol exposed sediments 
demonstrated reduced NO3-N exchange when compared to erythromycin and mixture.   
Table 7-5: Statistical analysis of nutrient and carbon change of artificial sediments 
exposed to erythromycin, propranolol and their mixture for seven days 
Analyte 
Difference from control 
Erythromycin Propranolol Mixture 
NO2-N H=6.89, DF=4, p=0.14 H=2.90, DF=4, p=0.58 H=3.82, DF=4, p=0.43 
NO3-N H=10.55, DF=4, p=0.03 
No differences from control 
 
H=1.80, DF=4, p=0.77 
 
H=6.89, DF=4, p=0.14 
NH4-N H=14.44, DF=4, p=0.01 
VHT increased from control 
 
H=1.00, DF=4, p=0.91 
 
H=7.50, DF=4, p=0.11 
PO4-P H=9.56, DF=4, p<0.05 
HT reduced from control 
H=9.56, DF=4, p<0.05 
HT elevated from control 
 
H=3.40, DF=4, p=0.49 
DOC  
H=7.66, DF=4, p=0.105 
 
H=2.88, DF=4, p=0.58 
H=10.31, DF=4, p=0.04 
LT reduced from control 
Analyte Difference between experiments 
NO2-N F=44.57, DF=2, p<0.001 
ERY increased c.f. PRO and MIX 
NO3-N F=30.96, DF=2, p<0.001 
PRO reduced c.f. ERY and MIX 
NH4-N F=3.80, DF=2, p=0.03 
ERY reduced c.f. MIX 
PO4-P F=3.19, DF=2, p<0.05 
No differences with Tukey’s comparisons 
DOC F=131.65, DF=2, p<0.001 
ERY reduced c.f. PRO and MIX 
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Figure 7-5: Mean changes in (a) NO2--N, (b) NO3--N, (c) NH4+-N, (d) PO4--P and (e) DOC concentrations in the overlying water of artificial 
sediment exposed to 4 treatments of erythromycin, propranolol and their binary mixture over a 7 day period 
[Bars represent mean from n=6 replicates, error bars represent ±1 SD; asterisks indicate values significantly different from control: * < 
0.05] 
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7.5 Discussion 
7.5.1 The effects of pharmaceuticals on respiration and organic matter 
degradation in sediments 
The results presented here demonstrate the capacity for pharmaceuticals to significantly 
disrupt the processing of organic matter and nutrients in freshwater sediments which 
may represent a wider threat to the functioning of freshwater ecosystems with 
implications for catchment-wide water quality.  The contamination of river sediments by 
a variety of pollutants (e.g. metals, organic chemicals, mine drainage and nutrients) is 
widespread (Ryther & Dunstan, 1971; Rutherford & Hynes, 1987; Atlas & Bartha, 1997; 
Palmer, 1997; Neal et al., 2005; Byrne et al., 2010; Colas et al., 2013).  These 
contaminated sediments act as both a diffuse store for further contamination downstream 
and also represent a serious threat to the integrity of freshwater ecosystem biodiversity 
and ecosystem functioning (Colas et al., 2013).  This is of concern because sediments 
(and their associated microbial and invertebrate communities) play a vital role in organic 
matter decomposition, nutrient cycling, and pollutant degradation (Groffman & Bohlen, 
1999; Austen et al., 2002; Colas et al., 2013).   
Up to 80 % of the organic material fixed by primary producers flows to the detrital 
food chain (i.e. sediment biota (Odum, 1983)) which in turn recycles nutrients and carbon 
making these available at higher trophic levels (Groffman & Bohlen, 1999).  The 
importance of microbial communities in processing carbon is well documented and is 
known as ‘the microbial loop’ (Meyer, 1994; Fenchel, 2008) and the potential alterations 
to key microbial processes demonstrated in this study may have serious implications for 
the wider freshwater ecosystem.  Covich et al. (1999) describe these communities as 
‘invisible’ because they live below the surface whilst performing vital functions for the 
integrity of freshwater ecosystems and the supply of freshwater resources.  Clearly, 
disruption to the structure and function of sediment dwelling microbial communities as 
demonstrated in this study can have significant implications for the whole freshwater 
ecosystem. 
Sediments exposed to high but environmentally relevant levels of erythromycin 
(≥100 µg L-1) and the mixture in this study demonstrated up to 50 % increases in the 
retention of organic matter (i.e. a reduction in organic matter degradation) which supports 
the original hypothesis (H1).  Other studies have shown similar functional inhibition, for 
example Näslund et al. (2008) showed that the presence of the antibiotic ciprofloxacin 
(>200 µg L-1) significantly reduced the mineralisation of the polycyclic aromatic 
hydrocarbon pyrene over a 77 day period; the degree of inhibition was shown to be 
significantly correlated with ciprofloxacin concentration. This finding is in agreement with 
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the results presented here which showed a significant linear relationship between 
mixture exposure concentration and OM retention.  The linear relationship suggested a 
dose-dependent response for the effects of an erythromycin and propranolol mixture on 
organic matter degradation.  Disruptions to organic matter degradation can also have 
knock-on effects for the fate and release of contaminants bound to the organic phase 
(Holden & Firestone, 1997).  For example, studies have shown that the degree of OM 
degradation can influence the loads of dissolved, bioavailable heavy metals in overlying 
waters (Rae & Allen, 1993; Masson et al., 2011).  The reductions in OM degradation 
demonstrated in this study may disrupt the degradation, exchange and bioavailability of 
other sediment-associated contaminants by allowing them to remain bound to the solid 
phase.  
The research examining the effect of pharmaceuticals on microbial respiration is 
sparse and no published studies have evaluated the effects of erythromycin and 
propranolol on this important ecosystem function.  In this study, sediments exposed to 
very high levels of erythromycin (1 000 000 ng L-1) and low levels of propranolol (≥200 
ng L-1) demonstrated reduced respiration rates when compared to controls in agreement 
with hypothesis H2.  This finding is supported by Girardi et al. (2011) who demonstrated 
that high levels of the antibiotic ciprofloxacin (20 mg L-1 over 25 days) inhibited microbial 
respiration in both soil and water microcosms.  Disruptions to sediment respiration by 
other pollutants are well documented, for example, increased nutrient levels and STP 
effluent have been shown to stimulate respiration (Ryther & Dunstan, 1971; Ingendahl 
et al., 2002).  Furthermore, ibuprofen and paracetamol demonstrated a similar 
stimulation at low concentrations.  Higher concentrations of paracetamol (up to 10 000 
ng L-1) proved inhibitory whereas the stimulatory effect of ibuprofen was present even at 
the highest concentrations (Bunch & Bernot, 2011).  These results agree with those 
demonstrated in this study which highlighted a brief stimulation of respiration caused by 
very high levels of propranolol (200 000 ng L-1) during the first 32 hours of exposure.  
This stimulation may be explained by microbial communities possessing the ability to 
chemically alter some pharmaceutical compounds and use them as a nutritive source 
thus increasing respiration rates (Bradley et al., 2007).  At higher concentrations direct 
toxicity may override this stimulatory effect.  Clearly, measurement of sediment 
respiration is an appropriate method for examining the effects of emerging contaminants 
on ecosystem functioning. 
The net impact (stimulatory or inhibitory) of pharmaceuticals is highly dependent 
upon specific compound properties and exposure concentrations (Lawrence et al., 
2005).  In situ tests in pharmaceutical or wastewater impacted streams have so far not 
demonstrated such effects on microbial respiration.  This may be explained by the 
capacity of such microbial communities to adapt and develop tolerance as a result of a 
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long exposure history to specific stressors (Spain, 1983; Liebert et al., 1991).  The 
stimulation in community respiration is one of the expected trends in stressed 
ecosystems as energy is diverted from growth and production to maintenance and 
stressor response (Odum, 1985).  However, the opposite effect was observed in this 
study with a general decrease in respiration caused by erythromycin and propranolol 
which may be due to direct toxicity of these compounds on microorganisms (Lawrence 
et al., 2005).  The general decrease in respiration (R) observed in this study may lead to 
a disruption in the production: respiration (P/R) ratio which tends towards balance in non-
stressed ecosystems. Odum (1985) suggests P/R as a more sensitive and appropriate 
tool in measuring ecosystem stress and so any future studies examining the effects of 
pharmaceuticals on freshwater sediment functioning should examine both production 
and community respiration rates. 
Environmentally relevant concentrations of sulphonamide and tetracycline 
antibiotics have also been shown to significantly inhibit bacterial respiration and Fe(III) 
reduction in soils (Thiele-Bruhn & Beck, 2005).  These disruptions to important 
ecosystem functions in both matrices were accompanied by reductions in bacterial 
abundance or shifts in the bacterial community composition.  In some cases these 
changes are accompanied by increased dominance of fungal biomass (Thiele-Bruhn & 
Beck, 2005).  Lawrence et al. (2005) demonstrated that 10 000 ng L-1 of carbamazepine, 
furosemide and ibuprofen caused shifts in the structure of riverine biofilm communities.  
All four compounds suppressed cyanobacteria and bacterial biomass.  These results 
demonstrate the ability for pharmaceuticals to exhibit both nutrient-like and toxic effects 
in freshwater microbial communities (Lawrence et al., 2005).   
These linkages between ecosystem functioning and biodiversity (e.g. 
bacterial/fungal diversity or macroinvertebrate species richness) are poorly understood 
but it is likely that diverse communities are important for functions such as community 
respiration (Bell et al., 2005).  Freshwater sediments are of particular concern as the 
microbial communities inhabiting them have been shown to be susceptible to disruption 
by antibiotic compounds (e.g. Girardi et al., 2011).  No data on the structure of microbial 
communities were available for this study but it is likely that the changes in respiration 
rates were caused by a shift in the makeup of respiring bacteria and other 
microorganisms.  Clearly, any further research examining the effects of pharmaceuticals 
on sediment microbial communities should consider both structural and functional 
aspects if a full understanding is to be gained.   
7.5.2 The effect of pharmaceutical mixtures on sediment functioning 
Pharmaceuticals are not present in isolation in the aquatic environment but rather form 
part of dynamic, multi-component mixtures containing a vast array of other 
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pharmaceuticals and their metabolites and myriad other organic and inorganic pollutants 
(Fent, 2008).  Despite this, the research into the environmental effects of pharmaceutical 
mixtures is relatively sparse.  This study represents the first investigation of the effects 
of a simple pharmaceutical mixture on important aspects of ecosystem functioning in 
rivers. 
Sediments exposed to the binary mixture of erythromycin and propranolol 
displayed significant reductions in DOC exchange and organic matter degradation at 
concentrations up to three orders of magnitude below those displayed when these 
compounds were tested in isolation (200 and 1000 ng L-1 in mixture c.f. 20 000 and 1 
000 000 ng L-1 in isolation).  This suggests some form of interaction between these two 
compounds which allows them to elicit effects below their individual threshold levels for 
effects and partially confirms the original hypothesis (H4).  These compounds may follow 
the concentration addition model between erythromycin and propranolol despite their 
differing mechanisms of action (MOA) (Cedergreen et al., 2008); most existing work on 
pharmaceutical mixtures suggests they follow this model.  For example, Cleuvers (2003; 
2004) showed that anti-inflammatory and other drugs acted additively on Daphnia magna 
and Lemna minor, with mixtures demonstrating up to five fold increases in negative 
response at the same concentration of individual compounds.   
Other studies suggest that for some compounds, particularly those with very 
different MOAs (Backhaus, 2008), the Independent Action model may be more 
appropriate (Escher et al., 2005).  Dyer et al. (2000) suggest that the cumulative baseline 
toxicity (narcosis) of very complex mixtures may dominate over the independent effects 
of specific MOAs, particularly at low concentrations and as such the concentration 
addition model has been recommended unless specific evidence indicates otherwise 
(Cleuvers, 2003).  The results presented here appear to agree with this assumption 
although they and others have key limitations 
 Different degradation kinetics between compounds means the relative 
concentrations in the mixture will vary over time; 
 Inability to infer the effects of individual compounds from the mixture when no 
parallel studies of individual compounds are conducted.  This was addressed as 
part of this study by conducting identical exposures of mixtures and individual 
compounds; 
 The mixture is static with no compounds being added or lost whereas 
environmental mixtures are dynamic in time; 
 Toxicity can only be inferred for the specific mixture(s) tested for and the results 
are not applicable for different mixtures; 
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 The mixtures are relatively simple (generally containing <10 compounds) and do 
not reflect the highly complex nature of environmental mixtures containing 
potentially thousands of compounds. 
Clearly, the situation of contaminant mixtures is highly complex and much more research 
is necessary if we are to fully understand potential negative effects on the structure and 
functioning of freshwater ecosystems.  One promising area of research is metagenomics 
which allows the rapid characterisation of the structure and functional capacity of 
microbial communities in environmental samples.  Such techniques have already been 
successfully applied to characterise microbial communities in large rivers (Ghai et al., 
2011) and in understanding the effects of pollutants on such communities (George et al., 
2010).  These emerging techniques should be combined with more traditional endpoints 
of effects at the individual, structural and functional level to fully understand the risks of 
pharmaceutical pollution.  Furthermore, the contamination of sediments has been shown 
to disrupt macroinvertebrate communities which can in turn have implications for other 
important ecosystem functions such as leaf litter breakdown (Colas et al., 2013), which 
in itself may be directly affected by pharmaceutical pollution (Bundschuh et al., 2009; 
Hahn & Schulz, 2007).  Therefore, future research on pharmaceuticals in riverine 
sediments should also consider macroinvertebrate assemblages as these too play a key 
role.  The results presented here and elsewhere highlight the need to consider both 
structural and functional aspects of ecosystem integrity when evaluating the effects of 
pharmaceutical mixtures in freshwaters. 
7.5.3 Dissolved carbon and nutrient cycling 
Carbon, nitrogen and phosphorous are vital elements in aquatic ecosystems and play an 
important role in determining their level of productivity (Giller & Malmqvist, 1998).  
Freshwater sediments, particularly associated microbial communities, have a major role 
in the cycling of nutrients and carbon and rendering these available to higher trophic 
levels (Groffman & Bohlen, 1999).  In the current study, small but significant disruptions 
to the cycling of key nutrients between sediment and overlying water appear to have 
been caused by low level pharmaceutical exposure, supporting hypothesis H3.  
Erythromycin exposed sediments demonstrated increased ammonium exchange and 
decreased phosphate exchange when compared to controls albeit at relatively high 
levels (≥ 100 µg L-1).  Changes in NH4-N exchange with overlying waters are indicative 
of disruption of sediment microbial communities as the majority of N released from 
sediments via microbial action is in the form of NH4-N (Kemp et al., 1990).  This suggests 
that erythromycin may stimulate the bacteria responsible for converting mineralised 
nitrogen to NH4-N whilst inhibiting those responsible for the interconversion of organic 
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phosphorous to the mobile phase (PO4-P; Boström et al. (1988)).  Disruptions to NH4-N 
exchange have important implications for freshwater ecosystems as ammonium is an 
important source of nitrogen for numerous plant species and also supplies energy for 
nitrifying bacteria.  The resulting mineralised nitrate is a very important source of nitrogen 
for phytoplankton (Rheinheimer, 1985).   
The opposite trend was true for propranolol exposed sediments where the 
production of PO4-P by sediment microbial communities appeared to be enhanced.  A 
possible explanation for this may be the direct release of phosphorous from bacteria 
upon cell death (lysis; see Montigny & Prairie (1993)).  The disruption of cell membranes 
via baseline toxicity (narcosis) has been suggested as an important toxic mechanism for 
pharmaceuticals in aquatic systems (Dyer et al., 2000) and such disruption may lead to 
the release of phosphorous held within bacterial cells.   
Enhancements in nutrient uptake have been demonstrated by Bunch & Bernot 
(2011) which showed increased NO3-N uptake by sediments exposed to low 
concentrations of paracetamol (55 and 110 ng L-1) although much higher concentrations 
inhibited uptake (5055 and 10 000 ng L-1).  No differences were present in NO3-N uptake 
were present in this study.  The lack of any effect of erythromycin on the exchange of 
nitrite (NO2-N) and nitrate (NO3-N) may be explained by the fact that the majority of 
nitrifying bacteria (e.g. Nitrobacter and Nitrosomonas) are gram-negative (Skerman et 
al., 1980; Chain et al., 2003) whereas erythromycin targets gram-positive bacteria.  
Disruptions to nutrient cycling caused by a variety of stressors are well documented 
(Blann et al., 2009; Cataldo et al., 2012; Trimmer et al., 2012) and Odum (1985) 
suggested that disruptions to nutrient cycling are one of the key features of a stressed 
ecosystem.  In particular, vertical cycling (between water and sediment decreases) 
causing increased downstream transport and nutrient loss from the ecosystem.  A variety 
of factors can cause increased nutrient loss (Margalef, 1975) and the changes caused 
by pharmaceuticals in this study may play a role in altering downstream transport of 
nutrients. 
Costanzo et al. (2005) demonstrated significantly reduced denitrification rates of 
laboratory exposed marine sediments to high concentrations (1000 µg L-1) of the 
antibiotics erythromycin, clarithromycin and amoxicillin.  Denitrifying bacteria may be 
particularly susceptible to the above compounds given they specifically target such 
bacteria (Costanzo et al., 2005).  Evidence (albeit anecdotal) of the effect of antibiotics 
on nitrogen cycling bacteria is widespread in the aquarium industry which relies on such 
bacteria in biological filters.  Negative effects have also been demonstrated on nitrogen 
cycling processes in STPs although at very high concentrations (Luis Campos et al., 
2001).  The results presented here and elsewhere demonstrate the potential for 
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environmentally realistic concentrations of antibiotics to illicit small but varying and 
significant effects on nitrogen and phosphorous cycling in aquatic sediments. 
Microbial activity represents an interesting avenue for the effects testing of trace 
organic chemicals such as pharmaceuticals because they can be both toxic but also act 
as a nutritive source which act to simultaneously stimulate and inhibit the overall 
community (Bunch & Bernot, 2011).  Whether or not pharmaceuticals are net stimulatory 
or inhibitory is likely to depend strongly on individual compound properties and identifying 
these mechanisms of microbial response should be seen as a research priority 
(Lawrence et al., 2005).  Changes to nutrient cycling by pharmaceutical exposed 
microbial communities, such as that demonstrated in this study, may have cascading 
effects on whole freshwater ecosystems by altering the amount and availability of NO3-
N and NH4-N for other organisms and perhaps decreasing the potential for the mitigation 
of nutrient pollution by microbes (Bunch & Bernot, 2011).  This is of particular concern in 
rivers affected by STP effluent where high concentrations of both nitrogen and 
pharmaceutical compounds are likely to occur alongside each other (Paul & Meyer, 
2001; Glassmeyer et al., 2005).   
Sediments exposed to the pharmaceutical mixture at low levels (200 and 1000 
ng L-1 of erythromycin and propranolol respectively) demonstrated a net reduction in 
overlying water DOC concentrations when compared to the controls.  This suggests that 
mixture exposed sediments assimilated a greater amount of carbon from the water 
column when compared to controls.  However, this is not in agreement with the 
respiration data which showed mixture exposed sediments respired at a reduced rate 
which would suggest a reduction in the amount of carbon assimilated from the overlying 
water.  Clearly, these processes are complex with the availability and fate of carbon and 
nutrients (particularly N) and their effects on respiration strongly linked (Trimmer et al., 
2012).  However, any disruptions to the cycling and availability of carbon can have 
significant impacts on contaminant transport, energy supply, nutrient cycling and also 
drinking water treatment (Stewart & Wetzel, 1981; Wetzel, 1992; Alarcon-Herrera et al., 
1994; Lawlor & Tipping, 2003).  Furthermore, alterations to the export of terrestrially-
derived carbon to estuaries and oceans may significantly alter their energy and nutrient 
regimes (Raymond & Bauer, 2001).  Emerging technologies such as metagenomics may 
play a role in understanding how contaminants affect the structure and functional 
capacity of sediment microbial communities (e.g. Ghai et al., 2011). 
The results presented here demonstrate the capacity of low levels of 
pharmaceuticals to have significant impact on the exchange of nutrients and carbon 
between freshwater sediments and the overlying water.  These changes (although 
significant) represent only small perturbations when compared to the rates of exchange 
demonstrated by control sediments.  However, much more research is required on the 
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effects of emerging contaminants on such processes given the important role 
freshwaters play in global carbon and nutrient cycling where even small disruptions can 
lead to significant effects (Trimmer et al., 2012).  
7.6 Conclusions 
The results presented here indicate the potential for pharmaceuticals, in low but 
environmentally realistic concentrations over extended exposure periods, to alter 
important aspects of ecosystem functioning in freshwater sediment systems and their 
exchange of key nutrients with the water column.  This has potential implications for 
secondary production and the downstream transport of carbon, nitrogen and 
phosphorous.  Future assessments of ecosystem health and their response to stressors 
such as pharmaceuticals should utilise both established structural indices as well as 
functional measures tested here if a full understanding of the risk pharmaceuticals pose 
in freshwaters is to be obtained.  This is of particular importance in the context of the 
results presented here given the distinct possibility of disruptions to sediment metabolism 
and nutrient cycling to cascade causing additional indirect effects at higher trophic levels 
and downstream (Wallace et al., 1997).  Of particular concern is the identification of the 
additive effects of low level pharmaceutical exposure when acting as part of a mixture.  
This demonstrates the potential for pharmaceuticals to elicit negative effects on 
freshwater ecosystem function below their individual effects thresholds and may mean 
that existing ecotoxicological research of individual compounds has underestimated the 
risk that pharmaceuticals pose.   
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8 RESEARCH SYNTHESIS, WIDER IMPLICATIONS AND FUTURE 
OPPORTUNITIES 
8.1 Research synthesis 
This thesis has examined the occurrence and effects of widely used human-use 
pharmaceuticals in freshwater ecosystems.  The primary goals of the research were to: 
1) review and critique the state of the art in the subject, 2) quantify the presence and 
spatiotemporal variation of pharmaceutical compounds in STP effluent, CSO effluent and 
receiving waters, 3) examine the lethal, sublethal and metabolic effects of extended 
exposure of freshwater macroinvertebrates to pharmaceuticals, and 4) understand the 
effects of these compounds on some important aspects of ecosystem structure and 
functioning. 
Pharmaceuticals enter freshwater ecosystems via a variety of complex sources, 
pathways and receptors with consumption, disposal, sewage treatment, climate, risk 
assessment, policy and in-stream physicochemical,  biotic and ecological processes all 
playing a key role in the ultimate occurrence, fate and effects of pharmaceuticals in rivers 
(Figure 8-1).   An increasing global population with improving quality of life will be 
accompanied by increased consumption of pharmaceuticals worldwide which is likely to 
be the key driver of pharmaceutical pollution in coming decades (Daughton, 2003).  The 
environmental impact of increased consumption is unlikely to be offset in improvements 
to sewage treatment and may worsen key public health issues particularly that of 
antibiotic resistance (APUA, 2010; Figure 8-1).  Despite the requirement for 
environmental risk assessment of new pharmaceuticals, there remain large knowledge 
gaps in terms of the occurrence and effects of hundreds, if not thousands, of 
pharmaceuticals in rivers (Pascoe et al. 2003).  These have the potential to disrupt 
biodiversity and the vital ecosystem services provided by river ecosystems upon which 
human society relies (Costanza et al., 1997, Vorosmarty et al., 2010). 
Notably, this body of work has addressed several key components of this 
complex system and has shown that pharmaceuticals are consistently present 
throughout both the semi-rural and urban reaches of the Aire and Calder catchments 
and demonstrate high degrees of variation across diurnal and seasonal as well as reach 
and catchment scales.  Pharmaceuticals also demonstrated significant lethal and sub-
lethal metabolic effects on the important freshwater amphipod Gammarus pulex when 
exposed for extended periods at environmentally relevant concentrations.  This 
highlights the pressing need for similar investigations using other functionally important 
freshwater taxa including macroinvertebrates and fish.  Similar exposures to 
pharmaceuticals appeared to cause no significant effects on the microbially or 
macroinvertebrate mediated decomposition of leaf litter in freshwaters.   Both stimulatory 
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and inhibitory effects on the degradation of organic matter, nutrient exchange and 
respiration in freshwater sediments were also observed.  More specific key findings in 
relation to the individual research questions can be summarised as follows: 
 
Aim 1: What is the current spatial and compound coverage of existing pharmaceutical 
pollution research and how reliable/representative are data obtained from these studies? 
 
Research into pharmaceutical pollution of rivers has expanded rapidly from the late 
1990s onwards aided by advancements in analytical techniques.  However, the existing 
research is heavily biased towards Western Europe, North America and parts of China 
and furthermore spatially clustered within these countries around a relatively small 
number of urban areas.  Very little or no research has been conducted in Africa, central 
Asia and South America.  Research effort has focused on a small majority of commonly 
studied compounds leaving large numbers of potentially high risk compounds poorly 
investigated.  The sampling techniques frequently employed during such research are 
poor for capturing the high degree of temporal and spatial variability associated with 
pharmaceutical pollution.  Measured concentrations in rivers often approached or 
exceeded levels known to cause acute or chronic toxic effects in freshwater organisms 
with fish and macroinvertebrates at particular risk from antibiotics, antidepressants, 
cardiovascular drugs and painkillers.  This overlap between measured occurrence and 
effects concentrations should inform future risk assessment and regulatory systems to 
ensure that any conclusions are drawn from environmentally relevant data and will 
provide an adequate degree of protection to freshwater ecosystems.  The database of 
pharmaceutical occurrence assembled as part of this chapter should serve as a useful 
tool for industry professionals, academics and regulators in prioritising future research 
into both the occurrence and effects of pharmaceutical pollution in rivers. 
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Figure 8-1: Conceptual summary of the pharmaceutical pollution of rivers via STP and CSO effluent 
[coloured boxes represent key reservoirs of pharmaceutical pollution, white boxes represent the key pathways and processes operating 
between and within these reservoirs.  Text in bold red indicates research questions that have been specifically addressed as part of this 
thesis] 
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Aim 2: At what concentrations do pharmaceuticals occur in STP effluent, CSO effluent 
and receiving waters and how do these levels vary over temporal (diurnal and seasonal) 
and spatial (reach and catchment) scales? 
 
This work has confirmed STP effluent as a major source of pharmaceutical pollution to 
receiving waters and has further identified CSO effluent as a significant secondary 
source (Figure 8-1).   Significant spatial and temporal variation was evident across both 
STP effluent and receiving water concentrations (see Figure 8-2 for a conceptual 
summary of temporal changes).   Conceptually, changes over hourly and diurnal scales 
are driven by peaks in domestic activity and individual wastewater pulses in the morning 
and mid to late evening.  Variability may also be expressed at weekly scales in relation 
to higher levels of daily domestic consumption during the weekend when people are not 
at work.  Finally, seasonal variability is driven by altering patterns of pharmaceutical 
consumption in relation to seasonal illnesses and also by changes in the removal 
efficiencies and receiving water dilution dependent on temperature, weather and flow. 
Periods of high flow demonstrated greater frequencies of detection for 
pharmaceuticals but at generally lower concentrations than moderate or low flow 
conditions, suggesting that dilution may be an important mechanism for reducing ultimate 
receiving water concentrations at high flows.  The greater detection frequencies suggest 
that STP overflow/bypasses or reduced STP removal efficiencies may also be acting as 
additional pharmaceutical sources to rivers at high flows.  The consistent presence of 
pharmaceuticals in rivers with little or no attenuation along a 5 km study reach challenges 
some previous assumptions about in-stream degradation of such compounds and 
highlight the importance of locally relevant studies of pharmaceutical transport and fate 
in river ecosystems.  In particular, local weather and flow conditions, turbidity, vegetation 
and suspended sediment may play a key role in transport and fate processes (Kunkel & 
Radke, 2011; Figure 8-3).   
Seasonal trends were present in the receiving water and STP effluent 
concentrations of all compounds with winter months generally exhibiting elevated 
concentrations, which would be missed by shorter sampling campaigns (Figure 8-2).  For 
example, Chapter 3 of this thesis (Hughes et al., 2013) showed that just 13 % of studies 
collected samples for 12 months or more suggesting that the majority of existing 
occurrence data is not accounting for such seasonal trends.   Pharmaceuticals were 
confirmed as ubiquitous in both STP effluent, receiving waters and to a lesser extent in 
CSO effluent. New UK maximum concentrations were identified for diclofenac, 
erythromycin and ibuprofen (4388, 1378 and 93 863 ng L-1 respectively) in receiving 
waters and diclofenac in STP effluent (2830 ng L-1).  These concentrations represent a 
reduced margin of environmental safety for erythromycin and propranolol particularly 
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with some evidence of negative consequences for algae, invertebrates and fish at the 
low or sub µg L-1 range (Crane et al., 2006; Enick & Moore, 2007; Hughes et al., 2013; 
Santos et al., 2010).  Furthermore, the consistent identification of multiple compounds 
within samples confirms the presence of pharmaceuticals as part of complex mixtures, 
which represents an additional risk for likely ecotoxicological effects.  Finally, diclofenac 
was identified with a median receiving water concentration of 416 ng L-1 well in excess 
of the proposed Environmental Quality Standard limit of 10 ng L-1 for European Union 
member states (EC, 2012).  This limit has now been postponed but if this were adopted 
after the current five year review period then it is considered that pharmaceutical pollution 
prevention will represent a significant financial and regulatory cost for the Environment 
Agency and UK water industry (UK Parliament, 2012). 
 
Figure 8-2: Conceptual summary of temporal changes in pharmaceutical 
concentrations in STP and CSO effluent and receiving waters across (a) diurnal, (b) 
weekly and (c) seasonal timescales 
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Figure 8-3: Summary of key processes and parameters affecting the fate and transport 
of pharmaceuticals in rivers 
[note double headed arrows indicate feedbacks] 
 
Aim 3: What lethal and sublethal impact does extended exposure to environmentally 
relevant concentrations of pharmaceuticals have on important freshwater taxa? 
 
A 28 day exposure to environmentally realistic concentrations of erythromycin and a 
mixture with propranolol caused more than a doubling in mortality of the functionally 
important freshwater amphipod Gammarus pulex compared to controls but did not 
disrupt growth or feeding to a significant extent (Figure 8-1).  Propranolol acting in 
isolation showed no significant effects on mortality, feeding or growth although similar 
patterns of effects to erythromycin and the mixture were observed.  NMR spectroscopy 
environmental metabolomics was identified as a suitably sensitive technique for 
detecting sublethal effects of pharmaceuticals on the metabolome of G. pulex with 
potential future applications in biomarker development centred on the osmolyte TMAO.  
Surviving individuals demonstrated sublethal alterations to the metabolome associated 
with energy storage and metabolism.  Extended exposure tests coupled with relatively 
straightforward NMR metabolomics analysis represents a promising area for future 
research into the effects of long-term low level exposure to pharmaceuticals on important 
freshwater taxa.  Crucially, concentrations that have been readily detected in UK and 
global rivers were shown to elicit significant lethal and sublethal effects on G. pulex.  
Disruptions to the fitness, feeding rates, populations and communities of important 
shredders such as G. pulex are likely to have knock-on implications for leaf litter 
decomposition in rivers.  Such impacts and potential linkages between individual lethal 
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and sublethal effects and wider ecosystem functioning are considered in the next section 
(Figure 8-4). 
 
Aim 4: What impact does exposure to pharmaceuticals have on important aspects of 
ecosystem functioning? 
 
The results highlight the importance of both microbial and macroinvertebrate 
communities in the decomposition of Fagus sylvatica leaves in freshwater ecosystems.  
However, environmentally relevant concentrations of five pharmaceuticals were found to 
have no significant effect on the microbially or macroinvertebrate mediated 
decomposition of leaf litter during both the autumn/winter and summer periods.  
However, the shredder Asellus aquaticus and Oligochaeta preferentially colonised leaf 
litter exposed to higher concentrations of erythromycin and ibuprofen which shows that 
shredders are selective feeders capable of differentiating between available foods based 
on their exposure history to pharmaceuticals.  An examination of five pharmaceuticals in 
a mixture also showed no effects on leaf litter decomposition and colonisation by 
macroinvertebrates (Figure 8-1).   
However, Chapter 5 (Aim 3) did indicate some significant sublethal and lethal 
effects on the important freshwater shredder G. pulex which may have the potential to 
propagate effects on wider ecosystem functioning (Figure 8-4).  For example, direct 
mortality of G. pulex will reduce the overall decomposition rate attributable to shredders 
and sublethal changes to metabolism, energy storage and feeding may also alter 
shredder feeding rates, food selection and ultimately decomposition rates.  In turn, 
shredder food selection and decomposition is altered by pharmaceuticals via the indirect 
effects of fungal and bacterial colonisation of leaf litter.  Clearly, these effects are 
complex and mediated across food webs via bacterial, fungal and invertebrate predators 
which must be examined using a combination of single species laboratory tests and more 
complex experiments examining ecosystem structure and function.  The experiments 
presented in Chapters 5 and 6 of this thesis represent important early steps in examining 
the integrated effects of pharmaceuticals in this way. 
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Figure 8-4: Conceptual summary outlining the linkage between the effects of 
pharmaceuticals on single shredder species and leaf litter decomposition in rivers 
[green boxes highlight aspects considered in Chapters 6 and 7 of this thesis and 
similar studies, blue boxes highlight aspects considered by Chapter 5 and others for 
effects on individual organisms] 
 
Freshwater sediments exposed to high but environmentally relevant 
concentrations of erythromycin demonstrated reduced organic matter processing 
compared to controls with some suggestions of a dose-response relationship.  Very high 
levels of erythromycin and low levels of propranolol caused a reduction in the rate of 
respiration of freshwater sediments.  Some short term stimulation of respiration was also 
observed at high levels of propranolol.  This may have been caused by microbial 
communities utilising pharmaceutical compounds as a nutritive source overriding any 
direct toxic effects.  Erythromycin exposed sediments demonstrated increased 
ammonium and reduced phosphate exchange with overlying waters whereas phosphate 
exchange was enhanced in propranolol exposed sediments.  No effects on dissolved 
organic carbon (DOC) exchange were observed in the individual compound exposures.  
Disruptions to ammonium exchange is important as this is the dominant source of 
nitrogen for many aquatic plant species and supplies energy for important nitrifying 
bacteria (Rheinheimer, 1985). 
Sediments exposed to binary mixtures of erythromycin and propranolol 
demonstrated reductions in OM processing and DOC exchange up to three orders of 
magnitude below those displayed by pharmaceuticals acting in isolation (Figure 8-1).  
This suggests some form of interaction or additivity between the toxic effects of these 
compounds despite their differing mechanisms of action.  Disruptions to DOC cycling 
have important consequences for contaminant transport, energy supply, nutrient cycling 
and drinking water treatment (Stewart & Wetzel, 1981; Wetzel, 1992; Alarcon-Herrera et 
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al., 1994; Lawlor & Tipping, 2003) and perhaps even global carbon cycles (Raymond & 
Bauer, 2001).   The identification of significant effects on the functioning of microbial 
communities in sediments was contrary to the lack of effects identified on leaf litter 
decomposition in Chapter 6.  This was likely due to the relative importance of fungal and 
bacterial communities within each of the functional processes.  The preconditioning and 
decomposition of leaf litter is dominated by fungi (Gulis & Suberkropp, 2003a; 2003b) 
and competitive release of fungal communities may override any negative effects caused 
to bacterial communities by the presence of pharmaceuticals (Bundschuh et al., 2009).  
Contrary to this, respiration in sediments is dominated by bacteria (Smith, 1973) and as 
such, the capacity for fungi to maintain overall sediment respiration is reduced when 
pharmaceuticals exert a direct toxic effect on bacterial communities. 
Laboratory examination of sediment respiration rates was identified as an 
appropriately sensitive tool for examining the effects of pharmaceuticals on freshwater 
ecosystem functioning.  However, these interactions are complex and the magnitudes of 
change relatively small suggesting further work is required to fully understand the 
implications for wider freshwater ecosystems. 
8.2 Implications and future research 
This thesis has increased knowledge on the occurrence and effects of pharmaceuticals 
in freshwater ecosystems highlighting their consistent presence across the semi-rural to 
urban continuum and their potential to cause subtle but potentially significant effects on 
the structure and functioning of freshwater ecosystems.  The research raises concerns 
surrounding the release of pharmaceutical compounds alongside the myriad other 
chemicals consumed and disposed of in domestic and commercial settings that routinely 
enter rivers via the sewage system.  The work provides new information that can inform 
future management and policy decisions within the arenas of water quality and emerging 
contaminants.   For example, the data presented on spatial and temporal variation in 
pharmaceutical concentrations will aid in the design of future monitoring campaigns 
capable of capturing such variability.  The novel effects experiments presented here 
highlight pharmaceutical levels at significant lethal, sublethal and ecosystem-level 
effects manifest themselves and as such may prove useful in future risk assessment 
studies for new or existing pharmaceutical compounds.  This work also identifies many 
important areas to prioritise for further research including: 
8.2.1 Pharmaceutical pollution of rivers via STP and CSO effluent 
Pharmaceutical pollution of rivers is now of major policy concern at the European level 
with the proposed inclusion of diclofenac (and the synthetic oestrogen, EE2) on the list 
of Hazardous Substances under Annex X of the Water Framework Directive (EC, 2000; 
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EC, 2012).  An initial proposal suggested a mandatory environmental quality standard 
(EQS) for diclofenac of 10 ng L-1 which would have been exceeded by over 93 % (180 
out of 194) of samples in this study representing a significant potential future cost for the 
UK water industry and Environment Agency.  The proposed EQS was later dropped and 
diclofenac is now merely listed as a Priority Substance without an EQS.  This decision 
was based on knowledge gaps and ambiguities in both the environmental occurrence 
and effects of diclofenac in European rivers (UK Parliament, 2012).   Such a high 
exceedance of the proposed EQS compares poorly with pesticide pollution where only 6 
% of samples exceeded the 100 ng L-1 EQS (EA, 2009c). 
Clearly, if an EQS of 100 ng L-1 were mandated in the future, significant 
investment would be required by water companies to meet this target.  The costs of 
additional advanced waste water treatment required were estimated at £27 billion over 
20 years (UK Parliament, 2012).  These costs would predominantly arise from the need 
to upgrade a substantial number of STPs in the UK with advanced treatment 
technologies capable of removing diclofenac (UK Parliament, 2012).  This thesis has 
highlighted (Section 2.4.3.5) that technologies that are efficient at removing particular 
compounds often result in the same or reduced removal efficiencies for other 
pharmaceutical compounds.  Ozonation of STP effluent perhaps represents the most 
promising treatment option (Zhang et al., 2010) although this would have significant 
associated capital and energy costs (Heberer, 2008).  However, the estimated £27 billion 
investment required would not just reduce the pollution burden of diclofenac but would 
also drive remediation of many other compounds and help to reduce their combined 
effects in freshwater ecosystems.  Therefore, any proposed or future EQS for diclofenac 
or similar pharmaceuticals should be seen as an opportunity to drastically improve the 
quality of STP effluent discharged to rivers considering all domestically consumed 
substances and not just individual pharmaceutical compounds.  Furthermore, a cost of 
£27 billion over 20 years is equal to just over £1.35 billion per year which is low compared 
to the total of £10.4 billion spent annually on prescription and OTC drugs in England 
alone (see Section 2.3).  Finally, such an investment compares favourably with current 
UK water industry investments.  In the period 2010-2015 £22 billion was invested, a large 
proportion of which was into sewage treatment plants or associated environmental 
improvements (Ofwat, 2009).   
The data presented in Chapters 3 and 4 of this thesis highlight the high degree 
of spatiotemporal variability in pharmaceutical pollution across the globe.  This confirms 
the need for more intelligent, representative monitoring strategies that are capable of 
capturing spatiotemporal variation in order to fully understand the true extent of 
pharmaceutical pollution in rivers (Hughes et al., 2013; Ort et al., 2010a; 2010b).  
Continuous monitoring, composite samplers and passive integrative sampling 
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techniques represent the best options to fully quantify the variable pharmaceutical levels 
in complex STP and receiving water systems (Zhang et al., 2008; MacLeod & Wong, 
2010; Jacquet et al., 2012).  Future monitoring studies should provide adequate details 
on their sampling techniques and strategies and monitoring sites in order to facilitate 
meaningful comparisons between studies.  Such monitoring campaigns should address 
both long-term seasonal trends and the short term diurnal trends identified here and 
elsewhere (Kanda et al., 2003; Ort et al., 2010a; 2010b).  
An ideal monitoring campaign would consider temporal variation at hourly, diurnal 
and weekly scales using continuous autosampling techniques and at seasonal scales 
using repeated grab sampling and passive integrative samplers (Figure 8-5).  Spatial 
variability should be addressed at a range of scales including at key locations within 
sewer catchments, perhaps by direct sampling of sewers for untreated wastewater.  
Catchment scale monitoring should consider isolated rural areas where agricultural 
runoff (Kay et al., 2004), sewer misconnections (Ellis, 2006) or septic tanks may 
contribute low levels (USEPA, 2010) and smaller semi-rural STPs which may pose a 
particular risk (MacLead & Wong, 2010).  Reach sampling examining the downstream 
fate and transport of pharmaceuticals should be conducted across both rural and urban 
settings.  Comparisons should be made between STPs encompassing a range of 
populations and technologies with consideration of both influent and effluent to allow 
quantification of STP removal efficiencies.  STPs serving populations with differing 
demographics, and those containing large hospitals or care facilities should also be 
included (Daughton, 2003; Kümmerer, 2001a).  Finally, future monitoring studies should 
seek to expand the coverage of compound classes to those that until now have been 
poorly studied or demonstrate significant environmental risk (Hughes et al., 2013).   
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Figure 8-5: Schematic of idealised pharmaceutical monitoring project 
 
More novel monitoring techniques (biosensors) are now becoming available 
which use enzymes or other biomolecules that can detect analytes such as pesticides in 
extremely low concentrations (e.g. 10-10 M) in environmental samples (Vakurov et al., 
2004; Palchetti et al., 2009).  Molecularly imprinted polymers (MIPs) mimic the natural 
action of enzymes and are designed to recognise and retain specific template molecules 
and have shown great promise in improving the extraction of analytes (i.e. SPE) in 
complex samples (Tse-Sum-Bui & Haupt, 2010).  MIPs have already been successfully 
applied to the extraction and analysis of pharmaceuticals (including diclofenac and 
ibuprofen) in surface water, waste water and sediment and show great promise in 
dramatically improving sample extraction and limits of detection (Qiao et al., 2006; Sun 
et al., 2008; Demeestere et al., 2010; Duan et al., 2013).  However, SPE still represents 
a useful and straightforward method of sample cleanup and preconcentration which is 
confirmed by the low limits of detection (5 ng L-1) achieved in this thesis and elsewhere 
(Petrovic et al., 2006). 
The lack of downstream attenuation over a reach of approximately 5 km suggests 
that sampling effort should also address stretches of river not within the immediate 
vicinity of known waste water or STP effluent discharges.  A recent prioritisation exercise 
for antibiotics and anti-cancer drugs suggested that monitoring effort be focused around 
the major European urban areas (Oldenkamp et al., 2013).  However, other studies have 
suggested that smaller STPs in semi-rural areas or smaller towns should be monitored 
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as these may be more susceptible to pharmaceutical pollution (Macleod & Wong, 2010).  
Clearly, much further monitoring is required but risk assessment models (e.g. GREAT-
ER; Schowanek et al., 2001) should fully account for smaller STPs and in-stream 
fate/transport processes ideally through the collection of locally relevant laboratory and 
field data.  Metabolites and transformation products should also be seen as a research 
priority for both their environmental occurrence and ecotoxicology given their potential to 
demonstrate similar and even enhanced toxicity compared to their parent compounds 
(La Farré et al., 2008).  Furthermore, they are likely to be present in freshwater systems 
at concentrations comparable or greater than parent compounds given that the 
compounds studied here are excreted predominantly in the form or metabolised or 
conjugated transformation products (Chapter 4). 
8.2.2 The effects of pharmaceuticals on important freshwater taxa and the 
structure and function of freshwater ecosystems 
The sublethal and lethal effects demonstrated here on G. pulex, sediment metabolism, 
nutrient exchange and colonisation of leaf litter were all manifested at concentrations 
previously measured in the surface waters of the UK and similar western developed 
nations (Chapter 4; Calisto & Esteves, 2009; Hughes et al., 2013; Santos et al., 2010). 
Furthermore, these effects concentrations have been exceeded by several orders of 
magnitude in studies examining polluted rivers in China, India and the United States 
(Larsson et al., 2007, Li et al., 2008; Phillips et al., 2010) demonstrating the distinct 
likelihood that such complex and negative effects are occurring in freshwater ecosystems 
across the globe. 
8.2.2.1 Leaf litter decomposition 
Although the results presented here did not demonstrate effects of 
pharmaceuticals on leaf litter decomposition, both inhibitory and stimulatory responses 
have been demonstrated elsewhere (Bundschuh et al., 2009; Hahn & Schulz, 2007) 
which suggests that much further research is required to reconcile reasons for these 
differences.  Research effort should be expanded to focus on previously unstudied 
antibiotics and other high risk pharmaceutical groups (e.g. antidepressants), different 
leaf species, longer exposure periods and more complex mixtures of pharmaceuticals 
and other emerging contaminants.  Further examination of the fungal and microbial 
contribution to leaf litter colonisation and decomposition should also be a priority as it is 
likely that these elements are more susceptible to the presence of pharmaceuticals, 
particularly antibiotics (Schmitt et al., 2005).  Complex competitive mechanisms between 
fungi and bacteria have been demonstrated which can have knock-on effects for 
decomposition rates and food selection by macroinvertebrates (Gulis & Suberkropp, 
2003b).  Techniques for estimating bacterial abundance (e.g. epifluorescence 
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microscopy; Buesing, 2005) and fungal biomass using the indicator ergosterol (Mille-
Lindblom et al., 2004) are available and should be applied to unravel these intricate but 
important microbial systems.  Environmental metagenomics is a further promising 
research area that has already proven capable in characterising diverse microbial 
communities in large rivers and the effects of pollutants on them (George et al., 2010; 
Ghai et al., 2011). 
8.2.2.2 Sediment respiration and nutrient cycling 
Disruptions to the turnover of particulate and dissolved carbon and nutrients in 
freshwater sediments and the water column has implications for whole ecosystem 
efficiency by altering the degree and duration of storage within sediments (Battin, 1999; 
Battin et al., 2003) and also wider catchment scale impacts manifested through changes 
in downstream nutrient and carbon fluxes (Rutherford & Hynes, 1987).   Disruptions to 
the cycling of DOC will also have implications for the supply of carbon and energy to 
higher trophic levels through the ‘microbial loop’ (Meyer, 1994) and the transport of 
organic pollutants such as pesticides (Carter & Suffet, 1982) and pharmaceuticals 
(Figure 8-6).  Changes to carbon cycling and transport within rivers has important 
implications as storage within river systems and the transport of carbon to shallow ocean 
sediments are a major component of the global carbon cycle (Hope et al., 1994).  Future 
research in this area should also expand to include other high risk pharmaceutical 
groups, particularly antibiotics, given the important role that microbial communities play 
in these processes (Rutherford & Hynes, 1987).  Quantification of changes to microbial 
communities using the same techniques for leaf litter mentioned earlier should also be 
considered.   
 
Figure 8-6: The effect of pharmaceuticals on the microbial loop 
[modified from Moloney et al., 2011, line thickness indicates process turnover affected 
by pharmaceutical pollution] 
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A combination of laboratory and in situ techniques will allow researchers to 
understand how effects are mediated under variable environmental conditions (Boynton 
et al., 1981; Hedin, 1990; Wagner-Dobler et al., 1992; Mermillod-Blondin et al., 2005).  
Finally, the use of microcosms and mesocosms should be considered which will allow 
the evaluation of effects from the individual scale, through to populations, communities 
and ecosystem functioning mediated via complex food webs (Brown et al., 2011).  
Microcosms containing simple freshwater ecosystems have already been successfully 
applied in identifying the effects of pharmaceuticals on algae, macrophytes, 
invertebrates and fish with some effects at the population and community level (e.g. Brain 
et al., 2004; Brodin et al., 2013; Richards et al., 2004).  However, their use should be 
expanded to bridge the gap between more simplified laboratory experiments and the 
complex, dynamic exposure conditions exhibited in the freshwater environment allowing 
researchers to examine effects across multiple trophic levels. 
8.2.2.3 Environmental metabolomics 
NMR spectroscopic environmental metabolomics was identified in this thesis as 
a suitably sensitive technique to identify sub-lethal effects of pharmaceuticals on 
freshwater taxa.  As such, this technique should be expanded to examine the effects of 
other pharmaceutical groups that demonstrate a high risk of toxicity to freshwater 
macroinvertebrates and fish such as painkillers, antidepressants and cardiovascular 
drugs (Hughes et al., 2013; Jones et al., 2002). However, future studies should ensure 
to employ phenotypic anchoring by size, age and gender wherever possible as noise 
associated with these factors is one of the key limitations of metabolomics techniques 
(Hines et al., 2007; Viant, 2007).  Furthermore, sexual dimorphism in Gammarids is 
known to influence growth and feeding (Sutcliffe et al., 1981; Greenwood & Adams, 
1984) which in turn will have implications for their metabolic profile.  Expansion of these 
techniques to other sensitive freshwater taxa such as mayfly (Ephemeroptera) and 
stonefly larvae (Plecoptera) should also be considered (Peterson et al., 2001; 
Arciszewski et al., 2011).  The significantly increased mortality of G. pulex should be 
studied further to examine whether such changes would be significant at the population 
level.  A variety of population models have been developed which may prove useful in 
answering this question and may also help in identifying sensitive life stages (Sauer & 
Pendleton, 2002). 
8.3 Conclusions 
Human-use pharmaceuticals have been found to be ubiquitous and important 
pollutants in both semi-rural and urban river systems capable of eliciting significant lethal, 
sublethal and metabolic effects on important freshwater taxa and aspects of ecosystem 
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structure and functioning.  Continued research into the occurrence of pharmaceuticals in 
STP effluent and freshwaters should use the widely developing toolkit of sampling 
techniques and strategies in order to fully quantify spatiotemporal variation of 
pharmaceuticals and their associated metabolites and transformation products.  
Ecotoxicological research should aim to maximise environmental relevance and to 
combine standard laboratory procedures with more novel investigations of metabolomics 
and ecosystem structure and function both in the laboratory and in situ. 
Until the last ten years, the main thrust of water quality improvement was the 
reduction of organic pollution and nutrients in the effluent of STPs.  With the introduction 
of the Water Framework Directive (EC, 2000), regulatory effort has switched to a focus 
on more integrated, biological indicators of water quality.  If the targets of this Directive 
are ever to be met, then the myriad stressors affecting water quality beyond nutrients, 
organic pollution and hydromorphological alteration must be addressed.  This includes 
pharmaceuticals and the thousands of emerging contaminants that routinely enter rivers 
due to consumption in normal domestic settings.  This work provides valuable new 
information on their occurrence and effects that can be used towards this goal. 
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10 APPENDICES 
10.1.1 Appendix A1: Global pharmaceutical occurrence database 
This appendix presents the full database of pharmaceutical occurrence in global rivers 
assembled as part of the below paper: 
 
Hughes, S. R., P. Kay and L. E. Brown (2013). "Global Synthesis and Critical Evaluation 
of Pharmaceutical Data Sets Collected from River Systems." Environmental Science & 
Technology 47(2): 661-677. 
 
The full database is available on the attached CD-ROM.  Alternatively, an excel 
spreadsheet version of the database and associated reference list is available online by 
following the below instructions: 
 
To access the database, please go to http://www.wateratleeds.org/ and log into the 
Associate Members Area (on right hand side of page): 
Username: pharmadata 
Password: openaccess 
Once you are logged in, cut and paste this link into the address bar: 
http://www.wateratleeds.org/members-area/paper-reviews-and-materials/quality/ 
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10.2 Appendix B: Pharmaceutical monitoring data 
10.2.1 Appendix B1: Aire and Calder gauge information 
Table B-1: Summary of Environment Agency flow gauges used in this study 
Station name (ID) Watercourse Record start date OS NGR QMED1 (m3/s) 
Oulton Fleet Weir 
(8079) 
River Aire September 1985 SE 38100 28100 11.24 
Farrer Lane  
(8075) 
Oulton Beck November 1986 SE 36500 28100 0.09 
Armley  
(8009) 
River Aire January 1972 SE 28057 34020 8.83 
Keighley  
(8109) 
River Worth December 1980 SE 63690 40866 0.77 
Ripponden  
(8172) 
River Ryburn March 1981  SE 35470 18938 0.32 
Heaton Lodge 
(8096) 
River Calder March 1996 SE 17915 20591 
Median stage 
0.30m 
Horbury  
(8100) 
River Calder June 2000 SE 29012 17748 
Median stage 
0.34m 
10.2.2 Appendix B2: Sample physicochemical data 
Table B-2: Physicochemical data from routine monitoring samples 
Site Matrix Date pH 
DO 
(mg/L) 
Conductivity 
(µs/cm) 
Garforth Owlwood 
Channel 
31/03/201
1 7.32 9.12 1536 
Effluent channel 
31/03/201
1 7.08 8.61 1578 
Heaton Lodge 
Channel 
31/03/201
1 7.70 10.74 872 
Effluent 
31/03/201
1 7.10 9.61 2540 
Horbury Junction 
Channel 
31/03/201
1 7.50 9.49 977 
Effluent channel 
31/03/201
1 7.20 8.00 1099 
Knostrop 
Channel 
31/03/201
1 7.10 9.60 1869 
Effluent channel 
31/03/201
1 7.00 9.69 1898 
Oulton 
Channel 
31/03/201
1 7.50 9.75 1466 
Effluent 
31/03/201
1 7.10 9.88 1414 
Oxenhope No. 2 
Channel 
31/03/201
1 7.70 11.21 259 
Effluent 
31/03/201
1 7.07 8.12 796 
Ripponden Wood 
Channel 
31/03/201
1 7.30 10.95 297 
Effluent 
31/03/201
1 6.40 8.25 584 
      
Garforth Owlwood 
Channel 
03/05/201
1 7.50 9.74 1579 
Effluent channel 
03/05/201
1 7.30 9.10 1612 
Heaton Lodge 
Channel 
03/05/201
1 7.50 10.85 1121 
Effluent 
03/05/201
1 7.00 9.90 3560 
Horbury Junction 
Channel 
03/05/201
1 7.50 10.10 1195 
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Effluent channel 
03/05/201
1 7.10 8.51 1148 
Knostrop 
Channel 
03/05/201
1 7.49 11.13 1667 
Effluent channel 
03/05/201
1 7.20 10.06 1682 
Oulton 
Channel 
03/05/201
1 7.66 9.90 1569 
Effluent 
03/05/201
1 7.25 9.85 1476 
Oxenhope No. 2 
Channel 
03/05/201
1 7.70 11.21 259 
Effluent 
03/05/201
1 7.07 8.12 796 
Ripponden Wood 
Channel 
03/05/201
1 7.30 10.95 297 
Effluent 
03/05/201
1 6.40 8.25 584 
      
Garforth Owlwood 
Channel 
31/05/201
1   9.07 1261 
Effluent channel 
31/05/201
1   8.47 1263 
Heaton Lodge 
Channel 
31/05/201
1   10.04 682 
Effluent 
31/05/201
1   9.93 2280 
Horbury Junction 
Channel 
31/05/201
1   9.97 901 
Effluent channel 
31/05/201
1   9.16 918 
Knostrop 
Channel 
31/05/201
1   10.16 1270 
Effluent channel 
31/05/201
1   10.01 1287 
Oulton 
Channel 
31/05/201
1   9.71 1224 
Effluent 
31/05/201
1   9.55 1318 
Oxenhope No. 2 
Channel 
31/05/201
1   10.67 254 
Effluent 
31/05/201
1   9.22 763 
Ripponden Wood 
Channel 
31/05/201
1   10.92 325 
Effluent 
31/05/201
1   10.85 663 
      
Garforth Owlwood 
Channel 
05/07/201
1 7.90 9.12 1375 
Effluent channel 
05/07/201
1 7.90 8.98 1381 
Heaton Lodge 
Channel 
05/07/201
1 7.30   990 
Effluent 
05/07/201
1 7.20   2017 
Horbury Junction 
Channel 
05/07/201
1 7.52   1073 
Effluent channel 
05/07/201
1 7.40   1105 
Knostrop 
Channel 
05/07/201
1 7.50   1508 
Effluent channel 
05/07/201
1 7.40   1504 
Oulton 
Channel 
05/07/201
1 8.00   1069 
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Effluent 
05/07/201
1 8.30   907 
Oxenhope No. 2 
Channel 
05/07/201
1 7.60   208.1 
Effluent 
05/07/201
1 6.70   725 
Ripponden Wood 
Channel 
05/07/201
1 7.60   275 
Effluent 
05/07/201
1 6.60   646 
      
Garforth Owlwood 
Channel 
27/07/201
1 8.13 9.67 1342 
Effluent channel 
27/07/201
1 8.03 9.57 1285 
Heaton Lodge 
Channel 
27/07/201
1 7.51 9.08 867 
Effluent 
27/07/201
1 6.88 8.73 3180 
Horbury Junction 
Channel 
27/07/201
1 7.52 8.68 1004 
Effluent channel 
27/07/201
1 7.39 7.87 1067 
Knostrop 
Channel 
27/07/201
1 7.54 9.33 1555 
Effluent channel 
27/07/201
1 7.44 9.09 1564 
Oulton 
Channel 
27/07/201
1 7.76 8.54 1184 
Effluent 
27/07/201
1 8.03 9.52 799 
Oxenhope No. 2 
Channel 
27/07/201
1 7.61 9.63 224 
Effluent 
27/07/201
1 6.59 7.92 686 
Ripponden Wood 
Channel 
27/07/201
1 7.76 9.60 271 
Effluent 
27/07/201
1 6.55 7.66 680 
      
Garforth Owlwood 
Channel 
30/09/201
1 7.53 9.77 210.9 
Effluent channel 
30/09/201
1 6.73 7.52 649 
Heaton Lodge 
Channel 
30/09/201
1 7.51 9.16 770 
Effluent 
30/09/201
1 7.19 9.1 3210 
Horbury Junction 
Channel 
30/09/201
1 7.42 7.53 871 
Effluent channel 
30/09/201
1 7.45 3.31 1140 
Knostrop 
Channel 
30/09/201
1 7.57 9.21 1557 
Effluent channel 
30/09/201
1 7.39 8.98 1585 
Oulton 
Channel 
30/09/201
1 7.82 8.86 1272 
Effluent 
30/09/201
1 7.35 8.52 1409 
Oxenhope No. 2 
Channel 
30/09/201
1 7.53 9.77 210.9 
Effluent 
30/09/201
1 6.73 7.52 649 
Ripponden Wood 
Channel 
30/09/201
1 7.28 9.85 278 
290 
 
 
 
Effluent 
30/09/201
1 6.47 6.21 624 
      
Garforth Owlwood 
Channel 
31/10/201
1 7.71 8.33 1334 
Effluent channel 
31/10/201
1 7.47 8.84 1336 
Heaton Lodge 
Channel 
31/10/201
1 7.36 9.74 577 
Effluent 
31/10/201
1 6.90 9.62 2670 
Horbury Junction 
Channel 
31/10/201
1 7.37 9.19 696 
Effluent channel 
31/10/201
1 7.25 7.72 999 
Knostrop 
Channel 
31/10/201
1 7.41 9.48 1215 
Effluent channel 
31/10/201
1 7.17 9.09 1223 
Oulton 
Channel 
31/10/201
1 7.80 9.16 1137 
Effluent 
31/10/201
1 7.27 9.04 1299 
Oxenhope No. 2 
Channel 
31/10/201
1 7.38 9.66 240 
Effluent 
31/10/201
1 6.80 8.54 617 
Ripponden Wood 
Channel 
31/10/201
1 7.33 9.64 274 
Effluent 
31/10/201
1 6.37 7.55 576 
      
Garforth Owlwood 
Channel 
01/11/201
1 8.00 9.50 293.00 
Effluent channel 
01/11/201
1 8.80 9.40 841.00 
Heaton Lodge 
Channel 
01/11/201
1 8.50 10.90 1015.00 
Effluent 
01/11/201
1 7.00 9.90 3410.00 
Horbury Junction 
Channel 
01/11/201
1 8.70 9.80 1102.00 
Effluent channel 
01/11/201
1 8.00 4.00 1005.00 
Knostrop 
Channel 
01/11/201
1 9.00 10.20 1332.00 
Effluent channel 
01/11/201
1 7.40 11.00 1865.00 
Oulton 
Channel 
01/11/201
1 8.90 9.70 1197.00 
Effluent 
01/11/201
1 8.00 9.70 1422.00 
Oxenhope No. 2 
Channel 
01/11/201
1 8.70 10.30 252.00 
Effluent 
01/11/201
1 7.10 9.50 728.00 
Ripponden Wood 
Channel 
01/11/201
1 8.10 10.60 294.00 
Effluent 
01/11/201
1 7.30 8.10 668.00 
      
Garforth Owlwood 
Channel 
01/12/201
1 8.20 9.20 804 
Effluent channel 
01/12/201
1 7.60 9.30 1304 
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Heaton Lodge 
Channel 
01/12/201
1 8.00 10.10 1021 
Effluent 
01/12/201
1 7.10 9.90 3041 
Horbury Junction 
Channel 
01/12/201
1 9.00 10.00 855 
Effluent channel 
01/12/201
1 8.00 8.00 1018 
Knostrop 
Channel 
01/12/201
1 8.60 10.10 1522 
Effluent channel 
01/12/201
1 7.40 11.00 1441 
Oulton 
Channel 
01/12/201
1 8.30 9.40 1274 
Effluent 
01/12/201
1 8.10 9.20 951 
Oxenhope No. 2 
Channel 
01/12/201
1 8.10 11.00 209 
Effluent 
01/12/201
1 7.40 8.10 663 
Ripponden Wood 
Channel 
01/12/201
1 8.30 10.00 322 
Effluent 
01/12/201
1 7.00 9.00 667 
      
Garforth Owlwood 
Channel 
01/01/201
2 9 9.6 615 
Effluent channel 
01/01/201
2 7.8 8.6 867 
Heaton Lodge 
Channel 
01/01/201
2 8.00 10.8 781 
Effluent 
01/01/201
2 7.30 9 3501 
Horbury Junction 
Channel 
01/01/201
2 8.80 10.60 864 
Effluent channel 
01/01/201
2 8.20 7.50 923 
Knostrop 
Channel 
01/01/201
2 8.90 10.60 1463 
Effluent channel 
01/01/201
2 7.10 10.40 1305 
Oulton 
Channel 
01/01/201
2 8.10 9.50 1360 
Effluent 
01/01/201
2 8.00 9.40 978 
Oxenhope No. 2 
Channel 
01/01/201
2 8.50 11.40 221 
Effluent 
01/01/201
2 7.20 9.00 633 
Ripponden Wood 
Channel 
01/01/201
2 8.40 10.30 311 
Effluent 
01/01/201
2 7.20 8.40 679 
      
Garforth Owlwood 
Channel 
01/02/201
2 8.6 9.2 999 
Effluent channel 
01/02/201
2 8.1 8.2 1249 
Heaton Lodge 
Channel 
01/02/201
2 8.50 11 1037 
Effluent 
01/02/201
2 7.70 9.2 2680 
Horbury Junction 
Channel 
01/02/201
2 8.20 9.10 725 
Effluent channel 
01/02/201
2 8.30 5.20 1126 
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Knostrop 
Channel 
01/02/201
2 8.40 11.00 1779 
Effluent channel 
01/02/201
2 7.10 9.00 1291 
Oulton 
Channel 
01/02/201
2 8.70 9.80 1385 
Effluent 
01/02/201
2 8.40 9.40 800 
Oxenhope No. 2 
Channel 
01/02/201
2 8.70 11.00 244 
Effluent 
01/02/201
2 7.30 9.40 757 
Ripponden Wood 
Channel 
01/02/201
2 8.70 10.20 284 
Effluent 
01/02/201
2 7.70 9.30 638 
 
Table B-3: Physicochemical data from River Aire reach samples 
Sample 
Distance 
D/S (m) Date pH 
DO 
(mg/L) 
Conductivity 
(µs/cm) 
AIRE001 0 13/06/2011 7.8 9.66 1375 
AIRE002 100 13/06/2011 7.6     
AIRE003 200 13/06/2011 7.8 9.42 1273 
AIRE004 300 13/06/2011 8.1 8.53 1217 
AIRE005 400 13/06/2011 8.3 8.87 1193 
      
AIRE001 0 04/07/2011 8 9.07 1377 
AIRE002 100 04/07/2011 7.9     
AIRE003 200 04/07/2011 7.9 8.98 1395 
AIRE004 300 04/07/2011 7.7 8.92 1410 
AIRE005 400 04/07/2011 7.7 9.03 1344 
      
AIRE001 0 11/07/2011 8.1 10.02 794 
AIRE002 100 11/07/2011 8.1     
AIRE003 200 11/07/2011 8 9.92 907 
AIRE004 300 11/07/2011 7.8 9.23 921 
AIRE005 400 11/07/2011 7.9 9.22 991 
      
AIRE001 0 13/10/2011 8.08 10.48 428 
AIRE002 100 13/10/2011 8.13 10.22 448 
AIRE003 200 13/10/2011 7.97 9.99 473 
AIRE004 300 13/10/2011 7.99 9.95 472 
AIRE005 400 13/10/2011 7.97 10.09 568 
      
AIRE001 0 20/10/2011 8.09 10.47 702 
AIRE002 100 20/10/2011 8.1 10.58 779 
AIRE003 200 20/10/2011 7.9 10.61 831 
AIRE004 300 20/10/2011 8.05 10.32 806 
AIRE005 400 20/10/2011 7.97 10.64 793 
      
AIRE001 0 17/11/2011 7.87 10.27 1022 
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AIRE002 100 17/11/2011 7.92 10.21 1075 
AIRE003 200 17/11/2011 7.77 10.09 801 
AIRE004 300 17/11/2011 7.96 9.65 1099 
AIRE005 400 17/11/2011 7.88 9.67 1090 
 
Table B-4: Physicochemical data from intensive diurnal river samples 
Garforth 19/7/11 Oulton 19/07/2011 
Time pH DO  Cond Time pH DO  Cond 
05:05:00 8.05 9.45 1277 05:45:00 7.77 9.04 1122 
07:50:00 8.01 9.13 1242 08:25:00 7.8 9.4 1043 
11:05:00 7.9 9.44 1225 11:35:00 7.9 8.89 986 
13:50:00 8.1 9.28 1219 14:20:00 8 9.35 956 
16:50:00 8.3 9.05 1233 17:20:00 8 9.36 970 
19:55:00 8.1 9.6 1265 20:25:00 7.96 9.88 986 
22:35:00 8.08 9.43 1279 23:10:00 7.92 9.64 974 
Garforth 25/7/11 Oulton 25/7/11 
Time pH DO  Cond Time pH DO  Cond 
05:05:00 7.4 9.42 1352 05:40:00 7.1 8.21 1175 
07:55:00 7.3 9.83 1360 08:30:00 7.3 8.2 1152 
11:15:00 7.3 10.02 1352 11:50:00 7.1 8.39 1164 
13:50:00 7.9 9.31 1325 14:25:00 7.4 8.89 1141 
17:15:00 7.1 9.43 1331 17:45:00 7 9.55 1116 
19:55:00 7.7 9.65 1327 20:25:00 7.7 9.87 1144 
22:50:00 8 9.98 1343 23:20:00 7.7 10.41 1173 
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10.2.3 Appendix B3: Pharmaceutical concentration data 
Table B-5: Erythromycin concentrations (ng L-1) in STP effluent and receiving waters of the Rivers Aire and Calder (2010 to 2012) 
Month 
Garforth Owlwood Heaton Lodge Horbury Junction Knostrop Lower Oulton/Lemonroyd Oxenhope No. 2 Ripponden 
Effluent Channel Effluent Channel Effluent Channel Effluent Channel Effluent Channel Effluent Channel Effluent Channel 
September  
2010 812.7 684.7 396.3 138.0 777.5 293.7 266.2 213.7 27.5 76.2 67.9 100.3 687.5 55.1 
October  
2010 1757.2 778.5 407.7 64.0 793.1 165.7 372.1 350.2 1105.6 183.1 1089.2 13.6 280.8 8.7 
November  
2010 329.7 1377.8 10.7 179.5 19.0 161.3 30.5 844.5 40.5 278.2 64.3 19.6 96.5 29.8 
December  
2010 947.9 814.5 585.6 317.0 38.0 242.9 465.6 678.0 300.0 356.6 nd 56.3 nd 7.9 
January  
2011 44.0 539.3 12.0 262.2 27.3 317.8 15.6 627.2 36.1 450.5 256.5 110.1  nd 
February  
2011  190.6  337.8 88.4 275.9  292.3 487.9 92.9 416.4  8.2  
March  
2011 8.4 39.0 27.7 9.3 62.2 86.0 31.1 34.9 52.9 28.9 76.1 51.4 89.4 7.1 
April  
2011 8.9 38.3 nd 11.2 2.5 27.8 33.3 31.2 45.0 2.5 21.0 nd nd 2.5 
May  
2011 24.6 2.5 nd nd  40.4 5.0 81.5 2.5 45.5 nd nd nd 2.5 
June  
2011 701.1 nd 1020.1 42.5 25.0 53.1 6.7 30.8 390.2 254.9 1856.8 131.7 44.8 61.9 
July  
2011 69.3 430.9 2.5 412.7 214.4 8.4 1215.9 2.5 51.4 2.5 731.7 21.3 782.0 30.2 
August  
2011 161.5 60.7 102.0 112.3 286.5 131.0 54.2 132.2 409.1 85.5 232.5 16.9 113.3 29.0 
September  
2011 252.8 142.4 398.9 225.5 105.5 182.9 80.8 126.2 184.5 164.8 161.2 70.1 170.3 69.5 
October  
2011 360.3 375.5 157.7 68.2 184.9 154.7 105.2 69.7 401.9 92.8 461.8 43.2 130.0 23.4 
November  
2011 19.2 272.2 135.5 30.9 2.5 20.7 2.5 74.1 10.9 50.8 62.5 2.5  10.9 
December  
2011   133.0 81.6 291.6 11.7 6.6 152.4 23.8 58.4 409.4 29.8  20.1 
January  
2012 597.9 447.6 274.9 139.8 422.4 2.5 302.5 386.6 581.0 260.6 190.3 22.4 241.7 173.8 
February  
2012 200.0 250.5 70.9 5.3 55.1 2.5 143.9 2.5 333.2 2.5 282.8 nd  7.1 
Notes: limit of detection (LOD) was 5 ng L-1.  Values of 2.5 above indicate samples where a signal was present at a signal: noise ratio > 3 but below the LOD, 
indicating the sample was detected but not quantified.  nd indicates no signal detected.  
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Table B-6: Propranolol concentrations (ng L-1) in STP effluent and receiving waters of the Rivers Aire and Calder (2010 to 2012) 
Month 
Garforth Owlwood Heaton Lodge Horbury Junction Knostrop Lower Oulton/Lemonroyd Oxenhope No. 2 Ripponden 
Effluent Channel Effluent Channel Effluent Channel Effluent Channel Effluent Channel Effluent Channel Effluent Channel 
September  
2010 17.7 14.2 9.7 2.5 9.1 7.2 22.3 24.0 27.5 2.5 nd 2.5 12.1 nd 
October  
2010 37.5 16.4 19.4 nd 7.9 2.5 26.7 24.7 32.7 10.1 25.0 5.8 5.4 nd 
November  
2010 2.5 15.9 nd 6.2 nd 2.5 nd 19.8 nd 9.2 nd nd 16.7 nd 
December  
2010 24.1 12.9 12.9 nd 31.3 nd 41.2 16.7 28.3 6.8 nd nd nd nd 
January  
2011 nd 34.2 5.4 7.6 2.5 7.4 2.5 63.0 6.1 20.8 20.0 2.5  nd 
February  
2011  19.3  2.5 19.6 5.5  17.4 16.2 6.7 20.8  2.5  
March  
2011 nd 2.5 2.5 2.5 6.4 nd 2.5 6.2 5.7 2.5 2.5 nd 5.7 nd 
April  
2011 nd 2.5 nd nd nd 2.5 2.5 6.1 5.8 nd 2.5 nd nd nd 
May  
2011 nd nd nd nd  nd 2.5 25.3 2.5 7.7 nd nd nd nd 
June  
2011 39.2 nd 19.9 nd 2.5 2.5 8.6 24.3 2.5 25.1 35.4 2.5 nd 2.5 
July  
2011 12.9 33.2  21.8 34.5 6.1 34.8 nd nd nd 8.7 nd 12.0 2.5 
August  
2011 29.2 18.1 13.2 2.5 6.9 nd 17.4 18.3 36.2 6.9 16.9 nd 18.4 2.5 
September  
2011 146.4 28.3 12.0 2.5 22.9 5.4 22.5 165.0 15.1 15.6 27.1 2.5 7.8 6.0 
October  
2011 32.6 12.9  2.5 11.3 5.3 26.0 21.0 16.8 2.5 11.2 nd 10.1 nd 
November  
2011 nd 22.0 11.0 nd 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5  2.5 
December  
2011   8.9 2.5 9.6 2.5 2.5 25.2 2.5 2.5 20.0 2.5  2.5 
January  
2012 51.0 44.0 8.1 nd 15.4 2.5 26.6 48.0 14.8 5.2 7.5 2.5 6.3 2.5 
February  
2012 15.0 9.8 2.5 nd 5.0 2.5 13.9 2.5 13.6 nd 2.5 nd  2.5 
Notes: limit of detection (LOD) was 5 ng L-1.  Values of 2.5 above indicate samples where a signal was present at a signal: noise ratio > 3 but below the LOD, 
indicating the sample was detected but not quantified.  nd indicates no signal detected.   
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Table B-7: Mefenamic acid concentrations (ng L-1) in STP effluent and receiving waters of the Rivers Aire and Calder (2010 to 2012) 
Month 
Garforth Owlwood Heaton Lodge Horbury Junction Knostrop Lower Oulton/Lemonroyd Oxenhope No. 2 Ripponden 
Effluent Channel Effluent Channel Effluent Channel Effluent Channel Effluent Channel Effluent Channel Effluent Channel 
September  
2010 29.6 29.9 56.3 nd nd 96.6 10.5 8.0 2.5 14.6 2.5 nd 107.8 nd 
October  
2010 23.8 40.5  nd nd nd 11.9 21.9 33.3 22.4 nd nd nd 2.5 
November  
2010 6.9 18.4 nd 6.3 nd 59.1 2.5 21.2 2.5 22.6 nd 2.5 nd nd 
December  
2010 14.6 16.4 55.6 53.4 14.5 nd 34.7 38.9 11.7 22.2 nd 2.5 nd 2.5 
January  
2011 nd 2.5 36.6 11.2 2.5 14.8 2.5 10.6 2.5 17.8 2.5 2.5  2.5 
February  
2011  2.5  37.9 nd 37.6  2.5 2.5 22.3 nd  nd  
March  
2011 nd 2.5 58.7 25.7 nd 42.3 2.5 2.5 nd 6.5 nd nd nd nd 
April  
2011 15.5 nd 2.5 37.2 nd 2.5 2.5 12.3 10.0 12.2 nd nd nd nd 
May  
2011 2.5 2.5 nd 2.5  2.5 2.5 2.5 2.5 2.5 nd nd nd nd 
June  
2011 13.2 12.4 nd nd nd 22.2 10.1 31.2 7.3 7.9 nd nd nd nd 
July  
2011 11.3 5.3 6.1 10.5 2.5 7.4 nd 2.5 nd 2.5 nd 8.9 nd 9.4 
August  
2011 8.6 2.5 2.5 2.5 nd 2.5 nd 7.2 6.7 nd nd nd nd nd 
September  
2011 6.1 11.0 91.2 50.5 2.5 16.5 8.8 nd 7.7 7.0 nd nd nd nd 
October  
2011 2.5 2.5 2.5 2.5  2.5 7.1 nd 2.5 2.5 nd nd nd nd 
November  
2011 8.1 9.5 nd nd nd nd nd 2.5 nd 6.9 nd nd  nd 
December  
2011   nd nd 2.5 nd 2.5 6.7 nd 2.5 nd nd  nd 
January  
2012 6.7 9.0 nd nd 2.5 nd 10.5 8.4 2.5 2.5 nd nd nd nd 
February  
2012 8.3 2.5 2.5 nd nd 2.5 2.5 6.4 2.5 6.6 2.5 2.5  14.6 
Notes: limit of detection (LOD) was 5 ng L-1.  Values of 2.5 above indicate samples where a signal was present at a signal: noise ratio > 3 but below the LOD, 
indicating the sample was detected but not quantified.  nd indicates no signal detected. 
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Table B-8: Ibuprofen concentrations (ng L-1) in STP effluent and receiving waters of the Rivers Aire and Calder (2010 to 2012) 
Month 
Garforth Owlwood Heaton Lodge Horbury Junction Knostrop Lower Oulton/Lemonroyd Oxenhope No. 2 Ripponden 
Effluent Channel Effluent Channel Effluent Channel Effluent Channel Effluent Channel Effluent Channel Effluent Channel 
September  
2010 729.3 597.1 482.1 93863.1 1817.7 1195.1 236.6 280.2 126.9 196.4 126.9 205.2 2363.8 92.0 
October  
2010 1368.1 824.7 nd nd 1356.3 53633.9 277.2 248.5 876.5 255.7 583.0 81.5 350.2 12.5 
November  
2010 639.1 2960.3 nd nd 1359.2 2171.7 387.5 1495.5 1017.3 486.8 111.4 127.2 135.6 186.7 
December  
2010 3592.9 2821.0 nd 1409.2 3644.7 nd 536.1 4838.4 4617.1 2770.0 nd 151.2 912.3 115.4 
January  
2011 631.4 1565.9 949.4 627.5 1055.2 454.7 544.8 995.7 1183.9 801.4 1068.2 147.8  180.4 
February  
2011  554.7  259.5 706.0 225.5  808.1 891.0 495.2 951.4  432.1  
March  
2011 468.0 417.7 360.6 207.7 1042.2 397.9 345.3 557.2 322.0 488.4 403.8 nd 549.3 144.3 
April  
2011 645.2 375.7 877.1 619.8 281.2 282.5 433.2 518.4 1026.3 435.0 583.4 133.9 386.2 52.5 
May  
2011 565.8 830.6 280.3 327.7  344.1 298.8 448.4 474.3 625.6 nd 73.5 191.6 115.8 
June  
2011 603.6 606.0 381.9 585.6 847.1 511.7 198.8 597.1 47.5 137.5 91.0 125.0 251.8 131.8 
July  
2011 45.8 452.4 191.8 86.7 129.0 141.1 12.5 234.3 164.1 27.9 75.7 62.4 828.5 114.5 
August  
2011 298.3 213.2 192.3 168.0 316.1 nd 92.9 93.2 153.7 nd 319.3 nd 53.8 358.4 
September  
2011 394.6 311.5 197.3 108.7 2164.2 215.8 33.9 52.3 192.5 75.2 65.9 26.2 459.0 126.6 
October  
2011 743.6 416.0 43.9 109.7 938.9 54.6 178.1 115.7 518.3 117.1 54.9 38.3 310.9 12.5 
November  
2011 nd 52.3 34.3 35.8 451.8 62.1 232.7 140.8 692.3 168.6 96.4 12.5  12.5 
December  
2011   319.4 105.3 928.1 31.7 863.2 762.5 740.5 51.3 394.6 167.2  96.6 
January  
2012 578.8 449.1 93.9 64.1 1305.4 122.1 453.5 454.7 1209.8 97.5 305.3 46.9 117.1 36.9 
February  
2012 389.7 359.4 77.9 62.7 nd 12.5 12.5 317.4 33.3 530.3 576.2 97.2  312.7 
Notes: limit of detection (LOD) was 25 ng L-1.  Values of 12.5 above indicate samples where a signal was present at a signal: noise ratio > 3 but below the LOD, 
indicating the sample was detected but not quantified.  nd indicates no signal detected.   
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Table B-9: Diclofenac concentrations (ng L-1) in STP effluent and receiving waters of the Rivers Aire and Calder (2010 to 2012) 
Month 
Garforth Owlwood Heaton Lodge Horbury Junction Knostrop Oulton/Lemonroyd Oxenhope  Ripponden 
Effluent Channel Effluent Channel Effluent Channel Effluent Channel Effluent Channel Effluent Channel Effluent Channel 
September  
2010 2811.2 2990.7 139.9 198.7 526.6 116.0 768.9 936.7 230.2 591.5 85.4 81.5 411.4 76.4 
October  
2010 2830.4 2746.6 521.1 39.4 556.6 339.2 797.2 933.4 994.4 347.4 400.6 87.5 332.3 31.3 
November  
2010 612.5 2057.5 120.9 284.3 138.7 455.8 151.8 909.6 162.2 471.1 79.5 10.1 62.8 29.2 
December  
2010 744.7 635.1 1301.7 163.6 600.5 88.1 806.4 588.5 631.2 428.3 nd 123.5 380.8 nd 
January  
2011 136.4 451.7 78.1 97.5 54.6 74.2 154.1 393.5 238.8 293.2 45.9 35.8  47.5 
February  
2011  161.3  35.6 71.1 41.9  174.6 217.0 177.9 54.8  77.0  
March  
2011 168.3 86.5 45.7 44.3 56.0 121.7 87.9 125.0 19.2 162.2 nd nd 113.0 19.6 
April  
2011 187.0 9.6 98.4 246.8 20.7 33.6 155.6 202.2 207.2 145.6 26.7 17.3 12.2 2.5 
May  
2011 101.3 67.7 19.5 34.9  31.9 60.6 103.2 99.6 67.9 9.2 10.0 2.5 16.1 
June  
2011 172.3 168.4 50.9 47.2 86.5 104.4 194.0 245.7 22.4 61.4 35.0 28.2 9.3 20.8 
July  
2011 187.5 157.2 51.0 143.8 182.2 231.6 13.3 11.7 9.6 7.1 22.8 23.0 87.6 42.6 
August  
2011 228.2 165.9 29.8 56.4 92.5 7.6 178.0 209.2 256.0 14.8 34.0 nd 13.9 24.9 
September  
2011 224.2 322.0 29.4 20.5 43.0 66.5 373.6 47.7 281.4 186.0 19.2 nd 14.3 7.4 
October  
2011 265.6 189.6 25.2 18.6 95.6 25.8 244.7 108.4 208.9 73.0 23.5 nd 16.5 5.8 
November  
2011 305.1 389.1 11.5 25.8 54.7 53.2 71.1 160.0 220.1 101.2 10.7 9.1  20.6 
December  
2011   115.0 26.8 105.1 16.3 288.2 308.4 187.2 69.4 27.8 33.6  16.0 
January  
2012 260.3 221.9 18.8 nd 90.1 51.4 282.3 234.7 160.1 79.3 27.9 nd 14.0 19.5 
February  
2012 198.5 217.5 10.2 13.0 nd 2.5 10.6 123.4 17.9 89.9 70.0 8.4  21.3 
Notes: limit of detection (LOD) was 5 ng L-1.  Values of 2.5 above indicate samples where a signal was present at a signal: noise ratio > 3 but below the LOD, 
indicating the sample was detected but not quantified.  nd indicates no signal detected.   
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10.3 Appendix C: Environmental metabolomics 
10.3.1 Appendix C1: Gammarus pulex collection and acclimatisation 
Gammarus pulex is a common species of freshwater amphipod widespread across 
Europe and has been shown to be suitably sensitive and ecologically relevant for use in 
ecotoxicological testing (Alonso et al., 2010).  Live G. pulex were collected in November 
2011 from Silsden Beck, West Yorkshire (OSNGR SE 0446147504).  This site was 
chosen because of the known abundance of G. pulex and its location above any known 
point sources likely to contain pharmaceutical contaminated effluent.  A preliminary 
analysis of a 1L water grab sample from Silsden Beck by HPLC-MS/MS indicated that 
both of the preliminary study compounds were below detection limits.   
After collection, G. pulex were transported to a constant temperature laboratory 
immediately and acclimatised in 10L glass aquaria with Silsden Beck water for a period 
of 7 days; the water was oxygenated throughout using air pumps (Hailea Group 
Company Ltd., China).  On day 7, individual G. pulex were weighed wet then placed at 
random in groups of four into 42x 1L clear glass treatment flasks containing 0.5L of 
Silsden Beck water, thus giving a total of 168 individuals.  Wet weighing was achieved 
by carefully placing individuals into a pre-weighed flask of stream water on a 4d.p. 
balance.  
After being placed into flasks, they were then allowed to acclimatise for a further 3 days; 
during this total 10 day period the G. pulex were fed to excess with beech (Fagus 
sylvatica) leaves which had been pre-conditioned in Silsden Beck stream water for a 
period of four weeks.  F. sylvatica was chosen as the feed material as it was predominant 
along the banks of Silsden Beck and as such would form the majority of the G. pulex diet 
at this site.  The 10 day acclimatisation was intended to allow recovery from the effects 
of stress caused during the capture or weighing process.   Immediately prior to treatment, 
excess feed material was removed and each flask was provided with 0.2 g (±0.06) of 
pre-conditioned beech leaves to provide both food and shelter during the exposure 
period.  Pilot studies demonstrated that 0.2g of feed material would be sufficient for the 
28d exposure period.  During acclimatisation and treatment mean water temperature 
was 7.7 (±0.3) °C and a 12:12 light: dark cycle was maintained throughout. 
 
 
 
  
300 
 
 
 
10.3.2 Appendix C2: Gammarus pulex masses and physicochemical data 
Table S1: Treatment schedule and physicochemical data for 28 day exposure of G. pulex to 
erythromycin and propranolol 
Treatment Nominal conc.  
(ng L-1) 
Mean day 0  G. 
pulex mass   
(mg) 
Mean 
dissolved 
oxygen  
(mg L-1) 
Mean pH Mean EC (µs 
cm-1±SD) 
Control 
(Silsden Beck 
water) 
n/a 26.8 (±13.0) 10.1 (±0.8) 7.7 (±0.0) 433.5 (±12.8) 
Low treatment 
erythromycin 
1000 25.9 (±9.6) 10.4 (±0.3) 7.8 (±0.1) 446.1 (±27.5) 
High treatment 
erythromycin 
100 000 26.0 (±10.0) 9.8 (±0.8) 7.8 (±0.1) 435.3 (±24.1) 
Low treatment 
propranolol 
200 24.6 (±9.9) 10.6 (±0.1) 7.7 (±0.1) 439.1 (±23.5) 
High treatment 
propranolol 
20 000 27.2 (±11.8) 10.5 (±0.1) 7.8 (±0.1) 464.7 (±27.0) 
Low treatment 
mixture 
1000 
+ 200 
26.9 (±11.9) 10.7 (±0.1) 7.9 (±0.0) 472.6 (±28.1) 
High treatment 
mixture 
100 000 
+ 20 000 
27.8 (±13.3) 10.2 (±1.0) 7.4  (±0.3) 426 (±7.9) 
Notes: 
All values are means ± 1 standard deviation 
 
10.3.3 Appendix C3: NMR spectra 
The raw NMR spectra in ACD Labs format are included on the attached CD-ROM for 
reference. 
 
